[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fljJ9C-2S0NH5hfqMiV26b6lz-V_AJQd62Sz_39AIZTo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Emory University",[4],1383,false,273,58,566806,175,791,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"HIV",33,{"name":18,"count":19},"Diabetes",32,{"name":21,"count":22},"Depression",28,{"name":24,"count":25},"Sickle Cell Disease",26,{"name":27,"count":28},"Coronary Artery Disease",25,{"name":30,"count":31},"Breast Cancer",24,{"name":33,"count":34},"Obesity",19,{"name":36,"count":37},"Dementia",16,[39,44,48,53,58,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04022343","Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer","2022-02-02","Cabozantinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT03468218","Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer","2022-05-02",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03872180","Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","2022-06-06","Bendamustine",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03719131","Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy","2022-09-27","Nivolumab",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03983993","Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer","2023-05-17","Niraparib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03769155","VX15\u002F2503 With or Without Ipilimumab and\u002For Nivolumab in Patients With Resectable Stage IIIB-D Melanoma","2023-12-15","Ipilimumab",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05245682","Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer","2024-01-15","Tolinapant",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05779943","Comparison of 18F-rhPSMA-7.3 PET\u002FCT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer","2024-03-15","Furosemide",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04393350","Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma","2024-09-13","Lenvatinib",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05031078","Assessing Durable Antibody Response to HPV Vaccination","2024-10-23","Gardasil-9",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,326,360,409,468,524,582,622,656,691,721,753,779,802,827,851,876,894,912,930,948,974,992,1016,1034,1052,1070,1088,1116,1134,1159,1183,1201,1224,1250,1298,1329,1366,1414,1436,1474,1525,1561,1584,1611,1629,1647,1665,1683,1706,1724,1742,2082,2276,2319,2447,2553,2601,2642,2709,2759,2824,2890,2930,2995,3029,3064,3089,3129,3156,3190,3218,3251,3280,3302,3331,3353,3375,3406,3437,3475,3513,3594,3621,3698,3749,3783,3823,3857,3895,3938,3970,3992,4014,4044,4068,4100,4135,4157,4182,4205,4228,4251,4274,4292,4310,4328,4346,4369,4387,4413,4431,4452,4474,4498,4533,4557,4575,4593,4615,4636,4662,4680,4706,4724,4747,4765,4796,4814,4837,4855,4883,4901,4919,4937,4955,4977,5001,5019,5037,5055,5077,5108,5130,5157,5179,5202,5220,5246,5264,5282,5300,5318,5341,5365,5393,5418,5436,5454,5479,5503,5537,5595,5617,5643,5682,5700,5726,5744,5762,5780,5798,5822,5840,5862,5886,5950,6005,6052,6095,6136,6173,6200,6231,6264,6286,6314,6351,6376,6407,6437,6459,6486,6515,6548,6583,6608,6633,6651,6669,6695,6713,6731,6754,6772,6790,6808,6826,6844,6867,6889,6907,6930,6948,6973,6998,7016,7039,7057,7080,7104,7129,7147,7172,7190,7208,7232,7250,7273,7291,7309,7327,7353,7371,7394,7412,7436,7460,7485,7503,7527,7551,7578,7596,7620,7638,7664,7682,7700,7724,7742,7765,7789,7813,7837,7862,7885,7908,7930,7948,7976,7994,8012,8030,8052,8070,8088,8106,8124,8142,8160,8178,8196,8214,8232,8250,8268,8286,8304,8322,8347,8370,8396,8422,8440,8463,8487,8512,8530,8553,8576,8598,8623,8641,8659,8682,8700,8722,8740,8762,8787,8810,8828,8851,8874,8892,8917,8935,8956,8978,8996,9014,9032,9050,9073,9091,9109,9127,9152,9170,9188,9211,9229,9247,9270,9293,9311,9335,9353,9371,9398,9416,9434,9458,9482,9505,9528,9552,9576,9597,9621,9655,9692,9734,9756,9779,9801,9819,9849,9873,9900,9918,9944,9962,9980,10004,10022,10040,10063,10081,10106,10124,10150,10168,10186,10204,10222,10248,10266,10290,10308,10334,10352,10373,10391,10409,10427,10445,10463,10485,10514,10532,10550,10568,10586,10604,10622,10640,10664,10682,10705,10790,10822,10852,10893,10927,10960,11002,11034,11068,11090,11112,11134,11164,11186,11208,11234,11263,11290,11326,11348,11375,11404,11426,11456,11478,11512,11535,11558,11583,11607,11625,11643,11666,11684,11702,11726,11749,11767,11785,11808,11831,11849,11867,11885,11903,11927,11951,11969,11987,12008,12026,12044,12062,12087,12111,12136,12154,12172,12196,12221,12246,12264,12288,12306,12334,12357,12383,12406,12428,12449,12467,12490,12508,12531,12554,12576,12600,12625,12647,12668,12694,12712,12730,12748,12766,12784,12809,12827,12845,12874,12892,12910,12935,12961,12979,12997,13015,13037,13055,13077,13101,13124,13142,13167,13185,13206,13229,13257,13278,13300,13323,13341,13359,13377,13403,13421,13444,13462,13480,13502,13525,13551,13569,13595,13613,13638,13656,13674,13692,13713,13737,13758,13776,13798,13820,13838,13861,13879,13897,13915,13933,13957,13975,13998,14022,14040,14064,14082,14107,14128,14153,14171,14194,14212,14230,14248,14266,14284,14332,14358,14390,14417,14457,14487,14505,14523,14544,14567,14589,14611,14642,14660,14681,14699,14722,14740,14758,14779,14803,14821,14843,14864,14890,14908,14934,14952,14970,14992,15010,15028,15050,15073,15091,15114,15137,15155,15180,15201,15229,15247,15265,15287,15305,15326,15344,15362,15380,15403,15421,15442,15467,15485,15503,15521,15549,15567,15585,15610,15628,15646,15668,15690,15713,15736,15759,15777,15795,15813,15831,15849,15872,15893,15918,15936,15961,15979,16002,16023,16047,16073,16091,16109,16127,16150,16204,16252,16287,16325,16358,16388,16417,16445,16472,16498,16525,16547,16577,16606,16637,16664,16691,16716,16742,16771,16794,16818,16841,16859,16884,16902,16920,16943,16964,16982,17000,17018,17036,17059,17077,17098,17120,17142,17160,17178,17196,17214,17236,17262,17280,17304,17325,17348,17372,17395,17413,17436,17454,17472,17494,17515,17536,17561,17583,17601,17619,17637,17660,17681,17703,17725,17743,17761,17783,17807,17829,17855,17873,17891,17913,17931,17952,17974,17997,18015,18033,18051,18072,18094,18112,18130,18152,18176,18194],{"intervention":97,"totalTrials":98,"cells":99},"Dexamethasone",18,{"EARLY_PHASE1":100,"PHASE1":115,"PHASE2":187,"PHASE3":293,"PHASE4":295,"NA":314},{"trials":101,"activeCount":114},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":25,"conditions":110,"interventions":113},"NCT04895592","Radiosurgery Before Surgery for the Treatment of Brain Metastases","COMPLETED",[89],"2023-09-09","2026-03-04","2021-07-20",[111,112],"Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm",[97],0,{"trials":116,"activeCount":186,"soonestReadout":147},[117,130,142,156,167,177],{"nctId":118,"briefTitle":119,"status":105,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT01038388","A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma",[90],"2021-08-05","2010-01-15",30,[125],"Multiple Myeloma",[127,128,97,129],"Bortezomib","Lenalidomide","Vorinostat",{"nctId":131,"briefTitle":132,"status":105,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"NCT03605719","Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed\u002FRefractory Multiple Myeloma",[90],"2022-10-10","2018-10-24",23,[138],"Recurrent Plasma Cell Myeloma",[140,97,57,141],"Carfilzomib","Pelareorep",{"nctId":143,"briefTitle":144,"status":145,"phases":146,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT04754945","Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","ACTIVE_NOT_RECRUITING",[90],"2026-05-06","2026-07-24","2021-04-28",11,[152],"AL Amyloidosis",[127,154,97,155],"Cyclophosphamide","Isatuximab",{"nctId":157,"briefTitle":158,"status":105,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":166},"NCT02257476","Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors",[90],"2016-11","2014-08",22,[164,165],"Neoplasms","Malignancies",[140,97],{"nctId":168,"briefTitle":169,"status":105,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":19,"conditions":174,"interventions":175},"NCT01549431","Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &\u002For Refractory Multiple Myeloma",[90],"2016-02","2017-04","2012-01",[125],[176,140,97],"Panobinostat",{"nctId":178,"briefTitle":179,"status":105,"phases":180,"primaryCompletion":181,"completion":181,"start":173,"enrollment":182,"conditions":183,"interventions":184},"NCT01485835","A Phase I Study of Ganetespib +\u002F- Bortezomib in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[90],"2015-09",8,[125],[185,127,97],"Ganetespib",1,{"trials":188,"activeCount":292,"soonestReadout":240},[189,202,212,227,236,247,258,270,281],{"nctId":190,"briefTitle":191,"status":145,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT03942224","Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma",[91],"2025-07-31","2026-07-31","2019-07-03",49,[198],"Plasma Cell Myeloma",[127,200,97,201],"Daratumumab","Ixazomib",{"nctId":203,"briefTitle":204,"status":105,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT02765854","Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement",[91],"2023-05-23","2016-09-01",70,[138,210],"Refractory Plasma Cell Myeloma",[97,201,128],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":226},"NCT06132685","Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","RECRUITING",[91],"2027-07-30","2028-07-30","2025-01-09",200,[222,223,224,225],"Low Grade Glioma","Malignant Brain Glioma","Malignant Brain Neoplasm","Meningioma",[97],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":186,"conditions":234,"interventions":235},"NCT01969565","Study of Carfilzomib in Combination w\u002FDexamethasone in Patients w\u002FNewly Diagnosed Multiple Myeloma","TERMINATED",[91],"2014-10","2013-08",[125],[140,97],{"nctId":237,"briefTitle":238,"status":145,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT03756896","Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma",[91],"2025-06-24","2026-06-30","2019-01-25",29,[198],[140,97,246],"Pomalidomide",{"nctId":248,"briefTitle":249,"status":230,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":136,"conditions":253,"interventions":256},"NCT00832338","Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores",[91],"2015-10","2009-04",[254,30,255],"Breast Neoplasms","Cancer of the Breast",[257,97],"Docetaxel with Cytoxan",{"nctId":259,"briefTitle":260,"status":215,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT04776395","Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma",[91],"2027-09-01","2029-09-01","2021-07-09",68,[267],"Smoldering Plasma Cell Myeloma",[97,269],"Iberdomide Hydrochloride",{"nctId":271,"briefTitle":272,"status":230,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},"NCT04352205","Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure",[91],"2024-01-19","2020-05-07",17,[198,278],"Renal Failure",[127,200,97,128,280],"Thalidomide",{"nctId":282,"briefTitle":283,"status":215,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma",[91],"2026-10-21","2027-10-21","2022-07-21",34,[198],[291,97,246],"Belantamab Mafodotin",5,{"trials":294,"activeCount":114},[],{"trials":296,"activeCount":186,"soonestReadout":301},[297],{"nctId":298,"briefTitle":299,"status":215,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT07101445","Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial",[93],"2026-12-31","2027-12-31","2025-09-24",94,[125],[307,97,308,309,310,311,312,313],"Acetaminophen","Famotidine","Loratadine","Methylprednisolone","Montelukast","Motixafortide","Recombinant Granulocyte Colony-Stimulating Factor",{"trials":315,"activeCount":114},[316],{"nctId":317,"briefTitle":318,"status":105,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT01477762","Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)",[94],"2015-07","2011-11",165,[324],"Post Traumatic Stress Disorder",[97],{"intervention":87,"totalTrials":327,"cells":328},2,{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":358},{"trials":330,"activeCount":114},[],{"trials":332,"activeCount":114},[],{"trials":334,"activeCount":114},[],{"trials":336,"activeCount":114},[],{"trials":338,"activeCount":327,"soonestReadout":86},[339,351],{"nctId":340,"briefTitle":341,"status":215,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT06799494","HPV Vaccine Reduced Dose",[93],"2028-09","2025-08-06",100,[347],"HPV",[87,349,350],"Lidocaine","Lorazepam",{"nctId":84,"briefTitle":85,"status":145,"phases":352,"primaryCompletion":86,"completion":353,"start":354,"enrollment":276,"conditions":355,"interventions":356},[93],"2026-05","2021-12-21",[347],[87,357],"Lidocaine injections",{"trials":359,"activeCount":114},[],{"intervention":361,"totalTrials":362,"cells":363},"Standard of Care",3,{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":396},{"trials":365,"activeCount":114},[],{"trials":367,"activeCount":114},[],{"trials":369,"activeCount":114},[],{"trials":371,"activeCount":114},[],{"trials":373,"activeCount":186,"soonestReadout":389},[374,385],{"nctId":375,"briefTitle":376,"status":105,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT03467750","Effect of Ketorolac on Post Adenotonsillectomy Pain",[93],"2023-08-22","2018-07-19",63,[382],"Obstructive Sleep Apnea",[384,361],"Ketorolac",{"nctId":386,"briefTitle":387,"status":215,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":394},"NCT05561725","Perioperative Steroid Dosing on the APR in AIS",[93],"2026-03","2023-01-03",50,[393],"Adolescent Idiopathic Scoliosis (AIS)",[395,361],"Dexamethasone postoperative",{"trials":397,"activeCount":186,"soonestReadout":402},[398],{"nctId":399,"briefTitle":400,"status":215,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},"NCT05999084","Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry",[],"2028-07","2025-03-06",735,[406],"Alzheimer Disease",[408,361],"Anti-amyloid Monoclonal Antibodies",{"intervention":410,"totalTrials":292,"cells":411},"Infliximab",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":466},{"trials":413,"activeCount":114},[],{"trials":415,"activeCount":114},[416],{"nctId":417,"briefTitle":418,"status":105,"phases":419,"completion":420,"conditions":421,"interventions":423},"NCT00228839","GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease",[90],"2006-10",[422],"Graft vs Host Disease",[410],{"trials":425,"activeCount":114},[],{"trials":427,"activeCount":114},[],{"trials":429,"activeCount":186,"soonestReadout":452},[430,439,448,458],{"nctId":431,"briefTitle":432,"status":105,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":438},"NCT00463580","A Study of Infliximab for Treatment Resistant Major Depression",[93],"2011-06","2008-12",60,[21],[410],{"nctId":440,"briefTitle":441,"status":105,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":447},"NCT03006393","Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression",[93],"2020-09-26","2016-08",42,[21],[410],{"nctId":449,"briefTitle":450,"status":215,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT05823532","Anti-Inflammatory Challenge in Schizophrenia",[93],"2028-03","2024-04-18",20,[456],"Schizophrenia",[410],{"nctId":459,"briefTitle":460,"status":230,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":162,"conditions":464,"interventions":465},"NCT03004443","Inflammation-Induced CNS Glutamate Changes in Depression",[93],"2019-11-27","2017-05-15",[21],[410],{"trials":467,"activeCount":114},[],{"intervention":469,"totalTrials":470,"cells":471},"Supplemental insulin",4,{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":522},{"trials":473,"activeCount":114},[],{"trials":475,"activeCount":114},[],{"trials":477,"activeCount":114},[],{"trials":479,"activeCount":114},[],{"trials":481,"activeCount":186,"soonestReadout":389},[482,493,503,514],{"nctId":483,"briefTitle":484,"status":105,"phases":485,"primaryCompletion":486,"completion":486,"start":487,"enrollment":265,"conditions":488,"interventions":489},"NCT02443402","Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery",[93],"2016-12","2016-01",[27],[490,491,492,469,469],"Sitagliptin","Regular Human Insulin","Insulin glargine",{"nctId":494,"briefTitle":495,"status":105,"phases":496,"primaryCompletion":172,"completion":172,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT02741687","Sitagliptin in Non-Diabetic Patients Undergoing General Surgery",[93],"2016-06",80,[500],"Hyperglycemia",[490,469,469,502,502],"Long acting basal insulin",{"nctId":504,"briefTitle":505,"status":145,"phases":506,"primaryCompletion":389,"completion":389,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT04416269","Oral Anti Diabetic Agents in the Hospital",[93],"2020-08-07",255,[510],"Diabetes Mellitus",[512,513,469],"Oral Anti-diabetes Drugs alone","Basal bolus insulin",{"nctId":515,"briefTitle":516,"status":105,"phases":517,"primaryCompletion":518,"completion":518,"start":487,"enrollment":519,"conditions":520,"interventions":521},"NCT02556918","Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery",[93],"2018-11-06",202,[500],[490,491,492,469,469],{"trials":523,"activeCount":114},[],{"intervention":349,"totalTrials":362,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":543,"PHASE4":545,"NA":580},{"trials":527,"activeCount":114},[],{"trials":529,"activeCount":114},[],{"trials":531,"activeCount":114},[532],{"nctId":533,"briefTitle":534,"status":230,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":541},"NCT05378113","Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial",[91],"2023-08-03","2023-05-18",6,[540],"Injection Site Irritation",[542,349],"Ondansetron",{"trials":544,"activeCount":114},[],{"trials":546,"activeCount":186,"soonestReadout":343},[547,551],{"nctId":340,"briefTitle":341,"status":215,"phases":548,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":549,"interventions":550},[93],[347],[87,349,350],{"nctId":552,"briefTitle":553,"status":230,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":561},"NCT04766996","PROUD Study - Preventing Opioid Use Disorders",[93],"2021-12-27","2021-05-17",57,[559,560],"Anesthesia","Opioid Use",[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],"Baby aspirin","Tylenol\u002FAcetaminophen","Pregabalin","Prednisone","Meloxicam","Prilosec","Tramadol","Voltaren","Zofran","Pepcid","Reglan","Versed","Propofol","Ancef","Tranexamic Acid","Decadron","Bupivacaine hydrochloride","Toradol",{"trials":581,"activeCount":114},[],{"intervention":310,"totalTrials":362,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":602,"PHASE4":604,"NA":620},{"trials":585,"activeCount":114},[],{"trials":587,"activeCount":114},[],{"trials":589,"activeCount":114},[590],{"nctId":591,"briefTitle":592,"status":105,"phases":593,"primaryCompletion":487,"completion":487,"start":594,"enrollment":595,"conditions":596,"interventions":598},"NCT01884571","Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)",[91],"2013-10",31,[597],"Amyotrophic Lateral Sclerosis (ALS)",[599,310,565,600,601],"Basiliximab","Tacrolimus","Mycophenolate mofetil",{"trials":603,"activeCount":114},[],{"trials":605,"activeCount":186,"soonestReadout":301},[606,616],{"nctId":607,"briefTitle":608,"status":105,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT05859269","Methylprednisolone Taper After Total Knee Replacement",[93],"2025-07-23","2023-10-16",101,[614],"Knee Arthritis",[310],{"nctId":298,"briefTitle":299,"status":215,"phases":617,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":618,"interventions":619},[93],[125],[307,97,308,309,310,311,312,313],{"trials":621,"activeCount":114},[],{"intervention":623,"totalTrials":327,"cells":624},"Levodopa",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":641,"PHASE4":643,"NA":654},{"trials":626,"activeCount":114},[],{"trials":628,"activeCount":114},[],{"trials":630,"activeCount":114},[631],{"nctId":632,"briefTitle":633,"status":105,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT07444892","Levodopa for Diabetic Retinopathy",[91],"2025-11-17","2022-04-18",230,[639],"Diabetic Retinopathy",[623],{"trials":642,"activeCount":114},[],{"trials":644,"activeCount":186,"soonestReadout":649},[645],{"nctId":646,"briefTitle":647,"status":215,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":498,"conditions":651,"interventions":653},"NCT06234995","Cortical Electrophysiology of Response Inhibition in Parkinson's Disease",[93],"2026-07","2021-08-09",[652],"Parkinson Disease",[623],{"trials":655,"activeCount":114},[],{"intervention":657,"totalTrials":327,"cells":658},"Quadrivalent seasonal influenza vaccine",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":689},{"trials":660,"activeCount":114},[],{"trials":662,"activeCount":114},[],{"trials":664,"activeCount":114},[],{"trials":666,"activeCount":114},[],{"trials":668,"activeCount":186,"soonestReadout":683},[669,679],{"nctId":670,"briefTitle":671,"status":105,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":380,"conditions":675,"interventions":677},"NCT06024096","Systems Biological Assessment of Statin Effect on Vaccine Responses",[93],"2024-12-16","2023-09-20",[676],"Vaccine Response",[678,657],"Atorvastatin",{"nctId":680,"briefTitle":681,"status":215,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":687},"NCT05801978","Durability of Vaccine Responses",[93],"2026-09-30","2023-04-11",66,[676],[688,657],"Live Attenuated Yellow Fever 17D Vaccine",{"trials":690,"activeCount":114},[],{"intervention":308,"totalTrials":327,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":713,"NA":719},{"trials":694,"activeCount":114},[],{"trials":696,"activeCount":114},[],{"trials":698,"activeCount":114},[],{"trials":700,"activeCount":114},[701],{"nctId":702,"briefTitle":703,"status":230,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"enrollment":292,"conditions":707,"interventions":709},"NCT05946551","Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial",[92],"2024-06-24","2024-03-08",[708],"COVID-19",[710,308,711,712],"Cetirizine","Cetirizine Placebo","Famotidine Placebo",{"trials":714,"activeCount":186,"soonestReadout":301},[715],{"nctId":298,"briefTitle":299,"status":215,"phases":716,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":717,"interventions":718},[93],[125],[307,97,308,309,310,311,312,313],{"trials":720,"activeCount":114},[],{"intervention":722,"totalTrials":327,"cells":723},"Carbidopa Levodopa",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":751},{"trials":725,"activeCount":114},[],{"trials":727,"activeCount":114},[],{"trials":729,"activeCount":114},[],{"trials":731,"activeCount":114},[],{"trials":733,"activeCount":186,"soonestReadout":738},[734,743],{"nctId":735,"briefTitle":736,"status":215,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":208,"conditions":740,"interventions":742},"NCT06075771","Dopaminergic Therapy for Anhedonia - 2",[93],"2027-01","2023-11-21",[741,21],"Anhedonia",[722],{"nctId":744,"briefTitle":745,"status":105,"phases":746,"primaryCompletion":747,"completion":747,"start":748,"enrollment":34,"conditions":749,"interventions":750},"NCT04723147","DTA (Dopaminergic Therapy for Anhedonia) Study",[93],"2023-10-11","2021-01-29",[21,741],[722],{"trials":752,"activeCount":114},[],{"intervention":311,"totalTrials":327,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":769,"PHASE4":771,"NA":777},{"trials":756,"activeCount":114},[],{"trials":758,"activeCount":114},[],{"trials":760,"activeCount":114},[761],{"nctId":762,"briefTitle":763,"status":105,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":19,"conditions":767,"interventions":768},"NCT03991988","Montelukast Therapy on Alzheimer's Disease",[91],"2022-11-18","2019-09-25",[406],[311],{"trials":770,"activeCount":114},[],{"trials":772,"activeCount":186,"soonestReadout":301},[773],{"nctId":298,"briefTitle":299,"status":215,"phases":774,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":775,"interventions":776},[93],[125],[307,97,308,309,310,311,312,313],{"trials":778,"activeCount":114},[],{"intervention":780,"totalTrials":186,"cells":781},"Atropine challenge",{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":800},{"trials":783,"activeCount":114},[],{"trials":785,"activeCount":114},[],{"trials":787,"activeCount":114},[],{"trials":789,"activeCount":114},[],{"trials":791,"activeCount":186,"soonestReadout":683},[792],{"nctId":793,"briefTitle":794,"status":215,"phases":795,"primaryCompletion":683,"completion":301,"start":796,"enrollment":498,"conditions":797,"interventions":799},"NCT04641702","Comprehensive Esophageal Diagnostics Study",[93],"2021-03-17",[798],"Achalasia",[780],{"trials":801,"activeCount":114},[],{"intervention":803,"totalTrials":186,"cells":804},"Low Dose Naltrexone",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":825},{"trials":806,"activeCount":114},[],{"trials":808,"activeCount":114},[],{"trials":810,"activeCount":114},[],{"trials":812,"activeCount":114},[],{"trials":814,"activeCount":186,"soonestReadout":819},[815],{"nctId":816,"briefTitle":817,"status":215,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":436,"conditions":821,"interventions":824},"NCT05537935","Low Dose Naltrexone for Pain in Patients With HIV",[93],"2027-06-30","2023-04-28",[822,823],"Human Immunodeficiency Virus","Chronic Neuropathic Pain",[803],{"trials":826,"activeCount":114},[],{"intervention":828,"totalTrials":186,"cells":829},"Influenza Vaccine",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":849},{"trials":831,"activeCount":114},[],{"trials":833,"activeCount":114},[],{"trials":835,"activeCount":114},[],{"trials":837,"activeCount":114},[],{"trials":839,"activeCount":186,"soonestReadout":844},[840],{"nctId":841,"briefTitle":842,"status":215,"phases":843,"primaryCompletion":844,"completion":844,"start":611,"enrollment":845,"conditions":846,"interventions":848},"NCT05616546","Bone Marrow and Peripheral Blood Immune Responses Study",[93],"2029-12",90,[847],"Influenza",[828],{"trials":850,"activeCount":114},[],{"intervention":852,"totalTrials":186,"cells":853},"Insulin",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":862,"NA":874},{"trials":855,"activeCount":114},[],{"trials":857,"activeCount":114},[],{"trials":859,"activeCount":114},[],{"trials":861,"activeCount":114},[],{"trials":863,"activeCount":186,"soonestReadout":868},[864],{"nctId":865,"briefTitle":866,"status":145,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT06699810","Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity",[93],"2026-06","2025-01-23",12,[872],"Ketosis Prone Diabetes",[852],{"trials":875,"activeCount":114},[],{"intervention":512,"totalTrials":186,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":892},{"trials":879,"activeCount":114},[],{"trials":881,"activeCount":114},[],{"trials":883,"activeCount":114},[],{"trials":885,"activeCount":114},[],{"trials":887,"activeCount":186,"soonestReadout":389},[888],{"nctId":504,"briefTitle":505,"status":145,"phases":889,"primaryCompletion":389,"completion":389,"start":507,"enrollment":508,"conditions":890,"interventions":891},[93],[510],[512,513,469],{"trials":893,"activeCount":114},[],{"intervention":513,"totalTrials":186,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":910},{"trials":897,"activeCount":114},[],{"trials":899,"activeCount":114},[],{"trials":901,"activeCount":114},[],{"trials":903,"activeCount":114},[],{"trials":905,"activeCount":186,"soonestReadout":389},[906],{"nctId":504,"briefTitle":505,"status":145,"phases":907,"primaryCompletion":389,"completion":389,"start":507,"enrollment":508,"conditions":908,"interventions":909},[93],[510],[512,513,469],{"trials":911,"activeCount":114},[],{"intervention":357,"totalTrials":186,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":928},{"trials":915,"activeCount":114},[],{"trials":917,"activeCount":114},[],{"trials":919,"activeCount":114},[],{"trials":921,"activeCount":114},[],{"trials":923,"activeCount":186,"soonestReadout":86},[924],{"nctId":84,"briefTitle":85,"status":145,"phases":925,"primaryCompletion":86,"completion":353,"start":354,"enrollment":276,"conditions":926,"interventions":927},[93],[347],[87,357],{"trials":929,"activeCount":114},[],{"intervention":395,"totalTrials":186,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":946},{"trials":933,"activeCount":114},[],{"trials":935,"activeCount":114},[],{"trials":937,"activeCount":114},[],{"trials":939,"activeCount":114},[],{"trials":941,"activeCount":186,"soonestReadout":389},[942],{"nctId":386,"briefTitle":387,"status":215,"phases":943,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":944,"interventions":945},[93],[393],[395,361],{"trials":947,"activeCount":114},[],{"intervention":949,"totalTrials":186,"cells":950},"Trumenba",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":972},{"trials":952,"activeCount":114},[],{"trials":954,"activeCount":114},[],{"trials":956,"activeCount":114},[],{"trials":958,"activeCount":114},[],{"trials":960,"activeCount":186,"soonestReadout":965},[961],{"nctId":962,"briefTitle":963,"status":215,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT07197762","MenB-FHbp or MenACWY-TT\u002FMenB-FHbp Vaccine in MenB-4C Primed Young Adults",[93],"2026-12","2025-11-04",125,[969],"Neisseria Meningitidis",[949,971],"PENBRAYA",{"trials":973,"activeCount":114},[],{"intervention":971,"totalTrials":186,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":990},{"trials":977,"activeCount":114},[],{"trials":979,"activeCount":114},[],{"trials":981,"activeCount":114},[],{"trials":983,"activeCount":114},[],{"trials":985,"activeCount":186,"soonestReadout":965},[986],{"nctId":962,"briefTitle":963,"status":215,"phases":987,"primaryCompletion":965,"completion":965,"start":966,"enrollment":967,"conditions":988,"interventions":989},[93],[969],[949,971],{"trials":991,"activeCount":114},[],{"intervention":993,"totalTrials":186,"cells":994},"Doxycycline monohydrate 200 mg",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1014},{"trials":996,"activeCount":114},[],{"trials":998,"activeCount":114},[],{"trials":1000,"activeCount":114},[],{"trials":1002,"activeCount":114},[],{"trials":1004,"activeCount":186,"soonestReadout":1009},[1005],{"nctId":1006,"briefTitle":1007,"status":215,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":220,"conditions":1011,"interventions":1013},"NCT07215325","Got Doxy- 'Flipping the Script' on STI PEP",[93],"2029-04-13","2025-10-13",[1012],"Sexually Transmitted Infections (STI)",[993],{"trials":1015,"activeCount":114},[],{"intervention":307,"totalTrials":186,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1032},{"trials":1019,"activeCount":114},[],{"trials":1021,"activeCount":114},[],{"trials":1023,"activeCount":114},[],{"trials":1025,"activeCount":114},[],{"trials":1027,"activeCount":186,"soonestReadout":301},[1028],{"nctId":298,"briefTitle":299,"status":215,"phases":1029,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":1030,"interventions":1031},[93],[125],[307,97,308,309,310,311,312,313],{"trials":1033,"activeCount":114},[],{"intervention":309,"totalTrials":186,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1044,"NA":1050},{"trials":1037,"activeCount":114},[],{"trials":1039,"activeCount":114},[],{"trials":1041,"activeCount":114},[],{"trials":1043,"activeCount":114},[],{"trials":1045,"activeCount":186,"soonestReadout":301},[1046],{"nctId":298,"briefTitle":299,"status":215,"phases":1047,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":1048,"interventions":1049},[93],[125],[307,97,308,309,310,311,312,313],{"trials":1051,"activeCount":114},[],{"intervention":312,"totalTrials":186,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1068},{"trials":1055,"activeCount":114},[],{"trials":1057,"activeCount":114},[],{"trials":1059,"activeCount":114},[],{"trials":1061,"activeCount":114},[],{"trials":1063,"activeCount":186,"soonestReadout":301},[1064],{"nctId":298,"briefTitle":299,"status":215,"phases":1065,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":1066,"interventions":1067},[93],[125],[307,97,308,309,310,311,312,313],{"trials":1069,"activeCount":114},[],{"intervention":313,"totalTrials":186,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1086},{"trials":1073,"activeCount":114},[],{"trials":1075,"activeCount":114},[],{"trials":1077,"activeCount":114},[],{"trials":1079,"activeCount":114},[],{"trials":1081,"activeCount":186,"soonestReadout":301},[1082],{"nctId":298,"briefTitle":299,"status":215,"phases":1083,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":1084,"interventions":1085},[93],[125],[307,97,308,309,310,311,312,313],{"trials":1087,"activeCount":114},[],{"intervention":1089,"totalTrials":186,"cells":1090},"Triamcinolone injection to the shoulder, elbow, wrist, or hand",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1114},{"trials":1092,"activeCount":114},[],{"trials":1094,"activeCount":114},[],{"trials":1096,"activeCount":114},[],{"trials":1098,"activeCount":114},[],{"trials":1100,"activeCount":186,"soonestReadout":1105},[1101],{"nctId":1102,"briefTitle":1103,"status":215,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":1107,"conditions":1108,"interventions":1112},"NCT05292339","Ketorolac in Upper Extremity Tendinopathy and Arthropathy",[93],"2027-07","2023-01-31",160,[1109,1110,1111],"Osteoarthritis","Tendinopathy","Arthropathy",[1089,1113],"Ketorolac injection to the shoulder, elbow, wrist, or hand",{"trials":1115,"activeCount":114},[],{"intervention":1113,"totalTrials":186,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1132},{"trials":1119,"activeCount":114},[],{"trials":1121,"activeCount":114},[],{"trials":1123,"activeCount":114},[],{"trials":1125,"activeCount":114},[],{"trials":1127,"activeCount":186,"soonestReadout":1105},[1128],{"nctId":1102,"briefTitle":1103,"status":215,"phases":1129,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":1107,"conditions":1130,"interventions":1131},[93],[1109,1110,1111],[1089,1113],{"trials":1133,"activeCount":114},[],{"intervention":1135,"totalTrials":186,"cells":1136},"Botulinum toxin",{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1157},{"trials":1138,"activeCount":114},[],{"trials":1140,"activeCount":114},[],{"trials":1142,"activeCount":114},[],{"trials":1144,"activeCount":114},[],{"trials":1146,"activeCount":186,"soonestReadout":1151},[1147],{"nctId":1148,"briefTitle":1149,"status":215,"phases":1150,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1156},"NCT05125029","Botulinum Toxin in Raynaud's Phenomenon",[93],"2025-12","2022-02-10",36,[1155],"Raynaud Phenomenon",[1135],{"trials":1158,"activeCount":114},[],{"intervention":1160,"totalTrials":186,"cells":1161},"Prophylactic Transfusion Intervention group: Transfusion",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1170,"NA":1181},{"trials":1163,"activeCount":114},[],{"trials":1165,"activeCount":114},[],{"trials":1167,"activeCount":114},[],{"trials":1169,"activeCount":114},[],{"trials":1171,"activeCount":186,"soonestReadout":1176},[1172],{"nctId":1173,"briefTitle":1174,"status":215,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":1177,"enrollment":391,"conditions":1178,"interventions":1180},"NCT06979492","Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease",[93],"2028-05","2026-04",[24,1179],"Pregnancy Related",[1160],{"trials":1182,"activeCount":114},[],{"intervention":688,"totalTrials":186,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1199},{"trials":1186,"activeCount":114},[],{"trials":1188,"activeCount":114},[],{"trials":1190,"activeCount":114},[],{"trials":1192,"activeCount":114},[],{"trials":1194,"activeCount":186,"soonestReadout":683},[1195],{"nctId":680,"briefTitle":681,"status":215,"phases":1196,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":1197,"interventions":1198},[93],[676],[688,657],{"trials":1200,"activeCount":114},[],{"intervention":1202,"totalTrials":186,"cells":1203},"Moderna RSV vaccine",{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1222},{"trials":1205,"activeCount":114},[],{"trials":1207,"activeCount":114},[],{"trials":1209,"activeCount":114},[],{"trials":1211,"activeCount":114},[],{"trials":1213,"activeCount":186,"soonestReadout":649},[1214],{"nctId":1215,"briefTitle":1216,"status":145,"phases":1217,"primaryCompletion":649,"completion":649,"start":1010,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT07185399","Systems Biological Analysis of Immune Responses to RSV Vaccine",[93],14,[1220],"Respiratory Syncytial Virus (RSV)",[1202],{"trials":1223,"activeCount":114},[],{"intervention":1225,"totalTrials":186,"cells":1226},"10 mg IV dexamethasone & 6 day oral methylprednisolone taper",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1248},{"trials":1228,"activeCount":114},[],{"trials":1230,"activeCount":114},[],{"trials":1232,"activeCount":114},[],{"trials":1234,"activeCount":114},[],{"trials":1236,"activeCount":186,"soonestReadout":1242},[1237],{"nctId":1238,"briefTitle":1239,"status":1240,"phases":1241,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1247},"NCT03661645","Post-operative Methylprednisolone Taper Course for Orthopedic Surgery","ENROLLING_BY_INVITATION",[93],"2029-01","2018-09-07",500,[1246],"Orthopedic Surgeries",[1225],{"trials":1249,"activeCount":114},[],{"intervention":1251,"totalTrials":362,"cells":1252},"Glycerin Suppository",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1259,"PHASE4":1273,"NA":1285},{"trials":1254,"activeCount":114},[],{"trials":1256,"activeCount":114},[],{"trials":1258,"activeCount":114},[],{"trials":1260,"activeCount":114},[1261],{"nctId":1262,"briefTitle":1263,"status":105,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1271},"NCT03197922","Treatment of Encopresis in Children With Autism Spectrum Disorders",[92],"2022-11-17","2017-10-25",117,[1269,1270],"Encopresis","Autism Spectrum Disorder",[1251,1272],"Treatment as Usual",{"trials":1274,"activeCount":186,"soonestReadout":1280},[1275],{"nctId":1276,"briefTitle":1277,"status":1278,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":353,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT07226739","Comprehensive Toileting Program","NOT_YET_RECRUITING",[93],"2031-01",150,[1269,1283],"ASD",[1251],{"trials":1286,"activeCount":114},[1287],{"nctId":1288,"briefTitle":1289,"status":105,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":162,"conditions":1293,"interventions":1295},"NCT02383758","An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders",[94],"2017-01-01","2015-02-01",[1269,1294],"Autistic Disorder",[1251,1296,1297],"Bisacodyl suppository","Senna",{"intervention":350,"totalTrials":327,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1314},{"trials":1301,"activeCount":114},[],{"trials":1303,"activeCount":114},[],{"trials":1305,"activeCount":114},[],{"trials":1307,"activeCount":114},[],{"trials":1309,"activeCount":186,"soonestReadout":343},[1310],{"nctId":340,"briefTitle":341,"status":215,"phases":1311,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":1312,"interventions":1313},[93],[347],[87,349,350],{"trials":1315,"activeCount":114},[1316],{"nctId":1317,"briefTitle":1318,"status":105,"phases":1319,"primaryCompletion":160,"completion":160,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},"NCT01566539","Biological Basis of Individual Variation in Social Cooperation",[94],"2008-04",707,[1323],"Healthy",[1325,1326,1327,1328,350],"Intranasal Oxytocin (OT) 24 IU","Intranasal Vasopressin","Intranasal Placebo","Intranasal Vasopressin (AVP) 40 IU",{"intervention":1330,"totalTrials":327,"cells":1331},"Oxycodone 5 mg",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1362,"NA":1364},{"trials":1333,"activeCount":114},[],{"trials":1335,"activeCount":114},[],{"trials":1337,"activeCount":114},[],{"trials":1339,"activeCount":327,"soonestReadout":1344},[1340,1351],{"nctId":1341,"briefTitle":1342,"status":215,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1347,"interventions":1350},"NCT07348627","Opioid-Sparing Joint Replacement",[92],"2028-08","2026-03-19",120,[1348,1349],"Pain Management","Opioid Consumption",[1330],{"nctId":1352,"briefTitle":1353,"status":215,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":498,"conditions":1357,"interventions":1360},"NCT04659317","Opioid-Free Orthopaedics",[92],"2028-12","2020-12-11",[1358,1359],"Pain","Pain, Postoperative",[1361],"Oxycodone 5 mg Oral",{"trials":1363,"activeCount":114},[],{"trials":1365,"activeCount":114},[],{"intervention":1367,"totalTrials":327,"cells":1368},"Leuprolide",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1395,"PHASE4":1410,"NA":1412},{"trials":1370,"activeCount":114},[],{"trials":1372,"activeCount":114},[],{"trials":1374,"activeCount":186,"soonestReadout":1379},[1375],{"nctId":1376,"briefTitle":1377,"status":145,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":51,"enrollment":304,"conditions":1381,"interventions":1393},"NCT05320406","RElugolix VErsus LeUprolide Cardiac Trial",[91],"2025-01-30","2026-10-30",[1382,1383,1384,1385,1386,1387,1388,1389,1390,1391,1392],"Biochemically Recurrent Prostate Carcinoma","Localized Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[1367,1394],"Relugolix",{"trials":1396,"activeCount":186,"soonestReadout":1401},[1397],{"nctId":1398,"briefTitle":1399,"status":215,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1407},"NCT06650579","REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial",[92],"2029-07-01","2025-01-31",72,[1405,1389,1406],"Recurrent Prostate Carcinoma","Stage IVA Prostate Cancer AJCC v8",[1408,1409,1367,565,1394],"Abiraterone Acetate","Bicalutamide",{"trials":1411,"activeCount":114},[],{"trials":1413,"activeCount":114},[],{"intervention":1394,"totalTrials":327,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1426,"PHASE4":1432,"NA":1434},{"trials":1417,"activeCount":114},[],{"trials":1419,"activeCount":114},[],{"trials":1421,"activeCount":186,"soonestReadout":1379},[1422],{"nctId":1376,"briefTitle":1377,"status":145,"phases":1423,"primaryCompletion":1379,"completion":1380,"start":51,"enrollment":304,"conditions":1424,"interventions":1425},[91],[1382,1383,1384,1385,1386,1387,1388,1389,1390,1391,1392],[1367,1394],{"trials":1427,"activeCount":186,"soonestReadout":1401},[1428],{"nctId":1398,"briefTitle":1399,"status":215,"phases":1429,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1430,"interventions":1431},[92],[1405,1389,1406],[1408,1409,1367,565,1394],{"trials":1433,"activeCount":114},[],{"trials":1435,"activeCount":114},[],{"intervention":1437,"totalTrials":327,"cells":1438},"Emicizumab",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1457,"NA":1459},{"trials":1440,"activeCount":114},[],{"trials":1442,"activeCount":114},[],{"trials":1444,"activeCount":114},[],{"trials":1446,"activeCount":186,"soonestReadout":1451},[1447],{"nctId":1448,"briefTitle":1449,"status":215,"phases":1450,"primaryCompletion":1451,"completion":1451,"start":868,"enrollment":292,"conditions":1452,"interventions":1454},"NCT04563520","SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis",[92],"2027-03",[1453],"Hemophilia A",[1437,1455,1456],"FEIBA","rFVIIa",{"trials":1458,"activeCount":114},[],{"trials":1460,"activeCount":186,"soonestReadout":1355},[1461],{"nctId":1462,"briefTitle":1463,"status":215,"phases":1464,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":1467,"interventions":1468},"NCT04023019","Treatment of Hemophilia A Patients With FVIII Inhibitors",[],"2029-06","2020-03-17",[1453],[1469,1470,1471,1437,1472,1473],"Nuwiq","Octanate","Wilate","Recombinant factor VIIa","Activated prothrombin complex concentrate",{"intervention":565,"totalTrials":292,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1491,"PHASE3":1511,"PHASE4":1517,"NA":1523},{"trials":1477,"activeCount":114},[],{"trials":1479,"activeCount":114},[1480],{"nctId":1481,"briefTitle":1482,"status":230,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":186,"conditions":1486,"interventions":1488},"NCT05035862","Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma",[90],"2022-12-16","2022-03-16",[1487],"Asthma",[1489,1490,565],"Albuterol Sulfate","Interferon gamma-primed mesenchymal stromal cells",{"trials":1492,"activeCount":114},[1493,1507],{"nctId":1494,"briefTitle":1495,"status":105,"phases":1496,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1503},"NCT00634179","A Phase I\u002FII Trial of VR-CHOP in Lymphoma Patients",[90,91],"2015-11","2008-02",37,[1501,1502],"Lymphoma, B-Cell","Follicular Lymphoma",[127,1504,1505,154,1506,565],"Rituximab","Doxorubicin","Vincristine",{"nctId":591,"briefTitle":592,"status":105,"phases":1508,"primaryCompletion":487,"completion":487,"start":594,"enrollment":595,"conditions":1509,"interventions":1510},[91],[597],[599,310,565,600,601],{"trials":1512,"activeCount":186,"soonestReadout":1401},[1513],{"nctId":1398,"briefTitle":1399,"status":215,"phases":1514,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1515,"interventions":1516},[92],[1405,1389,1406],[1408,1409,1367,565,1394],{"trials":1518,"activeCount":114},[1519],{"nctId":552,"briefTitle":553,"status":230,"phases":1520,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":1521,"interventions":1522},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":1524,"activeCount":114},[],{"intervention":1526,"totalTrials":327,"cells":1527},"Exparel",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1549,"NA":1559},{"trials":1529,"activeCount":114},[],{"trials":1531,"activeCount":114},[],{"trials":1533,"activeCount":114},[],{"trials":1535,"activeCount":186,"soonestReadout":1540},[1536],{"nctId":1537,"briefTitle":1538,"status":215,"phases":1539,"primaryCompletion":1540,"completion":1540,"start":635,"enrollment":1541,"conditions":1542,"interventions":1545},"NCT07212114","Efficacy of EXPAREL vs. Bupivacaine",[92],"2029-08",104,[1543,1544],"Total Ankle Arthroplasty","Postsurgical Analgesia",[1546,1547,1548],"EXPAREL","0.25% bupivacaine (HCl): 50 ml","0.25% bupivacaine (HCl): 30 ml",{"trials":1550,"activeCount":114},[1551],{"nctId":1552,"briefTitle":1553,"status":105,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":161,"enrollment":391,"conditions":1556,"interventions":1558},"NCT02189317","Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction",[93],"2015-03",[1557],"Anterior Cruciate Ligament Rupture",[1526],{"trials":1560,"activeCount":114},[],{"intervention":1562,"totalTrials":186,"cells":1563},"Zolpidem",{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1580,"NA":1582},{"trials":1565,"activeCount":114},[],{"trials":1567,"activeCount":114},[],{"trials":1569,"activeCount":114},[],{"trials":1571,"activeCount":186,"soonestReadout":649},[1572],{"nctId":1573,"briefTitle":1574,"status":1278,"phases":1575,"primaryCompletion":649,"completion":649,"start":868,"enrollment":123,"conditions":1576,"interventions":1579},"NCT07336277","Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients",[92],[1577,1578],"Orthopedic Trauma","Sleep Quality",[1562],{"trials":1581,"activeCount":114},[],{"trials":1583,"activeCount":114},[],{"intervention":1585,"totalTrials":186,"cells":1586},"[F-18]Fallypride",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1607,"NA":1609},{"trials":1588,"activeCount":114},[],{"trials":1590,"activeCount":114},[],{"trials":1592,"activeCount":114},[],{"trials":1594,"activeCount":186,"soonestReadout":1599},[1595],{"nctId":1596,"briefTitle":1597,"status":215,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1606},"NCT05834478","Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3",[92],"2027-02","2027-04","2024-02-20",103,[1604,1605,560],"Withdrawal Symptoms","Opioid Use Disorder",[1585],{"trials":1608,"activeCount":114},[],{"trials":1610,"activeCount":114},[],{"intervention":1455,"totalTrials":186,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":114},[],{"trials":1616,"activeCount":114},[],{"trials":1618,"activeCount":114},[],{"trials":1620,"activeCount":186,"soonestReadout":1451},[1621],{"nctId":1448,"briefTitle":1449,"status":215,"phases":1622,"primaryCompletion":1451,"completion":1451,"start":868,"enrollment":292,"conditions":1623,"interventions":1624},[92],[1453],[1437,1455,1456],{"trials":1626,"activeCount":114},[],{"trials":1628,"activeCount":114},[],{"intervention":1456,"totalTrials":186,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":114},[],{"trials":1634,"activeCount":114},[],{"trials":1636,"activeCount":114},[],{"trials":1638,"activeCount":186,"soonestReadout":1451},[1639],{"nctId":1448,"briefTitle":1449,"status":215,"phases":1640,"primaryCompletion":1451,"completion":1451,"start":868,"enrollment":292,"conditions":1641,"interventions":1642},[92],[1453],[1437,1455,1456],{"trials":1644,"activeCount":114},[],{"trials":1646,"activeCount":114},[],{"intervention":1547,"totalTrials":186,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1661,"NA":1663},{"trials":1650,"activeCount":114},[],{"trials":1652,"activeCount":114},[],{"trials":1654,"activeCount":114},[],{"trials":1656,"activeCount":186,"soonestReadout":1540},[1657],{"nctId":1537,"briefTitle":1538,"status":215,"phases":1658,"primaryCompletion":1540,"completion":1540,"start":635,"enrollment":1541,"conditions":1659,"interventions":1660},[92],[1543,1544],[1546,1547,1548],{"trials":1662,"activeCount":114},[],{"trials":1664,"activeCount":114},[],{"intervention":1548,"totalTrials":186,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1679,"NA":1681},{"trials":1668,"activeCount":114},[],{"trials":1670,"activeCount":114},[],{"trials":1672,"activeCount":114},[],{"trials":1674,"activeCount":186,"soonestReadout":1540},[1675],{"nctId":1537,"briefTitle":1538,"status":215,"phases":1676,"primaryCompletion":1540,"completion":1540,"start":635,"enrollment":1541,"conditions":1677,"interventions":1678},[92],[1543,1544],[1546,1547,1548],{"trials":1680,"activeCount":114},[],{"trials":1682,"activeCount":114},[],{"intervention":1684,"totalTrials":186,"cells":1685},"Semaglutide",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1702,"NA":1704},{"trials":1687,"activeCount":114},[],{"trials":1689,"activeCount":114},[],{"trials":1691,"activeCount":114},[],{"trials":1693,"activeCount":186,"soonestReadout":1698},[1694],{"nctId":1695,"briefTitle":1696,"status":1278,"phases":1697,"primaryCompletion":1698,"completion":1698,"start":1177,"enrollment":454,"conditions":1699,"interventions":1701},"NCT07428746","Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes",[92],"2028-11",[1700],"Diabetes Mellitus, Type 2",[1684],{"trials":1703,"activeCount":114},[],{"trials":1705,"activeCount":114},[],{"intervention":1408,"totalTrials":186,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1714,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":114},[],{"trials":1711,"activeCount":114},[],{"trials":1713,"activeCount":114},[],{"trials":1715,"activeCount":186,"soonestReadout":1401},[1716],{"nctId":1398,"briefTitle":1399,"status":215,"phases":1717,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1718,"interventions":1719},[92],[1405,1389,1406],[1408,1409,1367,565,1394],{"trials":1721,"activeCount":114},[],{"trials":1723,"activeCount":114},[],{"intervention":1409,"totalTrials":186,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":114},[],{"trials":1729,"activeCount":114},[],{"trials":1731,"activeCount":114},[],{"trials":1733,"activeCount":186,"soonestReadout":1401},[1734],{"nctId":1398,"briefTitle":1399,"status":215,"phases":1735,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1736,"interventions":1737},[92],[1405,1389,1406],[1408,1409,1367,565,1394],{"trials":1739,"activeCount":114},[],{"trials":1741,"activeCount":114},[],{"intervention":1743,"totalTrials":34,"cells":1744},"Pembrolizumab",{"EARLY_PHASE1":1745,"PHASE1":1762,"PHASE2":1885,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":1746,"activeCount":186,"soonestReadout":1751},[1747],{"nctId":1748,"briefTitle":1749,"status":215,"phases":1750,"primaryCompletion":1751,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1760},"NCT05493566","Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer",[89],"2027-01-07","2028-01-07","2022-11-01",15,[1756,1757,1758,1759],"Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[1761,1743],"Aldesleukin",{"trials":1763,"activeCount":327,"soonestReadout":301},[1764,1789,1823,1858,1873],{"nctId":1765,"briefTitle":1766,"status":105,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1787},"NCT03095781","Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer",[90],"2021-06-10","2017-07-07",47,[1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784,1785,1786],"Colorectal Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Recurrent Colorectal Carcinoma","Recurrent Pancreatic Carcinoma","Stage III Colorectal Cancer","Stage III Pancreatic Cancer","Stage IIIA Colorectal Cancer","Stage IIIB Colorectal Cancer","Stage IV Colorectal Cancer","Stage IV Pancreatic Cancer","Stage IVA Colorectal Cancer","Stage IVA Pancreatic Cancer","Stage IVB Colorectal Cancer","Stage IVB Pancreatic Cancer","Unresectable Pancreatic Carcinoma",[1788,1743],"XL888",{"nctId":1790,"briefTitle":1791,"status":215,"phases":1792,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1821},"NCT06868433","TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and\u002For Metastatic Head and Neck Squamous Cell Cancer",[90],"2028-01-31","2028-12-31","2025-05-08",40,[1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Nasopharyngeal Squamous Cell Carcinoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma","Metastatic Sinonasal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Nasopharyngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Sinonasal Squamous Cell Carcinoma","Squamous Cell Carcinoma of Unknown Primary","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Sinonasal Cancer AJCC v8",[1822,1743],"Autologous Tumor Membrane Vesicles Vaccine",{"nctId":1824,"briefTitle":1825,"status":215,"phases":1826,"primaryCompletion":301,"completion":301,"start":1827,"enrollment":98,"conditions":1828,"interventions":1856},"NCT06324240","Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer",[90],"2025-12-02",[1829,1830,1831,1832,1833,1834,1835,1836,1837,1838,1839,1840,1841,1842,1843,1844,1845,1846,1847,1848,1849,1850,1851,1852,1853,1854,1855],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Early Stage Triple-Negative Breast Carcinoma","Locally Advanced Triple-Negative Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Recurrent Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma",[67,1743,1857],"Vaccine Therapy",{"nctId":1859,"briefTitle":1860,"status":105,"phases":1861,"primaryCompletion":1862,"completion":1863,"start":1864,"enrollment":28,"conditions":1865,"interventions":1872},"NCT02858869","Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases",[90],"2020-11-19","2023-10-28","2016-10-04",[111,1866,1867,1868,1869,1870,1871],"Metastatic Melanoma","Mucosal Melanoma","Ocular Melanoma","Stage IV Non-Small Cell Lung Cancer","Stage IV Skin Melanoma","Melanoma of Unknown Primary",[1743],{"nctId":1874,"briefTitle":1875,"status":230,"phases":1876,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":186,"conditions":1879,"interventions":1884},"NCT05341349","Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases",[90],"2024-05-31","2022-10-13",[1880,1871,111,1866,1881,1882,1883],"Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Mucosal Melanoma","Metastatic Ocular Melanoma","Pathologic Stage IV Cutaneous Melanoma AJCC v8",[67,57,1743],{"trials":1886,"activeCount":2075,"soonestReadout":47},[1887,1898,1923,1939,1950,1960,1970,1983,2008,2019,2028,2041,2056],{"nctId":1888,"briefTitle":1889,"status":1278,"phases":1890,"primaryCompletion":1891,"completion":1892,"start":1893,"enrollment":1499,"conditions":1894,"interventions":1896},"NCT05741164","Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer",[91],"2028-06-30","2028-11-30","2026-03-30",[1835,1839,1842,1895,1855],"Refractory Triple-Negative Breast Carcinoma",[1743,1897],"Propranolol",{"nctId":45,"briefTitle":46,"status":145,"phases":1899,"primaryCompletion":47,"completion":1900,"start":1901,"enrollment":1153,"conditions":1902,"interventions":1922},[91],"2026-10-29","2018-09-18",[1903,1904,1806,1807,1808,1810,1811,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1915,1916,1917,1918,1919,1920,1921],"Metastatic Head and Neck Carcinoma","Paranasal Sinus Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Unresectable Head and Neck Squamous Cell Carcinoma",[43,1743],{"nctId":1924,"briefTitle":1925,"status":215,"phases":1926,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":1930,"conditions":1931,"interventions":1937},"NCT06006013","Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer",[91],"2027-12-16","2028-12-16","2025-01-15",21,[1932,1933,1934,1935,1936],"Locally Advanced Adrenal Cortex Carcinoma","Adrenal Cortical Carcinoma","Stage III Adrenal Cortex Carcinoma","Stage IV Adrenal Cortex Carcinoma AJCC v8","Unresectable Adrenal Cortex Carcinoma",[1743,1938],"Cabozantinib S-malate",{"nctId":1940,"briefTitle":1941,"status":215,"phases":1942,"primaryCompletion":302,"completion":1794,"start":1943,"enrollment":22,"conditions":1944,"interventions":1948},"NCT06636734","Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial",[91],"2024-12-09",[1798,1945,1799,1800,1801,1802,1803,1804,1946,1806,1807,1808,1809,1810,1811,1947,1815,1816,1817,1818,1819,1820],"Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary","Metastatic Paranasal Sinus Squamous Cell Carcinoma","Recurrent Paranasal Sinus Squamous Cell Carcinoma",[1949,1743],"Lovastatin",{"nctId":1951,"briefTitle":1952,"status":105,"phases":1953,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":150,"conditions":1956,"interventions":1959},"NCT02964559","Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer",[91],"2021-05-18","2017-01-27",[1957,1958],"Recurrent Skin Carcinoma","Skin Squamous Cell Carcinoma",[1743],{"nctId":79,"briefTitle":80,"status":145,"phases":1961,"primaryCompletion":81,"completion":1962,"start":1963,"enrollment":98,"conditions":1964,"interventions":1968},[91],"2026-12-11","2020-06-22",[1965,1966,1967],"Kidney Cancer","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8",[82,1969,1743],"Lenvatinib Mesylate",{"nctId":1971,"briefTitle":1972,"status":215,"phases":1973,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":243,"conditions":1977,"interventions":1978},"NCT06492759","High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer",[91],"2027-02-12","2028-02-13","2025-10-22",[1839,1842],[1743,1979,1980,1981,1982],"Nab-paclitaxel","Paclitaxel","Carboplatin","Gemcitabine",{"nctId":1984,"briefTitle":1985,"status":145,"phases":1986,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":538,"conditions":1990,"interventions":2005},"NCT04848519","Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma",[91],"2025-10-15","2026-12-04","2021-05-20",[1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004],"Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urethral Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8",[1743,2006,57,2007],"Propranolol Hydrochloride","Avelumab",{"nctId":2009,"briefTitle":2010,"status":105,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":28,"conditions":2014,"interventions":2018},"NCT03267888","Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma",[90,91],"2022-09-02","2018-05-29",[2015,2016,2017,138,210],"ISS Stage I Plasma Cell Myeloma","ISS Stage II Plasma Cell Myeloma","ISS Stage III Plasma Cell Myeloma",[1743],{"nctId":2020,"briefTitle":2021,"status":2022,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":114,"conditions":2026,"interventions":2027},"NCT05204160","Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy","WITHDRAWN",[91],"2024-02-27","2022-04-11",[198],[1743],{"nctId":2029,"briefTitle":2030,"status":145,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":123,"conditions":2035,"interventions":2038},"NCT04340882","Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1\u002FPD-L1 Blockade",[91],"2026-09-02","2030-09-30","2020-06-05",[2036,2037,1757,1758,1759],"Metastatic Non-Small Lung Cell Cancer","Recurrent Non-Small Lung Cell Cancer",[2039,1743,2040],"Docetaxel","Ramucirumab",{"nctId":2042,"briefTitle":2043,"status":215,"phases":2044,"primaryCompletion":2045,"completion":2046,"start":2047,"enrollment":454,"conditions":2048,"interventions":2052},"NCT06731270","Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy",[91],"2027-01-01","2028-01-01","2025-04-09",[2049,2050,2051,1757],"Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8",[2053,2054,2055,57,1743],"Atezolizumab","Cemiplimab","Diclofenac Potassium",{"nctId":2057,"briefTitle":2058,"status":215,"phases":2059,"primaryCompletion":2060,"completion":1927,"start":2061,"enrollment":28,"conditions":2062,"interventions":2073},"NCT05756569","Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",[91],"2026-12-16","2023-09-26",[2063,2064,2065,2066,2067,2068,2069,2001,2070,2071,2072],"Bladder Squamous Cell Carcinoma","Locally Advanced Bladder Carcinoma","Malignant Renal Pelvis Neoplasm","Malignant Ureter Neoplasm","Malignant Urethral Neoplasm","Metastatic Bladder Carcinoma","Stage III Bladder Cancer AJCC v8","Unresectable Bladder Carcinoma","Urachal Adenocarcinoma","Bladder Adenocarcinoma",[2074,1743],"Enfortumab Vedotin",10,{"trials":2077,"activeCount":114},[],{"trials":2079,"activeCount":114},[],{"trials":2081,"activeCount":114},[],{"intervention":57,"totalTrials":276,"cells":2083},{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2148,"PHASE3":2270,"PHASE4":2272,"NA":2274},{"trials":2085,"activeCount":114},[],{"trials":2087,"activeCount":327,"soonestReadout":66},[2088,2092,2105,2116,2120,2130],{"nctId":131,"briefTitle":132,"status":105,"phases":2089,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":2090,"interventions":2091},[90],[138],[140,97,57,141],{"nctId":2093,"briefTitle":2094,"status":2022,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":114,"conditions":2098,"interventions":2103},"NCT03575234","Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer",[90],"2026-01-31","2020-07-01",[2099,2100,2101,1911,2102],"Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",[154,2104,57],"IRX-2",{"nctId":64,"briefTitle":65,"status":145,"phases":2106,"primaryCompletion":66,"completion":2107,"start":2108,"enrollment":2109,"conditions":2110,"interventions":2114},[90],"2032-12-15","2018-12-13",41,[2111,2112,2113],"Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8",[67,57,2115],"VX15\u002F2503",{"nctId":1874,"briefTitle":1875,"status":230,"phases":2117,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":186,"conditions":2118,"interventions":2119},[90],[1880,1871,111,1866,1881,1882,1883],[67,57,1743],{"nctId":2121,"briefTitle":2122,"status":215,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":391,"conditions":2127,"interventions":2129},"NCT03690986","VX15\u002F2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer",[90],"2026-06-04","2027-11-30","2018-11-01",[2128],"Squamous Cell Carcinoma of the Head and Neck",[2115,67,57],{"nctId":2131,"briefTitle":2132,"status":105,"phases":2133,"primaryCompletion":2134,"completion":2134,"start":2135,"enrollment":2075,"conditions":2136,"interventions":2146},"NCT03373188","VX15\u002F2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer",[90],"2021-10-28","2017-12-15",[2137,1772,2138,2139,2140,2141,2142,2143,2144,2145,1777,1780,1782,1784],"Colon Carcinoma Metastatic in the Liver","Pancreatic Adenocarcinoma","Resectable Pancreatic Carcinoma","Stage I Pancreatic Cancer","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage II Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer",[2147,67,57],"Anti-SEMA4D Monoclonal Antibody VX15\u002F2503",{"trials":2149,"activeCount":538,"soonestReadout":56},[2150,2164,2173,2186,2196,2209,2213,2224,2237,2250,2266],{"nctId":2151,"briefTitle":2152,"status":105,"phases":2153,"primaryCompletion":2154,"completion":2155,"start":2156,"enrollment":243,"conditions":2157,"interventions":2162},"NCT03800602","Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer",[91],"2020-09-04","2021-09-04","2019-01-15",[1772,2158,2159,1780,1782,1784,2160,2161],"Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Colorectal Carcinoma","Stage IVC Colorectal Cancer","Colorectal Cancer Metastatic",[2163,57],"Metformin",{"nctId":2165,"briefTitle":2166,"status":2022,"phases":2167,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":114,"conditions":2170,"interventions":2172},"NCT03121417","Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer",[91],"2019-03-09","2017-07-21",[2171,1869],"Recurrent Non-Small Cell Lung Carcinoma",[57],{"nctId":54,"briefTitle":55,"status":145,"phases":2174,"primaryCompletion":56,"completion":241,"start":2175,"enrollment":1754,"conditions":2176,"interventions":2184},[91],"2019-06-05",[2177,2178,2179,2180,2181,2182,1870,2183],"Cutaneous Melanoma, Stage III","Cutaneous Melanoma, Stage IV","Stage III Melanoma","Stage IIIA Skin Melanoma","Stage IIIB Skin Melanoma","Stage IIIC Skin Melanoma","Unresectable Melanoma",[57,2185,67],"Rituximab and Hyaluronidase Human",{"nctId":2187,"briefTitle":2188,"status":105,"phases":2189,"primaryCompletion":2190,"completion":2191,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2195},"NCT03521570","Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer",[91],"2022-07-25","2023-09-07","2018-06-28",62,[1806],[57],{"nctId":2197,"briefTitle":2198,"status":215,"phases":2199,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":391,"conditions":2203,"interventions":2206},"NCT06495125","Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer",[91],"2029-03-17","2029-09-17","2024-07-31",[2204,2205,2051,1757],"Advanced Lung Adenocarcinoma","Refractory Lung Adenocarcinoma",[2207,2208,57],"Avutometinib","Defactinib",{"nctId":1984,"briefTitle":1985,"status":145,"phases":2210,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":538,"conditions":2211,"interventions":2212},[91],[1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004],[1743,2006,57,2007],{"nctId":2214,"briefTitle":2215,"status":215,"phases":2216,"primaryCompletion":2217,"completion":2125,"start":47,"enrollment":2218,"conditions":2219,"interventions":2222},"NCT05039073","Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed\u002FRefractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors",[91],"2026-11-30",46,[2220,2221],"Recurrent Classic Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma",[2223,57],"Brentuximab Vedotin",{"nctId":2225,"briefTitle":2226,"status":105,"phases":2227,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":362,"conditions":2231,"interventions":2236},"NCT03739619","Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",[90,91],"2023-12-22","2025-04-30","2018-11-26",[2232,2233,2234,2235],"Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Classical Hodgkin Lymphoma","Hodgkin Lymphoma",[52,1982,57],{"nctId":2238,"briefTitle":2239,"status":2240,"phases":2241,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":2075,"conditions":2245,"interventions":2248},"NCT05445609","Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer","SUSPENDED",[91],"2027-06-23","2028-06-23","2023-06-07",[2246,2247],"Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8",[2249,57],"VLP-encapsulated TLR9 Agonist CMP-001,",{"nctId":2251,"briefTitle":2252,"status":215,"phases":2253,"primaryCompletion":301,"completion":302,"start":2254,"enrollment":2255,"conditions":2256,"interventions":2265},"NCT07155317","Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial",[91],"2025-10-29",99,[2257,2258,2259,1880,2260,2261,1881,2262,2263,2264],"Advanced Acral Melanoma","Advanced Cutaneous Melanoma","Advanced Mucosal Melanoma","Metastatic Acral Melanoma","Metastatic Cutaneous Melanoma","Unresectable Acral Melanoma","Unresectable Cutaneous Melanoma","Unresectable Mucosal Melanoma",[67,57],{"nctId":2042,"briefTitle":2043,"status":215,"phases":2267,"primaryCompletion":2045,"completion":2046,"start":2047,"enrollment":454,"conditions":2268,"interventions":2269},[91],[2049,2050,2051,1757],[2053,2054,2055,57,1743],{"trials":2271,"activeCount":114},[],{"trials":2273,"activeCount":114},[],{"trials":2275,"activeCount":114},[],{"intervention":67,"totalTrials":2277,"cells":2278},7,{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2303,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2280,"activeCount":114},[],{"trials":2282,"activeCount":362,"soonestReadout":66},[2283,2287,2291,2295,2299],{"nctId":64,"briefTitle":65,"status":145,"phases":2284,"primaryCompletion":66,"completion":2107,"start":2108,"enrollment":2109,"conditions":2285,"interventions":2286},[90],[2111,2112,2113],[67,57,2115],{"nctId":1824,"briefTitle":1825,"status":215,"phases":2288,"primaryCompletion":301,"completion":301,"start":1827,"enrollment":98,"conditions":2289,"interventions":2290},[90],[1829,1830,1831,1832,1833,1834,1835,1836,1837,1838,1839,1840,1841,1842,1843,1844,1845,1846,1847,1848,1849,1850,1851,1852,1853,1854,1855],[67,1743,1857],{"nctId":1874,"briefTitle":1875,"status":230,"phases":2292,"primaryCompletion":1877,"completion":1877,"start":1878,"enrollment":186,"conditions":2293,"interventions":2294},[90],[1880,1871,111,1866,1881,1882,1883],[67,57,1743],{"nctId":2121,"briefTitle":2122,"status":215,"phases":2296,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":391,"conditions":2297,"interventions":2298},[90],[2128],[2115,67,57],{"nctId":2131,"briefTitle":2132,"status":105,"phases":2300,"primaryCompletion":2134,"completion":2134,"start":2135,"enrollment":2075,"conditions":2301,"interventions":2302},[90],[2137,1772,2138,2139,2140,2141,2142,2143,2144,2145,1777,1780,1782,1784],[2147,67,57],{"trials":2304,"activeCount":327,"soonestReadout":56},[2305,2309],{"nctId":54,"briefTitle":55,"status":145,"phases":2306,"primaryCompletion":56,"completion":241,"start":2175,"enrollment":1754,"conditions":2307,"interventions":2308},[91],[2177,2178,2179,2180,2181,2182,1870,2183],[57,2185,67],{"nctId":2251,"briefTitle":2252,"status":215,"phases":2310,"primaryCompletion":301,"completion":302,"start":2254,"enrollment":2255,"conditions":2311,"interventions":2312},[91],[2257,2258,2259,1880,2260,2261,1881,2262,2263,2264],[67,57],{"trials":2314,"activeCount":114},[],{"trials":2316,"activeCount":114},[],{"trials":2318,"activeCount":114},[],{"intervention":1982,"totalTrials":150,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2346,"PHASE3":2425,"PHASE4":2443,"NA":2445},{"trials":2322,"activeCount":114},[],{"trials":2324,"activeCount":186,"soonestReadout":1176},[2325,2334],{"nctId":2326,"briefTitle":2327,"status":105,"phases":2328,"primaryCompletion":2329,"completion":2329,"start":2330,"enrollment":31,"conditions":2331,"interventions":2333},"NCT03507491","Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors",[90],"2024-02-02","2018-08-27",[2332],"Cancer",[1982,1979],{"nctId":2335,"briefTitle":2336,"status":215,"phases":2337,"primaryCompletion":1176,"completion":1176,"start":2338,"enrollment":31,"conditions":2339,"interventions":2344},"NCT07144254","Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma",[90],"2026-01-22",[2340,2341,2342,2343],"Osteosarcoma Recurrent","Osteosarcoma in Children","Relapsed Osteosarcoma","Refractory Osteosarcoma",[2345,1982],"Tegavivint",{"trials":2347,"activeCount":327,"soonestReadout":301},[2348,2360,2370,2383,2397,2401,2412,2421],{"nctId":2349,"briefTitle":2350,"status":105,"phases":2351,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2075,"conditions":2354,"interventions":2357},"NCT04524702","Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer",[91],"2023-06-06","2020-09-14",[2355,1773,2356],"Advanced Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8",[1982,2358,1979,2359],"Hydroxychloroquine","Paricalcitol",{"nctId":2361,"briefTitle":2362,"status":230,"phases":2363,"primaryCompletion":2364,"completion":2365,"start":2366,"enrollment":538,"conditions":2367,"interventions":2368},"NCT00674206","A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer",[91],"2009-08","2009-10","2008-10",[30],[1982,2369],"Oxaliplatin",{"nctId":2371,"briefTitle":2372,"status":215,"phases":2373,"primaryCompletion":301,"completion":302,"start":2374,"enrollment":1153,"conditions":2375,"interventions":2381},"NCT06423326","Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer",[91],"2024-08-06",[2376,2377,2378,2379,2380],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Adenocarcinoma","Stage I Pancreatic Cancer AJCC v8","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8",[2382,1982,1979],"Cisplatin",{"nctId":2384,"briefTitle":2385,"status":105,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":123,"conditions":2389,"interventions":2396},"NCT03579771","Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer",[91],"2023-09-16","2018-09-26",[2390,2391,2392,2393,2394,2395],"Resectable Cholangiocarcinoma","Stage IB Intrahepatic Cholangiocarcinoma AJCC v8","Stage II Intrahepatic Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8",[2382,1982,1979],{"nctId":1971,"briefTitle":1972,"status":215,"phases":2398,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":243,"conditions":2399,"interventions":2400},[91],[1839,1842],[1743,1979,1980,1981,1982],{"nctId":2402,"briefTitle":2403,"status":105,"phases":2404,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":136,"conditions":2407,"interventions":2410},"NCT03910387","Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer",[91],"2022-06-29","2019-04-17",[2408,1773,2409,2380,2356],"Locally Advanced Unresectable Pancreatic Adenocarcinoma","Recurrent Pancreatic Adenocarcinoma",[1982,1979,2411],"Telotristat Ethyl",{"nctId":2413,"briefTitle":2414,"status":230,"phases":2415,"primaryCompletion":320,"completion":320,"start":2416,"enrollment":28,"conditions":2417,"interventions":2420},"NCT01188109","Gemcitabine\u002FCisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision",[91],"2010-07",[2418,2419],"Pancreatic Neoplasms","Pancreatic Cancer",[1982,2382],{"nctId":2225,"briefTitle":2226,"status":105,"phases":2422,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":362,"conditions":2423,"interventions":2424},[90,91],[2232,2233,2234,2235],[52,1982,57],{"trials":2426,"activeCount":114},[2427],{"nctId":2428,"briefTitle":2429,"status":2022,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":114,"conditions":2433,"interventions":2441},"NCT03579758","Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer",[92],"2020-06-01","2019-04-03",[2434,2435,2436,2437,2438,2439,2440],"Stage I Gallbladder Cancer AJCC v8","Stage II Gallbladder Cancer AJCC v8","Stage IIA Gallbladder Cancer AJCC v8","Stage IIB Gallbladder Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage IIIA Gallbladder Cancer AJCC v8","Stage IIIB Gallbladder Cancer AJCC v8",[2442,2382,1982],"Capecitabine",{"trials":2444,"activeCount":114},[],{"trials":2446,"activeCount":114},[],{"intervention":154,"totalTrials":2448,"cells":2449},9,{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2499,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2451,"activeCount":114},[],{"trials":2453,"activeCount":186,"soonestReadout":147},[2454,2458,2462,2475],{"nctId":2093,"briefTitle":2094,"status":2022,"phases":2455,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":114,"conditions":2456,"interventions":2457},[90],[2099,2100,2101,1911,2102],[154,2104,57],{"nctId":143,"briefTitle":144,"status":145,"phases":2459,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":2460,"interventions":2461},[90],[152],[127,154,97,155],{"nctId":2463,"briefTitle":2464,"status":105,"phases":2465,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":182,"conditions":2468,"interventions":2471},"NCT03328104","Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia\u002FLymphoma",[90],"2023-06-29","2018-07-24",[2469,2470],"Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[2472,2473,154,2474],"Everolimus","Nelarabine","Etoposide",{"nctId":2476,"briefTitle":2477,"status":105,"phases":2478,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2495},"NCT02390843","Simvastatin With Topotecan and Cyclophosphamide in Relapsed and\u002For Refractory Pediatric Solid and CNS Tumors",[90],"2019-09-22","2015-02",13,[2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494],"Retinoblastoma","Clear Cell Sarcoma","Renal Cell Carcinoma","Rhabdoid Tumor","Wilms Tumor","Hepatoblastoma","Neuroblastoma","Germ Cell Tumors","Ewings Sarcoma","Non-rhabdomyosarcoma Soft Tissue Sarcoma","Osteosarcoma","Rhabdomyosarcoma",[2496,154,2497,2498],"Simvastatin","Topotecan","Myeloid growth factor",{"trials":2500,"activeCount":327,"soonestReadout":868},[2501,2513,2525,2529,2541],{"nctId":2502,"briefTitle":2503,"status":215,"phases":2504,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2510},"NCT04469530","Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors",[91],"2029-02","2020-09-16",55,[2509],"Solid Tumor",[2511,154,2474,2512],"Sirolimus","Celecoxib",{"nctId":2514,"briefTitle":2515,"status":105,"phases":2516,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2075,"conditions":2520,"interventions":2521},"NCT02757885","Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow",[91],"2021-12-12","2021-12-14","2019-07-10",[24],[2522,2523,2524,154],"Hydroxyurea","Thiotepa","Fludarabine monophosphate",{"nctId":1494,"briefTitle":1495,"status":105,"phases":2526,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":2527,"interventions":2528},[90,91],[1501,1502],[127,1504,1505,154,1506,565],{"nctId":2530,"briefTitle":2531,"status":230,"phases":2532,"primaryCompletion":2533,"completion":2533,"start":321,"enrollment":2277,"conditions":2534,"interventions":2538},"NCT01498588","Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer",[91],"2015-06",[254,30,2535,255,2536,2537],"Breast Tumors","Neoplasms, Breast","Tumors, Breast",[2539,1505,154,2540],"Eribulin","Pegfilgrastim",{"nctId":2542,"briefTitle":2543,"status":145,"phases":2544,"primaryCompletion":868,"completion":868,"start":2533,"enrollment":2218,"conditions":2545,"interventions":2546},"NCT02574728","Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and\u002For Refractory Solid and CNS Tumors",[91],[2332],[2511,2512,2474,154],{"trials":2548,"activeCount":114},[],{"trials":2550,"activeCount":114},[],{"trials":2552,"activeCount":114},[],{"intervention":2512,"totalTrials":470,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2569,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2556,"activeCount":114},[],{"trials":2558,"activeCount":114},[2559],{"nctId":2560,"briefTitle":2561,"status":105,"phases":2562,"primaryCompletion":2563,"completion":160,"start":2564,"enrollment":2075,"conditions":2565,"interventions":2567},"NCT00400374","Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2",[90],"2012-12","2007-08",[2566],"Head and Neck Cancer",[2568,2512],"Erlotinib",{"trials":2570,"activeCount":362,"soonestReadout":868},[2571,2575,2591],{"nctId":2502,"briefTitle":2503,"status":215,"phases":2572,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":2507,"conditions":2573,"interventions":2574},[91],[2509],[2511,154,2474,2512],{"nctId":2576,"briefTitle":2577,"status":215,"phases":2578,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":2583,"interventions":2588},"NCT07174570","Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer",[91],"2026-11-13","2027-11-13","2026-01-02",39,[2584,2585,2586,2587],"Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8",[2512,2589,2590],"Durvalumab","Tremelimumab",{"nctId":2542,"briefTitle":2543,"status":145,"phases":2592,"primaryCompletion":868,"completion":868,"start":2533,"enrollment":2218,"conditions":2593,"interventions":2594},[91],[2332],[2511,2512,2474,154],{"trials":2596,"activeCount":114},[],{"trials":2598,"activeCount":114},[],{"trials":2600,"activeCount":114},[],{"intervention":2602,"totalTrials":362,"cells":2603},"Baricitinib",{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2605,"activeCount":114},[],{"trials":2607,"activeCount":114},[],{"trials":2609,"activeCount":362,"soonestReadout":2631},[2610,2618,2627],{"nctId":2611,"briefTitle":2612,"status":215,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":436,"conditions":2616,"interventions":2617},"NCT05849038","Inflammation and Depression in People With HIV",[91],"2027-11","2023-12-11",[15,21,741],[2602],{"nctId":2619,"briefTitle":2620,"status":215,"phases":2621,"primaryCompletion":2622,"completion":2622,"start":2623,"enrollment":345,"conditions":2624,"interventions":2626},"NCT07003997","JAK Signaling in Depression",[91],"2030-02","2025-09-03",[2625],"Major Depressive Disorder",[2602],{"nctId":2628,"briefTitle":2629,"status":1278,"phases":2630,"primaryCompletion":2631,"completion":2631,"start":868,"enrollment":123,"conditions":2632,"interventions":2635},"NCT07608796","JAK Signaling in Depression and Cognition in Male Football Players",[91],"2027-10",[2633,2634],"Depressive Symptoms","Cognitive Symptom",[2602],{"trials":2637,"activeCount":114},[],{"trials":2639,"activeCount":114},[],{"trials":2641,"activeCount":114},[],{"intervention":127,"totalTrials":182,"cells":2643},{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2660,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2645,"activeCount":114},[],{"trials":2647,"activeCount":186,"soonestReadout":147},[2648,2652,2656],{"nctId":118,"briefTitle":119,"status":105,"phases":2649,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":2650,"interventions":2651},[90],[125],[127,128,97,129],{"nctId":143,"briefTitle":144,"status":145,"phases":2653,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":2654,"interventions":2655},[90],[152],[127,154,97,155],{"nctId":178,"briefTitle":179,"status":105,"phases":2657,"primaryCompletion":181,"completion":181,"start":173,"enrollment":182,"conditions":2658,"interventions":2659},[90],[125],[185,127,97],{"trials":2661,"activeCount":186,"soonestReadout":193},[2662,2666,2670,2679,2699],{"nctId":190,"briefTitle":191,"status":145,"phases":2663,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":2664,"interventions":2665},[91],[198],[127,200,97,201],{"nctId":1494,"briefTitle":1495,"status":105,"phases":2667,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":2668,"interventions":2669},[90,91],[1501,1502],[127,1504,1505,154,1506,565],{"nctId":2671,"briefTitle":2672,"status":230,"phases":2673,"primaryCompletion":2365,"completion":2674,"start":2675,"enrollment":2582,"conditions":2676,"interventions":2677},"NCT00793650","Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study",[90,91],"2011-09","2005-05",[2332,125],[127,2678],"Melphalan",{"nctId":2680,"briefTitle":2681,"status":230,"phases":2682,"primaryCompletion":2683,"completion":2683,"start":2684,"enrollment":292,"conditions":2685,"interventions":2697},"NCT02877082","Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients",[91],"2017-07","2016-09",[2686,2687,2688,2689,1502,2690,2691,2692,2693,2694,2695,2696],"Acute Leukemia","Chronic Lymphocytic Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Diffuse Large B-Cell Lymphoma","Graft Versus Host Disease","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndrome","Myelofibrosis","Myeloproliferative Neoplasm","Small Lymphocytic Lymphoma",[2698,127,600],"Thymoglobulin",{"nctId":271,"briefTitle":272,"status":230,"phases":2700,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":2701,"interventions":2702},[91],[198,278],[127,200,97,128,280],{"trials":2704,"activeCount":114},[],{"trials":2706,"activeCount":114},[],{"trials":2708,"activeCount":114},[],{"intervention":1979,"totalTrials":2277,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2719,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2712,"activeCount":114},[],{"trials":2714,"activeCount":114},[2715],{"nctId":2326,"briefTitle":2327,"status":105,"phases":2716,"primaryCompletion":2329,"completion":2329,"start":2330,"enrollment":31,"conditions":2717,"interventions":2718},[90],[2332],[1982,1979],{"trials":2720,"activeCount":327,"soonestReadout":301},[2721,2725,2737,2741,2745,2749],{"nctId":2349,"briefTitle":2350,"status":105,"phases":2722,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2075,"conditions":2723,"interventions":2724},[91],[2355,1773,2356],[1982,2358,1979,2359],{"nctId":2726,"briefTitle":2727,"status":2022,"phases":2728,"primaryCompletion":2242,"completion":2242,"start":2729,"enrollment":114,"conditions":2730,"interventions":2734},"NCT05514912","Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial",[91],"2024-03-01",[2731,2732,2733,2392,2393],"Resectable Intrahepatic Cholangiocarcinoma","Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8","Stage I Intrahepatic Cholangiocarcinoma AJCC v8",[2382,2735,2736,1979],"Gemcitabine Hydrochloride","Infigratinib Phosphate",{"nctId":2371,"briefTitle":2372,"status":215,"phases":2738,"primaryCompletion":301,"completion":302,"start":2374,"enrollment":1153,"conditions":2739,"interventions":2740},[91],[2376,2377,2378,2379,2380],[2382,1982,1979],{"nctId":2384,"briefTitle":2385,"status":105,"phases":2742,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":123,"conditions":2743,"interventions":2744},[91],[2390,2391,2392,2393,2394,2395],[2382,1982,1979],{"nctId":1971,"briefTitle":1972,"status":215,"phases":2746,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":243,"conditions":2747,"interventions":2748},[91],[1839,1842],[1743,1979,1980,1981,1982],{"nctId":2402,"briefTitle":2403,"status":105,"phases":2750,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":136,"conditions":2751,"interventions":2752},[91],[2408,1773,2409,2380,2356],[1982,1979,2411],{"trials":2754,"activeCount":114},[],{"trials":2756,"activeCount":114},[],{"trials":2758,"activeCount":114},[],{"intervention":2511,"totalTrials":292,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2808,"PHASE3":2818,"PHASE4":2820,"NA":2822},{"trials":2762,"activeCount":114},[],{"trials":2764,"activeCount":114},[2765,2775,2792],{"nctId":2766,"briefTitle":2767,"status":2022,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":114,"conditions":2771,"interventions":2773},"NCT00957320","Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)",[90],"2012-08","2009-06",[2772],"Acute Lymphoblastic Leukemia",[2511,2774],"PEG-asparaginase",{"nctId":2776,"briefTitle":2777,"status":230,"phases":2778,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":362,"conditions":2781,"interventions":2791},"NCT04348292","Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer",[90],"2022-11-04","2021-01-22",[1756,2782,2783,2784,2785,2786,2787,2788,2789,2790],"Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8",[2589,2511],{"nctId":2793,"briefTitle":2794,"status":105,"phases":2795,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":98,"conditions":2798,"interventions":2806},"NCT01331135","Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",[90],"2017-08-09","2011-04",[2799,2493,2800,2801,2802,2803,2804,2805,2486,2483,2484,2485,2487,2488,2489,2494],"Ewing's Sarcoma","Astrocytoma","Atypical Teratoid\u002FRhabdoid Tumor","Ependymoma","Germ Cell Tumor","Glioma","Medulloblastoma",[2807],"sirolimus",{"trials":2809,"activeCount":327,"soonestReadout":868},[2810,2814],{"nctId":2502,"briefTitle":2503,"status":215,"phases":2811,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":2507,"conditions":2812,"interventions":2813},[91],[2509],[2511,154,2474,2512],{"nctId":2542,"briefTitle":2543,"status":145,"phases":2815,"primaryCompletion":868,"completion":868,"start":2533,"enrollment":2218,"conditions":2816,"interventions":2817},[91],[2332],[2511,2512,2474,154],{"trials":2819,"activeCount":114},[],{"trials":2821,"activeCount":114},[],{"trials":2823,"activeCount":114},[],{"intervention":1980,"totalTrials":292,"cells":2825},{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2845,"PHASE3":2884,"PHASE4":2886,"NA":2888},{"trials":2827,"activeCount":114},[],{"trials":2829,"activeCount":114},[2830],{"nctId":2831,"briefTitle":2832,"status":2833,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":37,"conditions":2837,"interventions":2842},"NCT01711697","An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","UNKNOWN",[90],"2022-05-31","2012-09-04",[2838,2839,2840,2841],"Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[2843,2844],"carboplatin","paclitaxel",{"trials":2846,"activeCount":327,"soonestReadout":301},[2847,2862,2866,2876],{"nctId":2848,"briefTitle":2849,"status":215,"phases":2850,"primaryCompletion":301,"completion":302,"start":2851,"enrollment":208,"conditions":2852,"interventions":2860},"NCT06492070","Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers",[91],"2024-08-01",[2853,2854,2855,2856,2857,2858,2859],"Cervical Carcinoma","Fallopian Tube Carcinoma","Malignant Solid Neoplasm","Malignant Uterine Neoplasm","Ovarian Carcinoma","Primary Peritoneal Carcinoma","Vulvar Carcinoma",[2861,1980],"Cilostazol",{"nctId":1971,"briefTitle":1972,"status":215,"phases":2863,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":243,"conditions":2864,"interventions":2865},[91],[1839,1842],[1743,1979,1980,1981,1982],{"nctId":2867,"briefTitle":2868,"status":2022,"phases":2869,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":114,"conditions":2872,"interventions":2874},"NCT04262869","Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer",[91],"2021-10-18","2020-03-27",[1756,2873,1757,1758,1759],"Stage IIIB Lung Cancer AJCC v8",[1981,2589,1980,2875],"Pemetrexed",{"nctId":2877,"briefTitle":2878,"status":230,"phases":2879,"primaryCompletion":2533,"completion":2533,"start":2880,"enrollment":28,"conditions":2881,"interventions":2882},"NCT01194869","Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer",[91],"2010-06",[30],[2883,2382,1980],"Sorafenib",{"trials":2885,"activeCount":114},[],{"trials":2887,"activeCount":114},[],{"trials":2889,"activeCount":114},[],{"intervention":2474,"totalTrials":470,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2900,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2893,"activeCount":114},[],{"trials":2895,"activeCount":114},[2896],{"nctId":2463,"briefTitle":2464,"status":105,"phases":2897,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":182,"conditions":2898,"interventions":2899},[90],[2469,2470],[2472,2473,154,2474],{"trials":2901,"activeCount":327,"soonestReadout":868},[2902,2906,2920],{"nctId":2502,"briefTitle":2503,"status":215,"phases":2903,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":2507,"conditions":2904,"interventions":2905},[91],[2509],[2511,154,2474,2512],{"nctId":2907,"briefTitle":2908,"status":230,"phases":2909,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":2912,"interventions":2915},"NCT04326439","AflacLL1901 (CHOA-AML)",[91],"2022-03-15","2020-01-24",[2913,2914],"Acute Myeloid Leukemia","AML, Childhood",[2916,2917,2918,2474,2919,2883],"Cytarabine","Daunorubicin","Erwinase","Gemtuzumab ozogamicin",{"nctId":2542,"briefTitle":2543,"status":145,"phases":2921,"primaryCompletion":868,"completion":868,"start":2533,"enrollment":2218,"conditions":2922,"interventions":2923},[91],[2332],[2511,2512,2474,154],{"trials":2925,"activeCount":114},[],{"trials":2927,"activeCount":114},[],{"trials":2929,"activeCount":114},[],{"intervention":2931,"totalTrials":470,"cells":2932},"Abatacept",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2959,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2934,"activeCount":114},[],{"trials":2936,"activeCount":114},[2937],{"nctId":2938,"briefTitle":2939,"status":105,"phases":2940,"primaryCompletion":2941,"completion":2941,"start":2942,"enrollment":2075,"conditions":2943,"interventions":2958},"NCT01917708","Bone Marrow Transplant With Abatacept for Non-Malignant Diseases",[90],"2019-09-19","2014-01",[2944,2945,2946,2947,2948,2949,2950,2951,2952,2953,2954,2955,2956,2957,24],"Hurler Syndrome","Fanconi Anemia","Glanzmann Thrombasthenia","Wiskott-Aldrich Syndrome","Chronic Granulomatous Disease","Severe Congenital Neutropenia","Leukocyte Adhesion Deficiency","Shwachman-Diamond Syndrome","Diamond-Blackfan Anemia","Dyskeratosis-congenita","Chediak-Higashi Syndrome","Severe Aplastic Anemia","Thalassemia Major","Hemophagocytic Lymphohistiocytosis",[2931],{"trials":2960,"activeCount":327,"soonestReadout":868},[2961,2972,2981],{"nctId":2962,"briefTitle":2963,"status":105,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":292,"conditions":2967,"interventions":2969},"NCT00276250","Islet Transplantation Using Abatacept",[91],"2014-12","2005-12",[2968],"Type 1 Diabetes Mellitus",[2970,2931,2971],"Efalizumab","Belatacept",{"nctId":2973,"briefTitle":2974,"status":145,"phases":2975,"primaryCompletion":868,"completion":868,"start":2976,"enrollment":2977,"conditions":2978,"interventions":2980},"NCT04955366","Abatacept Conversion in Kidney Transplantation",[91],"2021-09-22",87,[2979],"Renal Transplant Recipient",[2971,2931],{"nctId":2982,"briefTitle":2983,"status":145,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2986,"enrollment":123,"conditions":2987,"interventions":2988},"NCT03924401","Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant",[91],"2027-03-01","2019-08-22",[2690],[2931],{"trials":2990,"activeCount":114},[],{"trials":2992,"activeCount":114},[],{"trials":2994,"activeCount":114},[],{"intervention":2053,"totalTrials":362,"cells":2996},{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3009,"PHASE3":3023,"PHASE4":3025,"NA":3027},{"trials":2998,"activeCount":114},[],{"trials":3000,"activeCount":186,"soonestReadout":3005},[3001],{"nctId":3002,"briefTitle":3003,"status":215,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":649,"enrollment":870,"conditions":3006,"interventions":3008},"NCT06492954","Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma",[90],"2027-06",[2493,3007],"Pulmonary Recurrence of Osteosarcoma",[2053],{"trials":3010,"activeCount":186,"soonestReadout":2045},[3011,3019],{"nctId":3012,"briefTitle":3013,"status":2240,"phases":3014,"primaryCompletion":2060,"completion":2060,"start":3015,"enrollment":454,"conditions":3016,"interventions":3018},"NCT06254911","Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma",[91],"2023-10-27",[3017],"Oropharynx Cancer, Stage I",[2053],{"nctId":2042,"briefTitle":2043,"status":215,"phases":3020,"primaryCompletion":2045,"completion":2046,"start":2047,"enrollment":454,"conditions":3021,"interventions":3022},[91],[2049,2050,2051,1757],[2053,2054,2055,57,1743],{"trials":3024,"activeCount":114},[],{"trials":3026,"activeCount":114},[],{"trials":3028,"activeCount":114},[],{"intervention":2678,"totalTrials":362,"cells":3030},{"EARLY_PHASE1":3031,"PHASE1":3033,"PHASE2":3041,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3032,"activeCount":114},[],{"trials":3034,"activeCount":186,"soonestReadout":241},[3035],{"nctId":3036,"briefTitle":3037,"status":215,"phases":3038,"primaryCompletion":241,"completion":301,"start":1989,"enrollment":845,"conditions":3039,"interventions":3040},"NCT04483206","Personalized Autologous Transplant for Multiple Myeloma",[90],[125],[2678],{"trials":3042,"activeCount":186,"soonestReadout":3051},[3043,3047],{"nctId":2671,"briefTitle":2672,"status":230,"phases":3044,"primaryCompletion":2365,"completion":2674,"start":2675,"enrollment":2582,"conditions":3045,"interventions":3046},[90,91],[2332,125],[127,2678],{"nctId":3048,"briefTitle":3049,"status":145,"phases":3050,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":3053,"conditions":3054,"interventions":3055},"NCT04018937","Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation",[91],"2026-11","2019-03-22",43,[24],[3056,3057,2678],"Alemtuzumab","Fludarabine",{"trials":3059,"activeCount":114},[],{"trials":3061,"activeCount":114},[],{"trials":3063,"activeCount":114},[],{"intervention":43,"totalTrials":327,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3083,"PHASE4":3085,"NA":3087},{"trials":3067,"activeCount":114},[],{"trials":3069,"activeCount":114},[],{"trials":3071,"activeCount":327,"soonestReadout":42},[3072,3079],{"nctId":40,"briefTitle":41,"status":145,"phases":3073,"primaryCompletion":42,"completion":3074,"start":3075,"enrollment":162,"conditions":3076,"interventions":3078},[91],"2026-12-09","2019-08-06",[3077,2485,1966],"Clear Cell Renal Cell Carcinoma",[43],{"nctId":45,"briefTitle":46,"status":145,"phases":3080,"primaryCompletion":47,"completion":1900,"start":1901,"enrollment":1153,"conditions":3081,"interventions":3082},[91],[1903,1904,1806,1807,1808,1810,1811,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1915,1916,1917,1918,1919,1920,1921],[43,1743],{"trials":3084,"activeCount":114},[],{"trials":3086,"activeCount":114},[],{"trials":3088,"activeCount":114},[],{"intervention":3090,"totalTrials":327,"cells":3091},"Obinutuzumab",{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3093,"activeCount":114},[],{"trials":3095,"activeCount":114},[],{"trials":3097,"activeCount":327,"soonestReadout":51},[3098,3107],{"nctId":49,"briefTitle":50,"status":145,"phases":3099,"primaryCompletion":51,"completion":3100,"start":3101,"enrollment":136,"conditions":3102,"interventions":3105},[91],"2026-04-30","2019-04-11",[3103,2691,3104],"CCND1 Positive","t(11;14) Positive",[52,3090,3106],"Venetoclax",{"nctId":3108,"briefTitle":3109,"status":215,"phases":3110,"primaryCompletion":3111,"completion":3112,"start":3113,"enrollment":196,"conditions":3114,"interventions":3121},"NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",[91],"2026-09-23","2027-01-15","2021-09-03",[3115,3116,3117,3118,3119,3120,2691,2692],"Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Indolent Non-Hodgkin Lymphoma","Lymphoplasmacytic Lymphoma","Lymphoproliferative Disorder",[3122,3090],"Acalabrutinib",{"trials":3124,"activeCount":114},[],{"trials":3126,"activeCount":114},[],{"trials":3128,"activeCount":114},[],{"intervention":3106,"totalTrials":327,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3144,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3132,"activeCount":114},[],{"trials":3134,"activeCount":186,"soonestReadout":1974},[3135],{"nctId":3136,"briefTitle":3137,"status":145,"phases":3138,"primaryCompletion":1974,"completion":3139,"start":3140,"enrollment":2277,"conditions":3141,"interventions":3142},"NCT05391750","Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma",[90],"2028-02-12","2022-10-19",[138,210],[3143,3106],"Tocilizumab",{"trials":3145,"activeCount":186,"soonestReadout":51},[3146],{"nctId":49,"briefTitle":50,"status":145,"phases":3147,"primaryCompletion":51,"completion":3100,"start":3101,"enrollment":136,"conditions":3148,"interventions":3149},[91],[3103,2691,3104],[52,3090,3106],{"trials":3151,"activeCount":114},[],{"trials":3153,"activeCount":114},[],{"trials":3155,"activeCount":114},[],{"intervention":3157,"totalTrials":327,"cells":3158},"Atovaquone",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3173,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3160,"activeCount":114},[],{"trials":3162,"activeCount":186,"soonestReadout":2631},[3163],{"nctId":3164,"briefTitle":3165,"status":215,"phases":3166,"primaryCompletion":2631,"completion":2631,"start":3167,"enrollment":98,"conditions":3168,"interventions":3172},"NCT06624371","Atovaquone Combined With Radiation in Children With Malignant Brain Tumors",[90],"2025-03-28",[3169,2805,3170,3171],"High-grade Glioma","Diffuse Intrinsic Pontine Glioma","Diffuse Midline Glioma, H3 K27M-Mutant",[3157],{"trials":3174,"activeCount":186,"soonestReadout":241},[3175],{"nctId":3176,"briefTitle":3177,"status":215,"phases":3178,"primaryCompletion":241,"completion":819,"start":3179,"enrollment":22,"conditions":3180,"interventions":3183},"NCT05998135","Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer",[91],"2023-11-09",[3181,3182],"Ovarian High Grade Serous Adenocarcinoma","Platinum-Resistant Ovarian Carcinoma",[3157],{"trials":3185,"activeCount":114},[],{"trials":3187,"activeCount":114},[],{"trials":3189,"activeCount":114},[],{"intervention":1938,"totalTrials":327,"cells":3191},{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3206,"PHASE3":3212,"PHASE4":3214,"NA":3216},{"trials":3193,"activeCount":114},[],{"trials":3195,"activeCount":186,"soonestReadout":2580},[3196],{"nctId":3197,"briefTitle":3198,"status":215,"phases":3199,"primaryCompletion":2580,"completion":3200,"start":3201,"enrollment":19,"conditions":3202,"interventions":3205},"NCT04878029","Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer",[90],"2028-12-21","2021-07-23",[3203,1995,2000,3204],"Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation","Unresectable Urothelial Carcinoma",[1938,2074],{"trials":3207,"activeCount":186,"soonestReadout":1927},[3208],{"nctId":1924,"briefTitle":1925,"status":215,"phases":3209,"primaryCompletion":1927,"completion":1928,"start":1929,"enrollment":1930,"conditions":3210,"interventions":3211},[91],[1932,1933,1934,1935,1936],[1743,1938],{"trials":3213,"activeCount":114},[],{"trials":3215,"activeCount":114},[],{"trials":3217,"activeCount":114},[],{"intervention":3219,"totalTrials":327,"cells":3220},"Sodium Bicarbonate",{"EARLY_PHASE1":3221,"PHASE1":3223,"PHASE2":3234,"PHASE3":3245,"PHASE4":3247,"NA":3249},{"trials":3222,"activeCount":114},[],{"trials":3224,"activeCount":186,"soonestReadout":3005},[3225],{"nctId":3226,"briefTitle":3227,"status":215,"phases":3228,"primaryCompletion":3005,"completion":3005,"start":3229,"enrollment":3230,"conditions":3231,"interventions":3233},"NCT02411773","Sympatholysis in Chronic Kidney Disease",[90],"2015-06-11",110,[3232],"Chronic Kidney Disease",[3219],{"trials":3235,"activeCount":186,"soonestReadout":3240},[3236],{"nctId":3237,"briefTitle":3238,"status":215,"phases":3239,"primaryCompletion":3240,"completion":3240,"start":3241,"enrollment":3242,"conditions":3243,"interventions":3244},"NCT05928936","Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD",[91],"2028-06-01","2022-11-11",156,[3232],[3219],{"trials":3246,"activeCount":114},[],{"trials":3248,"activeCount":114},[],{"trials":3250,"activeCount":114},[],{"intervention":2207,"totalTrials":327,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3266,"PHASE2":3268,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3254,"activeCount":186,"soonestReadout":3259},[3255],{"nctId":3256,"briefTitle":3257,"status":145,"phases":3258,"primaryCompletion":3259,"completion":3260,"start":3261,"enrollment":1218,"conditions":3262,"interventions":3265},"NCT05798507","Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma",[89],"2026-12-03","2027-12-03","2023-07-28",[3263,3264],"Glioblastoma","Recurrent Glioblastoma",[2207,2208],{"trials":3267,"activeCount":114},[],{"trials":3269,"activeCount":186,"soonestReadout":2200},[3270],{"nctId":2197,"briefTitle":2198,"status":215,"phases":3271,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":391,"conditions":3272,"interventions":3273},[91],[2204,2205,2051,1757],[2207,2208,57],{"trials":3275,"activeCount":114},[],{"trials":3277,"activeCount":114},[],{"trials":3279,"activeCount":114},[],{"intervention":2208,"totalTrials":327,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3288,"PHASE2":3290,"PHASE3":3296,"PHASE4":3298,"NA":3300},{"trials":3283,"activeCount":186,"soonestReadout":3259},[3284],{"nctId":3256,"briefTitle":3257,"status":145,"phases":3285,"primaryCompletion":3259,"completion":3260,"start":3261,"enrollment":1218,"conditions":3286,"interventions":3287},[89],[3263,3264],[2207,2208],{"trials":3289,"activeCount":114},[],{"trials":3291,"activeCount":186,"soonestReadout":2200},[3292],{"nctId":2197,"briefTitle":2198,"status":215,"phases":3293,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":391,"conditions":3294,"interventions":3295},[91],[2204,2205,2051,1757],[2207,2208,57],{"trials":3297,"activeCount":114},[],{"trials":3299,"activeCount":114},[],{"trials":3301,"activeCount":114},[],{"intervention":2054,"totalTrials":327,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3319,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3305,"activeCount":114},[],{"trials":3307,"activeCount":186,"soonestReadout":3312},[3308],{"nctId":3309,"briefTitle":3310,"status":215,"phases":3311,"primaryCompletion":3312,"completion":3313,"start":3314,"enrollment":454,"conditions":3315,"interventions":3318},"NCT04428671","Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer",[90],"2030-10-01","2031-10-01","2020-05-15",[3316,3317],"Metastatic Skin Squamous Cell Carcinoma","Recurrent Skin Squamous Cell Carcinoma",[2054],{"trials":3320,"activeCount":186,"soonestReadout":2045},[3321],{"nctId":2042,"briefTitle":2043,"status":215,"phases":3322,"primaryCompletion":2045,"completion":2046,"start":2047,"enrollment":454,"conditions":3323,"interventions":3324},[91],[2049,2050,2051,1757],[2053,2054,2055,57,1743],{"trials":3326,"activeCount":114},[],{"trials":3328,"activeCount":114},[],{"trials":3330,"activeCount":114},[],{"intervention":246,"totalTrials":327,"cells":3332},{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3337,"PHASE3":3347,"PHASE4":3349,"NA":3351},{"trials":3334,"activeCount":114},[],{"trials":3336,"activeCount":114},[],{"trials":3338,"activeCount":327,"soonestReadout":240},[3339,3343],{"nctId":237,"briefTitle":238,"status":145,"phases":3340,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":3341,"interventions":3342},[91],[198],[140,97,246],{"nctId":282,"briefTitle":283,"status":215,"phases":3344,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":3345,"interventions":3346},[91],[198],[291,97,246],{"trials":3348,"activeCount":114},[],{"trials":3350,"activeCount":114},[],{"trials":3352,"activeCount":114},[],{"intervention":2074,"totalTrials":327,"cells":3354},{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3363,"PHASE3":3369,"PHASE4":3371,"NA":3373},{"trials":3356,"activeCount":114},[],{"trials":3358,"activeCount":186,"soonestReadout":2580},[3359],{"nctId":3197,"briefTitle":3198,"status":215,"phases":3360,"primaryCompletion":2580,"completion":3200,"start":3201,"enrollment":19,"conditions":3361,"interventions":3362},[90],[3203,1995,2000,3204],[1938,2074],{"trials":3364,"activeCount":186,"soonestReadout":2060},[3365],{"nctId":2057,"briefTitle":2058,"status":215,"phases":3366,"primaryCompletion":2060,"completion":1927,"start":2061,"enrollment":28,"conditions":3367,"interventions":3368},[91],[2063,2064,2065,2066,2067,2068,2069,2001,2070,2071,2072],[2074,1743],{"trials":3370,"activeCount":114},[],{"trials":3372,"activeCount":114},[],{"trials":3374,"activeCount":114},[],{"intervention":2971,"totalTrials":362,"cells":3376},{"EARLY_PHASE1":3377,"PHASE1":3379,"PHASE2":3381,"PHASE3":3391,"PHASE4":3393,"NA":3404},{"trials":3378,"activeCount":114},[],{"trials":3380,"activeCount":114},[],{"trials":3382,"activeCount":186,"soonestReadout":868},[3383,3387],{"nctId":2962,"briefTitle":2963,"status":105,"phases":3384,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":292,"conditions":3385,"interventions":3386},[91],[2968],[2970,2931,2971],{"nctId":2973,"briefTitle":2974,"status":145,"phases":3388,"primaryCompletion":868,"completion":868,"start":2976,"enrollment":2977,"conditions":3389,"interventions":3390},[91],[2979],[2971,2931],{"trials":3392,"activeCount":114},[],{"trials":3394,"activeCount":114},[3395],{"nctId":3396,"briefTitle":3397,"status":105,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":181,"enrollment":3400,"conditions":3401,"interventions":3403},"NCT02560558","Bela 8 Week Dosing",[93],"2019-08-29",166,[3402],"Kidney Transplantation",[2971],{"trials":3405,"activeCount":114},[],{"intervention":1897,"totalTrials":327,"cells":3407},{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3418,"PHASE4":3420,"NA":3435},{"trials":3409,"activeCount":114},[],{"trials":3411,"activeCount":114},[],{"trials":3413,"activeCount":186,"soonestReadout":1891},[3414],{"nctId":1888,"briefTitle":1889,"status":1278,"phases":3415,"primaryCompletion":1891,"completion":1892,"start":1893,"enrollment":1499,"conditions":3416,"interventions":3417},[91],[1835,1839,1842,1895,1855],[1743,1897],{"trials":3419,"activeCount":114},[],{"trials":3421,"activeCount":114},[3422],{"nctId":3423,"briefTitle":3424,"status":105,"phases":3425,"primaryCompletion":232,"completion":3426,"start":3427,"enrollment":98,"conditions":3428,"interventions":3434},"NCT02111369","Propranolol and Botulinum Toxin for Essential Vocal Tremor",[93],"2014-11","2014-05",[3429,3430,3431,3432,3433],"Essential Vocal Tremor","Essential Voice Tremor","Essential Tremor","Voice Tremor","Vocal Tremor",[1897],{"trials":3436,"activeCount":114},[],{"intervention":3438,"totalTrials":327,"cells":3439},"Atenolol",{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3458,"PHASE4":3460,"NA":3473},{"trials":3441,"activeCount":114},[],{"trials":3443,"activeCount":114},[],{"trials":3445,"activeCount":186,"soonestReadout":3450},[3446],{"nctId":3447,"briefTitle":3448,"status":215,"phases":3449,"primaryCompletion":3450,"completion":3450,"start":251,"enrollment":3451,"conditions":3452,"interventions":3454},"NCT02560805","Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV",[91],"2027-03-30",134,[3453],"Stress Disorders, Post-Traumatic",[3455,3456,3457,3438],"Sodium Nitroprusside","Phenylephrine","Losartan",{"trials":3459,"activeCount":114},[],{"trials":3461,"activeCount":114},[3462],{"nctId":3463,"briefTitle":3464,"status":105,"phases":3465,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":243,"conditions":3468,"interventions":3471},"NCT01230892","Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques",[93],"2013-09","2010-02",[3469,3470],"Atherosclerosis","Endothelial Function",[3472,3438],"Nebivolol",{"trials":3474,"activeCount":114},[],{"intervention":3476,"totalTrials":327,"cells":3477},"Azithromycin",{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3493,"PHASE4":3495,"NA":3511},{"trials":3479,"activeCount":114},[],{"trials":3481,"activeCount":114},[],{"trials":3483,"activeCount":186,"soonestReadout":353},[3484],{"nctId":3485,"briefTitle":3486,"status":215,"phases":3487,"primaryCompletion":353,"completion":353,"start":3488,"enrollment":3489,"conditions":3490,"interventions":3492},"NCT06618534","Azithromycin for Meningococcal Carriage",[91],"2024-11-12",1120,[3491],"Meningococcal Infections",[3476],{"trials":3494,"activeCount":114},[],{"trials":3496,"activeCount":114},[3497],{"nctId":3498,"briefTitle":3499,"status":2022,"phases":3500,"primaryCompletion":3501,"completion":3502,"start":3503,"enrollment":114,"conditions":3504,"interventions":3507},"NCT01903057","Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis",[93],"2014-03","2014-07","2014-02",[3505,3506],"Trachoma","Lymphatic Filariasis",[3508,3509,3510],"azithromycin","ivermectin","albendazole",{"trials":3512,"activeCount":114},[],{"intervention":2382,"totalTrials":2448,"cells":3514},{"EARLY_PHASE1":3515,"PHASE1":3517,"PHASE2":3551,"PHASE3":3584,"PHASE4":3590,"NA":3592},{"trials":3516,"activeCount":114},[],{"trials":3518,"activeCount":114},[3519,3529],{"nctId":3520,"briefTitle":3521,"status":105,"phases":3522,"primaryCompletion":3523,"completion":3523,"start":3524,"enrollment":31,"conditions":3525,"interventions":3527},"NCT02075112","Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck",[90],"2019-09","2013-11",[3526],"Cancer of Head and Neck",[3528,2382],"Soy isoflavone",{"nctId":3530,"briefTitle":3531,"status":105,"phases":3532,"primaryCompletion":3533,"completion":3533,"start":3534,"enrollment":3535,"conditions":3536,"interventions":3549},"NCT02897375","Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors",[90],"2021-10-15","2016-10-24",71,[3537,1777,3538,3539,3540,3541,3542,3543,1869,1783,1785,3544,3545,2566,3546,3547,3548],"Solid Neoplasm","Stage IIIA Breast Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Breast Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer","Sarcoma","Colorectal Cancer","Cancer of Unknown Primary","Bladder Cancer","Ovarian Cancer",[1981,2382,3550],"Palbociclib",{"trials":3552,"activeCount":186,"soonestReadout":301},[3553,3557,3561,3565,3569,3573],{"nctId":2726,"briefTitle":2727,"status":2022,"phases":3554,"primaryCompletion":2242,"completion":2242,"start":2729,"enrollment":114,"conditions":3555,"interventions":3556},[91],[2731,2732,2733,2392,2393],[2382,2735,2736,1979],{"nctId":2371,"briefTitle":2372,"status":215,"phases":3558,"primaryCompletion":301,"completion":302,"start":2374,"enrollment":1153,"conditions":3559,"interventions":3560},[91],[2376,2377,2378,2379,2380],[2382,1982,1979],{"nctId":2384,"briefTitle":2385,"status":105,"phases":3562,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":123,"conditions":3563,"interventions":3564},[91],[2390,2391,2392,2393,2394,2395],[2382,1982,1979],{"nctId":2413,"briefTitle":2414,"status":230,"phases":3566,"primaryCompletion":320,"completion":320,"start":2416,"enrollment":28,"conditions":3567,"interventions":3568},[91],[2418,2419],[1982,2382],{"nctId":2877,"briefTitle":2878,"status":230,"phases":3570,"primaryCompletion":2533,"completion":2533,"start":2880,"enrollment":28,"conditions":3571,"interventions":3572},[91],[30],[2883,2382,1980],{"nctId":3574,"briefTitle":3575,"status":230,"phases":3576,"primaryCompletion":3577,"completion":3577,"start":3578,"enrollment":1218,"conditions":3579,"interventions":3582},"NCT00400205","Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil",[91],"2009-09","2006-08",[3580,3581],"Squamous Cell Carcinoma","Oral Cancer",[2039,2382,3583],"5-fluorouracil",{"trials":3585,"activeCount":114},[3586],{"nctId":2428,"briefTitle":2429,"status":2022,"phases":3587,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":114,"conditions":3588,"interventions":3589},[92],[2434,2435,2436,2437,2438,2439,2440],[2442,2382,1982],{"trials":3591,"activeCount":114},[],{"trials":3593,"activeCount":114},[],{"intervention":2006,"totalTrials":327,"cells":3595},{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3600,"PHASE3":3606,"PHASE4":3617,"NA":3619},{"trials":3597,"activeCount":114},[],{"trials":3599,"activeCount":114},[],{"trials":3601,"activeCount":186,"soonestReadout":1987},[3602],{"nctId":1984,"briefTitle":1985,"status":145,"phases":3603,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":538,"conditions":3604,"interventions":3605},[91],[1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004],[1743,2006,57,2007],{"trials":3607,"activeCount":114},[3608],{"nctId":3609,"briefTitle":3610,"status":2022,"phases":3611,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":114,"conditions":3614,"interventions":3616},"NCT03254186","Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia",[91,92],"2019-02-01","2017-09-18",[3615],"Tardive Dyskinesia",[2006],{"trials":3618,"activeCount":114},[],{"trials":3620,"activeCount":114},[],{"intervention":2039,"totalTrials":2277,"cells":3622},{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3654,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3624,"activeCount":114},[],{"trials":3626,"activeCount":114},[3627,3639],{"nctId":3628,"briefTitle":3629,"status":230,"phases":3630,"primaryCompletion":3631,"completion":3631,"start":536,"enrollment":470,"conditions":3632,"interventions":3635},"NCT05733351","Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer",[90],"2025-06-12",[3633,2246,3634],"Castration-Sensitive Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8",[3636,2039,3637,3638],"Abiraterone","Enzalutamide","Vudalimab",{"nctId":3640,"briefTitle":3641,"status":230,"phases":3642,"primaryCompletion":3643,"completion":3644,"start":3645,"enrollment":3646,"conditions":3647,"interventions":3652},"NCT00288444","Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer",[90],"2008-05","2009-03","2006-01",38,[3648,3649,3650,30,3651],"Lung Cancer","Soft Tissue Sarcoma","Colorectal Carcinoma","Prostate Cancer",[3653,2039],"Lonafarnib",{"trials":3655,"activeCount":186,"soonestReadout":2032},[3656,3666,3675,3684,3688],{"nctId":3657,"briefTitle":3658,"status":230,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":22,"conditions":3663,"interventions":3664},"NCT00406276","Phase I\u002FII Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer",[90,91],"2010-12","2013-02","2006-11",[3648],[3665,2039],"RAD001",{"nctId":3667,"briefTitle":3668,"status":105,"phases":3669,"primaryCompletion":3670,"completion":3671,"start":3578,"enrollment":3672,"conditions":3673,"interventions":3674},"NCT00209092","Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer",[91],"2009-07","2012-10",51,[30],[2039,2442],{"nctId":3676,"briefTitle":3677,"status":105,"phases":3678,"primaryCompletion":3679,"completion":3679,"start":3670,"enrollment":595,"conditions":3680,"interventions":3681},"NCT00941330","Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers",[91],"2015-05",[30],[3682,2039,3683],"Exemestane","Cytoxan",{"nctId":2029,"briefTitle":2030,"status":145,"phases":3685,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":123,"conditions":3686,"interventions":3687},[91],[2036,2037,1757,1758,1759],[2039,1743,2040],{"nctId":3574,"briefTitle":3575,"status":230,"phases":3689,"primaryCompletion":3577,"completion":3577,"start":3578,"enrollment":1218,"conditions":3690,"interventions":3691},[91],[3580,3581],[2039,2382,3583],{"trials":3693,"activeCount":114},[],{"trials":3695,"activeCount":114},[],{"trials":3697,"activeCount":114},[],{"intervention":1981,"totalTrials":538,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3723,"PHASE3":3743,"PHASE4":3745,"NA":3747},{"trials":3701,"activeCount":114},[],{"trials":3703,"activeCount":114},[3704,3715,3719],{"nctId":3705,"briefTitle":3706,"status":105,"phases":3707,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":276,"conditions":3710,"interventions":3713},"NCT01490749","Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer",[90],"2019-02","2012-02",[3711,3712],"Esophageal Cancer","Neoplasms, Esophageal",[3665,3714,1981],"XELOX",{"nctId":2831,"briefTitle":2832,"status":2833,"phases":3716,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":37,"conditions":3717,"interventions":3718},[90],[2838,2839,2840,2841],[2843,2844],{"nctId":3530,"briefTitle":3531,"status":105,"phases":3720,"primaryCompletion":3533,"completion":3533,"start":3534,"enrollment":3535,"conditions":3721,"interventions":3722},[90],[3537,1777,3538,3539,3540,3541,3542,3543,1869,1783,1785,3544,3545,2566,3546,3547,3548],[1981,2382,3550],{"trials":3724,"activeCount":186,"soonestReadout":1974},[3725,3729,3739],{"nctId":1971,"briefTitle":1972,"status":215,"phases":3726,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":243,"conditions":3727,"interventions":3728},[91],[1839,1842],[1743,1979,1980,1981,1982],{"nctId":3730,"briefTitle":3731,"status":105,"phases":3732,"primaryCompletion":3524,"completion":3426,"start":3733,"enrollment":454,"conditions":3734,"interventions":3737},"NCT01283334","A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer",[90,91],"2011-01",[3735,3736],"Head and Neck Neoplasms","Cancer of the Head and Neck",[1981,3738,3665],"Cetuximab",{"nctId":2867,"briefTitle":2868,"status":2022,"phases":3740,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":114,"conditions":3741,"interventions":3742},[91],[1756,2873,1757,1758,1759],[1981,2589,1980,2875],{"trials":3744,"activeCount":114},[],{"trials":3746,"activeCount":114},[],{"trials":3748,"activeCount":114},[],{"intervention":140,"totalTrials":292,"cells":3750},{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3767,"PHASE3":3777,"PHASE4":3779,"NA":3781},{"trials":3752,"activeCount":114},[],{"trials":3754,"activeCount":114},[3755,3759,3763],{"nctId":131,"briefTitle":132,"status":105,"phases":3756,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":3757,"interventions":3758},[90],[138],[140,97,57,141],{"nctId":157,"briefTitle":158,"status":105,"phases":3760,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":3761,"interventions":3762},[90],[164,165],[140,97],{"nctId":168,"briefTitle":169,"status":105,"phases":3764,"primaryCompletion":171,"completion":172,"start":173,"enrollment":19,"conditions":3765,"interventions":3766},[90],[125],[176,140,97],{"trials":3768,"activeCount":186,"soonestReadout":240},[3769,3773],{"nctId":228,"briefTitle":229,"status":230,"phases":3770,"primaryCompletion":232,"completion":232,"start":233,"enrollment":186,"conditions":3771,"interventions":3772},[91],[125],[140,97],{"nctId":237,"briefTitle":238,"status":145,"phases":3774,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":3775,"interventions":3776},[91],[198],[140,97,246],{"trials":3778,"activeCount":114},[],{"trials":3780,"activeCount":114},[],{"trials":3782,"activeCount":114},[],{"intervention":201,"totalTrials":470,"cells":3784},{"EARLY_PHASE1":3785,"PHASE1":3796,"PHASE2":3798,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3786,"activeCount":114},[3787],{"nctId":3788,"briefTitle":3789,"status":105,"phases":3790,"primaryCompletion":3791,"completion":3792,"start":3793,"enrollment":362,"conditions":3794,"interventions":3795},"NCT02630030","Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma",[89],"2018-07-01","2020-09-03","2016-03-24",[3263],[201],{"trials":3797,"activeCount":114},[],{"trials":3799,"activeCount":186,"soonestReadout":193},[3800,3804,3808],{"nctId":190,"briefTitle":191,"status":145,"phases":3801,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":3802,"interventions":3803},[91],[198],[127,200,97,201],{"nctId":203,"briefTitle":204,"status":105,"phases":3805,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":3806,"interventions":3807},[91],[138,210],[97,201,128],{"nctId":3809,"briefTitle":3810,"status":2833,"phases":3811,"primaryCompletion":3812,"completion":3813,"start":3814,"enrollment":870,"conditions":3815,"interventions":3816},"NCT02632396","Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission",[90,91],"2023-08-15","2024-08","2016-03-01",[2691],[201,1504],{"trials":3818,"activeCount":114},[],{"trials":3820,"activeCount":114},[],{"trials":3822,"activeCount":114},[],{"intervention":2589,"totalTrials":470,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3833,"PHASE3":3851,"PHASE4":3853,"NA":3855},{"trials":3826,"activeCount":114},[],{"trials":3828,"activeCount":114},[3829],{"nctId":2776,"briefTitle":2777,"status":230,"phases":3830,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":362,"conditions":3831,"interventions":3832},[90],[1756,2782,2783,2784,2785,2786,2787,2788,2789,2790],[2589,2511],{"trials":3834,"activeCount":186,"soonestReadout":2579},[3835,3843,3847],{"nctId":3836,"briefTitle":3837,"status":105,"phases":3838,"primaryCompletion":507,"completion":507,"start":3839,"enrollment":98,"conditions":3840,"interventions":3842},"NCT02701400","Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer",[91],"2016-04-14",[3841],"Recurrent Small Cell Lung Carcinoma",[2589,2590],{"nctId":2867,"briefTitle":2868,"status":2022,"phases":3844,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":114,"conditions":3845,"interventions":3846},[91],[1756,2873,1757,1758,1759],[1981,2589,1980,2875],{"nctId":2576,"briefTitle":2577,"status":215,"phases":3848,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":3849,"interventions":3850},[91],[2584,2585,2586,2587],[2512,2589,2590],{"trials":3852,"activeCount":114},[],{"trials":3854,"activeCount":114},[],{"trials":3856,"activeCount":114},[],{"intervention":3057,"totalTrials":362,"cells":3858},{"EARLY_PHASE1":3859,"PHASE1":3861,"PHASE2":3883,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3860,"activeCount":114},[],{"trials":3862,"activeCount":114},[3863,3873],{"nctId":3864,"briefTitle":3865,"status":105,"phases":3866,"primaryCompletion":3501,"completion":3867,"start":3868,"enrollment":182,"conditions":3869,"interventions":3871},"NCT00968162","Sickle Cell Disease Conditioning for Bone Marrow Transplant",[90],"2016-01-11","2009-02",[3870,24],"Bone Marrow Transplantation",[3872],"fludarabine",{"nctId":3874,"briefTitle":3875,"status":2022,"phases":3876,"primaryCompletion":2135,"completion":2135,"start":3877,"enrollment":114,"conditions":3878,"interventions":3879},"NCT02680951","Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia",[90],"2015-12",[2913],[3880,3057,2916,3881,3882],"Dasatinib","Idarubicin","Intrathecal (IT) cytarabine",{"trials":3884,"activeCount":186,"soonestReadout":3051},[3885],{"nctId":3048,"briefTitle":3049,"status":145,"phases":3886,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":3053,"conditions":3887,"interventions":3888},[91],[24],[3056,3057,2678],{"trials":3890,"activeCount":114},[],{"trials":3892,"activeCount":114},[],{"trials":3894,"activeCount":114},[],{"intervention":82,"totalTrials":362,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3932,"PHASE4":3934,"NA":3936},{"trials":3898,"activeCount":114},[],{"trials":3900,"activeCount":114},[],{"trials":3902,"activeCount":186,"soonestReadout":81},[3903,3914,3918],{"nctId":3904,"briefTitle":3905,"status":230,"phases":3906,"primaryCompletion":3907,"completion":3907,"start":3908,"enrollment":470,"conditions":3909,"interventions":3913},"NCT03506048","Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer",[91],"2021-06-24","2019-01-16",[3910,3911,3912],"Differentiated Thyroid Gland Carcinoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Papillary Carcinoma",[82],{"nctId":79,"briefTitle":80,"status":145,"phases":3915,"primaryCompletion":81,"completion":1962,"start":1963,"enrollment":98,"conditions":3916,"interventions":3917},[91],[1965,1966,1967],[82,1969,1743],{"nctId":3919,"briefTitle":3920,"status":230,"phases":3921,"primaryCompletion":3922,"completion":3922,"start":3923,"enrollment":362,"conditions":3924,"interventions":3931},"NCT05103904","Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant",[91],"2025-05-09","2022-04-19",[3925,2586,3926,3927,2587,3928,3929,3930],"Recurrent Hepatocellular Carcinoma","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Hepatocellular Carcinoma",[82],{"trials":3933,"activeCount":114},[],{"trials":3935,"activeCount":114},[],{"trials":3937,"activeCount":114},[],{"intervention":3939,"totalTrials":327,"cells":3940},"Allogeneic Microbiota in Glycerol",{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3954,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3942,"activeCount":114},[],{"trials":3944,"activeCount":114},[3945],{"nctId":3946,"briefTitle":3947,"status":105,"phases":3948,"primaryCompletion":3949,"completion":3949,"start":3950,"enrollment":2075,"conditions":3951,"interventions":3953},"NCT05780801","Sentinel Cohort REACT",[90],"2024-01-31","2023-04-24",[3952],"Multi-Drug Resistant Organism",[3939],{"trials":3955,"activeCount":186,"soonestReadout":649},[3956],{"nctId":3957,"briefTitle":3958,"status":215,"phases":3959,"primaryCompletion":649,"completion":965,"start":3960,"enrollment":436,"conditions":3961,"interventions":3963},"NCT06321536","Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)",[91],"2025-01-13",[3962],"Multi-Drug Resistant Organism Colonization",[3939],{"trials":3965,"activeCount":114},[],{"trials":3967,"activeCount":114},[],{"trials":3969,"activeCount":114},[],{"intervention":200,"totalTrials":327,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3973,"activeCount":114},[],{"trials":3975,"activeCount":114},[],{"trials":3977,"activeCount":186,"soonestReadout":193},[3978,3982],{"nctId":190,"briefTitle":191,"status":145,"phases":3979,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":3980,"interventions":3981},[91],[198],[127,200,97,201],{"nctId":271,"briefTitle":272,"status":230,"phases":3983,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":3984,"interventions":3985},[91],[198,278],[127,200,97,128,280],{"trials":3987,"activeCount":114},[],{"trials":3989,"activeCount":114},[],{"trials":3991,"activeCount":114},[],{"intervention":52,"totalTrials":327,"cells":3993},{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3995,"activeCount":114},[],{"trials":3997,"activeCount":114},[],{"trials":3999,"activeCount":186,"soonestReadout":51},[4000,4004],{"nctId":49,"briefTitle":50,"status":145,"phases":4001,"primaryCompletion":51,"completion":3100,"start":3101,"enrollment":136,"conditions":4002,"interventions":4003},[91],[3103,2691,3104],[52,3090,3106],{"nctId":2225,"briefTitle":2226,"status":105,"phases":4005,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":362,"conditions":4006,"interventions":4007},[90,91],[2232,2233,2234,2235],[52,1982,57],{"trials":4009,"activeCount":114},[],{"trials":4011,"activeCount":114},[],{"trials":4013,"activeCount":114},[],{"intervention":2369,"totalTrials":327,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4017,"activeCount":114},[],{"trials":4019,"activeCount":114},[],{"trials":4021,"activeCount":186,"soonestReadout":4026},[4022,4034],{"nctId":4023,"briefTitle":4024,"status":215,"phases":4025,"primaryCompletion":4026,"completion":4027,"start":4028,"enrollment":436,"conditions":4029,"interventions":4031},"NCT03800693","2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers",[91],"2026-08-05","2026-09-17","2019-03-14",[4030],"Malignant Digestive System Neoplasm",[4032,4033,2369],"Fluorouracil","Leucovorin",{"nctId":2361,"briefTitle":2362,"status":230,"phases":4035,"primaryCompletion":2364,"completion":2365,"start":2366,"enrollment":538,"conditions":4036,"interventions":4037},[91],[30],[1982,2369],{"trials":4039,"activeCount":114},[],{"trials":4041,"activeCount":114},[],{"trials":4043,"activeCount":114},[],{"intervention":3457,"totalTrials":327,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4054,"PHASE2":4056,"PHASE3":4062,"PHASE4":4064,"NA":4066},{"trials":4047,"activeCount":114},[4048],{"nctId":4049,"briefTitle":4050,"status":105,"phases":4051,"primaryCompletion":486,"completion":486,"start":2563,"enrollment":31,"conditions":4052,"interventions":4053},"NCT01989078","Losartan for Sickle Cell Kidney Disease",[89],[24],[3457],{"trials":4055,"activeCount":114},[],{"trials":4057,"activeCount":186,"soonestReadout":3450},[4058],{"nctId":3447,"briefTitle":3448,"status":215,"phases":4059,"primaryCompletion":3450,"completion":3450,"start":251,"enrollment":3451,"conditions":4060,"interventions":4061},[91],[3453],[3455,3456,3457,3438],{"trials":4063,"activeCount":114},[],{"trials":4065,"activeCount":114},[],{"trials":4067,"activeCount":114},[],{"intervention":4069,"totalTrials":327,"cells":4070},"psilocybin",{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4085,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4072,"activeCount":114},[],{"trials":4074,"activeCount":114},[4075],{"nctId":4076,"briefTitle":4077,"status":105,"phases":4078,"primaryCompletion":4079,"completion":4080,"start":1753,"enrollment":150,"conditions":4081,"interventions":4083},"NCT05506982","Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain",[90],"2024-04-25","2025-01-24",[4082,2855],"Hematopoietic and Lymphoid Cell Neoplasm",[4084],"Psilocybin",{"trials":4086,"activeCount":186,"soonestReadout":1451},[4087],{"nctId":4088,"briefTitle":4089,"status":1278,"phases":4090,"primaryCompletion":1451,"completion":1451,"start":868,"enrollment":1281,"conditions":4091,"interventions":4093},"NCT07332143","Psilocybin-Assisted Therapy",[91],[4092],"PTSD",[4069],{"trials":4095,"activeCount":114},[],{"trials":4097,"activeCount":114},[],{"trials":4099,"activeCount":114},[],{"intervention":3455,"totalTrials":327,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4129,"PHASE4":4131,"NA":4133},{"trials":4103,"activeCount":114},[],{"trials":4105,"activeCount":114},[],{"trials":4107,"activeCount":186,"soonestReadout":3450},[4108,4112],{"nctId":3447,"briefTitle":3448,"status":215,"phases":4109,"primaryCompletion":3450,"completion":3450,"start":251,"enrollment":3451,"conditions":4110,"interventions":4111},[91],[3453],[3455,3456,3457,3438],{"nctId":4113,"briefTitle":4114,"status":230,"phases":4115,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":4119,"interventions":4121},"NCT00166166","Endothelial Hyperpolarization in Humans",[91],"2013-01","2002-07",174,[4120],"Hyperlipidemia",[4122,4123,4124,4125,4126,4127,4128],"Tetraethylammonium","L-NG-monomethyl Arginine","Bradykinin","Sodium nitroprusside","Acetylcholine","Saline","Fluconazole",{"trials":4130,"activeCount":114},[],{"trials":4132,"activeCount":114},[],{"trials":4134,"activeCount":114},[],{"intervention":2590,"totalTrials":327,"cells":4136},{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4151,"PHASE4":4153,"NA":4155},{"trials":4138,"activeCount":114},[],{"trials":4140,"activeCount":114},[],{"trials":4142,"activeCount":186,"soonestReadout":2579},[4143,4147],{"nctId":3836,"briefTitle":3837,"status":105,"phases":4144,"primaryCompletion":507,"completion":507,"start":3839,"enrollment":98,"conditions":4145,"interventions":4146},[91],[3841],[2589,2590],{"nctId":2576,"briefTitle":2577,"status":215,"phases":4148,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":2582,"conditions":4149,"interventions":4150},[91],[2584,2585,2586,2587],[2512,2589,2590],{"trials":4152,"activeCount":114},[],{"trials":4154,"activeCount":114},[],{"trials":4156,"activeCount":114},[],{"intervention":4158,"totalTrials":186,"cells":4159},"Pioglitazone 30mg",{"EARLY_PHASE1":4160,"PHASE1":4162,"PHASE2":4164,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4161,"activeCount":114},[],{"trials":4163,"activeCount":114},[],{"trials":4165,"activeCount":186,"soonestReadout":4170},[4166],{"nctId":4167,"briefTitle":4168,"status":215,"phases":4169,"primaryCompletion":4170,"completion":4170,"start":4171,"enrollment":454,"conditions":4172,"interventions":4175},"NCT06336798","Bioenergetic Effect of Pioglitazone in CLD-PH",[91],"2028-02","2024-12-17",[4173,4174],"Pulmonary Hypertension","Pulmonary Hypertension Due to Lung Diseases",[4158],{"trials":4177,"activeCount":114},[],{"trials":4179,"activeCount":114},[],{"trials":4181,"activeCount":114},[],{"intervention":4183,"totalTrials":186,"cells":4184},"Microbiome Therapeutic",{"EARLY_PHASE1":4185,"PHASE1":4187,"PHASE2":4189,"PHASE3":4199,"PHASE4":4201,"NA":4203},{"trials":4186,"activeCount":114},[],{"trials":4188,"activeCount":114},[],{"trials":4190,"activeCount":186,"soonestReadout":4195},[4191],{"nctId":4192,"briefTitle":4193,"status":215,"phases":4194,"primaryCompletion":4195,"completion":4195,"start":4079,"enrollment":1796,"conditions":4196,"interventions":4198},"NCT05835206","Further MT for Antibiotic-Resistant Bacterial Colonization",[91],"2027-09",[4197],"Intestinal Multi-drug Resistant Organism Colonization",[4183],{"trials":4200,"activeCount":114},[],{"trials":4202,"activeCount":114},[],{"trials":4204,"activeCount":114},[],{"intervention":4206,"totalTrials":186,"cells":4207},"Verteporfin",{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4212,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4209,"activeCount":114},[],{"trials":4211,"activeCount":114},[],{"trials":4213,"activeCount":186,"soonestReadout":4218},[4214],{"nctId":4215,"briefTitle":4216,"status":215,"phases":4217,"primaryCompletion":4218,"completion":4218,"start":4219,"enrollment":31,"conditions":4220,"interventions":4221},"NCT04590664","Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma",[90,91],"2025-08-15","2021-01-15",[3263,3264],[4206],{"trials":4223,"activeCount":114},[],{"trials":4225,"activeCount":114},[],{"trials":4227,"activeCount":114},[],{"intervention":4229,"totalTrials":186,"cells":4230},"Bone marrow-derived mesenchymal stromal cells",{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4232,"activeCount":114},[],{"trials":4234,"activeCount":114},[],{"trials":4236,"activeCount":186,"soonestReadout":1242},[4237],{"nctId":4238,"briefTitle":4239,"status":1278,"phases":4240,"primaryCompletion":1242,"completion":1242,"start":738,"enrollment":870,"conditions":4241,"interventions":4244},"NCT05559801","Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)",[90,91],[4242,4243],"Osteogenesis Imperfecta","Osteogenesis Imperfecta Type III",[4229],{"trials":4246,"activeCount":114},[],{"trials":4248,"activeCount":114},[],{"trials":4250,"activeCount":114},[],{"intervention":4252,"totalTrials":186,"cells":4253},"Progesterone",{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4255,"activeCount":114},[],{"trials":4257,"activeCount":114},[],{"trials":4259,"activeCount":186,"soonestReadout":1599},[4260],{"nctId":4261,"briefTitle":4262,"status":215,"phases":4263,"primaryCompletion":1599,"completion":1599,"start":4264,"enrollment":1796,"conditions":4265,"interventions":4267},"NCT06807580","Progesterone in Gender Affirming Hormone Therapy Study",[91],"2025-05-12",[4266],"Transgender Women",[4252],{"trials":4269,"activeCount":114},[],{"trials":4271,"activeCount":114},[],{"trials":4273,"activeCount":114},[],{"intervention":2185,"totalTrials":186,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4277,"activeCount":114},[],{"trials":4279,"activeCount":114},[],{"trials":4281,"activeCount":186,"soonestReadout":56},[4282],{"nctId":54,"briefTitle":55,"status":145,"phases":4283,"primaryCompletion":56,"completion":241,"start":2175,"enrollment":1754,"conditions":4284,"interventions":4285},[91],[2177,2178,2179,2180,2181,2182,1870,2183],[57,2185,67],{"trials":4287,"activeCount":114},[],{"trials":4289,"activeCount":114},[],{"trials":4291,"activeCount":114},[],{"intervention":4032,"totalTrials":186,"cells":4293},{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4295,"activeCount":114},[],{"trials":4297,"activeCount":114},[],{"trials":4299,"activeCount":186,"soonestReadout":4026},[4300],{"nctId":4023,"briefTitle":4024,"status":215,"phases":4301,"primaryCompletion":4026,"completion":4027,"start":4028,"enrollment":436,"conditions":4302,"interventions":4303},[91],[4030],[4032,4033,2369],{"trials":4305,"activeCount":114},[],{"trials":4307,"activeCount":114},[],{"trials":4309,"activeCount":114},[],{"intervention":4033,"totalTrials":186,"cells":4311},{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4313,"activeCount":114},[],{"trials":4315,"activeCount":114},[],{"trials":4317,"activeCount":186,"soonestReadout":4026},[4318],{"nctId":4023,"briefTitle":4024,"status":215,"phases":4319,"primaryCompletion":4026,"completion":4027,"start":4028,"enrollment":436,"conditions":4320,"interventions":4321},[91],[4030],[4032,4033,2369],{"trials":4323,"activeCount":114},[],{"trials":4325,"activeCount":114},[],{"trials":4327,"activeCount":114},[],{"intervention":3122,"totalTrials":186,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4331,"activeCount":114},[],{"trials":4333,"activeCount":114},[],{"trials":4335,"activeCount":186,"soonestReadout":3111},[4336],{"nctId":3108,"briefTitle":3109,"status":215,"phases":4337,"primaryCompletion":3111,"completion":3112,"start":3113,"enrollment":196,"conditions":4338,"interventions":4339},[91],[3115,3116,3117,3118,3119,3120,2691,2692],[3122,3090],{"trials":4341,"activeCount":114},[],{"trials":4343,"activeCount":114},[],{"trials":4345,"activeCount":114},[],{"intervention":4347,"totalTrials":186,"cells":4348},"Recombinant Vesicular Stomatitis Vaccine for Ebola",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4363,"PHASE4":4365,"NA":4367},{"trials":4350,"activeCount":114},[],{"trials":4352,"activeCount":114},[],{"trials":4354,"activeCount":186,"soonestReadout":4359},[4355],{"nctId":4356,"briefTitle":4357,"status":145,"phases":4358,"primaryCompletion":4359,"completion":4359,"start":2374,"enrollment":123,"conditions":4360,"interventions":4362},"NCT06100913","Immunology of Ebola Vaccine",[91],"2027-08-31",[4361],"Ebola Virus Disease",[4347],{"trials":4364,"activeCount":114},[],{"trials":4366,"activeCount":114},[],{"trials":4368,"activeCount":114},[],{"intervention":1949,"totalTrials":186,"cells":4370},{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4381,"PHASE4":4383,"NA":4385},{"trials":4372,"activeCount":114},[],{"trials":4374,"activeCount":114},[],{"trials":4376,"activeCount":186,"soonestReadout":302},[4377],{"nctId":1940,"briefTitle":1941,"status":215,"phases":4378,"primaryCompletion":302,"completion":1794,"start":1943,"enrollment":22,"conditions":4379,"interventions":4380},[91],[1798,1945,1799,1800,1801,1802,1803,1804,1946,1806,1807,1808,1809,1810,1811,1947,1815,1816,1817,1818,1819,1820],[1949,1743],{"trials":4382,"activeCount":114},[],{"trials":4384,"activeCount":114},[],{"trials":4386,"activeCount":114},[],{"intervention":4388,"totalTrials":186,"cells":4389},"L-leucine",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4407,"PHASE4":4409,"NA":4411},{"trials":4391,"activeCount":114},[],{"trials":4393,"activeCount":114},[],{"trials":4395,"activeCount":186,"soonestReadout":4400},[4396],{"nctId":4397,"briefTitle":4398,"status":215,"phases":4399,"primaryCompletion":4400,"completion":1465,"start":4401,"enrollment":4402,"conditions":4403,"interventions":4405},"NCT06580145","Leucine in Midlife Depression",[91],"2028-06","2025-02-01",75,[4404],"Major Depression",[4388,4406],"L-lysine",{"trials":4408,"activeCount":114},[],{"trials":4410,"activeCount":114},[],{"trials":4412,"activeCount":114},[],{"intervention":4406,"totalTrials":186,"cells":4414},{"EARLY_PHASE1":4415,"PHASE1":4417,"PHASE2":4419,"PHASE3":4425,"PHASE4":4427,"NA":4429},{"trials":4416,"activeCount":114},[],{"trials":4418,"activeCount":114},[],{"trials":4420,"activeCount":186,"soonestReadout":4400},[4421],{"nctId":4397,"briefTitle":4398,"status":215,"phases":4422,"primaryCompletion":4400,"completion":1465,"start":4401,"enrollment":4402,"conditions":4423,"interventions":4424},[91],[4404],[4388,4406],{"trials":4426,"activeCount":114},[],{"trials":4428,"activeCount":114},[],{"trials":4430,"activeCount":114},[],{"intervention":77,"totalTrials":186,"cells":4432},{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4437,"PHASE3":4446,"PHASE4":4448,"NA":4450},{"trials":4434,"activeCount":114},[],{"trials":4436,"activeCount":114},[],{"trials":4438,"activeCount":186,"soonestReadout":76},[4439],{"nctId":74,"briefTitle":75,"status":145,"phases":4440,"primaryCompletion":76,"completion":4441,"start":4442,"enrollment":454,"conditions":4443,"interventions":4445},[91],"2028-07-01","2023-04-27",[4444,1405],"Prostate Adenocarcinoma",[77],{"trials":4447,"activeCount":114},[],{"trials":4449,"activeCount":114},[],{"trials":4451,"activeCount":114},[],{"intervention":4453,"totalTrials":186,"cells":4454},"EPTACOG BETA",{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4456,"activeCount":114},[],{"trials":4458,"activeCount":114},[],{"trials":4460,"activeCount":186,"soonestReadout":965},[4461],{"nctId":4462,"briefTitle":4463,"status":215,"phases":4464,"primaryCompletion":965,"completion":965,"start":4465,"enrollment":538,"conditions":4466,"interventions":4467},"NCT07136857","Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)",[91],"2025-10-02",[2946],[4453],{"trials":4469,"activeCount":114},[],{"trials":4471,"activeCount":114},[],{"trials":4473,"activeCount":114},[],{"intervention":4475,"totalTrials":186,"cells":4476},"Flotufolastat F-18 Gallium",{"EARLY_PHASE1":4477,"PHASE1":4479,"PHASE2":4481,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4478,"activeCount":114},[],{"trials":4480,"activeCount":114},[],{"trials":4482,"activeCount":186,"soonestReadout":1794},[4483],{"nctId":4484,"briefTitle":4485,"status":215,"phases":4486,"primaryCompletion":1794,"completion":4487,"start":4488,"enrollment":845,"conditions":4489,"interventions":4491},"NCT06865768","An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique",[91],"2029-12-31","2025-04-18",[4490],"Prostate Carcinoma",[4475],{"trials":4493,"activeCount":114},[],{"trials":4495,"activeCount":114},[],{"trials":4497,"activeCount":114},[],{"intervention":4499,"totalTrials":186,"cells":4500},"Zanidatamab",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4527,"PHASE4":4529,"NA":4531},{"trials":4502,"activeCount":114},[],{"trials":4504,"activeCount":114},[],{"trials":4506,"activeCount":186,"soonestReadout":4511},[4507],{"nctId":4508,"briefTitle":4509,"status":215,"phases":4510,"primaryCompletion":4511,"completion":4512,"start":4513,"enrollment":3646,"conditions":4514,"interventions":4526},"NCT07405476","Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment",[91],"2028-12-18","2029-12-18","2026-04-07",[4515,3650,4516,4517,4518,4519,4520,4521,4522,4523,4524,4525],"Colon Carcinoma","Rectal Carcinoma","Stage I Colon Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Rectal Cancer AJCC v8","Stage II Colon Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Rectal Cancer AJCC v8","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8",[4499],{"trials":4528,"activeCount":114},[],{"trials":4530,"activeCount":114},[],{"trials":4532,"activeCount":114},[],{"intervention":4534,"totalTrials":186,"cells":4535},"6R-BH4",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4551,"PHASE4":4553,"NA":4555},{"trials":4537,"activeCount":114},[],{"trials":4539,"activeCount":114},[],{"trials":4541,"activeCount":186,"soonestReadout":4546},[4542],{"nctId":4543,"briefTitle":4544,"status":215,"phases":4545,"primaryCompletion":4546,"completion":4546,"start":4547,"enrollment":1281,"conditions":4548,"interventions":4550},"NCT02947750","Neurovascular Transduction During Exercise in Chronic Kidney Disease",[91],"2027-04-30","2016-10",[4549],"Renal Insufficiency, Chronic",[4534],{"trials":4552,"activeCount":114},[],{"trials":4554,"activeCount":114},[],{"trials":4556,"activeCount":114},[],{"intervention":3456,"totalTrials":186,"cells":4558},{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4569,"PHASE4":4571,"NA":4573},{"trials":4560,"activeCount":114},[],{"trials":4562,"activeCount":114},[],{"trials":4564,"activeCount":186,"soonestReadout":3450},[4565],{"nctId":3447,"briefTitle":3448,"status":215,"phases":4566,"primaryCompletion":3450,"completion":3450,"start":251,"enrollment":3451,"conditions":4567,"interventions":4568},[91],[3453],[3455,3456,3457,3438],{"trials":4570,"activeCount":114},[],{"trials":4572,"activeCount":114},[],{"trials":4574,"activeCount":114},[],{"intervention":2861,"totalTrials":186,"cells":4576},{"EARLY_PHASE1":4577,"PHASE1":4579,"PHASE2":4581,"PHASE3":4587,"PHASE4":4589,"NA":4591},{"trials":4578,"activeCount":114},[],{"trials":4580,"activeCount":114},[],{"trials":4582,"activeCount":186,"soonestReadout":301},[4583],{"nctId":2848,"briefTitle":2849,"status":215,"phases":4584,"primaryCompletion":301,"completion":302,"start":2851,"enrollment":208,"conditions":4585,"interventions":4586},[91],[2853,2854,2855,2856,2857,2858,2859],[2861,1980],{"trials":4588,"activeCount":114},[],{"trials":4590,"activeCount":114},[],{"trials":4592,"activeCount":114},[],{"intervention":4594,"totalTrials":186,"cells":4595},"3,4-Methylenedioxymethamphetamine",{"EARLY_PHASE1":4596,"PHASE1":4598,"PHASE2":4600,"PHASE3":4609,"PHASE4":4611,"NA":4613},{"trials":4597,"activeCount":114},[],{"trials":4599,"activeCount":114},[],{"trials":4601,"activeCount":186,"soonestReadout":4606},[4602],{"nctId":4603,"briefTitle":4604,"status":215,"phases":4605,"primaryCompletion":4606,"completion":4606,"start":649,"enrollment":220,"conditions":4607,"interventions":4608},"NCT07288151","MDMA-Assisted Massed Exposure Therapy for PTSD",[91],"2030-01",[324],[4594],{"trials":4610,"activeCount":114},[],{"trials":4612,"activeCount":114},[],{"trials":4614,"activeCount":114},[],{"intervention":4616,"totalTrials":186,"cells":4617},"Arginine",{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4622,"PHASE3":4630,"PHASE4":4632,"NA":4634},{"trials":4619,"activeCount":114},[],{"trials":4621,"activeCount":114},[],{"trials":4623,"activeCount":186,"soonestReadout":649},[4624],{"nctId":4625,"briefTitle":4626,"status":215,"phases":4627,"primaryCompletion":649,"completion":649,"start":3679,"enrollment":1930,"conditions":4628,"interventions":4629},"NCT02447874","Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease",[90,91],[24],[4616,4616,4616],{"trials":4631,"activeCount":114},[],{"trials":4633,"activeCount":114},[],{"trials":4635,"activeCount":114},[],{"intervention":4637,"totalTrials":186,"cells":4638},"Toripalimab",{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4640,"activeCount":114},[],{"trials":4642,"activeCount":114},[],{"trials":4644,"activeCount":186,"soonestReadout":4649},[4645],{"nctId":4646,"briefTitle":4647,"status":215,"phases":4648,"primaryCompletion":4649,"completion":4487,"start":4650,"enrollment":1796,"conditions":4651,"interventions":4655},"NCT07140679","Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer",[91],"2029-09-30","2025-09-19",[4652,4653,4654,4523],"Localized Colon Carcinoma","Stage IIB Colon Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8",[4637],{"trials":4657,"activeCount":114},[],{"trials":4659,"activeCount":114},[],{"trials":4661,"activeCount":114},[],{"intervention":1969,"totalTrials":186,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4665,"activeCount":114},[],{"trials":4667,"activeCount":114},[],{"trials":4669,"activeCount":186,"soonestReadout":81},[4670],{"nctId":79,"briefTitle":80,"status":145,"phases":4671,"primaryCompletion":81,"completion":1962,"start":1963,"enrollment":98,"conditions":4672,"interventions":4673},[91],[1965,1966,1967],[82,1969,1743],{"trials":4675,"activeCount":114},[],{"trials":4677,"activeCount":114},[],{"trials":4679,"activeCount":114},[],{"intervention":62,"totalTrials":186,"cells":4681},{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4686,"PHASE3":4700,"PHASE4":4702,"NA":4704},{"trials":4683,"activeCount":114},[],{"trials":4685,"activeCount":114},[],{"trials":4687,"activeCount":186,"soonestReadout":61},[4688],{"nctId":59,"briefTitle":60,"status":145,"phases":4689,"primaryCompletion":61,"completion":4690,"start":4691,"enrollment":25,"conditions":4692,"interventions":4698},[91],"2026-12-01","2019-10-15",[4693,2158,4694,4695,4696,4697],"Advanced Microsatellite Stable Colorectal Carcinoma","Microsatellite Stable","RAS Wild Type","Stage IV Colorectal Cancer AJCC v8","MSI-H Colorectal Cancer",[62,4699],"Panitumumab",{"trials":4701,"activeCount":114},[],{"trials":4703,"activeCount":114},[],{"trials":4705,"activeCount":114},[],{"intervention":4699,"totalTrials":186,"cells":4707},{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4718,"PHASE4":4720,"NA":4722},{"trials":4709,"activeCount":114},[],{"trials":4711,"activeCount":114},[],{"trials":4713,"activeCount":186,"soonestReadout":61},[4714],{"nctId":59,"briefTitle":60,"status":145,"phases":4715,"primaryCompletion":61,"completion":4690,"start":4691,"enrollment":25,"conditions":4716,"interventions":4717},[91],[4693,2158,4694,4695,4696,4697],[62,4699],{"trials":4719,"activeCount":114},[],{"trials":4721,"activeCount":114},[],{"trials":4723,"activeCount":114},[],{"intervention":4725,"totalTrials":186,"cells":4726},"Thyroid hormone T3",{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4741,"PHASE4":4743,"NA":4745},{"trials":4728,"activeCount":114},[],{"trials":4730,"activeCount":114},[],{"trials":4732,"activeCount":186,"soonestReadout":353},[4733],{"nctId":4734,"briefTitle":4735,"status":145,"phases":4736,"primaryCompletion":353,"completion":353,"start":4737,"enrollment":454,"conditions":4738,"interventions":4740},"NCT05384847","Effects of Triiodothyronine (T3) in Ischemic Heart Failure",[90,91],"2022-12-02",[4739],"Heart Failure",[4725],{"trials":4742,"activeCount":114},[],{"trials":4744,"activeCount":114},[],{"trials":4746,"activeCount":114},[],{"intervention":2007,"totalTrials":186,"cells":4748},{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4753,"PHASE3":4759,"PHASE4":4761,"NA":4763},{"trials":4750,"activeCount":114},[],{"trials":4752,"activeCount":114},[],{"trials":4754,"activeCount":186,"soonestReadout":1987},[4755],{"nctId":1984,"briefTitle":1985,"status":145,"phases":4756,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":538,"conditions":4757,"interventions":4758},[91],[1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004],[1743,2006,57,2007],{"trials":4760,"activeCount":114},[],{"trials":4762,"activeCount":114},[],{"trials":4764,"activeCount":114},[],{"intervention":4766,"totalTrials":186,"cells":4767},"Nanoliposomal Irinotecan",{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4790,"PHASE4":4792,"NA":4794},{"trials":4769,"activeCount":114},[],{"trials":4771,"activeCount":114},[],{"trials":4773,"activeCount":186,"soonestReadout":4778},[4774],{"nctId":4775,"briefTitle":4776,"status":145,"phases":4777,"primaryCompletion":4778,"completion":4779,"start":4780,"enrollment":4781,"conditions":4782,"interventions":4788},"NCT03368963","TAS102 in Combination With NAL-IRI in Advanced GI Cancers",[90,91],"2025-06-28","2025-11-28","2018-01-30",64,[1772,4783,1773,4784,1780,4785,1781,1782,1784,1776,4786,1777,4787,1786],"Gastric Adenocarcinoma","Non-Resectable Cholangiocarcinoma","Stage IV Gastric Cancer","Stage III Gastric Cancer","Unresectable Digestive System Adenocarcinoma",[4766,4789],"Trifluridine and Tipiracil Hydrochloride",{"trials":4791,"activeCount":114},[],{"trials":4793,"activeCount":114},[],{"trials":4795,"activeCount":114},[],{"intervention":4789,"totalTrials":186,"cells":4797},{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4808,"PHASE4":4810,"NA":4812},{"trials":4799,"activeCount":114},[],{"trials":4801,"activeCount":114},[],{"trials":4803,"activeCount":186,"soonestReadout":4778},[4804],{"nctId":4775,"briefTitle":4776,"status":145,"phases":4805,"primaryCompletion":4778,"completion":4779,"start":4780,"enrollment":4781,"conditions":4806,"interventions":4807},[90,91],[1772,4783,1773,4784,1780,4785,1781,1782,1784,1776,4786,1777,4787,1786],[4766,4789],{"trials":4809,"activeCount":114},[],{"trials":4811,"activeCount":114},[],{"trials":4813,"activeCount":114},[],{"intervention":4815,"totalTrials":186,"cells":4816},"MDMA",{"EARLY_PHASE1":4817,"PHASE1":4819,"PHASE2":4821,"PHASE3":4831,"PHASE4":4833,"NA":4835},{"trials":4818,"activeCount":114},[],{"trials":4820,"activeCount":114},[],{"trials":4822,"activeCount":186,"soonestReadout":4827},[4823],{"nctId":4824,"briefTitle":4825,"status":1240,"phases":4826,"primaryCompletion":4827,"completion":4827,"start":4828,"enrollment":1796,"conditions":4829,"interventions":4830},"NCT05746572","MDMA Plus Exposure Therapy for PTSD",[91],"2026-05-29","2024-02-13",[4092],[4815],{"trials":4832,"activeCount":114},[],{"trials":4834,"activeCount":114},[],{"trials":4836,"activeCount":114},[],{"intervention":3056,"totalTrials":186,"cells":4838},{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4843,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4840,"activeCount":114},[],{"trials":4842,"activeCount":114},[],{"trials":4844,"activeCount":186,"soonestReadout":3051},[4845],{"nctId":3048,"briefTitle":3049,"status":145,"phases":4846,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":3053,"conditions":4847,"interventions":4848},[91],[24],[3056,3057,2678],{"trials":4850,"activeCount":114},[],{"trials":4852,"activeCount":114},[],{"trials":4854,"activeCount":114},[],{"intervention":4856,"totalTrials":186,"cells":4857},"medrol dosepak",{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4859,"activeCount":114},[],{"trials":4861,"activeCount":114},[],{"trials":4863,"activeCount":186,"soonestReadout":3005},[4864],{"nctId":4865,"briefTitle":4866,"status":215,"phases":4867,"primaryCompletion":3005,"completion":4868,"start":4869,"enrollment":4870,"conditions":4871,"interventions":4875},"NCT06780202","Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients",[91],"2027-12","2025-01-27",180,[4872,4873,4874],"Foot Injuries and Disorders","Ankle Injuries and Disorders","Achilles Tendon Injury",[4856,4876],"HYDROcodone Oral",{"trials":4878,"activeCount":114},[],{"trials":4880,"activeCount":114},[],{"trials":4882,"activeCount":114},[],{"intervention":4876,"totalTrials":186,"cells":4884},{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4895,"PHASE4":4897,"NA":4899},{"trials":4886,"activeCount":114},[],{"trials":4888,"activeCount":114},[],{"trials":4890,"activeCount":186,"soonestReadout":3005},[4891],{"nctId":4865,"briefTitle":4866,"status":215,"phases":4892,"primaryCompletion":3005,"completion":4868,"start":4869,"enrollment":4870,"conditions":4893,"interventions":4894},[91],[4872,4873,4874],[4856,4876],{"trials":4896,"activeCount":114},[],{"trials":4898,"activeCount":114},[],{"trials":4900,"activeCount":114},[],{"intervention":2040,"totalTrials":186,"cells":4902},{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4907,"PHASE3":4913,"PHASE4":4915,"NA":4917},{"trials":4904,"activeCount":114},[],{"trials":4906,"activeCount":114},[],{"trials":4908,"activeCount":186,"soonestReadout":2032},[4909],{"nctId":2029,"briefTitle":2030,"status":145,"phases":4910,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":123,"conditions":4911,"interventions":4912},[91],[2036,2037,1757,1758,1759],[2039,1743,2040],{"trials":4914,"activeCount":114},[],{"trials":4916,"activeCount":114},[],{"trials":4918,"activeCount":114},[],{"intervention":2223,"totalTrials":186,"cells":4920},{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4922,"activeCount":114},[],{"trials":4924,"activeCount":114},[],{"trials":4926,"activeCount":186,"soonestReadout":2217},[4927],{"nctId":2214,"briefTitle":2215,"status":215,"phases":4928,"primaryCompletion":2217,"completion":2125,"start":47,"enrollment":2218,"conditions":4929,"interventions":4930},[91],[2220,2221],[2223,57],{"trials":4932,"activeCount":114},[],{"trials":4934,"activeCount":114},[],{"trials":4936,"activeCount":114},[],{"intervention":269,"totalTrials":186,"cells":4938},{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4949,"PHASE4":4951,"NA":4953},{"trials":4940,"activeCount":114},[],{"trials":4942,"activeCount":114},[],{"trials":4944,"activeCount":186,"soonestReadout":262},[4945],{"nctId":259,"briefTitle":260,"status":215,"phases":4946,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":4947,"interventions":4948},[91],[267],[97,269],{"trials":4950,"activeCount":114},[],{"trials":4952,"activeCount":114},[],{"trials":4954,"activeCount":114},[],{"intervention":4956,"totalTrials":186,"cells":4957},"Arginine Hydrochloride",{"EARLY_PHASE1":4958,"PHASE1":4960,"PHASE2":4962,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4959,"activeCount":114},[],{"trials":4961,"activeCount":114},[],{"trials":4963,"activeCount":186,"soonestReadout":4400},[4964],{"nctId":4965,"briefTitle":4966,"status":215,"phases":4967,"primaryCompletion":4400,"completion":4400,"start":4968,"enrollment":1930,"conditions":4969,"interventions":4970},"NCT05855330","Arginine Replacement Therapy in COVID-19",[91],"2024-01-08",[708],[4956],{"trials":4972,"activeCount":114},[],{"trials":4974,"activeCount":114},[],{"trials":4976,"activeCount":114},[],{"intervention":4978,"totalTrials":186,"cells":4979},"Antiretroviral Therapy",{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4981,"activeCount":114},[],{"trials":4983,"activeCount":114},[],{"trials":4985,"activeCount":186,"soonestReadout":4990},[4986],{"nctId":4987,"briefTitle":4988,"status":1278,"phases":4989,"primaryCompletion":4990,"completion":4990,"start":649,"enrollment":454,"conditions":4991,"interventions":4993},"NCT07209267","Baricitinib Curative Repression of HIV-1",[91],"2028-01",[4992,15],"HIV Infection",[4978,4994],"Baricitinib (LY3009104) 2 mg",{"trials":4996,"activeCount":114},[],{"trials":4998,"activeCount":114},[],{"trials":5000,"activeCount":114},[],{"intervention":4994,"totalTrials":186,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5004,"activeCount":114},[],{"trials":5006,"activeCount":114},[],{"trials":5008,"activeCount":186,"soonestReadout":4990},[5009],{"nctId":4987,"briefTitle":4988,"status":1278,"phases":5010,"primaryCompletion":4990,"completion":4990,"start":649,"enrollment":454,"conditions":5011,"interventions":5012},[91],[4992,15],[4978,4994],{"trials":5014,"activeCount":114},[],{"trials":5016,"activeCount":114},[],{"trials":5018,"activeCount":114},[],{"intervention":291,"totalTrials":186,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5031,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":114},[],{"trials":5024,"activeCount":114},[],{"trials":5026,"activeCount":186,"soonestReadout":285},[5027],{"nctId":282,"briefTitle":283,"status":215,"phases":5028,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":5029,"interventions":5030},[91],[198],[291,97,246],{"trials":5032,"activeCount":114},[],{"trials":5034,"activeCount":114},[],{"trials":5036,"activeCount":114},[],{"intervention":2055,"totalTrials":186,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5043,"PHASE3":5049,"PHASE4":5051,"NA":5053},{"trials":5040,"activeCount":114},[],{"trials":5042,"activeCount":114},[],{"trials":5044,"activeCount":186,"soonestReadout":2045},[5045],{"nctId":2042,"briefTitle":2043,"status":215,"phases":5046,"primaryCompletion":2045,"completion":2046,"start":2047,"enrollment":454,"conditions":5047,"interventions":5048},[91],[2049,2050,2051,1757],[2053,2054,2055,57,1743],{"trials":5050,"activeCount":114},[],{"trials":5052,"activeCount":114},[],{"trials":5054,"activeCount":114},[],{"intervention":2115,"totalTrials":327,"cells":5056},{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5069,"PHASE3":5071,"PHASE4":5073,"NA":5075},{"trials":5058,"activeCount":114},[],{"trials":5060,"activeCount":327,"soonestReadout":66},[5061,5065],{"nctId":64,"briefTitle":65,"status":145,"phases":5062,"primaryCompletion":66,"completion":2107,"start":2108,"enrollment":2109,"conditions":5063,"interventions":5064},[90],[2111,2112,2113],[67,57,2115],{"nctId":2121,"briefTitle":2122,"status":215,"phases":5066,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":391,"conditions":5067,"interventions":5068},[90],[2128],[2115,67,57],{"trials":5070,"activeCount":114},[],{"trials":5072,"activeCount":114},[],{"trials":5074,"activeCount":114},[],{"trials":5076,"activeCount":114},[],{"intervention":3143,"totalTrials":327,"cells":5078},{"EARLY_PHASE1":5079,"PHASE1":5081,"PHASE2":5087,"PHASE3":5089,"PHASE4":5104,"NA":5106},{"trials":5080,"activeCount":114},[],{"trials":5082,"activeCount":186,"soonestReadout":1974},[5083],{"nctId":3136,"briefTitle":3137,"status":145,"phases":5084,"primaryCompletion":1974,"completion":3139,"start":3140,"enrollment":2277,"conditions":5085,"interventions":5086},[90],[138,210],[3143,3106],{"trials":5088,"activeCount":114},[],{"trials":5090,"activeCount":114},[5091],{"nctId":5092,"briefTitle":5093,"status":2022,"phases":5094,"primaryCompletion":5095,"completion":5095,"start":5096,"enrollment":114,"conditions":5097,"interventions":5103},"NCT04361552","Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",[92],"2020-06-02","2020-04-07",[5098,5099,5100,27,510,5101,5102],"Cerebrovascular Accident","Chronic Obstructive Pulmonary Disease","Chronic Renal Failure","Malignant Neoplasm","SARS Coronavirus 2 Infection",[3143],{"trials":5105,"activeCount":114},[],{"trials":5107,"activeCount":114},[],{"intervention":5109,"totalTrials":186,"cells":5110},"Influenza Virus influenza A H3N2 strain",{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5122,"PHASE3":5124,"PHASE4":5126,"NA":5128},{"trials":5112,"activeCount":114},[],{"trials":5114,"activeCount":186,"soonestReadout":4868},[5115],{"nctId":5116,"briefTitle":5117,"status":215,"phases":5118,"primaryCompletion":4868,"completion":4868,"start":5119,"enrollment":391,"conditions":5120,"interventions":5121},"NCT06753474","A\u002FTexas Flu Challenge",[90],"2025-02-04",[847],[5109],{"trials":5123,"activeCount":114},[],{"trials":5125,"activeCount":114},[],{"trials":5127,"activeCount":114},[],{"trials":5129,"activeCount":114},[],{"intervention":5131,"totalTrials":186,"cells":5132},"Lutetium Lu 177 Dotatate",{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5149,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5134,"activeCount":114},[],{"trials":5136,"activeCount":186,"soonestReadout":683},[5137],{"nctId":5138,"briefTitle":5139,"status":215,"phases":5140,"primaryCompletion":683,"completion":5141,"start":5142,"enrollment":1754,"conditions":5143,"interventions":5148},"NCT07150546","Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.",[90],"2027-09-30","2025-10-14",[5144,5145,5146,5147],"Digestive System Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2",[5131],{"trials":5150,"activeCount":114},[],{"trials":5152,"activeCount":114},[],{"trials":5154,"activeCount":114},[],{"trials":5156,"activeCount":114},[],{"intervention":5158,"totalTrials":186,"cells":5159},"Influenza Virus Type A H3N2 Challenge",{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5171,"PHASE3":5173,"PHASE4":5175,"NA":5177},{"trials":5161,"activeCount":114},[],{"trials":5163,"activeCount":186,"soonestReadout":4868},[5164],{"nctId":5165,"briefTitle":5166,"status":215,"phases":5167,"primaryCompletion":4868,"completion":4868,"start":5168,"enrollment":498,"conditions":5169,"interventions":5170},"NCT05332899","Influenza Human Challenge Model",[90],"2022-05-24",[847],[5158],{"trials":5172,"activeCount":114},[],{"trials":5174,"activeCount":114},[],{"trials":5176,"activeCount":114},[],{"trials":5178,"activeCount":114},[],{"intervention":5180,"totalTrials":186,"cells":5181},"Ventrix Bio Extracellular Matrix",{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5194,"PHASE3":5196,"PHASE4":5198,"NA":5200},{"trials":5183,"activeCount":114},[],{"trials":5185,"activeCount":186,"soonestReadout":343},[5186],{"nctId":5187,"briefTitle":5188,"status":1278,"phases":5189,"primaryCompletion":343,"completion":343,"start":5190,"enrollment":870,"conditions":5191,"interventions":5193},"NCT06461676","Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)",[90],"2025-08",[5192],"Hypoplastic Left Heart Syndrome",[5180],{"trials":5195,"activeCount":114},[],{"trials":5197,"activeCount":114},[],{"trials":5199,"activeCount":114},[],{"trials":5201,"activeCount":114},[],{"intervention":1822,"totalTrials":186,"cells":5203},{"EARLY_PHASE1":5204,"PHASE1":5206,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5205,"activeCount":114},[],{"trials":5207,"activeCount":186,"soonestReadout":1793},[5208],{"nctId":1790,"briefTitle":1791,"status":215,"phases":5209,"primaryCompletion":1793,"completion":1794,"start":1795,"enrollment":1796,"conditions":5210,"interventions":5211},[90],[1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820],[1822,1743],{"trials":5213,"activeCount":114},[],{"trials":5215,"activeCount":114},[],{"trials":5217,"activeCount":114},[],{"trials":5219,"activeCount":114},[],{"intervention":5221,"totalTrials":186,"cells":5222},"Dose Level 1 ACU-D1 ointment",{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5244},{"trials":5224,"activeCount":114},[],{"trials":5226,"activeCount":186,"soonestReadout":4868},[5227],{"nctId":5228,"briefTitle":5229,"status":1278,"phases":5230,"primaryCompletion":4868,"completion":4868,"start":868,"enrollment":2448,"conditions":5231,"interventions":5235},"NCT06233331","Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV",[90],[5232,822,5233,5234],"Human Papilloma Virus","Anal Intraepithelial Neoplasia","High-Grade Squamous Intraepithelial Lesions",[5221,5236,5237],"Dose Level 2 ACU-D1 ointment","Dose Level 3 ACU-D1 ointment",{"trials":5239,"activeCount":114},[],{"trials":5241,"activeCount":114},[],{"trials":5243,"activeCount":114},[],{"trials":5245,"activeCount":114},[],{"intervention":5236,"totalTrials":186,"cells":5247},{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5256,"PHASE3":5258,"PHASE4":5260,"NA":5262},{"trials":5249,"activeCount":114},[],{"trials":5251,"activeCount":186,"soonestReadout":4868},[5252],{"nctId":5228,"briefTitle":5229,"status":1278,"phases":5253,"primaryCompletion":4868,"completion":4868,"start":868,"enrollment":2448,"conditions":5254,"interventions":5255},[90],[5232,822,5233,5234],[5221,5236,5237],{"trials":5257,"activeCount":114},[],{"trials":5259,"activeCount":114},[],{"trials":5261,"activeCount":114},[],{"trials":5263,"activeCount":114},[],{"intervention":5237,"totalTrials":186,"cells":5265},{"EARLY_PHASE1":5266,"PHASE1":5268,"PHASE2":5274,"PHASE3":5276,"PHASE4":5278,"NA":5280},{"trials":5267,"activeCount":114},[],{"trials":5269,"activeCount":186,"soonestReadout":4868},[5270],{"nctId":5228,"briefTitle":5229,"status":1278,"phases":5271,"primaryCompletion":4868,"completion":4868,"start":868,"enrollment":2448,"conditions":5272,"interventions":5273},[90],[5232,822,5233,5234],[5221,5236,5237],{"trials":5275,"activeCount":114},[],{"trials":5277,"activeCount":114},[],{"trials":5279,"activeCount":114},[],{"trials":5281,"activeCount":114},[],{"intervention":155,"totalTrials":186,"cells":5283},{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5292,"PHASE3":5294,"PHASE4":5296,"NA":5298},{"trials":5285,"activeCount":114},[],{"trials":5287,"activeCount":186,"soonestReadout":147},[5288],{"nctId":143,"briefTitle":144,"status":145,"phases":5289,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":5290,"interventions":5291},[90],[152],[127,154,97,155],{"trials":5293,"activeCount":114},[],{"trials":5295,"activeCount":114},[],{"trials":5297,"activeCount":114},[],{"trials":5299,"activeCount":114},[],{"intervention":1857,"totalTrials":186,"cells":5301},{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5310,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5303,"activeCount":114},[],{"trials":5305,"activeCount":186,"soonestReadout":301},[5306],{"nctId":1824,"briefTitle":1825,"status":215,"phases":5307,"primaryCompletion":301,"completion":301,"start":1827,"enrollment":98,"conditions":5308,"interventions":5309},[90],[1829,1830,1831,1832,1833,1834,1835,1836,1837,1838,1839,1840,1841,1842,1843,1844,1845,1846,1847,1848,1849,1850,1851,1852,1853,1854,1855],[67,1743,1857],{"trials":5311,"activeCount":114},[],{"trials":5313,"activeCount":114},[],{"trials":5315,"activeCount":114},[],{"trials":5317,"activeCount":114},[],{"intervention":5319,"totalTrials":186,"cells":5320},"Allogeneic Neonatal mesenchymal stromal cells",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5333,"PHASE3":5335,"PHASE4":5337,"NA":5339},{"trials":5322,"activeCount":114},[],{"trials":5324,"activeCount":186,"soonestReadout":1105},[5325],{"nctId":5326,"briefTitle":5327,"status":215,"phases":5328,"primaryCompletion":1105,"completion":1105,"start":5329,"enrollment":1153,"conditions":5330,"interventions":5332},"NCT06464588","A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)",[90],"2025-07-14",[5331],"Dilated Cardiomyopathy",[5319],{"trials":5334,"activeCount":114},[],{"trials":5336,"activeCount":114},[],{"trials":5338,"activeCount":114},[],{"trials":5340,"activeCount":114},[],{"intervention":5342,"totalTrials":186,"cells":5343},"Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate",{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5357,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5345,"activeCount":114},[],{"trials":5347,"activeCount":186,"soonestReadout":965},[5348],{"nctId":5349,"briefTitle":5350,"status":215,"phases":5351,"primaryCompletion":965,"completion":965,"start":5352,"enrollment":31,"conditions":5353,"interventions":5356},"NCT05400603","Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed \u002FRefractory Neuroblastoma or Refractory\u002F Relapsed Osteosarcoma",[90],"2023-11-06",[2489,5354,5355,2342,2343],"Refractory Neuroblastoma","Relapsed Neuroblastoma",[5342],{"trials":5358,"activeCount":114},[],{"trials":5360,"activeCount":114},[],{"trials":5362,"activeCount":114},[],{"trials":5364,"activeCount":114},[],{"intervention":5366,"totalTrials":186,"cells":5367},"Testosterone Cypionate",{"EARLY_PHASE1":5368,"PHASE1":5370,"PHASE2":5385,"PHASE3":5387,"PHASE4":5389,"NA":5391},{"trials":5369,"activeCount":114},[],{"trials":5371,"activeCount":186,"soonestReadout":5376},[5372],{"nctId":5373,"briefTitle":5374,"status":145,"phases":5375,"primaryCompletion":5376,"completion":301,"start":5377,"enrollment":5378,"conditions":5379,"interventions":5384},"NCT04731376","Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone",[90],"2024-11-26","2021-01-25",56,[5380,5381,5382,5383],"Hypogonadism","Malignant Urinary System Neoplasm","Urinary System Disorder","Urinary System Neoplasm",[5366],{"trials":5386,"activeCount":114},[],{"trials":5388,"activeCount":114},[],{"trials":5390,"activeCount":114},[],{"trials":5392,"activeCount":114},[],{"intervention":5394,"totalTrials":186,"cells":5395},"Flt3\u002FMerTK Inhibitor MRX-2843",{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5410,"PHASE3":5412,"PHASE4":5414,"NA":5416},{"trials":5397,"activeCount":114},[],{"trials":5399,"activeCount":186,"soonestReadout":5404},[5400],{"nctId":5401,"briefTitle":5402,"status":215,"phases":5403,"primaryCompletion":5404,"completion":5404,"start":5405,"enrollment":5406,"conditions":5407,"interventions":5408},"NCT04762199","MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer",[90],"2026-12-27","2021-02-24",69,[2049,2050,1757,1758,1759],[5394,5409],"Osimertinib",{"trials":5411,"activeCount":114},[],{"trials":5413,"activeCount":114},[],{"trials":5415,"activeCount":114},[],{"trials":5417,"activeCount":114},[],{"intervention":5409,"totalTrials":186,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5428,"PHASE3":5430,"PHASE4":5432,"NA":5434},{"trials":5421,"activeCount":114},[],{"trials":5423,"activeCount":186,"soonestReadout":5404},[5424],{"nctId":5401,"briefTitle":5402,"status":215,"phases":5425,"primaryCompletion":5404,"completion":5404,"start":5405,"enrollment":5406,"conditions":5426,"interventions":5427},[90],[2049,2050,1757,1758,1759],[5394,5409],{"trials":5429,"activeCount":114},[],{"trials":5431,"activeCount":114},[],{"trials":5433,"activeCount":114},[],{"trials":5435,"activeCount":114},[],{"intervention":2345,"totalTrials":186,"cells":5437},{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5446,"PHASE3":5448,"PHASE4":5450,"NA":5452},{"trials":5439,"activeCount":114},[],{"trials":5441,"activeCount":186,"soonestReadout":1176},[5442],{"nctId":2335,"briefTitle":2336,"status":215,"phases":5443,"primaryCompletion":1176,"completion":1176,"start":2338,"enrollment":31,"conditions":5444,"interventions":5445},[90],[2340,2341,2342,2343],[2345,1982],{"trials":5447,"activeCount":114},[],{"trials":5449,"activeCount":114},[],{"trials":5451,"activeCount":114},[],{"trials":5453,"activeCount":114},[],{"intervention":5455,"totalTrials":186,"cells":5456},"Lurbinectedin",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5471,"PHASE3":5473,"PHASE4":5475,"NA":5477},{"trials":5458,"activeCount":114},[],{"trials":5460,"activeCount":186,"soonestReadout":5465},[5461],{"nctId":5462,"briefTitle":5463,"status":215,"phases":5464,"primaryCompletion":5465,"completion":5466,"start":5467,"enrollment":162,"conditions":5468,"interventions":5470},"NCT05244239","Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer",[90],"2026-07-28","2027-07-28","2022-07-27",[5469,1757],"Extensive Stage Lung Small Cell Carcinoma",[5455],{"trials":5472,"activeCount":114},[],{"trials":5474,"activeCount":114},[],{"trials":5476,"activeCount":114},[],{"trials":5478,"activeCount":114},[],{"intervention":5480,"totalTrials":186,"cells":5481},"Lutetium Lu 177 PSMA-10.1",{"EARLY_PHASE1":5482,"PHASE1":5484,"PHASE2":5495,"PHASE3":5497,"PHASE4":5499,"NA":5501},{"trials":5483,"activeCount":114},[],{"trials":5485,"activeCount":186,"soonestReadout":5490},[5486],{"nctId":5487,"briefTitle":5488,"status":145,"phases":5489,"primaryCompletion":5490,"completion":5491,"start":5492,"enrollment":538,"conditions":5493,"interventions":5494},"NCT06105918","Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer",[90],"2028-04-01","2029-04-01","2023-11-29",[1382,4444],[5480],{"trials":5496,"activeCount":114},[],{"trials":5498,"activeCount":114},[],{"trials":5500,"activeCount":114},[],{"trials":5502,"activeCount":114},[],{"intervention":5504,"totalTrials":327,"cells":5505},"Ketamine",{"EARLY_PHASE1":5506,"PHASE1":5517,"PHASE2":5519,"PHASE3":5521,"PHASE4":5523,"NA":5535},{"trials":5507,"activeCount":186,"soonestReadout":5512},[5508],{"nctId":5509,"briefTitle":5510,"status":215,"phases":5511,"primaryCompletion":5512,"completion":5512,"start":5513,"enrollment":5514,"conditions":5515,"interventions":5516},"NCT05327699","Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine",[89],"2028-03-02","2022-11-08",140,[2625],[5504],{"trials":5518,"activeCount":114},[],{"trials":5520,"activeCount":114},[],{"trials":5522,"activeCount":114},[],{"trials":5524,"activeCount":114},[5525],{"nctId":5526,"briefTitle":5527,"status":230,"phases":5528,"primaryCompletion":5529,"completion":5530,"start":5531,"enrollment":3535,"conditions":5532,"interventions":5534},"NCT03040024","Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients",[93],"2020-02-24","2020-04-24","2017-03-17",[5533],"Otolaryngeal Cancer",[5504],{"trials":5536,"activeCount":114},[],{"intervention":5538,"totalTrials":362,"cells":5539},"Letrozole",{"EARLY_PHASE1":5540,"PHASE1":5553,"PHASE2":5555,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5541,"activeCount":186,"soonestReadout":5546},[5542],{"nctId":5543,"briefTitle":5544,"status":215,"phases":5545,"primaryCompletion":5546,"completion":5547,"start":2012,"enrollment":1796,"conditions":5548,"interventions":5552},"NCT05464810","Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",[89],"2026-04-15","2027-04-15",[1829,1832,1835,5549,5550,5551],"HER2-Negative Breast Carcinoma","Hormone Receptor-Positive Breast Carcinoma","Invasive Breast Carcinoma",[5538,2496],{"trials":5554,"activeCount":114},[],{"trials":5556,"activeCount":114},[5557,5574],{"nctId":5558,"briefTitle":5559,"status":230,"phases":5560,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":5562,"interventions":5567},"NCT02269670","Phase II Study of Everolimus Beyond Progression",[91],"2014-11-25",[5563,5564,5565,5566,3538,3540,3542,3543],"Estrogen Receptor-positive Breast Cancer","HER2-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer","Recurrent Breast Cancer",[5568,5569,5570,5571,5572,5573],"everolimus","anastrozole","letrozole","tamoxifen citrate","fulvestrant","megestrol acetate",{"nctId":5575,"briefTitle":5576,"status":105,"phases":5577,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":5579,"interventions":5585},"NCT03691493","Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",[91],"2019-02-08",[1839,5580,5581,5582,5583,5584,1853],"Estrogen Receptor Positive","HER2\u002FNeu Negative","Metastatic Breast Carcinoma","Metastatic Malignant Neoplasm in the Bone","Progesterone Receptor Positive",[5586,3682,5587,5538,3550,5588],"Anastrozole","Fulvestrant","Tamoxifen",{"trials":5590,"activeCount":114},[],{"trials":5592,"activeCount":114},[],{"trials":5594,"activeCount":114},[],{"intervention":2496,"totalTrials":327,"cells":5596},{"EARLY_PHASE1":5597,"PHASE1":5603,"PHASE2":5609,"PHASE3":5611,"PHASE4":5613,"NA":5615},{"trials":5598,"activeCount":186,"soonestReadout":5546},[5599],{"nctId":5543,"briefTitle":5544,"status":215,"phases":5600,"primaryCompletion":5546,"completion":5547,"start":2012,"enrollment":1796,"conditions":5601,"interventions":5602},[89],[1829,1832,1835,5549,5550,5551],[5538,2496],{"trials":5604,"activeCount":114},[5605],{"nctId":2476,"briefTitle":2477,"status":105,"phases":5606,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":5607,"interventions":5608},[90],[2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494],[2496,154,2497,2498],{"trials":5610,"activeCount":114},[],{"trials":5612,"activeCount":114},[],{"trials":5614,"activeCount":114},[],{"trials":5616,"activeCount":114},[],{"intervention":72,"totalTrials":186,"cells":5618},{"EARLY_PHASE1":5619,"PHASE1":5633,"PHASE2":5635,"PHASE3":5637,"PHASE4":5639,"NA":5641},{"trials":5620,"activeCount":186,"soonestReadout":71},[5621],{"nctId":69,"briefTitle":70,"status":145,"phases":5622,"primaryCompletion":71,"completion":5623,"start":5624,"enrollment":2075,"conditions":5625,"interventions":5632},[89],"2026-07-21","2022-02-17",[5626,5627,5628,5629,5630,5631],"Head and Neck Carcinoma of Unknown Primary","Locally Advanced Head and Neck Squamous Cell Carcinoma","Locally Advanced Hypopharyngeal Squamous Cell Carcinoma","Locally Advanced Laryngeal Squamous Cell Carcinoma","Locally Advanced Nasopharyngeal Squamous Cell Carcinoma","Locally Advanced Oropharyngeal Squamous Cell Carcinoma",[72],{"trials":5634,"activeCount":114},[],{"trials":5636,"activeCount":114},[],{"trials":5638,"activeCount":114},[],{"trials":5640,"activeCount":114},[],{"trials":5642,"activeCount":114},[],{"intervention":5644,"totalTrials":186,"cells":5645},"Sodium Fluoride F-18",{"EARLY_PHASE1":5646,"PHASE1":5672,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5680},{"trials":5647,"activeCount":186,"soonestReadout":5652},[5648],{"nctId":5649,"briefTitle":5650,"status":215,"phases":5651,"primaryCompletion":5652,"completion":4359,"start":5653,"enrollment":454,"conditions":5654,"interventions":5671},"NCT06914999","Comparing an Investigational Scan (F-18 NaF PET\u002FCT) to Standard of Care Imaging (F-18 FDG PET\u002FCT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer",[89],"2026-08-31","2024-12-03",[5655,5656,5657,5658,5659,5660,5661,5662,5663,5664,5665,5666,5667,5668,5669,5670],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Head and Neck Squamous Cell Carcinoma","Hypopharyngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[5644],{"trials":5673,"activeCount":114},[],{"trials":5675,"activeCount":114},[],{"trials":5677,"activeCount":114},[],{"trials":5679,"activeCount":114},[],{"trials":5681,"activeCount":114},[],{"intervention":1761,"totalTrials":186,"cells":5683},{"EARLY_PHASE1":5684,"PHASE1":5690,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5698},{"trials":5685,"activeCount":186,"soonestReadout":1751},[5686],{"nctId":1748,"briefTitle":1749,"status":215,"phases":5687,"primaryCompletion":1751,"completion":1752,"start":1753,"enrollment":1754,"conditions":5688,"interventions":5689},[89],[1756,1757,1758,1759],[1761,1743],{"trials":5691,"activeCount":114},[],{"trials":5693,"activeCount":114},[],{"trials":5695,"activeCount":114},[],{"trials":5697,"activeCount":114},[],{"trials":5699,"activeCount":114},[],{"intervention":1469,"totalTrials":327,"cells":5701},{"EARLY_PHASE1":5702,"PHASE1":5704,"PHASE2":5706,"PHASE3":5708,"PHASE4":5718,"NA":5720},{"trials":5703,"activeCount":114},[],{"trials":5705,"activeCount":114},[],{"trials":5707,"activeCount":114},[],{"trials":5709,"activeCount":114},[5710],{"nctId":5711,"briefTitle":5712,"status":2022,"phases":5713,"primaryCompletion":5714,"completion":5714,"start":5624,"enrollment":114,"conditions":5715,"interventions":5716},"NCT04030052","Emicizumab PUPs and Nuwiq ITI Study",[92],"2023-01-19",[1453],[1469,5717,1469],"HEMLIBRA",{"trials":5719,"activeCount":114},[],{"trials":5721,"activeCount":186,"soonestReadout":1355},[5722],{"nctId":1462,"briefTitle":1463,"status":215,"phases":5723,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":5724,"interventions":5725},[],[1453],[1469,1470,1471,1437,1472,1473],{"intervention":1470,"totalTrials":186,"cells":5727},{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5729,"activeCount":114},[],{"trials":5731,"activeCount":114},[],{"trials":5733,"activeCount":114},[],{"trials":5735,"activeCount":114},[],{"trials":5737,"activeCount":114},[],{"trials":5739,"activeCount":186,"soonestReadout":1355},[5740],{"nctId":1462,"briefTitle":1463,"status":215,"phases":5741,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":5742,"interventions":5743},[],[1453],[1469,1470,1471,1437,1472,1473],{"intervention":1471,"totalTrials":186,"cells":5745},{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5750,"PHASE3":5752,"PHASE4":5754,"NA":5756},{"trials":5747,"activeCount":114},[],{"trials":5749,"activeCount":114},[],{"trials":5751,"activeCount":114},[],{"trials":5753,"activeCount":114},[],{"trials":5755,"activeCount":114},[],{"trials":5757,"activeCount":186,"soonestReadout":1355},[5758],{"nctId":1462,"briefTitle":1463,"status":215,"phases":5759,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":5760,"interventions":5761},[],[1453],[1469,1470,1471,1437,1472,1473],{"intervention":1472,"totalTrials":186,"cells":5763},{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5765,"activeCount":114},[],{"trials":5767,"activeCount":114},[],{"trials":5769,"activeCount":114},[],{"trials":5771,"activeCount":114},[],{"trials":5773,"activeCount":114},[],{"trials":5775,"activeCount":186,"soonestReadout":1355},[5776],{"nctId":1462,"briefTitle":1463,"status":215,"phases":5777,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":5778,"interventions":5779},[],[1453],[1469,1470,1471,1437,1472,1473],{"intervention":1473,"totalTrials":186,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5786,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5783,"activeCount":114},[],{"trials":5785,"activeCount":114},[],{"trials":5787,"activeCount":114},[],{"trials":5789,"activeCount":114},[],{"trials":5791,"activeCount":114},[],{"trials":5793,"activeCount":186,"soonestReadout":1355},[5794],{"nctId":1462,"briefTitle":1463,"status":215,"phases":5795,"primaryCompletion":1355,"completion":1465,"start":1466,"enrollment":1346,"conditions":5796,"interventions":5797},[],[1453],[1469,1470,1471,1437,1472,1473],{"intervention":5799,"totalTrials":186,"cells":5800},"Palynziq",{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5807,"PHASE4":5809,"NA":5811},{"trials":5802,"activeCount":114},[],{"trials":5804,"activeCount":114},[],{"trials":5806,"activeCount":114},[],{"trials":5808,"activeCount":114},[],{"trials":5810,"activeCount":114},[],{"trials":5812,"activeCount":186,"soonestReadout":1355},[5813],{"nctId":5814,"briefTitle":5815,"status":215,"phases":5816,"primaryCompletion":1355,"completion":1355,"start":5817,"enrollment":5818,"conditions":5819,"interventions":5821},"NCT04404530","Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)",[],"2019-10-08",45,[5820],"Phenylketonurias",[5799],{"intervention":408,"totalTrials":186,"cells":5823},{"EARLY_PHASE1":5824,"PHASE1":5826,"PHASE2":5828,"PHASE3":5830,"PHASE4":5832,"NA":5834},{"trials":5825,"activeCount":114},[],{"trials":5827,"activeCount":114},[],{"trials":5829,"activeCount":114},[],{"trials":5831,"activeCount":114},[],{"trials":5833,"activeCount":114},[],{"trials":5835,"activeCount":186,"soonestReadout":402},[5836],{"nctId":399,"briefTitle":400,"status":215,"phases":5837,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":5838,"interventions":5839},[],[406],[408,361],{"intervention":5841,"totalTrials":186,"cells":5842},"Aromatase Inhibition Therapy",{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5844,"activeCount":114},[],{"trials":5846,"activeCount":114},[],{"trials":5848,"activeCount":114},[],{"trials":5850,"activeCount":114},[],{"trials":5852,"activeCount":114},[],{"trials":5854,"activeCount":186,"soonestReadout":301},[5855],{"nctId":5856,"briefTitle":5857,"status":215,"phases":5858,"primaryCompletion":301,"completion":302,"start":5859,"enrollment":1281,"conditions":5860,"interventions":5861},"NCT06534125","Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer",[94],"2024-12-12",[1829,1832,1835,5549,5550],[5841],{"intervention":5863,"totalTrials":186,"cells":5864},"Inactivated Influenza Vaccine",{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5871,"PHASE4":5873,"NA":5875},{"trials":5866,"activeCount":114},[],{"trials":5868,"activeCount":114},[],{"trials":5870,"activeCount":114},[],{"trials":5872,"activeCount":114},[],{"trials":5874,"activeCount":114},[],{"trials":5876,"activeCount":186,"soonestReadout":5881},[5877],{"nctId":5878,"briefTitle":5879,"status":215,"phases":5880,"primaryCompletion":5881,"completion":5881,"start":5882,"enrollment":220,"conditions":5883,"interventions":5885},"NCT03501576","Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma",[],"2026-05-26","2018-04-06",[2687,2689,1502,2691,5884],"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",[5863],{"intervention":490,"totalTrials":538,"cells":5887},{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5892,"PHASE3":5894,"PHASE4":5907,"NA":5948},{"trials":5889,"activeCount":114},[],{"trials":5891,"activeCount":114},[],{"trials":5893,"activeCount":114},[],{"trials":5895,"activeCount":114},[5896],{"nctId":5897,"briefTitle":5898,"status":230,"phases":5899,"primaryCompletion":5900,"completion":5901,"start":5902,"enrollment":16,"conditions":5903,"interventions":5906},"NCT00967798","Prevention of Cystic Fibrosis Diabetes",[92],"2017-03-31","2017-12-31","2010-05",[5904,5905],"Cystic Fibrosis","Prediabetes",[490],{"trials":5908,"activeCount":114},[5909,5913,5917,5921,5935],{"nctId":483,"briefTitle":484,"status":105,"phases":5910,"primaryCompletion":486,"completion":486,"start":487,"enrollment":265,"conditions":5911,"interventions":5912},[93],[27],[490,491,492,469,469],{"nctId":494,"briefTitle":495,"status":105,"phases":5914,"primaryCompletion":172,"completion":172,"start":497,"enrollment":498,"conditions":5915,"interventions":5916},[93],[500],[490,469,469,502,502],{"nctId":515,"briefTitle":516,"status":105,"phases":5918,"primaryCompletion":518,"completion":518,"start":487,"enrollment":519,"conditions":5919,"interventions":5920},[93],[500],[490,491,492,469,469],{"nctId":5922,"briefTitle":5923,"status":105,"phases":5924,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":5927,"interventions":5929},"NCT01845831","Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes",[93],"2016-04",292,[5928],"Type 2 Diabetes",[490,5930,5931,5932,5933,5934],"Basal Bolus","Metformin and Sitagliptin","Glargine","Glargine 50%","Glargine 80%",{"nctId":5936,"briefTitle":5937,"status":105,"phases":5938,"primaryCompletion":5939,"completion":5940,"start":5941,"enrollment":845,"conditions":5942,"interventions":5945},"NCT01378117","Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes",[93],"2012-05","2012-06","2011-08",[5943,5944,500],"Type 2 Diabetes Mellitus","Hospitalization",[490,5946,5947],"glargine","lispro",{"trials":5949,"activeCount":114},[],{"intervention":492,"totalTrials":292,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5958,"PHASE4":5960,"NA":6003},{"trials":5953,"activeCount":114},[],{"trials":5955,"activeCount":114},[],{"trials":5957,"activeCount":114},[],{"trials":5959,"activeCount":114},[],{"trials":5961,"activeCount":114},[5962,5966,5979,5983,5993],{"nctId":483,"briefTitle":484,"status":105,"phases":5963,"primaryCompletion":486,"completion":486,"start":487,"enrollment":265,"conditions":5964,"interventions":5965},[93],[27],[490,491,492,469,469],{"nctId":5967,"briefTitle":5968,"status":105,"phases":5969,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":5974,"interventions":5976},"NCT00596687","Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery",[93],"2009-12","2013-07","2007-12",234,[5928,5975],"Inpatient Hyperglycemia",[492,5977,5978],"Regular insulin","Insulin glulisine",{"nctId":515,"briefTitle":516,"status":105,"phases":5980,"primaryCompletion":518,"completion":518,"start":487,"enrollment":519,"conditions":5981,"interventions":5982},[93],[500],[490,491,492,469,469],{"nctId":5984,"briefTitle":5985,"status":105,"phases":5986,"primaryCompletion":5987,"completion":5987,"start":5988,"enrollment":5514,"conditions":5989,"interventions":5990},"NCT02061969","ADA Linagliptin in Long Term Care",[93],"2017-04-10","2014-04-25",[18],[5991,5992],"linagliptin","insulin glargine",{"nctId":5994,"briefTitle":5995,"status":105,"phases":5996,"primaryCompletion":5997,"completion":5997,"start":251,"enrollment":5998,"conditions":5999,"interventions":6000},"NCT02408120","Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes",[93],"2019-12-11",226,[1700],[492,6001,6002],"Insulin aspart","Supplemental insulin aspart",{"trials":6004,"activeCount":114},[],{"intervention":5932,"totalTrials":292,"cells":6006},{"EARLY_PHASE1":6007,"PHASE1":6009,"PHASE2":6011,"PHASE3":6013,"PHASE4":6015,"NA":6050},{"trials":6008,"activeCount":114},[],{"trials":6010,"activeCount":114},[],{"trials":6012,"activeCount":114},[],{"trials":6014,"activeCount":114},[],{"trials":6016,"activeCount":114},[6017,6023,6027,6031,6040],{"nctId":6018,"briefTitle":6019,"status":105,"phases":6020,"primaryCompletion":2769,"completion":2563,"start":3733,"enrollment":196,"conditions":6021,"interventions":6022},"NCT01240200","Satisfaction of Treatment Among Elderly Patients With Insulin Therapy",[93],[510],[5932],{"nctId":5922,"briefTitle":5923,"status":105,"phases":6024,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":6025,"interventions":6026},[93],[5928],[490,5930,5931,5932,5933,5934],{"nctId":5936,"briefTitle":5937,"status":105,"phases":6028,"primaryCompletion":5939,"completion":5940,"start":5941,"enrollment":845,"conditions":6029,"interventions":6030},[93],[5943,5944,500],[490,5946,5947],{"nctId":6032,"briefTitle":6033,"status":105,"phases":6034,"primaryCompletion":6035,"completion":6035,"start":181,"enrollment":1281,"conditions":6036,"interventions":6037},"NCT02455076","Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes",[93],"2018-03",[5928],[6038,5932,6039],"Exenatide","Rapid-acting insulin analogs",{"nctId":6041,"briefTitle":6042,"status":105,"phases":6043,"primaryCompletion":6044,"completion":6044,"start":6045,"enrollment":4870,"conditions":6046,"interventions":6047},"NCT03336528","Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes",[93],"2021-03-01","2018-01-02",[5928],[6048,5932,6049],"Degludec","Aspart",{"trials":6051,"activeCount":114},[],{"intervention":6053,"totalTrials":362,"cells":6054},"Truvada",{"EARLY_PHASE1":6055,"PHASE1":6057,"PHASE2":6070,"PHASE3":6072,"PHASE4":6074,"NA":6093},{"trials":6056,"activeCount":114},[],{"trials":6058,"activeCount":114},[6059],{"nctId":6060,"briefTitle":6061,"status":105,"phases":6062,"primaryCompletion":6063,"completion":6063,"start":6064,"enrollment":6065,"conditions":6066,"interventions":6068},"NCT02985996","Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities",[90],"2017-11-29","2017-02-06",48,[6067],"HIV Infections",[6053,6069],"Genvoya",{"trials":6071,"activeCount":114},[],{"trials":6073,"activeCount":114},[],{"trials":6075,"activeCount":114},[6076,6084],{"nctId":6077,"briefTitle":6078,"status":105,"phases":6079,"primaryCompletion":6080,"completion":6080,"start":1555,"enrollment":6081,"conditions":6082,"interventions":6083},"NCT02401230","PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV",[93],"2017-01-25",86,[15],[6053],{"nctId":6085,"briefTitle":6086,"status":230,"phases":6087,"primaryCompletion":6088,"completion":6088,"start":2684,"enrollment":162,"conditions":6089,"interventions":6090},"NCT02924389","Dolutegravir in Reservoirs",[93],"2019-09-11",[15],[6091,6092,6053],"dolutegravir","Triumeq",{"trials":6094,"activeCount":114},[],{"intervention":6096,"totalTrials":362,"cells":6097},"Doxycycline",{"EARLY_PHASE1":6098,"PHASE1":6100,"PHASE2":6102,"PHASE3":6104,"PHASE4":6106,"NA":6134},{"trials":6099,"activeCount":114},[],{"trials":6101,"activeCount":114},[],{"trials":6103,"activeCount":114},[],{"trials":6105,"activeCount":114},[],{"trials":6107,"activeCount":114},[6108,6118,6126],{"nctId":6109,"briefTitle":6110,"status":105,"phases":6111,"primaryCompletion":6112,"completion":6113,"start":6114,"enrollment":5818,"conditions":6115,"interventions":6117},"NCT05853120","Doxy-Post-exposure Prophylaxis",[93],"2024-09-25","2024-12-24","2023-05-31",[6116],"Sexually Transmitted Diseases",[6096],{"nctId":6119,"briefTitle":6120,"status":105,"phases":6121,"primaryCompletion":6122,"completion":6122,"start":81,"enrollment":31,"conditions":6123,"interventions":6125},"NCT06545656","Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens",[93],"2025-04-29",[6124],"Sexually Transmitted Infection",[6096],{"nctId":6127,"briefTitle":6128,"status":105,"phases":6129,"primaryCompletion":6130,"completion":6130,"start":1989,"enrollment":454,"conditions":6131,"interventions":6132},"NCT04860505","Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens",[93],"2022-05-09",[6116],[6096,6133],"Biktarvy",{"trials":6135,"activeCount":114},[],{"intervention":3472,"totalTrials":362,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6144,"PHASE4":6146,"NA":6171},{"trials":6139,"activeCount":114},[],{"trials":6141,"activeCount":114},[],{"trials":6143,"activeCount":114},[],{"trials":6145,"activeCount":114},[],{"trials":6147,"activeCount":114},[6148,6158,6167],{"nctId":6149,"briefTitle":6150,"status":105,"phases":6151,"primaryCompletion":6152,"completion":6152,"start":5970,"enrollment":6153,"conditions":6154,"interventions":6156},"NCT01041287","Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells",[93],"2013-12",96,[6155],"Hypertension",[3472,6157],"Metoprolol succinate",{"nctId":6159,"briefTitle":6160,"status":105,"phases":6161,"primaryCompletion":5940,"completion":5940,"start":5970,"enrollment":6162,"conditions":6163,"interventions":6165},"NCT01049009","The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension",[93],91,[6164],"High Blood Pressure",[3472,6166],"Metoprolol XL",{"nctId":3463,"briefTitle":3464,"status":105,"phases":6168,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":243,"conditions":6169,"interventions":6170},[93],[3469,3470],[3472,3438],{"trials":6172,"activeCount":114},[],{"intervention":6133,"totalTrials":327,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6181,"PHASE4":6183,"NA":6198},{"trials":6176,"activeCount":114},[],{"trials":6178,"activeCount":114},[],{"trials":6180,"activeCount":114},[],{"trials":6182,"activeCount":114},[],{"trials":6184,"activeCount":114},[6185,6194],{"nctId":6186,"briefTitle":6187,"status":105,"phases":6188,"primaryCompletion":6189,"completion":6189,"start":6190,"enrollment":454,"conditions":6191,"interventions":6193},"NCT04039217","Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM",[93],"2020-08-28","2019-09-30",[6192,15],"ART",[6133],{"nctId":6127,"briefTitle":6128,"status":105,"phases":6195,"primaryCompletion":6130,"completion":6130,"start":1989,"enrollment":454,"conditions":6196,"interventions":6197},[93],[6116],[6096,6133],{"trials":6199,"activeCount":114},[],{"intervention":6201,"totalTrials":327,"cells":6202},"Trikafta",{"EARLY_PHASE1":6203,"PHASE1":6205,"PHASE2":6207,"PHASE3":6216,"PHASE4":6218,"NA":6229},{"trials":6204,"activeCount":114},[],{"trials":6206,"activeCount":114},[],{"trials":6208,"activeCount":114},[6209],{"nctId":6210,"briefTitle":6211,"status":105,"phases":6212,"primaryCompletion":4828,"completion":4828,"start":6213,"enrollment":445,"conditions":6214,"interventions":6215},"NCT03506061","Trikafta in Cystic Fibrosis Patients",[91],"2019-09-04",[5904],[6201],{"trials":6217,"activeCount":114},[],{"trials":6219,"activeCount":114},[6220],{"nctId":6221,"briefTitle":6222,"status":105,"phases":6223,"primaryCompletion":6224,"completion":6224,"start":6225,"enrollment":19,"conditions":6226,"interventions":6228},"NCT05743946","Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis",[93],"2025-12-23","2023-04-18",[6227],"Non-cystic Fibrosis Bronchiectasis",[6201],{"trials":6230,"activeCount":114},[],{"intervention":6232,"totalTrials":327,"cells":6233},"Dulaglutide",{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6238,"PHASE3":6240,"PHASE4":6242,"NA":6262},{"trials":6235,"activeCount":114},[],{"trials":6237,"activeCount":114},[],{"trials":6239,"activeCount":114},[],{"trials":6241,"activeCount":114},[],{"trials":6243,"activeCount":114},[6244,6253],{"nctId":6245,"briefTitle":6246,"status":230,"phases":6247,"primaryCompletion":6248,"completion":6248,"start":6249,"enrollment":22,"conditions":6250,"interventions":6252},"NCT03743025","Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients",[93],"2023-05-02","2019-03-08",[6251],"Stress Hyperglycemia",[6232],{"nctId":6254,"briefTitle":6255,"status":230,"phases":6256,"primaryCompletion":6257,"completion":6257,"start":6258,"enrollment":37,"conditions":6259,"interventions":6261},"NCT04862234","Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients",[93],"2023-06-22","2021-08-06",[6260],"Hyperglycemia Stress",[6232],{"trials":6263,"activeCount":114},[],{"intervention":491,"totalTrials":327,"cells":6265},{"EARLY_PHASE1":6266,"PHASE1":6268,"PHASE2":6270,"PHASE3":6272,"PHASE4":6274,"NA":6284},{"trials":6267,"activeCount":114},[],{"trials":6269,"activeCount":114},[],{"trials":6271,"activeCount":114},[],{"trials":6273,"activeCount":114},[],{"trials":6275,"activeCount":114},[6276,6280],{"nctId":483,"briefTitle":484,"status":105,"phases":6277,"primaryCompletion":486,"completion":486,"start":487,"enrollment":265,"conditions":6278,"interventions":6279},[93],[27],[490,491,492,469,469],{"nctId":515,"briefTitle":516,"status":105,"phases":6281,"primaryCompletion":518,"completion":518,"start":487,"enrollment":519,"conditions":6282,"interventions":6283},[93],[500],[490,491,492,469,469],{"trials":6285,"activeCount":114},[],{"intervention":5977,"totalTrials":327,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6292,"PHASE3":6294,"PHASE4":6296,"NA":6312},{"trials":6289,"activeCount":114},[],{"trials":6291,"activeCount":114},[],{"trials":6293,"activeCount":114},[],{"trials":6295,"activeCount":114},[],{"trials":6297,"activeCount":114},[6298,6302],{"nctId":5967,"briefTitle":5968,"status":105,"phases":6299,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":6300,"interventions":6301},[93],[5928,5975],[492,5977,5978],{"nctId":6303,"briefTitle":6304,"status":2022,"phases":6305,"primaryCompletion":6306,"completion":6306,"start":594,"enrollment":114,"conditions":6307,"interventions":6309},"NCT01971047","Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery",[93],"2018-09",[6308,5928],"Type 1 Diabetes",[6310,6311],"Regular Insulin","Humalog",{"trials":6313,"activeCount":114},[],{"intervention":6315,"totalTrials":327,"cells":6316},"Corticosteroid",{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6321,"PHASE3":6323,"PHASE4":6336,"NA":6349},{"trials":6318,"activeCount":114},[],{"trials":6320,"activeCount":114},[],{"trials":6322,"activeCount":114},[],{"trials":6324,"activeCount":114},[6325],{"nctId":6326,"briefTitle":6327,"status":105,"phases":6328,"primaryCompletion":2835,"completion":2835,"start":6329,"enrollment":6330,"conditions":6331,"interventions":6332},"NCT03818737","Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)",[92],"2019-03-28",475,[1109],[6333,6334,6335,6315],"Bone Marrow Derived MSCs","Adipose-derived MSCs","Umbilical Cord Tissue (UCT) MSCs",{"trials":6337,"activeCount":114},[6338],{"nctId":6339,"briefTitle":6340,"status":105,"phases":6341,"primaryCompletion":3877,"completion":5925,"start":173,"enrollment":6342,"conditions":6343,"interventions":6346},"NCT01524913","A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction",[93],102,[6344,1358,6345],"Temporomandibular Joint Dysfunction","Arthrocentesis",[6347,6315,6348],"Hyaluronic acid","Lactated Ringers",{"trials":6350,"activeCount":114},[],{"intervention":576,"totalTrials":327,"cells":6352},{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6357,"PHASE3":6359,"PHASE4":6361,"NA":6374},{"trials":6354,"activeCount":114},[],{"trials":6356,"activeCount":114},[],{"trials":6358,"activeCount":114},[],{"trials":6360,"activeCount":114},[],{"trials":6362,"activeCount":114},[6363,6370],{"nctId":6364,"briefTitle":6365,"status":2022,"phases":6366,"primaryCompletion":2533,"completion":2533,"start":2965,"enrollment":114,"conditions":6367,"interventions":6369},"NCT02122679","Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass",[93],[6368],"Heart Defect, Congenital",[576],{"nctId":552,"briefTitle":553,"status":230,"phases":6371,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":6372,"interventions":6373},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":6375,"activeCount":114},[],{"intervention":574,"totalTrials":327,"cells":6377},{"EARLY_PHASE1":6378,"PHASE1":6380,"PHASE2":6382,"PHASE3":6397,"PHASE4":6399,"NA":6405},{"trials":6379,"activeCount":114},[],{"trials":6381,"activeCount":114},[],{"trials":6383,"activeCount":114},[6384],{"nctId":6385,"briefTitle":6386,"status":230,"phases":6387,"primaryCompletion":6388,"completion":6388,"start":6389,"enrollment":870,"conditions":6390,"interventions":6392},"NCT01369147","The Energy Dose Study",[91],"2014-12-02","2011-07",[6391],"Critical Illness",[6393,574,6394,6395,6396],"Parenteral Nutrition","Clevidipine","Dextrose-containing IV Fluids","Enteral feeding",{"trials":6398,"activeCount":114},[],{"trials":6400,"activeCount":114},[6401],{"nctId":552,"briefTitle":553,"status":230,"phases":6402,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":6403,"interventions":6404},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":6406,"activeCount":114},[],{"intervention":6408,"totalTrials":327,"cells":6409},"Linagliptin",{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6414,"PHASE3":6416,"PHASE4":6418,"NA":6435},{"trials":6411,"activeCount":114},[],{"trials":6413,"activeCount":114},[],{"trials":6415,"activeCount":114},[],{"trials":6417,"activeCount":114},[],{"trials":6419,"activeCount":114},[6420,6431],{"nctId":6421,"briefTitle":6422,"status":105,"phases":6423,"primaryCompletion":6424,"completion":6425,"start":2942,"enrollment":6426,"conditions":6427,"interventions":6428},"NCT02004366","Linagliptin Inpatient Trial",[93],"2017-02","2017-03",295,[5928],[6408,5930,6408,6429,6430],"Linagliptin + 50% Glargine dose on discharge","Linagliptin + 80% Glargine",{"nctId":5984,"briefTitle":5985,"status":105,"phases":6432,"primaryCompletion":5987,"completion":5987,"start":5988,"enrollment":5514,"conditions":6433,"interventions":6434},[93],[18],[5991,5992],{"trials":6436,"activeCount":114},[],{"intervention":5930,"totalTrials":327,"cells":6438},{"EARLY_PHASE1":6439,"PHASE1":6441,"PHASE2":6443,"PHASE3":6445,"PHASE4":6447,"NA":6457},{"trials":6440,"activeCount":114},[],{"trials":6442,"activeCount":114},[],{"trials":6444,"activeCount":114},[],{"trials":6446,"activeCount":114},[],{"trials":6448,"activeCount":114},[6449,6453],{"nctId":6421,"briefTitle":6422,"status":105,"phases":6450,"primaryCompletion":6424,"completion":6425,"start":2942,"enrollment":6426,"conditions":6451,"interventions":6452},[93],[5928],[6408,5930,6408,6429,6430],{"nctId":5922,"briefTitle":5923,"status":105,"phases":6454,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":6455,"interventions":6456},[93],[5928],[490,5930,5931,5932,5933,5934],{"trials":6458,"activeCount":114},[],{"intervention":384,"totalTrials":327,"cells":6460},{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6465,"PHASE3":6467,"PHASE4":6478,"NA":6484},{"trials":6462,"activeCount":114},[],{"trials":6464,"activeCount":114},[],{"trials":6466,"activeCount":114},[],{"trials":6468,"activeCount":114},[6469],{"nctId":6470,"briefTitle":6471,"status":105,"phases":6472,"completion":6473,"start":3662,"enrollment":6474,"conditions":6475,"interventions":6477},"NCT00576329","Topical 0.4% Ketorolac and Vitreoretinal Surgery",[91,92],"2007-10",76,[6476],"Surgery",[384],{"trials":6479,"activeCount":114},[6480],{"nctId":375,"briefTitle":376,"status":105,"phases":6481,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":6482,"interventions":6483},[93],[382],[384,361],{"trials":6485,"activeCount":114},[],{"intervention":6001,"totalTrials":327,"cells":6487},{"EARLY_PHASE1":6488,"PHASE1":6490,"PHASE2":6492,"PHASE3":6494,"PHASE4":6507,"NA":6513},{"trials":6489,"activeCount":114},[],{"trials":6491,"activeCount":114},[],{"trials":6493,"activeCount":114},[],{"trials":6495,"activeCount":114},[6496],{"nctId":6497,"briefTitle":6498,"status":105,"phases":6499,"primaryCompletion":6500,"completion":6500,"start":2156,"enrollment":6501,"conditions":6502,"interventions":6503},"NCT03737240","IDegLira HIGH Trial",[92],"2022-07-08",145,[510],[6504,6505,6506],"IDegLira","Insulin Degludec","Insulin Aspart",{"trials":6508,"activeCount":114},[6509],{"nctId":5994,"briefTitle":5995,"status":105,"phases":6510,"primaryCompletion":5997,"completion":5997,"start":251,"enrollment":5998,"conditions":6511,"interventions":6512},[93],[1700],[492,6001,6002],{"trials":6514,"activeCount":114},[],{"intervention":6516,"totalTrials":327,"cells":6517},"Gabapentin",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6524,"PHASE4":6535,"NA":6546},{"trials":6519,"activeCount":114},[],{"trials":6521,"activeCount":114},[],{"trials":6523,"activeCount":114},[],{"trials":6525,"activeCount":114},[6526],{"nctId":6527,"briefTitle":6528,"status":2022,"phases":6529,"primaryCompletion":6530,"completion":6530,"start":6531,"enrollment":114,"conditions":6532,"interventions":6534},"NCT03867240","Gabapentin and Chronic Post Surgical Pain",[92],"2022-09","2019-06",[1359,6533],"Scoliosis Idiopathic",[6516],{"trials":6536,"activeCount":114},[6537],{"nctId":6538,"briefTitle":6539,"status":105,"phases":6540,"primaryCompletion":6541,"completion":6541,"start":6542,"enrollment":6543,"conditions":6544,"interventions":6545},"NCT02944656","Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management",[93],"2018-06-26","2016-12-08",114,[1358],[6516],{"trials":6547,"activeCount":114},[],{"intervention":6549,"totalTrials":327,"cells":6550},"Sugammadex",{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6557,"PHASE4":6559,"NA":6581},{"trials":6552,"activeCount":114},[],{"trials":6554,"activeCount":114},[],{"trials":6556,"activeCount":114},[],{"trials":6558,"activeCount":114},[],{"trials":6560,"activeCount":114},[6561,6572],{"nctId":6562,"briefTitle":6563,"status":230,"phases":6564,"primaryCompletion":6565,"completion":6566,"start":6567,"enrollment":162,"conditions":6568,"interventions":6570},"NCT05256901","Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy",[93],"2024-07-05","2024-08-05","2023-07-19",[6569,6476],"Appendicitis",[6549,6571],"Neostigmine\u002FGlycopyrrolate",{"nctId":6573,"briefTitle":6574,"status":105,"phases":6575,"primaryCompletion":6576,"completion":6576,"start":6577,"enrollment":2218,"conditions":6578,"interventions":6580},"NCT05661409","Sugammadex as Rescue Therapy",[93],"2024-08-02","2023-07-21",[6579],"Neuromuscular Blockade",[6549],{"trials":6582,"activeCount":114},[],{"intervention":6584,"totalTrials":186,"cells":6585},"Seasonal Influenza Vaccine",{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6592,"PHASE4":6594,"NA":6606},{"trials":6587,"activeCount":114},[],{"trials":6589,"activeCount":114},[],{"trials":6591,"activeCount":114},[],{"trials":6593,"activeCount":114},[],{"trials":6595,"activeCount":114},[6596],{"nctId":6597,"briefTitle":6598,"status":105,"phases":6599,"primaryCompletion":6600,"completion":6601,"start":6602,"enrollment":870,"conditions":6603,"interventions":6605},"NCT03701061","Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response",[93],"2019-02-28","2020-01-31","2018-10-11",[6604],"Influenza A Subtype H5N1 Infection",[6584,6584],{"trials":6607,"activeCount":114},[],{"intervention":6609,"totalTrials":186,"cells":6610},"Ropivacaine 0.5%",{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6615,"PHASE3":6617,"PHASE4":6619,"NA":6631},{"trials":6612,"activeCount":114},[],{"trials":6614,"activeCount":114},[],{"trials":6616,"activeCount":114},[],{"trials":6618,"activeCount":114},[],{"trials":6620,"activeCount":114},[6621],{"nctId":6622,"briefTitle":6623,"status":105,"phases":6624,"primaryCompletion":5925,"completion":5925,"start":1497,"enrollment":6625,"conditions":6626,"interventions":6628},"NCT02604550","Anterior Cruciate Ligament Pain Study",[93],115,[6627],"Anterior Cruciate Ligament Reconstruction",[6609,6629,6630],"Percocet 7.5\u002F325","Naprosyn 500 mg",{"trials":6632,"activeCount":114},[],{"intervention":6629,"totalTrials":186,"cells":6634},{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6639,"PHASE3":6641,"PHASE4":6643,"NA":6649},{"trials":6636,"activeCount":114},[],{"trials":6638,"activeCount":114},[],{"trials":6640,"activeCount":114},[],{"trials":6642,"activeCount":114},[],{"trials":6644,"activeCount":114},[6645],{"nctId":6622,"briefTitle":6623,"status":105,"phases":6646,"primaryCompletion":5925,"completion":5925,"start":1497,"enrollment":6625,"conditions":6647,"interventions":6648},[93],[6627],[6609,6629,6630],{"trials":6650,"activeCount":114},[],{"intervention":6630,"totalTrials":186,"cells":6652},{"EARLY_PHASE1":6653,"PHASE1":6655,"PHASE2":6657,"PHASE3":6659,"PHASE4":6661,"NA":6667},{"trials":6654,"activeCount":114},[],{"trials":6656,"activeCount":114},[],{"trials":6658,"activeCount":114},[],{"trials":6660,"activeCount":114},[],{"trials":6662,"activeCount":114},[6663],{"nctId":6622,"briefTitle":6623,"status":105,"phases":6664,"primaryCompletion":5925,"completion":5925,"start":1497,"enrollment":6625,"conditions":6665,"interventions":6666},[93],[6627],[6609,6629,6630],{"trials":6668,"activeCount":114},[],{"intervention":6670,"totalTrials":186,"cells":6671},"Azithromycin for Routine Community-wide MDA",{"EARLY_PHASE1":6672,"PHASE1":6674,"PHASE2":6676,"PHASE3":6678,"PHASE4":6680,"NA":6693},{"trials":6673,"activeCount":114},[],{"trials":6675,"activeCount":114},[],{"trials":6677,"activeCount":114},[],{"trials":6679,"activeCount":114},[],{"trials":6681,"activeCount":114},[6682],{"nctId":6683,"briefTitle":6684,"status":105,"phases":6685,"primaryCompletion":6686,"completion":6686,"start":6687,"enrollment":6688,"conditions":6689,"interventions":6690},"NCT05634759","Enhancing the A in SAFE for Trachoma",[93],"2023-08-05","2022-05-04",34630,[3505],[6670,6691,6692],"Two Additional Rounds of Azithromycin for Children","Azithromycin for Second Community-wide MDA",{"trials":6694,"activeCount":114},[],{"intervention":6691,"totalTrials":186,"cells":6696},{"EARLY_PHASE1":6697,"PHASE1":6699,"PHASE2":6701,"PHASE3":6703,"PHASE4":6705,"NA":6711},{"trials":6698,"activeCount":114},[],{"trials":6700,"activeCount":114},[],{"trials":6702,"activeCount":114},[],{"trials":6704,"activeCount":114},[],{"trials":6706,"activeCount":114},[6707],{"nctId":6683,"briefTitle":6684,"status":105,"phases":6708,"primaryCompletion":6686,"completion":6686,"start":6687,"enrollment":6688,"conditions":6709,"interventions":6710},[93],[3505],[6670,6691,6692],{"trials":6712,"activeCount":114},[],{"intervention":6692,"totalTrials":186,"cells":6714},{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6719,"PHASE3":6721,"PHASE4":6723,"NA":6729},{"trials":6716,"activeCount":114},[],{"trials":6718,"activeCount":114},[],{"trials":6720,"activeCount":114},[],{"trials":6722,"activeCount":114},[],{"trials":6724,"activeCount":114},[6725],{"nctId":6683,"briefTitle":6684,"status":105,"phases":6726,"primaryCompletion":6686,"completion":6686,"start":6687,"enrollment":6688,"conditions":6727,"interventions":6728},[93],[3505],[6670,6691,6692],{"trials":6730,"activeCount":114},[],{"intervention":6732,"totalTrials":186,"cells":6733},"Kaletra + Isentress",{"EARLY_PHASE1":6734,"PHASE1":6736,"PHASE2":6738,"PHASE3":6740,"PHASE4":6742,"NA":6752},{"trials":6735,"activeCount":114},[],{"trials":6737,"activeCount":114},[],{"trials":6739,"activeCount":114},[],{"trials":6741,"activeCount":114},[],{"trials":6743,"activeCount":114},[6744],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6747,"primaryCompletion":3733,"completion":3733,"start":6748,"enrollment":436,"conditions":6749,"interventions":6750},"NCT00700115","Kaletra-isentress Treatment Evaluation",[93],"2008-06",[6067],[6732,6751],"Pre-study antiretroviral regimen",{"trials":6753,"activeCount":114},[],{"intervention":6751,"totalTrials":186,"cells":6755},{"EARLY_PHASE1":6756,"PHASE1":6758,"PHASE2":6760,"PHASE3":6762,"PHASE4":6764,"NA":6770},{"trials":6757,"activeCount":114},[],{"trials":6759,"activeCount":114},[],{"trials":6761,"activeCount":114},[],{"trials":6763,"activeCount":114},[],{"trials":6765,"activeCount":114},[6766],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6767,"primaryCompletion":3733,"completion":3733,"start":6748,"enrollment":436,"conditions":6768,"interventions":6769},[93],[6067],[6732,6751],{"trials":6771,"activeCount":114},[],{"intervention":6091,"totalTrials":186,"cells":6773},{"EARLY_PHASE1":6774,"PHASE1":6776,"PHASE2":6778,"PHASE3":6780,"PHASE4":6782,"NA":6788},{"trials":6775,"activeCount":114},[],{"trials":6777,"activeCount":114},[],{"trials":6779,"activeCount":114},[],{"trials":6781,"activeCount":114},[],{"trials":6783,"activeCount":114},[6784],{"nctId":6085,"briefTitle":6086,"status":230,"phases":6785,"primaryCompletion":6088,"completion":6088,"start":2684,"enrollment":162,"conditions":6786,"interventions":6787},[93],[15],[6091,6092,6053],{"trials":6789,"activeCount":114},[],{"intervention":6092,"totalTrials":186,"cells":6791},{"EARLY_PHASE1":6792,"PHASE1":6794,"PHASE2":6796,"PHASE3":6798,"PHASE4":6800,"NA":6806},{"trials":6793,"activeCount":114},[],{"trials":6795,"activeCount":114},[],{"trials":6797,"activeCount":114},[],{"trials":6799,"activeCount":114},[],{"trials":6801,"activeCount":114},[6802],{"nctId":6085,"briefTitle":6086,"status":230,"phases":6803,"primaryCompletion":6088,"completion":6088,"start":2684,"enrollment":162,"conditions":6804,"interventions":6805},[93],[15],[6091,6092,6053],{"trials":6807,"activeCount":114},[],{"intervention":6157,"totalTrials":186,"cells":6809},{"EARLY_PHASE1":6810,"PHASE1":6812,"PHASE2":6814,"PHASE3":6816,"PHASE4":6818,"NA":6824},{"trials":6811,"activeCount":114},[],{"trials":6813,"activeCount":114},[],{"trials":6815,"activeCount":114},[],{"trials":6817,"activeCount":114},[],{"trials":6819,"activeCount":114},[6820],{"nctId":6149,"briefTitle":6150,"status":105,"phases":6821,"primaryCompletion":6152,"completion":6152,"start":5970,"enrollment":6153,"conditions":6822,"interventions":6823},[93],[6155],[3472,6157],{"trials":6825,"activeCount":114},[],{"intervention":502,"totalTrials":186,"cells":6827},{"EARLY_PHASE1":6828,"PHASE1":6830,"PHASE2":6832,"PHASE3":6834,"PHASE4":6836,"NA":6842},{"trials":6829,"activeCount":114},[],{"trials":6831,"activeCount":114},[],{"trials":6833,"activeCount":114},[],{"trials":6835,"activeCount":114},[],{"trials":6837,"activeCount":114},[6838],{"nctId":494,"briefTitle":495,"status":105,"phases":6839,"primaryCompletion":172,"completion":172,"start":497,"enrollment":498,"conditions":6840,"interventions":6841},[93],[500],[490,469,469,502,502],{"trials":6843,"activeCount":114},[],{"intervention":6845,"totalTrials":186,"cells":6846},"Indinavir\u002FRitonavir\u002FFosamprenavir",{"EARLY_PHASE1":6847,"PHASE1":6849,"PHASE2":6851,"PHASE3":6853,"PHASE4":6855,"NA":6865},{"trials":6848,"activeCount":114},[],{"trials":6850,"activeCount":114},[],{"trials":6852,"activeCount":114},[],{"trials":6854,"activeCount":114},[],{"trials":6856,"activeCount":114},[6857],{"nctId":6858,"briefTitle":6859,"status":105,"phases":6860,"completion":6861,"start":6862,"enrollment":1754,"conditions":6863,"interventions":6864},"NCT00148785","A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir",[93],"2007-01","2005-07",[6067],[6845],{"trials":6866,"activeCount":114},[],{"intervention":6868,"totalTrials":186,"cells":6869},"Minocycline",{"EARLY_PHASE1":6870,"PHASE1":6872,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6887},{"trials":6871,"activeCount":114},[],{"trials":6873,"activeCount":114},[],{"trials":6875,"activeCount":114},[],{"trials":6877,"activeCount":114},[],{"trials":6879,"activeCount":114},[6880],{"nctId":6881,"briefTitle":6882,"status":105,"phases":6883,"primaryCompletion":160,"completion":160,"start":2480,"enrollment":2075,"conditions":6884,"interventions":6886},"NCT02124811","Minocycline Augmentation to Clozapine",[93],[456,6885],"Schizoaffective Disorder",[6868],{"trials":6888,"activeCount":114},[],{"intervention":5978,"totalTrials":186,"cells":6890},{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6897,"PHASE4":6899,"NA":6905},{"trials":6892,"activeCount":114},[],{"trials":6894,"activeCount":114},[],{"trials":6896,"activeCount":114},[],{"trials":6898,"activeCount":114},[],{"trials":6900,"activeCount":114},[6901],{"nctId":5967,"briefTitle":5968,"status":105,"phases":6902,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":6903,"interventions":6904},[93],[5928,5975],[492,5977,5978],{"trials":6906,"activeCount":114},[],{"intervention":6908,"totalTrials":186,"cells":6909},"Liraglutide + OADs",{"EARLY_PHASE1":6910,"PHASE1":6912,"PHASE2":6914,"PHASE3":6916,"PHASE4":6918,"NA":6928},{"trials":6911,"activeCount":114},[],{"trials":6913,"activeCount":114},[],{"trials":6915,"activeCount":114},[],{"trials":6917,"activeCount":114},[],{"trials":6919,"activeCount":114},[6920],{"nctId":6921,"briefTitle":6922,"status":105,"phases":6923,"primaryCompletion":6924,"completion":6924,"start":3501,"enrollment":8,"conditions":6925,"interventions":6926},"NCT01919489","Liraglutide Hospital Discharge Trial",[93],"2020-08-30",[5928],[6908,6927],"Glargine + OADs",{"trials":6929,"activeCount":114},[],{"intervention":6927,"totalTrials":186,"cells":6931},{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6936,"PHASE3":6938,"PHASE4":6940,"NA":6946},{"trials":6933,"activeCount":114},[],{"trials":6935,"activeCount":114},[],{"trials":6937,"activeCount":114},[],{"trials":6939,"activeCount":114},[],{"trials":6941,"activeCount":114},[6942],{"nctId":6921,"briefTitle":6922,"status":105,"phases":6943,"primaryCompletion":6924,"completion":6924,"start":3501,"enrollment":8,"conditions":6944,"interventions":6945},[93],[5928],[6908,6927],{"trials":6947,"activeCount":114},[],{"intervention":6949,"totalTrials":186,"cells":6950},"Quetiapine XR",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6957,"PHASE4":6959,"NA":6971},{"trials":6952,"activeCount":114},[],{"trials":6954,"activeCount":114},[],{"trials":6956,"activeCount":114},[],{"trials":6958,"activeCount":114},[],{"trials":6960,"activeCount":114},[6961],{"nctId":6962,"briefTitle":6963,"status":230,"phases":6964,"primaryCompletion":6965,"completion":6965,"start":6966,"enrollment":19,"conditions":6967,"interventions":6970},"NCT00746421","Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder",[93],"2012-04","2010-01",[6968,6969],"Bipolar Disorder","Cognitive Impairment",[6949],{"trials":6972,"activeCount":114},[],{"intervention":6974,"totalTrials":186,"cells":6975},"Ospemifene",{"EARLY_PHASE1":6976,"PHASE1":6978,"PHASE2":6980,"PHASE3":6982,"PHASE4":6984,"NA":6996},{"trials":6977,"activeCount":114},[],{"trials":6979,"activeCount":114},[],{"trials":6981,"activeCount":114},[],{"trials":6983,"activeCount":114},[],{"trials":6985,"activeCount":114},[6986],{"nctId":6987,"briefTitle":6988,"status":230,"phases":6989,"primaryCompletion":6990,"completion":6990,"start":6991,"enrollment":186,"conditions":6992,"interventions":6994},"NCT03018106","Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction",[93],"2017-09-29","2017-06-30",[6993],"Sexual Dysfunction, Physiological",[6974,6995],"Vaginal conjugated estrogens",{"trials":6997,"activeCount":114},[],{"intervention":6995,"totalTrials":186,"cells":6999},{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7004,"PHASE3":7006,"PHASE4":7008,"NA":7014},{"trials":7001,"activeCount":114},[],{"trials":7003,"activeCount":114},[],{"trials":7005,"activeCount":114},[],{"trials":7007,"activeCount":114},[],{"trials":7009,"activeCount":114},[7010],{"nctId":6987,"briefTitle":6988,"status":230,"phases":7011,"primaryCompletion":6990,"completion":6990,"start":6991,"enrollment":186,"conditions":7012,"interventions":7013},[93],[6993],[6974,6995],{"trials":7015,"activeCount":114},[],{"intervention":7017,"totalTrials":186,"cells":7018},"Azithromycin mass treatment",{"EARLY_PHASE1":7019,"PHASE1":7021,"PHASE2":7023,"PHASE3":7025,"PHASE4":7027,"NA":7037},{"trials":7020,"activeCount":114},[],{"trials":7022,"activeCount":114},[],{"trials":7024,"activeCount":114},[],{"trials":7026,"activeCount":114},[],{"trials":7028,"activeCount":114},[7029],{"nctId":7030,"briefTitle":7031,"status":2022,"phases":7032,"primaryCompletion":1177,"completion":1600,"start":7033,"enrollment":114,"conditions":7034,"interventions":7035},"NCT03523156","Trachoma Elimination Study by Focused Antibiotic (TESFA)",[93],"2025-06",[3505],[7017,7036],"Azithromycin targeted treatment",{"trials":7038,"activeCount":114},[],{"intervention":7036,"totalTrials":186,"cells":7040},{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7045,"PHASE3":7047,"PHASE4":7049,"NA":7055},{"trials":7042,"activeCount":114},[],{"trials":7044,"activeCount":114},[],{"trials":7046,"activeCount":114},[],{"trials":7048,"activeCount":114},[],{"trials":7050,"activeCount":114},[7051],{"nctId":7030,"briefTitle":7031,"status":2022,"phases":7052,"primaryCompletion":1177,"completion":1600,"start":7033,"enrollment":114,"conditions":7053,"interventions":7054},[93],[3505],[7017,7036],{"trials":7056,"activeCount":114},[],{"intervention":7058,"totalTrials":186,"cells":7059},"AbobotulinumtoxinA",{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7064,"PHASE3":7066,"PHASE4":7068,"NA":7078},{"trials":7061,"activeCount":114},[],{"trials":7063,"activeCount":114},[],{"trials":7065,"activeCount":114},[],{"trials":7067,"activeCount":114},[],{"trials":7069,"activeCount":114},[7070],{"nctId":7071,"briefTitle":7072,"status":105,"phases":7073,"primaryCompletion":7074,"completion":7074,"start":4079,"enrollment":362,"conditions":7075,"interventions":7077},"NCT05466539","Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A",[93],"2025-08-13",[7076],"Compartment Syndrome of Leg",[7058],{"trials":7079,"activeCount":114},[],{"intervention":7081,"totalTrials":186,"cells":7082},"Enoxaparin",{"EARLY_PHASE1":7083,"PHASE1":7085,"PHASE2":7087,"PHASE3":7089,"PHASE4":7091,"NA":7102},{"trials":7084,"activeCount":114},[],{"trials":7086,"activeCount":114},[],{"trials":7088,"activeCount":114},[],{"trials":7090,"activeCount":114},[],{"trials":7092,"activeCount":114},[7093],{"nctId":7094,"briefTitle":7095,"status":105,"phases":7096,"primaryCompletion":7097,"completion":7098,"start":7099,"enrollment":2193,"conditions":7100,"interventions":7101},"NCT01798550","Enoxaparin Dosing in Obesity",[93],"2016-10-01","2016-10-15","2013-03",[33],[7081],{"trials":7103,"activeCount":114},[],{"intervention":7105,"totalTrials":186,"cells":7106},"Detemir + aspart insulin before meals",{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7113,"PHASE4":7115,"NA":7127},{"trials":7108,"activeCount":114},[],{"trials":7110,"activeCount":114},[],{"trials":7112,"activeCount":114},[],{"trials":7114,"activeCount":114},[],{"trials":7116,"activeCount":114},[7117],{"nctId":7118,"briefTitle":7119,"status":105,"phases":7120,"primaryCompletion":7121,"completion":1320,"start":7122,"enrollment":7123,"conditions":7124,"interventions":7125},"NCT00590226","Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes",[93],"2008-01","2006-12",130,[5928],[7105,7126],"NPH insulin + regular insulin",{"trials":7128,"activeCount":114},[],{"intervention":7126,"totalTrials":186,"cells":7130},{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7135,"PHASE3":7137,"PHASE4":7139,"NA":7145},{"trials":7132,"activeCount":114},[],{"trials":7134,"activeCount":114},[],{"trials":7136,"activeCount":114},[],{"trials":7138,"activeCount":114},[],{"trials":7140,"activeCount":114},[7141],{"nctId":7118,"briefTitle":7119,"status":105,"phases":7142,"primaryCompletion":7121,"completion":1320,"start":7122,"enrollment":7123,"conditions":7143,"interventions":7144},[93],[5928],[7105,7126],{"trials":7146,"activeCount":114},[],{"intervention":7148,"totalTrials":186,"cells":7149},"Bubble-Enhanced FAST",{"EARLY_PHASE1":7150,"PHASE1":7152,"PHASE2":7154,"PHASE3":7156,"PHASE4":7158,"NA":7170},{"trials":7151,"activeCount":114},[],{"trials":7153,"activeCount":114},[],{"trials":7155,"activeCount":114},[],{"trials":7157,"activeCount":114},[],{"trials":7159,"activeCount":114},[7160],{"nctId":7161,"briefTitle":7162,"status":105,"phases":7163,"primaryCompletion":7164,"completion":7164,"start":7165,"enrollment":7166,"conditions":7167,"interventions":7169},"NCT05025449","BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury",[93],"2023-09-14","2021-09-30",267,[7168],"Abdominal Trauma",[7148],{"trials":7171,"activeCount":114},[],{"intervention":6347,"totalTrials":186,"cells":7173},{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7180,"PHASE4":7182,"NA":7188},{"trials":7175,"activeCount":114},[],{"trials":7177,"activeCount":114},[],{"trials":7179,"activeCount":114},[],{"trials":7181,"activeCount":114},[],{"trials":7183,"activeCount":114},[7184],{"nctId":6339,"briefTitle":6340,"status":105,"phases":7185,"primaryCompletion":3877,"completion":5925,"start":173,"enrollment":6342,"conditions":7186,"interventions":7187},[93],[6344,1358,6345],[6347,6315,6348],{"trials":7189,"activeCount":114},[],{"intervention":6348,"totalTrials":186,"cells":7191},{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7196,"PHASE3":7198,"PHASE4":7200,"NA":7206},{"trials":7193,"activeCount":114},[],{"trials":7195,"activeCount":114},[],{"trials":7197,"activeCount":114},[],{"trials":7199,"activeCount":114},[],{"trials":7201,"activeCount":114},[7202],{"nctId":6339,"briefTitle":6340,"status":105,"phases":7203,"primaryCompletion":3877,"completion":5925,"start":173,"enrollment":6342,"conditions":7204,"interventions":7205},[93],[6344,1358,6345],[6347,6315,6348],{"trials":7207,"activeCount":114},[],{"intervention":7209,"totalTrials":186,"cells":7210},"Ropivacaine 0.1%",{"EARLY_PHASE1":7211,"PHASE1":7213,"PHASE2":7215,"PHASE3":7217,"PHASE4":7219,"NA":7230},{"trials":7212,"activeCount":114},[],{"trials":7214,"activeCount":114},[],{"trials":7216,"activeCount":114},[],{"trials":7218,"activeCount":114},[],{"trials":7220,"activeCount":114},[7221],{"nctId":7222,"briefTitle":7223,"status":105,"phases":7224,"primaryCompletion":7225,"completion":7225,"start":320,"enrollment":4781,"conditions":7226,"interventions":7227},"NCT02579629","Use of On-Q Pump for Pain Post C-Section",[93],"2019-07-25",[1358],[7209,7228,7229],"Ropivacaine 0.2%","Normal saline",{"trials":7231,"activeCount":114},[],{"intervention":7228,"totalTrials":186,"cells":7233},{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7238,"PHASE3":7240,"PHASE4":7242,"NA":7248},{"trials":7235,"activeCount":114},[],{"trials":7237,"activeCount":114},[],{"trials":7239,"activeCount":114},[],{"trials":7241,"activeCount":114},[],{"trials":7243,"activeCount":114},[7244],{"nctId":7222,"briefTitle":7223,"status":105,"phases":7245,"primaryCompletion":7225,"completion":7225,"start":320,"enrollment":4781,"conditions":7246,"interventions":7247},[93],[1358],[7209,7228,7229],{"trials":7249,"activeCount":114},[],{"intervention":7251,"totalTrials":186,"cells":7252},"Liposomal Injection Bupivacaine",{"EARLY_PHASE1":7253,"PHASE1":7255,"PHASE2":7257,"PHASE3":7259,"PHASE4":7261,"NA":7271},{"trials":7254,"activeCount":114},[],{"trials":7256,"activeCount":114},[],{"trials":7258,"activeCount":114},[],{"trials":7260,"activeCount":114},[],{"trials":7262,"activeCount":114},[7263],{"nctId":7264,"briefTitle":7265,"status":230,"phases":7266,"primaryCompletion":3502,"completion":3502,"start":7267,"enrollment":470,"conditions":7268,"interventions":7269},"NCT01853176","Exparel vs. Standard Bupivicaine for Abdominoplasty",[93],"2013-05",[1359],[7251,7270],"Standard bupivicaine",{"trials":7272,"activeCount":114},[],{"intervention":7270,"totalTrials":186,"cells":7274},{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7279,"PHASE3":7281,"PHASE4":7283,"NA":7289},{"trials":7276,"activeCount":114},[],{"trials":7278,"activeCount":114},[],{"trials":7280,"activeCount":114},[],{"trials":7282,"activeCount":114},[],{"trials":7284,"activeCount":114},[7285],{"nctId":7264,"briefTitle":7265,"status":230,"phases":7286,"primaryCompletion":3502,"completion":3502,"start":7267,"enrollment":470,"conditions":7287,"interventions":7288},[93],[1359],[7251,7270],{"trials":7290,"activeCount":114},[],{"intervention":6429,"totalTrials":186,"cells":7292},{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7299,"PHASE4":7301,"NA":7307},{"trials":7294,"activeCount":114},[],{"trials":7296,"activeCount":114},[],{"trials":7298,"activeCount":114},[],{"trials":7300,"activeCount":114},[],{"trials":7302,"activeCount":114},[7303],{"nctId":6421,"briefTitle":6422,"status":105,"phases":7304,"primaryCompletion":6424,"completion":6425,"start":2942,"enrollment":6426,"conditions":7305,"interventions":7306},[93],[5928],[6408,5930,6408,6429,6430],{"trials":7308,"activeCount":114},[],{"intervention":6430,"totalTrials":186,"cells":7310},{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7317,"PHASE4":7319,"NA":7325},{"trials":7312,"activeCount":114},[],{"trials":7314,"activeCount":114},[],{"trials":7316,"activeCount":114},[],{"trials":7318,"activeCount":114},[],{"trials":7320,"activeCount":114},[7321],{"nctId":6421,"briefTitle":6422,"status":105,"phases":7322,"primaryCompletion":6424,"completion":6425,"start":2942,"enrollment":6426,"conditions":7323,"interventions":7324},[93],[5928],[6408,5930,6408,6429,6430],{"trials":7326,"activeCount":114},[],{"intervention":7328,"totalTrials":186,"cells":7329},"Triamcinolone",{"EARLY_PHASE1":7330,"PHASE1":7332,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7351},{"trials":7331,"activeCount":114},[],{"trials":7333,"activeCount":114},[],{"trials":7335,"activeCount":114},[],{"trials":7337,"activeCount":114},[],{"trials":7339,"activeCount":114},[7340],{"nctId":7341,"briefTitle":7342,"status":105,"phases":7343,"primaryCompletion":3877,"completion":3877,"start":7344,"enrollment":9,"conditions":7345,"interventions":7349},"NCT01995045","Postoperative Pain Control Following Vitreoretinal Surgery",[93],"2012-07",[7346,7347,7348],"Retinal Detachment","Proliferative Vitreoretinopathy","Retinoschisis",[7328,7350],"Bupivicaine Hydrochloride",{"trials":7352,"activeCount":114},[],{"intervention":7350,"totalTrials":186,"cells":7354},{"EARLY_PHASE1":7355,"PHASE1":7357,"PHASE2":7359,"PHASE3":7361,"PHASE4":7363,"NA":7369},{"trials":7356,"activeCount":114},[],{"trials":7358,"activeCount":114},[],{"trials":7360,"activeCount":114},[],{"trials":7362,"activeCount":114},[],{"trials":7364,"activeCount":114},[7365],{"nctId":7341,"briefTitle":7342,"status":105,"phases":7366,"primaryCompletion":3877,"completion":3877,"start":7344,"enrollment":9,"conditions":7367,"interventions":7368},[93],[7346,7347,7348],[7328,7350],{"trials":7370,"activeCount":114},[],{"intervention":7372,"totalTrials":186,"cells":7373},"Fresh red blood cell (RBC) transfusion",{"EARLY_PHASE1":7374,"PHASE1":7376,"PHASE2":7378,"PHASE3":7380,"PHASE4":7382,"NA":7392},{"trials":7375,"activeCount":114},[],{"trials":7377,"activeCount":114},[],{"trials":7379,"activeCount":114},[],{"trials":7381,"activeCount":114},[],{"trials":7383,"activeCount":114},[7384],{"nctId":7385,"briefTitle":7386,"status":230,"phases":7387,"primaryCompletion":6035,"completion":6035,"start":5971,"enrollment":1754,"conditions":7388,"interventions":7390},"NCT02566577","Physiologic Effects of RBC Transfusion",[93],[7389],"Red Blood Cell Transfusion",[7372,7391],"Storage-aged red blood cell (RBC) transfusion",{"trials":7393,"activeCount":114},[],{"intervention":7391,"totalTrials":186,"cells":7395},{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7402,"PHASE4":7404,"NA":7410},{"trials":7397,"activeCount":114},[],{"trials":7399,"activeCount":114},[],{"trials":7401,"activeCount":114},[],{"trials":7403,"activeCount":114},[],{"trials":7405,"activeCount":114},[7406],{"nctId":7385,"briefTitle":7386,"status":230,"phases":7407,"primaryCompletion":6035,"completion":6035,"start":5971,"enrollment":1754,"conditions":7408,"interventions":7409},[93],[7389],[7372,7391],{"trials":7411,"activeCount":114},[],{"intervention":7413,"totalTrials":186,"cells":7414},"Orlistat",{"EARLY_PHASE1":7415,"PHASE1":7417,"PHASE2":7419,"PHASE3":7421,"PHASE4":7423,"NA":7434},{"trials":7416,"activeCount":114},[],{"trials":7418,"activeCount":114},[],{"trials":7420,"activeCount":114},[],{"trials":7422,"activeCount":114},[],{"trials":7424,"activeCount":114},[7425],{"nctId":7426,"briefTitle":7427,"status":105,"phases":7428,"primaryCompletion":7429,"completion":7429,"start":7430,"enrollment":345,"conditions":7431,"interventions":7433},"NCT03582722","Weight Loss Aid in an Exposed Population",[93],"2022-06-30","2018-09-14",[7432],"Polybrominated Biphenyl Poisoning",[7413],{"trials":7435,"activeCount":114},[],{"intervention":7437,"totalTrials":186,"cells":7438},"Riluzole",{"EARLY_PHASE1":7439,"PHASE1":7441,"PHASE2":7443,"PHASE3":7445,"PHASE4":7447,"NA":7458},{"trials":7440,"activeCount":114},[],{"trials":7442,"activeCount":114},[],{"trials":7444,"activeCount":114},[],{"trials":7446,"activeCount":114},[],{"trials":7448,"activeCount":114},[7449],{"nctId":7450,"briefTitle":7451,"status":105,"phases":7452,"primaryCompletion":7453,"completion":7453,"start":5925,"enrollment":123,"conditions":7454,"interventions":7457},"NCT02796755","Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation",[93],"2019-10-24",[7455,7456],"Inflammation","Fatigue",[7437],{"trials":7459,"activeCount":114},[],{"intervention":7461,"totalTrials":186,"cells":7462},"Bacteriostatic Normal Saline",{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7467,"PHASE3":7469,"PHASE4":7471,"NA":7483},{"trials":7464,"activeCount":114},[],{"trials":7466,"activeCount":114},[],{"trials":7468,"activeCount":114},[],{"trials":7470,"activeCount":114},[],{"trials":7472,"activeCount":114},[7473],{"nctId":7474,"briefTitle":7475,"status":105,"phases":7476,"primaryCompletion":7477,"completion":7477,"start":7478,"enrollment":1796,"conditions":7479,"interventions":7481},"NCT04495868","Bacteriostatic Normal Saline Versus Lidocaine for Intradermal Anesthesia",[93],"2022-04-06","2021-01-08",[7480],"Chronic Pain",[7461,7482],"1% Lidocaine",{"trials":7484,"activeCount":114},[],{"intervention":7482,"totalTrials":186,"cells":7486},{"EARLY_PHASE1":7487,"PHASE1":7489,"PHASE2":7491,"PHASE3":7493,"PHASE4":7495,"NA":7501},{"trials":7488,"activeCount":114},[],{"trials":7490,"activeCount":114},[],{"trials":7492,"activeCount":114},[],{"trials":7494,"activeCount":114},[],{"trials":7496,"activeCount":114},[7497],{"nctId":7474,"briefTitle":7475,"status":105,"phases":7498,"primaryCompletion":7477,"completion":7477,"start":7478,"enrollment":1796,"conditions":7499,"interventions":7500},[93],[7480],[7461,7482],{"trials":7502,"activeCount":114},[],{"intervention":7504,"totalTrials":186,"cells":7505},"Provigil",{"EARLY_PHASE1":7506,"PHASE1":7508,"PHASE2":7510,"PHASE3":7512,"PHASE4":7514,"NA":7525},{"trials":7507,"activeCount":114},[],{"trials":7509,"activeCount":114},[],{"trials":7511,"activeCount":114},[],{"trials":7513,"activeCount":114},[],{"trials":7515,"activeCount":114},[7516],{"nctId":7517,"briefTitle":7518,"status":105,"phases":7519,"completion":7520,"start":7521,"enrollment":345,"conditions":7522,"interventions":7524},"NCT00208715","Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.",[93],"2004-10","2003-02",[4404,7523],"Mental Health",[7504],{"trials":7526,"activeCount":114},[],{"intervention":7528,"totalTrials":186,"cells":7529},"2016-2017 Influenza Vaccine",{"EARLY_PHASE1":7530,"PHASE1":7532,"PHASE2":7534,"PHASE3":7536,"PHASE4":7538,"NA":7549},{"trials":7531,"activeCount":114},[],{"trials":7533,"activeCount":114},[],{"trials":7535,"activeCount":114},[],{"trials":7537,"activeCount":114},[],{"trials":7539,"activeCount":114},[7540],{"nctId":7541,"briefTitle":7542,"status":105,"phases":7543,"primaryCompletion":7544,"completion":7545,"start":7546,"enrollment":454,"conditions":7547,"interventions":7548},"NCT02876159","The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination",[93],"2016-10-18","2016-12-01","2016-07",[847],[7528],{"trials":7550,"activeCount":114},[],{"intervention":7552,"totalTrials":186,"cells":7553},"Rabies Vaccine",{"EARLY_PHASE1":7554,"PHASE1":7556,"PHASE2":7558,"PHASE3":7560,"PHASE4":7562,"NA":7576},{"trials":7555,"activeCount":114},[],{"trials":7557,"activeCount":114},[],{"trials":7559,"activeCount":114},[],{"trials":7561,"activeCount":114},[],{"trials":7563,"activeCount":114},[7564],{"nctId":7565,"briefTitle":7566,"status":105,"phases":7567,"primaryCompletion":7568,"completion":7568,"start":7569,"enrollment":1499,"conditions":7570,"interventions":7572},"NCT03557008","Responses to Rabies Vaccine in Adults With or Without Antibiotics",[93],"2022-06-02","2018-07-05",[7571],"Rabies Human",[7552,7573,7574,7575],"Metronidazole","Vancomycin","Neomycin Sulfate",{"trials":7577,"activeCount":114},[],{"intervention":7575,"totalTrials":186,"cells":7579},{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7584,"PHASE3":7586,"PHASE4":7588,"NA":7594},{"trials":7581,"activeCount":114},[],{"trials":7583,"activeCount":114},[],{"trials":7585,"activeCount":114},[],{"trials":7587,"activeCount":114},[],{"trials":7589,"activeCount":114},[7590],{"nctId":7565,"briefTitle":7566,"status":105,"phases":7591,"primaryCompletion":7568,"completion":7568,"start":7569,"enrollment":1499,"conditions":7592,"interventions":7593},[93],[7571],[7552,7573,7574,7575],{"trials":7595,"activeCount":114},[],{"intervention":7597,"totalTrials":186,"cells":7598},"sliding scale regular insulin",{"EARLY_PHASE1":7599,"PHASE1":7601,"PHASE2":7603,"PHASE3":7605,"PHASE4":7607,"NA":7618},{"trials":7600,"activeCount":114},[],{"trials":7602,"activeCount":114},[],{"trials":7604,"activeCount":114},[],{"trials":7606,"activeCount":114},[],{"trials":7608,"activeCount":114},[7609],{"nctId":7610,"briefTitle":7611,"status":105,"phases":7612,"primaryCompletion":7613,"completion":7613,"start":7614,"enrollment":7123,"conditions":7615,"interventions":7616},"NCT00394407","Basal\u002FBolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes",[93],"2006-06","2005-09",[18,500],[7597,7617],"glargine basal insulin and glulisine prandial insulin",{"trials":7619,"activeCount":114},[],{"intervention":7617,"totalTrials":186,"cells":7621},{"EARLY_PHASE1":7622,"PHASE1":7624,"PHASE2":7626,"PHASE3":7628,"PHASE4":7630,"NA":7636},{"trials":7623,"activeCount":114},[],{"trials":7625,"activeCount":114},[],{"trials":7627,"activeCount":114},[],{"trials":7629,"activeCount":114},[],{"trials":7631,"activeCount":114},[7632],{"nctId":7610,"briefTitle":7611,"status":105,"phases":7633,"primaryCompletion":7613,"completion":7613,"start":7614,"enrollment":7123,"conditions":7634,"interventions":7635},[93],[18,500],[7597,7617],{"trials":7637,"activeCount":114},[],{"intervention":7639,"totalTrials":186,"cells":7640},"Treatment Group: Corticosteroid",{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7645,"PHASE3":7647,"PHASE4":7649,"NA":7662},{"trials":7642,"activeCount":114},[],{"trials":7644,"activeCount":114},[],{"trials":7646,"activeCount":114},[],{"trials":7648,"activeCount":114},[],{"trials":7650,"activeCount":114},[7651],{"nctId":7652,"briefTitle":7653,"status":230,"phases":7654,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":2193,"conditions":7657,"interventions":7659},"NCT03704584","Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone",[93],"2020-01-14","2019-05-14",[7658],"Tenosynovitis",[7639,7660,7661],"Control Group","Treatment Group: Lidocaine",{"trials":7663,"activeCount":114},[],{"intervention":7660,"totalTrials":186,"cells":7665},{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7672,"PHASE4":7674,"NA":7680},{"trials":7667,"activeCount":114},[],{"trials":7669,"activeCount":114},[],{"trials":7671,"activeCount":114},[],{"trials":7673,"activeCount":114},[],{"trials":7675,"activeCount":114},[7676],{"nctId":7652,"briefTitle":7653,"status":230,"phases":7677,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":2193,"conditions":7678,"interventions":7679},[93],[7658],[7639,7660,7661],{"trials":7681,"activeCount":114},[],{"intervention":7661,"totalTrials":186,"cells":7683},{"EARLY_PHASE1":7684,"PHASE1":7686,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7698},{"trials":7685,"activeCount":114},[],{"trials":7687,"activeCount":114},[],{"trials":7689,"activeCount":114},[],{"trials":7691,"activeCount":114},[],{"trials":7693,"activeCount":114},[7694],{"nctId":7652,"briefTitle":7653,"status":230,"phases":7695,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":2193,"conditions":7696,"interventions":7697},[93],[7658],[7639,7660,7661],{"trials":7699,"activeCount":114},[],{"intervention":7701,"totalTrials":186,"cells":7702},"Rosiglitazone",{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7707,"PHASE3":7709,"PHASE4":7711,"NA":7722},{"trials":7704,"activeCount":114},[],{"trials":7706,"activeCount":114},[],{"trials":7708,"activeCount":114},[],{"trials":7710,"activeCount":114},[],{"trials":7712,"activeCount":114},[7713],{"nctId":7714,"briefTitle":7715,"status":105,"phases":7716,"primaryCompletion":5970,"completion":5970,"start":7717,"enrollment":1153,"conditions":7718,"interventions":7719},"NCT00738023","Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes",[93],"2004-03",[5928,6155],[7701,7720,7721],"Normal saline 0.9%","Intralipid 20%",{"trials":7723,"activeCount":114},[],{"intervention":7720,"totalTrials":186,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7730,"PHASE3":7732,"PHASE4":7734,"NA":7740},{"trials":7727,"activeCount":114},[],{"trials":7729,"activeCount":114},[],{"trials":7731,"activeCount":114},[],{"trials":7733,"activeCount":114},[],{"trials":7735,"activeCount":114},[7736],{"nctId":7714,"briefTitle":7715,"status":105,"phases":7737,"primaryCompletion":5970,"completion":5970,"start":7717,"enrollment":1153,"conditions":7738,"interventions":7739},[93],[5928,6155],[7701,7720,7721],{"trials":7741,"activeCount":114},[],{"intervention":7743,"totalTrials":186,"cells":7744},"Bupropion XL",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7751,"PHASE4":7753,"NA":7763},{"trials":7746,"activeCount":114},[],{"trials":7748,"activeCount":114},[],{"trials":7750,"activeCount":114},[],{"trials":7752,"activeCount":114},[],{"trials":7754,"activeCount":114},[7755],{"nctId":7756,"briefTitle":7757,"status":105,"phases":7758,"primaryCompletion":2190,"completion":2190,"start":7759,"enrollment":98,"conditions":7760,"interventions":7761},"NCT04352101","Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits",[93],"2020-09-23",[4404],[7743,7762],"Escitalopram",{"trials":7764,"activeCount":114},[],{"intervention":7766,"totalTrials":186,"cells":7767},"Standard of Care Anesthesia",{"EARLY_PHASE1":7768,"PHASE1":7770,"PHASE2":7772,"PHASE3":7774,"PHASE4":7776,"NA":7787},{"trials":7769,"activeCount":114},[],{"trials":7771,"activeCount":114},[],{"trials":7773,"activeCount":114},[],{"trials":7775,"activeCount":114},[],{"trials":7777,"activeCount":114},[7778],{"nctId":7779,"briefTitle":7780,"status":230,"phases":7781,"primaryCompletion":7782,"completion":7782,"start":7783,"enrollment":37,"conditions":7784,"interventions":7786},"NCT03408340","Paravertebral Nerve Blocks in Neonates",[93],"2020-07-28","2018-07-18",[7785],"Congenital Heart Disease",[7766],{"trials":7788,"activeCount":114},[],{"intervention":7790,"totalTrials":186,"cells":7791},"Doripenem",{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7798,"PHASE4":7800,"NA":7811},{"trials":7793,"activeCount":114},[],{"trials":7795,"activeCount":114},[],{"trials":7797,"activeCount":114},[],{"trials":7799,"activeCount":114},[],{"trials":7801,"activeCount":114},[7802],{"nctId":7803,"briefTitle":7804,"status":105,"phases":7805,"primaryCompletion":7806,"completion":7806,"start":7807,"enrollment":123,"conditions":7808,"interventions":7810},"NCT01027897","Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients",[93],"2011-12","2010-04",[7809],"Sepsis",[7790],{"trials":7812,"activeCount":114},[],{"intervention":7814,"totalTrials":186,"cells":7815},"Lubiprostone",{"EARLY_PHASE1":7816,"PHASE1":7818,"PHASE2":7820,"PHASE3":7822,"PHASE4":7824,"NA":7835},{"trials":7817,"activeCount":114},[],{"trials":7819,"activeCount":114},[],{"trials":7821,"activeCount":114},[],{"trials":7823,"activeCount":114},[],{"trials":7825,"activeCount":114},[7826],{"nctId":7827,"briefTitle":7828,"status":105,"phases":7829,"primaryCompletion":232,"completion":232,"start":7830,"enrollment":7831,"conditions":7832,"interventions":7834},"NCT01170039","The Effectiveness of Lubiprostone in Constipated Diabetics",[93],"2010-09",121,[7833,18],"Constipation",[7814],{"trials":7836,"activeCount":114},[],{"intervention":7838,"totalTrials":186,"cells":7839},"pantoprazole",{"EARLY_PHASE1":7840,"PHASE1":7842,"PHASE2":7844,"PHASE3":7846,"PHASE4":7848,"NA":7860},{"trials":7841,"activeCount":114},[],{"trials":7843,"activeCount":114},[],{"trials":7845,"activeCount":114},[],{"trials":7847,"activeCount":114},[],{"trials":7849,"activeCount":114},[7850],{"nctId":7851,"briefTitle":7852,"status":105,"phases":7853,"primaryCompletion":7854,"completion":7855,"start":7856,"enrollment":454,"conditions":7857,"interventions":7859},"NCT00133770","Intravenous (IV) Pantoprazole in Erosive Esophagitis",[93],"2006-07","2007-03","2004-07",[7858],"Esophagitis",[7838],{"trials":7861,"activeCount":114},[],{"intervention":7863,"totalTrials":186,"cells":7864},"Any FDA Approved Antidepressant",{"EARLY_PHASE1":7865,"PHASE1":7867,"PHASE2":7869,"PHASE3":7871,"PHASE4":7873,"NA":7883},{"trials":7866,"activeCount":114},[],{"trials":7868,"activeCount":114},[],{"trials":7870,"activeCount":114},[],{"trials":7872,"activeCount":114},[],{"trials":7874,"activeCount":114},[7875],{"nctId":7876,"briefTitle":7877,"status":105,"phases":7878,"primaryCompletion":3877,"completion":3877,"start":233,"enrollment":7879,"conditions":7880,"interventions":7882},"NCT01916824","Effects of Treatment on Decision-making in Major Depression",[93],53,[2625,7881],"Healthy Controls",[7863],{"trials":7884,"activeCount":114},[],{"intervention":7886,"totalTrials":186,"cells":7887},"Live Attenuated Influenza Vaccine",{"EARLY_PHASE1":7888,"PHASE1":7890,"PHASE2":7892,"PHASE3":7894,"PHASE4":7896,"NA":7906},{"trials":7889,"activeCount":114},[],{"trials":7891,"activeCount":114},[],{"trials":7893,"activeCount":114},[],{"trials":7895,"activeCount":114},[],{"trials":7897,"activeCount":114},[7898],{"nctId":7899,"briefTitle":7900,"status":105,"phases":7901,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":3672,"conditions":7904,"interventions":7905},"NCT06501963","Revealing Protective Immunity to Influenza Using Systems Immunology",[93],"2025-04-01","2024-10-14",[847],[7886],{"trials":7907,"activeCount":114},[],{"intervention":7909,"totalTrials":186,"cells":7910},"aspart insulin",{"EARLY_PHASE1":7911,"PHASE1":7913,"PHASE2":7915,"PHASE3":7917,"PHASE4":7919,"NA":7928},{"trials":7912,"activeCount":114},[],{"trials":7914,"activeCount":114},[],{"trials":7916,"activeCount":114},[],{"trials":7918,"activeCount":114},[],{"trials":7920,"activeCount":114},[7921],{"nctId":7922,"briefTitle":7923,"status":2022,"phases":7924,"enrollment":114,"conditions":7925,"interventions":7926},"NCT00663624","Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care",[93],[18],[7909,7927],"Usual care as prescribed by the ED physicians.",{"trials":7929,"activeCount":114},[],{"intervention":7927,"totalTrials":186,"cells":7931},{"EARLY_PHASE1":7932,"PHASE1":7934,"PHASE2":7936,"PHASE3":7938,"PHASE4":7940,"NA":7946},{"trials":7933,"activeCount":114},[],{"trials":7935,"activeCount":114},[],{"trials":7937,"activeCount":114},[],{"trials":7939,"activeCount":114},[],{"trials":7941,"activeCount":114},[7942],{"nctId":7922,"briefTitle":7923,"status":2022,"phases":7943,"enrollment":114,"conditions":7944,"interventions":7945},[93],[18],[7909,7927],{"trials":7947,"activeCount":114},[],{"intervention":7949,"totalTrials":186,"cells":7950},"risperidone",{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7955,"PHASE3":7957,"PHASE4":7959,"NA":7974},{"trials":7952,"activeCount":114},[],{"trials":7954,"activeCount":114},[],{"trials":7956,"activeCount":114},[],{"trials":7958,"activeCount":114},[],{"trials":7960,"activeCount":114},[7961],{"nctId":7962,"briefTitle":7963,"status":105,"phases":7964,"completion":7965,"start":7966,"enrollment":391,"conditions":7967,"interventions":7970},"NCT00208819","A Comparison of Two Standard Therapies in the Management of Dementia With Agitation",[93],"2007-07","2003-09",[7968,7969,406,36],"Senile Dementia, Alzheimer Type","Dementia, Alzheimer Type",[7949,7971,7972,7973],"quetiapine","olanzapine","divalproex",{"trials":7975,"activeCount":114},[],{"intervention":7971,"totalTrials":186,"cells":7977},{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7984,"PHASE4":7986,"NA":7992},{"trials":7979,"activeCount":114},[],{"trials":7981,"activeCount":114},[],{"trials":7983,"activeCount":114},[],{"trials":7985,"activeCount":114},[],{"trials":7987,"activeCount":114},[7988],{"nctId":7962,"briefTitle":7963,"status":105,"phases":7989,"completion":7965,"start":7966,"enrollment":391,"conditions":7990,"interventions":7991},[93],[7968,7969,406,36],[7949,7971,7972,7973],{"trials":7993,"activeCount":114},[],{"intervention":7972,"totalTrials":186,"cells":7995},{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8000,"PHASE3":8002,"PHASE4":8004,"NA":8010},{"trials":7997,"activeCount":114},[],{"trials":7999,"activeCount":114},[],{"trials":8001,"activeCount":114},[],{"trials":8003,"activeCount":114},[],{"trials":8005,"activeCount":114},[8006],{"nctId":7962,"briefTitle":7963,"status":105,"phases":8007,"completion":7965,"start":7966,"enrollment":391,"conditions":8008,"interventions":8009},[93],[7968,7969,406,36],[7949,7971,7972,7973],{"trials":8011,"activeCount":114},[],{"intervention":7973,"totalTrials":186,"cells":8013},{"EARLY_PHASE1":8014,"PHASE1":8016,"PHASE2":8018,"PHASE3":8020,"PHASE4":8022,"NA":8028},{"trials":8015,"activeCount":114},[],{"trials":8017,"activeCount":114},[],{"trials":8019,"activeCount":114},[],{"trials":8021,"activeCount":114},[],{"trials":8023,"activeCount":114},[8024],{"nctId":7962,"briefTitle":7963,"status":105,"phases":8025,"completion":7965,"start":7966,"enrollment":391,"conditions":8026,"interventions":8027},[93],[7968,7969,406,36],[7949,7971,7972,7973],{"trials":8029,"activeCount":114},[],{"intervention":8031,"totalTrials":186,"cells":8032},"LPV\u002Fr",{"EARLY_PHASE1":8033,"PHASE1":8035,"PHASE2":8037,"PHASE3":8039,"PHASE4":8041,"NA":8050},{"trials":8034,"activeCount":114},[],{"trials":8036,"activeCount":114},[],{"trials":8038,"activeCount":114},[],{"trials":8040,"activeCount":114},[],{"trials":8042,"activeCount":114},[8043],{"nctId":8044,"briefTitle":8045,"status":105,"phases":8046,"primaryCompletion":6861,"completion":6861,"start":8047,"enrollment":136,"conditions":8048,"interventions":8049},"NCT00148759","Kaletra Sex\u002FGender Pharmacokinetics (PK) Study",[93],"2005-06",[6067],[8031],{"trials":8051,"activeCount":114},[],{"intervention":562,"totalTrials":186,"cells":8053},{"EARLY_PHASE1":8054,"PHASE1":8056,"PHASE2":8058,"PHASE3":8060,"PHASE4":8062,"NA":8068},{"trials":8055,"activeCount":114},[],{"trials":8057,"activeCount":114},[],{"trials":8059,"activeCount":114},[],{"trials":8061,"activeCount":114},[],{"trials":8063,"activeCount":114},[8064],{"nctId":552,"briefTitle":553,"status":230,"phases":8065,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8066,"interventions":8067},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8069,"activeCount":114},[],{"intervention":563,"totalTrials":186,"cells":8071},{"EARLY_PHASE1":8072,"PHASE1":8074,"PHASE2":8076,"PHASE3":8078,"PHASE4":8080,"NA":8086},{"trials":8073,"activeCount":114},[],{"trials":8075,"activeCount":114},[],{"trials":8077,"activeCount":114},[],{"trials":8079,"activeCount":114},[],{"trials":8081,"activeCount":114},[8082],{"nctId":552,"briefTitle":553,"status":230,"phases":8083,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8084,"interventions":8085},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8087,"activeCount":114},[],{"intervention":564,"totalTrials":186,"cells":8089},{"EARLY_PHASE1":8090,"PHASE1":8092,"PHASE2":8094,"PHASE3":8096,"PHASE4":8098,"NA":8104},{"trials":8091,"activeCount":114},[],{"trials":8093,"activeCount":114},[],{"trials":8095,"activeCount":114},[],{"trials":8097,"activeCount":114},[],{"trials":8099,"activeCount":114},[8100],{"nctId":552,"briefTitle":553,"status":230,"phases":8101,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8102,"interventions":8103},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8105,"activeCount":114},[],{"intervention":566,"totalTrials":186,"cells":8107},{"EARLY_PHASE1":8108,"PHASE1":8110,"PHASE2":8112,"PHASE3":8114,"PHASE4":8116,"NA":8122},{"trials":8109,"activeCount":114},[],{"trials":8111,"activeCount":114},[],{"trials":8113,"activeCount":114},[],{"trials":8115,"activeCount":114},[],{"trials":8117,"activeCount":114},[8118],{"nctId":552,"briefTitle":553,"status":230,"phases":8119,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8120,"interventions":8121},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8123,"activeCount":114},[],{"intervention":567,"totalTrials":186,"cells":8125},{"EARLY_PHASE1":8126,"PHASE1":8128,"PHASE2":8130,"PHASE3":8132,"PHASE4":8134,"NA":8140},{"trials":8127,"activeCount":114},[],{"trials":8129,"activeCount":114},[],{"trials":8131,"activeCount":114},[],{"trials":8133,"activeCount":114},[],{"trials":8135,"activeCount":114},[8136],{"nctId":552,"briefTitle":553,"status":230,"phases":8137,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8138,"interventions":8139},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8141,"activeCount":114},[],{"intervention":568,"totalTrials":186,"cells":8143},{"EARLY_PHASE1":8144,"PHASE1":8146,"PHASE2":8148,"PHASE3":8150,"PHASE4":8152,"NA":8158},{"trials":8145,"activeCount":114},[],{"trials":8147,"activeCount":114},[],{"trials":8149,"activeCount":114},[],{"trials":8151,"activeCount":114},[],{"trials":8153,"activeCount":114},[8154],{"nctId":552,"briefTitle":553,"status":230,"phases":8155,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8156,"interventions":8157},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8159,"activeCount":114},[],{"intervention":569,"totalTrials":186,"cells":8161},{"EARLY_PHASE1":8162,"PHASE1":8164,"PHASE2":8166,"PHASE3":8168,"PHASE4":8170,"NA":8176},{"trials":8163,"activeCount":114},[],{"trials":8165,"activeCount":114},[],{"trials":8167,"activeCount":114},[],{"trials":8169,"activeCount":114},[],{"trials":8171,"activeCount":114},[8172],{"nctId":552,"briefTitle":553,"status":230,"phases":8173,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8174,"interventions":8175},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8177,"activeCount":114},[],{"intervention":570,"totalTrials":186,"cells":8179},{"EARLY_PHASE1":8180,"PHASE1":8182,"PHASE2":8184,"PHASE3":8186,"PHASE4":8188,"NA":8194},{"trials":8181,"activeCount":114},[],{"trials":8183,"activeCount":114},[],{"trials":8185,"activeCount":114},[],{"trials":8187,"activeCount":114},[],{"trials":8189,"activeCount":114},[8190],{"nctId":552,"briefTitle":553,"status":230,"phases":8191,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8192,"interventions":8193},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8195,"activeCount":114},[],{"intervention":571,"totalTrials":186,"cells":8197},{"EARLY_PHASE1":8198,"PHASE1":8200,"PHASE2":8202,"PHASE3":8204,"PHASE4":8206,"NA":8212},{"trials":8199,"activeCount":114},[],{"trials":8201,"activeCount":114},[],{"trials":8203,"activeCount":114},[],{"trials":8205,"activeCount":114},[],{"trials":8207,"activeCount":114},[8208],{"nctId":552,"briefTitle":553,"status":230,"phases":8209,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8210,"interventions":8211},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8213,"activeCount":114},[],{"intervention":572,"totalTrials":186,"cells":8215},{"EARLY_PHASE1":8216,"PHASE1":8218,"PHASE2":8220,"PHASE3":8222,"PHASE4":8224,"NA":8230},{"trials":8217,"activeCount":114},[],{"trials":8219,"activeCount":114},[],{"trials":8221,"activeCount":114},[],{"trials":8223,"activeCount":114},[],{"trials":8225,"activeCount":114},[8226],{"nctId":552,"briefTitle":553,"status":230,"phases":8227,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8228,"interventions":8229},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8231,"activeCount":114},[],{"intervention":573,"totalTrials":186,"cells":8233},{"EARLY_PHASE1":8234,"PHASE1":8236,"PHASE2":8238,"PHASE3":8240,"PHASE4":8242,"NA":8248},{"trials":8235,"activeCount":114},[],{"trials":8237,"activeCount":114},[],{"trials":8239,"activeCount":114},[],{"trials":8241,"activeCount":114},[],{"trials":8243,"activeCount":114},[8244],{"nctId":552,"briefTitle":553,"status":230,"phases":8245,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8246,"interventions":8247},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8249,"activeCount":114},[],{"intervention":575,"totalTrials":186,"cells":8251},{"EARLY_PHASE1":8252,"PHASE1":8254,"PHASE2":8256,"PHASE3":8258,"PHASE4":8260,"NA":8266},{"trials":8253,"activeCount":114},[],{"trials":8255,"activeCount":114},[],{"trials":8257,"activeCount":114},[],{"trials":8259,"activeCount":114},[],{"trials":8261,"activeCount":114},[8262],{"nctId":552,"briefTitle":553,"status":230,"phases":8263,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8264,"interventions":8265},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8267,"activeCount":114},[],{"intervention":577,"totalTrials":186,"cells":8269},{"EARLY_PHASE1":8270,"PHASE1":8272,"PHASE2":8274,"PHASE3":8276,"PHASE4":8278,"NA":8284},{"trials":8271,"activeCount":114},[],{"trials":8273,"activeCount":114},[],{"trials":8275,"activeCount":114},[],{"trials":8277,"activeCount":114},[],{"trials":8279,"activeCount":114},[8280],{"nctId":552,"briefTitle":553,"status":230,"phases":8281,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8282,"interventions":8283},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8285,"activeCount":114},[],{"intervention":578,"totalTrials":186,"cells":8287},{"EARLY_PHASE1":8288,"PHASE1":8290,"PHASE2":8292,"PHASE3":8294,"PHASE4":8296,"NA":8302},{"trials":8289,"activeCount":114},[],{"trials":8291,"activeCount":114},[],{"trials":8293,"activeCount":114},[],{"trials":8295,"activeCount":114},[],{"trials":8297,"activeCount":114},[8298],{"nctId":552,"briefTitle":553,"status":230,"phases":8299,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8300,"interventions":8301},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8303,"activeCount":114},[],{"intervention":579,"totalTrials":186,"cells":8305},{"EARLY_PHASE1":8306,"PHASE1":8308,"PHASE2":8310,"PHASE3":8312,"PHASE4":8314,"NA":8320},{"trials":8307,"activeCount":114},[],{"trials":8309,"activeCount":114},[],{"trials":8311,"activeCount":114},[],{"trials":8313,"activeCount":114},[],{"trials":8315,"activeCount":114},[8316],{"nctId":552,"briefTitle":553,"status":230,"phases":8317,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":8318,"interventions":8319},[93],[559,560],[562,563,564,565,566,567,568,569,570,571,572,573,349,574,575,576,577,578,579],{"trials":8321,"activeCount":114},[],{"intervention":8323,"totalTrials":186,"cells":8324},"Oxygen",{"EARLY_PHASE1":8325,"PHASE1":8327,"PHASE2":8329,"PHASE3":8331,"PHASE4":8333,"NA":8345},{"trials":8326,"activeCount":114},[],{"trials":8328,"activeCount":114},[],{"trials":8330,"activeCount":114},[],{"trials":8332,"activeCount":114},[],{"trials":8334,"activeCount":114},[8335],{"nctId":8336,"briefTitle":8337,"status":105,"phases":8338,"primaryCompletion":8339,"completion":8339,"start":8340,"enrollment":8341,"conditions":8342,"interventions":8344},"NCT03840486","Pre-oxygenation With Real Time End-tidal Oxygen Measurements Versus Single Breath Measurements",[93],"2023-10-20","2019-09-24",105,[8343],"Rapid Sequence Intubation",[8323,8323],{"trials":8346,"activeCount":114},[],{"intervention":8348,"totalTrials":186,"cells":8349},"Selective serotonin re-uptake inhibitor",{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8354,"PHASE3":8356,"PHASE4":8358,"NA":8368},{"trials":8351,"activeCount":114},[],{"trials":8353,"activeCount":114},[],{"trials":8355,"activeCount":114},[],{"trials":8357,"activeCount":114},[],{"trials":8359,"activeCount":114},[8360],{"nctId":8361,"briefTitle":8362,"status":105,"phases":8363,"primaryCompletion":7453,"completion":7453,"start":8364,"enrollment":8365,"conditions":8366,"interventions":8367},"NCT02137369","The ISLAND Study: InSuLa Assessed Needs for Depression",[93],"2014-09",77,[21],[8348],{"trials":8369,"activeCount":114},[],{"intervention":8371,"totalTrials":186,"cells":8372},"Pneumococcal 13-valent Conjugate Vaccine",{"EARLY_PHASE1":8373,"PHASE1":8375,"PHASE2":8377,"PHASE3":8379,"PHASE4":8381,"NA":8394},{"trials":8374,"activeCount":114},[],{"trials":8376,"activeCount":114},[],{"trials":8378,"activeCount":114},[],{"trials":8380,"activeCount":114},[],{"trials":8382,"activeCount":114},[8383],{"nctId":8384,"briefTitle":8385,"status":105,"phases":8386,"primaryCompletion":8387,"completion":8388,"start":8389,"enrollment":322,"conditions":8390,"interventions":8392},"NCT04080531","Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders",[93],"2021-05-11","2022-12-15","2019-10-18",[8391],"Plasma Cell Neoplasm",[8371,8393],"Trivalent Influenza Vaccine",{"trials":8395,"activeCount":114},[],{"intervention":8397,"totalTrials":186,"cells":8398},"Ibuprofen",{"EARLY_PHASE1":8399,"PHASE1":8401,"PHASE2":8403,"PHASE3":8405,"PHASE4":8407,"NA":8420},{"trials":8400,"activeCount":114},[],{"trials":8402,"activeCount":114},[],{"trials":8404,"activeCount":114},[],{"trials":8406,"activeCount":114},[],{"trials":8408,"activeCount":114},[8409],{"nctId":8410,"briefTitle":8411,"status":230,"phases":8412,"primaryCompletion":8413,"completion":8413,"start":3426,"enrollment":5818,"conditions":8414,"interventions":8418},"NCT02296840","Post-operative Pain Control After Pediatric Adenotonsillectomy",[93],"2016-11-30",[8415,382,8416,8417],"Recurrent Tonsillitis","Sleep Disordered Breathing","Adverse Reaction to Drug",[8397,8419],"Hydrocodone-Acetaminophen",{"trials":8421,"activeCount":114},[],{"intervention":8419,"totalTrials":186,"cells":8423},{"EARLY_PHASE1":8424,"PHASE1":8426,"PHASE2":8428,"PHASE3":8430,"PHASE4":8432,"NA":8438},{"trials":8425,"activeCount":114},[],{"trials":8427,"activeCount":114},[],{"trials":8429,"activeCount":114},[],{"trials":8431,"activeCount":114},[],{"trials":8433,"activeCount":114},[8434],{"nctId":8410,"briefTitle":8411,"status":230,"phases":8435,"primaryCompletion":8413,"completion":8413,"start":3426,"enrollment":5818,"conditions":8436,"interventions":8437},[93],[8415,382,8416,8417],[8397,8419],{"trials":8439,"activeCount":114},[],{"intervention":8441,"totalTrials":186,"cells":8442},"Ramelteon",{"EARLY_PHASE1":8443,"PHASE1":8445,"PHASE2":8447,"PHASE3":8449,"PHASE4":8451,"NA":8461},{"trials":8444,"activeCount":114},[],{"trials":8446,"activeCount":114},[],{"trials":8448,"activeCount":114},[],{"trials":8450,"activeCount":114},[],{"trials":8452,"activeCount":114},[8453],{"nctId":8454,"briefTitle":8455,"status":105,"phases":8456,"primaryCompletion":3467,"completion":5902,"start":6473,"enrollment":8457,"conditions":8458,"interventions":8460},"NCT00576927","Improving Sleep in Nursing Homes",[93],79,[8459],"Sleep Deprivation",[8441],{"trials":8462,"activeCount":114},[],{"intervention":8464,"totalTrials":186,"cells":8465},"Cetirizine and Famotidine",{"EARLY_PHASE1":8466,"PHASE1":8468,"PHASE2":8470,"PHASE3":8472,"PHASE4":8474,"NA":8485},{"trials":8467,"activeCount":114},[],{"trials":8469,"activeCount":114},[],{"trials":8471,"activeCount":114},[],{"trials":8473,"activeCount":114},[],{"trials":8475,"activeCount":114},[8476],{"nctId":8477,"briefTitle":8478,"status":2022,"phases":8479,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":114,"conditions":8482,"interventions":8484},"NCT04836806","Cetirizine and Famotidine for COVID-19",[93],"2022-07","2021-08",[8483],"Covid19",[8464],{"trials":8486,"activeCount":114},[],{"intervention":8488,"totalTrials":186,"cells":8489},"Triiodothyronine",{"EARLY_PHASE1":8490,"PHASE1":8492,"PHASE2":8494,"PHASE3":8496,"PHASE4":8498,"NA":8510},{"trials":8491,"activeCount":114},[],{"trials":8493,"activeCount":114},[],{"trials":8495,"activeCount":114},[],{"trials":8497,"activeCount":114},[],{"trials":8499,"activeCount":114},[8500],{"nctId":8501,"briefTitle":8502,"status":105,"phases":8503,"primaryCompletion":8504,"completion":8504,"start":8505,"enrollment":8506,"conditions":8507,"interventions":8508},"NCT00208702","Thyroid Medication and Antidepressants for Treating Major Depression",[93],"2003-07","1996-09",153,[4404],[8488,8509],"Sertraline",{"trials":8511,"activeCount":114},[],{"intervention":8509,"totalTrials":186,"cells":8513},{"EARLY_PHASE1":8514,"PHASE1":8516,"PHASE2":8518,"PHASE3":8520,"PHASE4":8522,"NA":8528},{"trials":8515,"activeCount":114},[],{"trials":8517,"activeCount":114},[],{"trials":8519,"activeCount":114},[],{"trials":8521,"activeCount":114},[],{"trials":8523,"activeCount":114},[8524],{"nctId":8501,"briefTitle":8502,"status":105,"phases":8525,"primaryCompletion":8504,"completion":8504,"start":8505,"enrollment":8506,"conditions":8526,"interventions":8527},[93],[4404],[8488,8509],{"trials":8529,"activeCount":114},[],{"intervention":8531,"totalTrials":186,"cells":8532},"Oxycodone",{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8537,"PHASE3":8539,"PHASE4":8541,"NA":8551},{"trials":8534,"activeCount":114},[],{"trials":8536,"activeCount":114},[],{"trials":8538,"activeCount":114},[],{"trials":8540,"activeCount":114},[],{"trials":8542,"activeCount":114},[8543],{"nctId":8544,"briefTitle":8545,"status":105,"phases":8546,"primaryCompletion":8547,"completion":8547,"start":2506,"enrollment":8548,"conditions":8549,"interventions":8550},"NCT04285853","Are Opioids Needed After ACL Reconstruction",[93],"2022-09-19",98,[1557],[8531],{"trials":8552,"activeCount":114},[],{"intervention":8554,"totalTrials":186,"cells":8555},"Dapagliflozin",{"EARLY_PHASE1":8556,"PHASE1":8558,"PHASE2":8560,"PHASE3":8562,"PHASE4":8564,"NA":8574},{"trials":8557,"activeCount":114},[],{"trials":8559,"activeCount":114},[],{"trials":8561,"activeCount":114},[],{"trials":8563,"activeCount":114},[],{"trials":8565,"activeCount":114},[8566],{"nctId":8567,"briefTitle":8568,"status":105,"phases":8569,"primaryCompletion":8570,"completion":8570,"start":8571,"enrollment":8341,"conditions":8572,"interventions":8573},"NCT04249778","Dapagliflozin at Discharge on Hospital Heart Failure Readmission",[93],"2022-03-03","2020-07-29",[4739,18],[8554],{"trials":8575,"activeCount":114},[],{"intervention":8577,"totalTrials":186,"cells":8578},"doxercalciferol",{"EARLY_PHASE1":8579,"PHASE1":8581,"PHASE2":8583,"PHASE3":8585,"PHASE4":8587,"NA":8596},{"trials":8580,"activeCount":114},[],{"trials":8582,"activeCount":114},[],{"trials":8584,"activeCount":114},[],{"trials":8586,"activeCount":114},[],{"trials":8588,"activeCount":114},[8589],{"nctId":8590,"briefTitle":8591,"status":230,"phases":8592,"primaryCompletion":6966,"completion":6966,"start":1320,"enrollment":870,"conditions":8593,"interventions":8595},"NCT00646282","Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients",[93],[8594],"Hyperparathyroidism, Secondary",[8577],{"trials":8597,"activeCount":114},[],{"intervention":8599,"totalTrials":186,"cells":8600},"Keppra",{"EARLY_PHASE1":8601,"PHASE1":8603,"PHASE2":8605,"PHASE3":8607,"PHASE4":8609,"NA":8621},{"trials":8602,"activeCount":114},[],{"trials":8604,"activeCount":114},[],{"trials":8606,"activeCount":114},[],{"trials":8608,"activeCount":114},[],{"trials":8610,"activeCount":114},[8611],{"nctId":8612,"briefTitle":8613,"status":105,"phases":8614,"primaryCompletion":435,"completion":435,"start":7965,"enrollment":8615,"conditions":8616,"interventions":8618},"NCT00510783","IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures",[93],158,[8617],"Tonic-clonic Seizure",[8599,8619,8620],"Fosphenytoin","Dilantin",{"trials":8622,"activeCount":114},[],{"intervention":8619,"totalTrials":186,"cells":8624},{"EARLY_PHASE1":8625,"PHASE1":8627,"PHASE2":8629,"PHASE3":8631,"PHASE4":8633,"NA":8639},{"trials":8626,"activeCount":114},[],{"trials":8628,"activeCount":114},[],{"trials":8630,"activeCount":114},[],{"trials":8632,"activeCount":114},[],{"trials":8634,"activeCount":114},[8635],{"nctId":8612,"briefTitle":8613,"status":105,"phases":8636,"primaryCompletion":435,"completion":435,"start":7965,"enrollment":8615,"conditions":8637,"interventions":8638},[93],[8617],[8599,8619,8620],{"trials":8640,"activeCount":114},[],{"intervention":8620,"totalTrials":186,"cells":8642},{"EARLY_PHASE1":8643,"PHASE1":8645,"PHASE2":8647,"PHASE3":8649,"PHASE4":8651,"NA":8657},{"trials":8644,"activeCount":114},[],{"trials":8646,"activeCount":114},[],{"trials":8648,"activeCount":114},[],{"trials":8650,"activeCount":114},[],{"trials":8652,"activeCount":114},[8653],{"nctId":8612,"briefTitle":8613,"status":105,"phases":8654,"primaryCompletion":435,"completion":435,"start":7965,"enrollment":8615,"conditions":8655,"interventions":8656},[93],[8617],[8599,8619,8620],{"trials":8658,"activeCount":114},[],{"intervention":8660,"totalTrials":186,"cells":8661},"Rapid-Acting Insulin",{"EARLY_PHASE1":8662,"PHASE1":8664,"PHASE2":8666,"PHASE3":8668,"PHASE4":8670,"NA":8680},{"trials":8663,"activeCount":114},[],{"trials":8665,"activeCount":114},[],{"trials":8667,"activeCount":114},[],{"trials":8669,"activeCount":114},[],{"trials":8671,"activeCount":114},[8672],{"nctId":8673,"briefTitle":8674,"status":105,"phases":8675,"primaryCompletion":8676,"completion":8676,"start":462,"enrollment":31,"conditions":8677,"interventions":8678},"NCT04157738","A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus",[93],"2020-12-17",[510,6308],[8660,8679],"Long acting insulin",{"trials":8681,"activeCount":114},[],{"intervention":8679,"totalTrials":186,"cells":8683},{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8690,"PHASE4":8692,"NA":8698},{"trials":8685,"activeCount":114},[],{"trials":8687,"activeCount":114},[],{"trials":8689,"activeCount":114},[],{"trials":8691,"activeCount":114},[],{"trials":8693,"activeCount":114},[8694],{"nctId":8673,"briefTitle":8674,"status":105,"phases":8695,"primaryCompletion":8676,"completion":8676,"start":462,"enrollment":31,"conditions":8696,"interventions":8697},[93],[510,6308],[8660,8679],{"trials":8699,"activeCount":114},[],{"intervention":8701,"totalTrials":186,"cells":8702},"Lansoprazole; Solutab",{"EARLY_PHASE1":8703,"PHASE1":8705,"PHASE2":8707,"PHASE3":8709,"PHASE4":8711,"NA":8720},{"trials":8704,"activeCount":114},[],{"trials":8706,"activeCount":114},[],{"trials":8708,"activeCount":114},[],{"trials":8710,"activeCount":114},[],{"trials":8712,"activeCount":114},[8713],{"nctId":8714,"briefTitle":8715,"status":2833,"phases":8716,"primaryCompletion":5970,"completion":3660,"start":8717,"enrollment":345,"conditions":8718,"interventions":8719},"NCT00237068","A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.",[93],"2006-03",[1487],[8701],{"trials":8721,"activeCount":114},[],{"intervention":6002,"totalTrials":186,"cells":8723},{"EARLY_PHASE1":8724,"PHASE1":8726,"PHASE2":8728,"PHASE3":8730,"PHASE4":8732,"NA":8738},{"trials":8725,"activeCount":114},[],{"trials":8727,"activeCount":114},[],{"trials":8729,"activeCount":114},[],{"trials":8731,"activeCount":114},[],{"trials":8733,"activeCount":114},[8734],{"nctId":5994,"briefTitle":5995,"status":105,"phases":8735,"primaryCompletion":5997,"completion":5997,"start":251,"enrollment":5998,"conditions":8736,"interventions":8737},[93],[1700],[492,6001,6002],{"trials":8739,"activeCount":114},[],{"intervention":8741,"totalTrials":186,"cells":8742},"Statin therapy",{"EARLY_PHASE1":8743,"PHASE1":8745,"PHASE2":8747,"PHASE3":8749,"PHASE4":8751,"NA":8760},{"trials":8744,"activeCount":114},[],{"trials":8746,"activeCount":114},[],{"trials":8748,"activeCount":114},[],{"trials":8750,"activeCount":114},[],{"trials":8752,"activeCount":114},[8753],{"nctId":8754,"briefTitle":8755,"status":230,"phases":8756,"primaryCompletion":2683,"completion":2683,"start":8757,"enrollment":2448,"conditions":8758,"interventions":8759},"NCT02114697","Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging",[93],"2014-04",[3469],[8741],{"trials":8761,"activeCount":114},[],{"intervention":8763,"totalTrials":186,"cells":8764},"Inulin",{"EARLY_PHASE1":8765,"PHASE1":8767,"PHASE2":8769,"PHASE3":8771,"PHASE4":8773,"NA":8785},{"trials":8766,"activeCount":114},[],{"trials":8768,"activeCount":114},[],{"trials":8770,"activeCount":114},[],{"trials":8772,"activeCount":114},[],{"trials":8774,"activeCount":114},[8775],{"nctId":8776,"briefTitle":8777,"status":105,"phases":8778,"primaryCompletion":8779,"completion":8779,"start":8780,"enrollment":1796,"conditions":8781,"interventions":8783},"NCT04118010","Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis",[93],"2022-12-31","2020-03-13",[5904,8782],"Dysbiosis",[8784,8763],"Vitamin D3",{"trials":8786,"activeCount":114},[],{"intervention":8788,"totalTrials":186,"cells":8789},"Depomedrol",{"EARLY_PHASE1":8790,"PHASE1":8792,"PHASE2":8794,"PHASE3":8796,"PHASE4":8798,"NA":8808},{"trials":8791,"activeCount":114},[],{"trials":8793,"activeCount":114},[],{"trials":8795,"activeCount":114},[],{"trials":8797,"activeCount":114},[],{"trials":8799,"activeCount":114},[8800],{"nctId":8801,"briefTitle":8802,"status":2022,"phases":8803,"primaryCompletion":3467,"completion":3467,"start":3644,"enrollment":114,"conditions":8804,"interventions":8806},"NCT00863889","Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome",[93],[8805],"Bursitis",[8788,8807],"Lidocaine, Marcaine",{"trials":8809,"activeCount":114},[],{"intervention":8807,"totalTrials":186,"cells":8811},{"EARLY_PHASE1":8812,"PHASE1":8814,"PHASE2":8816,"PHASE3":8818,"PHASE4":8820,"NA":8826},{"trials":8813,"activeCount":114},[],{"trials":8815,"activeCount":114},[],{"trials":8817,"activeCount":114},[],{"trials":8819,"activeCount":114},[],{"trials":8821,"activeCount":114},[8822],{"nctId":8801,"briefTitle":8802,"status":2022,"phases":8823,"primaryCompletion":3467,"completion":3467,"start":3644,"enrollment":114,"conditions":8824,"interventions":8825},[93],[8805],[8788,8807],{"trials":8827,"activeCount":114},[],{"intervention":8829,"totalTrials":186,"cells":8830},"IL-2",{"EARLY_PHASE1":8831,"PHASE1":8833,"PHASE2":8835,"PHASE3":8837,"PHASE4":8839,"NA":8849},{"trials":8832,"activeCount":114},[],{"trials":8834,"activeCount":114},[],{"trials":8836,"activeCount":114},[],{"trials":8838,"activeCount":114},[],{"trials":8840,"activeCount":114},[8841],{"nctId":8842,"briefTitle":8843,"status":105,"phases":8844,"primaryCompletion":8845,"completion":8845,"start":8846,"enrollment":454,"conditions":8847,"interventions":8848},"NCT00352885","Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment",[93],"2010-05-17","2006-10-06",[21],[7762,8829],{"trials":8850,"activeCount":114},[],{"intervention":8852,"totalTrials":186,"cells":8853},"Nefazodone",{"EARLY_PHASE1":8854,"PHASE1":8856,"PHASE2":8858,"PHASE3":8860,"PHASE4":8862,"NA":8872},{"trials":8855,"activeCount":114},[],{"trials":8857,"activeCount":114},[],{"trials":8859,"activeCount":114},[],{"trials":8861,"activeCount":114},[],{"trials":8863,"activeCount":114},[8864],{"nctId":8865,"briefTitle":8866,"status":105,"phases":8867,"completion":8868,"enrollment":31,"conditions":8869,"interventions":8871},"NCT00231348","Nefazodone in the Treatment of Social Phobia",[93],"2000-04",[8870],"Social Anxiety Disorder (SAD)",[8852],{"trials":8873,"activeCount":114},[],{"intervention":6571,"totalTrials":186,"cells":8875},{"EARLY_PHASE1":8876,"PHASE1":8878,"PHASE2":8880,"PHASE3":8882,"PHASE4":8884,"NA":8890},{"trials":8877,"activeCount":114},[],{"trials":8879,"activeCount":114},[],{"trials":8881,"activeCount":114},[],{"trials":8883,"activeCount":114},[],{"trials":8885,"activeCount":114},[8886],{"nctId":6562,"briefTitle":6563,"status":230,"phases":8887,"primaryCompletion":6565,"completion":6566,"start":6567,"enrollment":162,"conditions":8888,"interventions":8889},[93],[6569,6476],[6549,6571],{"trials":8891,"activeCount":114},[],{"intervention":8893,"totalTrials":186,"cells":8894},"insulin glargine+ glulisine",{"EARLY_PHASE1":8895,"PHASE1":8897,"PHASE2":8899,"PHASE3":8901,"PHASE4":8903,"NA":8915},{"trials":8896,"activeCount":114},[],{"trials":8898,"activeCount":114},[],{"trials":8900,"activeCount":114},[],{"trials":8902,"activeCount":114},[],{"trials":8904,"activeCount":114},[8905],{"nctId":8906,"briefTitle":8907,"status":105,"phases":8908,"primaryCompletion":6748,"completion":8909,"start":5972,"enrollment":8910,"conditions":8911,"interventions":8913},"NCT00590044","Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)",[93],"2008-08",74,[8912],"Diabetic Ketoacidosis",[8893,8914],"NPH + Regular insulin",{"trials":8916,"activeCount":114},[],{"intervention":8914,"totalTrials":186,"cells":8918},{"EARLY_PHASE1":8919,"PHASE1":8921,"PHASE2":8923,"PHASE3":8925,"PHASE4":8927,"NA":8933},{"trials":8920,"activeCount":114},[],{"trials":8922,"activeCount":114},[],{"trials":8924,"activeCount":114},[],{"trials":8926,"activeCount":114},[],{"trials":8928,"activeCount":114},[8929],{"nctId":8906,"briefTitle":8907,"status":105,"phases":8930,"primaryCompletion":6748,"completion":8909,"start":5972,"enrollment":8910,"conditions":8931,"interventions":8932},[93],[8912],[8893,8914],{"trials":8934,"activeCount":114},[],{"intervention":8936,"totalTrials":186,"cells":8937},"Risperdal Consta",{"EARLY_PHASE1":8938,"PHASE1":8940,"PHASE2":8942,"PHASE3":8944,"PHASE4":8946,"NA":8954},{"trials":8939,"activeCount":114},[],{"trials":8941,"activeCount":114},[],{"trials":8943,"activeCount":114},[],{"trials":8945,"activeCount":114},[],{"trials":8947,"activeCount":114},[8948],{"nctId":8949,"briefTitle":8950,"status":105,"phases":8951,"primaryCompletion":5972,"start":2966,"conditions":8952,"interventions":8953},"NCT00313391","Risperdal Consta and Health Care Utilization in Patients With Schizophrenia",[93],[456,6885],[8936],{"trials":8955,"activeCount":114},[],{"intervention":8957,"totalTrials":186,"cells":8958},"Lunesta",{"EARLY_PHASE1":8959,"PHASE1":8961,"PHASE2":8963,"PHASE3":8965,"PHASE4":8967,"NA":8976},{"trials":8960,"activeCount":114},[],{"trials":8962,"activeCount":114},[],{"trials":8964,"activeCount":114},[],{"trials":8966,"activeCount":114},[],{"trials":8968,"activeCount":114},[8969],{"nctId":8970,"briefTitle":8971,"status":105,"phases":8972,"primaryCompletion":6748,"completion":3660,"start":8047,"enrollment":3535,"conditions":8973,"interventions":8975},"NCT00460993","Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients",[93],[8974],"Poor Quality Sleep",[8957],{"trials":8977,"activeCount":114},[],{"intervention":6166,"totalTrials":186,"cells":8979},{"EARLY_PHASE1":8980,"PHASE1":8982,"PHASE2":8984,"PHASE3":8986,"PHASE4":8988,"NA":8994},{"trials":8981,"activeCount":114},[],{"trials":8983,"activeCount":114},[],{"trials":8985,"activeCount":114},[],{"trials":8987,"activeCount":114},[],{"trials":8989,"activeCount":114},[8990],{"nctId":6159,"briefTitle":6160,"status":105,"phases":8991,"primaryCompletion":5940,"completion":5940,"start":5970,"enrollment":6162,"conditions":8992,"interventions":8993},[93],[6164],[3472,6166],{"trials":8995,"activeCount":114},[],{"intervention":5931,"totalTrials":186,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9002,"PHASE3":9004,"PHASE4":9006,"NA":9012},{"trials":8999,"activeCount":114},[],{"trials":9001,"activeCount":114},[],{"trials":9003,"activeCount":114},[],{"trials":9005,"activeCount":114},[],{"trials":9007,"activeCount":114},[9008],{"nctId":5922,"briefTitle":5923,"status":105,"phases":9009,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":9010,"interventions":9011},[93],[5928],[490,5930,5931,5932,5933,5934],{"trials":9013,"activeCount":114},[],{"intervention":5933,"totalTrials":186,"cells":9015},{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9020,"PHASE3":9022,"PHASE4":9024,"NA":9030},{"trials":9017,"activeCount":114},[],{"trials":9019,"activeCount":114},[],{"trials":9021,"activeCount":114},[],{"trials":9023,"activeCount":114},[],{"trials":9025,"activeCount":114},[9026],{"nctId":5922,"briefTitle":5923,"status":105,"phases":9027,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":9028,"interventions":9029},[93],[5928],[490,5930,5931,5932,5933,5934],{"trials":9031,"activeCount":114},[],{"intervention":5934,"totalTrials":186,"cells":9033},{"EARLY_PHASE1":9034,"PHASE1":9036,"PHASE2":9038,"PHASE3":9040,"PHASE4":9042,"NA":9048},{"trials":9035,"activeCount":114},[],{"trials":9037,"activeCount":114},[],{"trials":9039,"activeCount":114},[],{"trials":9041,"activeCount":114},[],{"trials":9043,"activeCount":114},[9044],{"nctId":5922,"briefTitle":5923,"status":105,"phases":9045,"primaryCompletion":5925,"completion":5925,"start":233,"enrollment":5926,"conditions":9046,"interventions":9047},[93],[5928],[490,5930,5931,5932,5933,5934],{"trials":9049,"activeCount":114},[],{"intervention":9051,"totalTrials":186,"cells":9052},"FLUARIX QUADRIVALENT",{"EARLY_PHASE1":9053,"PHASE1":9055,"PHASE2":9057,"PHASE3":9059,"PHASE4":9061,"NA":9071},{"trials":9054,"activeCount":114},[],{"trials":9056,"activeCount":114},[],{"trials":9058,"activeCount":114},[],{"trials":9060,"activeCount":114},[],{"trials":9062,"activeCount":114},[9063],{"nctId":9064,"briefTitle":9065,"status":230,"phases":9066,"primaryCompletion":9067,"completion":9067,"start":9068,"enrollment":2582,"conditions":9069,"interventions":9070},"NCT03686514","The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics",[93],"2020-06-20","2018-10-22",[847],[9051],{"trials":9072,"activeCount":114},[],{"intervention":5947,"totalTrials":186,"cells":9074},{"EARLY_PHASE1":9075,"PHASE1":9077,"PHASE2":9079,"PHASE3":9081,"PHASE4":9083,"NA":9089},{"trials":9076,"activeCount":114},[],{"trials":9078,"activeCount":114},[],{"trials":9080,"activeCount":114},[],{"trials":9082,"activeCount":114},[],{"trials":9084,"activeCount":114},[9085],{"nctId":5936,"briefTitle":5937,"status":105,"phases":9086,"primaryCompletion":5939,"completion":5940,"start":5941,"enrollment":845,"conditions":9087,"interventions":9088},[93],[5943,5944,500],[490,5946,5947],{"trials":9090,"activeCount":114},[],{"intervention":3509,"totalTrials":186,"cells":9092},{"EARLY_PHASE1":9093,"PHASE1":9095,"PHASE2":9097,"PHASE3":9099,"PHASE4":9101,"NA":9107},{"trials":9094,"activeCount":114},[],{"trials":9096,"activeCount":114},[],{"trials":9098,"activeCount":114},[],{"trials":9100,"activeCount":114},[],{"trials":9102,"activeCount":114},[9103],{"nctId":3498,"briefTitle":3499,"status":2022,"phases":9104,"primaryCompletion":3501,"completion":3502,"start":3503,"enrollment":114,"conditions":9105,"interventions":9106},[93],[3505,3506],[3508,3509,3510],{"trials":9108,"activeCount":114},[],{"intervention":3510,"totalTrials":186,"cells":9110},{"EARLY_PHASE1":9111,"PHASE1":9113,"PHASE2":9115,"PHASE3":9117,"PHASE4":9119,"NA":9125},{"trials":9112,"activeCount":114},[],{"trials":9114,"activeCount":114},[],{"trials":9116,"activeCount":114},[],{"trials":9118,"activeCount":114},[],{"trials":9120,"activeCount":114},[9121],{"nctId":3498,"briefTitle":3499,"status":2022,"phases":9122,"primaryCompletion":3501,"completion":3502,"start":3503,"enrollment":114,"conditions":9123,"interventions":9124},[93],[3505,3506],[3508,3509,3510],{"trials":9126,"activeCount":114},[],{"intervention":9128,"totalTrials":186,"cells":9129},"Glargine U300",{"EARLY_PHASE1":9130,"PHASE1":9132,"PHASE2":9134,"PHASE3":9136,"PHASE4":9138,"NA":9150},{"trials":9131,"activeCount":114},[],{"trials":9133,"activeCount":114},[],{"trials":9135,"activeCount":114},[],{"trials":9137,"activeCount":114},[],{"trials":9139,"activeCount":114},[9140],{"nctId":9141,"briefTitle":9142,"status":105,"phases":9143,"primaryCompletion":3052,"completion":3052,"start":9144,"enrollment":9145,"conditions":9146,"interventions":9147},"NCT03013985","Glargine U300 Hospital Trial",[93],"2017-05-17",247,[5928],[9128,9148,9149],"Glargine U100","Glulisine Insulin",{"trials":9151,"activeCount":114},[],{"intervention":9148,"totalTrials":186,"cells":9153},{"EARLY_PHASE1":9154,"PHASE1":9156,"PHASE2":9158,"PHASE3":9160,"PHASE4":9162,"NA":9168},{"trials":9155,"activeCount":114},[],{"trials":9157,"activeCount":114},[],{"trials":9159,"activeCount":114},[],{"trials":9161,"activeCount":114},[],{"trials":9163,"activeCount":114},[9164],{"nctId":9141,"briefTitle":9142,"status":105,"phases":9165,"primaryCompletion":3052,"completion":3052,"start":9144,"enrollment":9145,"conditions":9166,"interventions":9167},[93],[5928],[9128,9148,9149],{"trials":9169,"activeCount":114},[],{"intervention":9149,"totalTrials":186,"cells":9171},{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9176,"PHASE3":9178,"PHASE4":9180,"NA":9186},{"trials":9173,"activeCount":114},[],{"trials":9175,"activeCount":114},[],{"trials":9177,"activeCount":114},[],{"trials":9179,"activeCount":114},[],{"trials":9181,"activeCount":114},[9182],{"nctId":9141,"briefTitle":9142,"status":105,"phases":9183,"primaryCompletion":3052,"completion":3052,"start":9144,"enrollment":9145,"conditions":9184,"interventions":9185},[93],[5928],[9128,9148,9149],{"trials":9187,"activeCount":114},[],{"intervention":9189,"totalTrials":186,"cells":9190},"Therapeutic plasma exchange",{"EARLY_PHASE1":9191,"PHASE1":9193,"PHASE2":9195,"PHASE3":9197,"PHASE4":9199,"NA":9209},{"trials":9192,"activeCount":114},[],{"trials":9194,"activeCount":114},[],{"trials":9196,"activeCount":114},[],{"trials":9198,"activeCount":114},[],{"trials":9200,"activeCount":114},[9201],{"nctId":9202,"briefTitle":9203,"status":105,"phases":9204,"primaryCompletion":9205,"completion":9205,"start":9206,"enrollment":454,"conditions":9207,"interventions":9208},"NCT04441996","Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity",[93],"2021-03-18","2020-07-17",[708],[9189],{"trials":9210,"activeCount":114},[],{"intervention":6038,"totalTrials":186,"cells":9212},{"EARLY_PHASE1":9213,"PHASE1":9215,"PHASE2":9217,"PHASE3":9219,"PHASE4":9221,"NA":9227},{"trials":9214,"activeCount":114},[],{"trials":9216,"activeCount":114},[],{"trials":9218,"activeCount":114},[],{"trials":9220,"activeCount":114},[],{"trials":9222,"activeCount":114},[9223],{"nctId":6032,"briefTitle":6033,"status":105,"phases":9224,"primaryCompletion":6035,"completion":6035,"start":181,"enrollment":1281,"conditions":9225,"interventions":9226},[93],[5928],[6038,5932,6039],{"trials":9228,"activeCount":114},[],{"intervention":6039,"totalTrials":186,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9235,"PHASE3":9237,"PHASE4":9239,"NA":9245},{"trials":9232,"activeCount":114},[],{"trials":9234,"activeCount":114},[],{"trials":9236,"activeCount":114},[],{"trials":9238,"activeCount":114},[],{"trials":9240,"activeCount":114},[9241],{"nctId":6032,"briefTitle":6033,"status":105,"phases":9242,"primaryCompletion":6035,"completion":6035,"start":181,"enrollment":1281,"conditions":9243,"interventions":9244},[93],[5928],[6038,5932,6039],{"trials":9246,"activeCount":114},[],{"intervention":9248,"totalTrials":186,"cells":9249},"Prevacid",{"EARLY_PHASE1":9250,"PHASE1":9252,"PHASE2":9254,"PHASE3":9256,"PHASE4":9258,"NA":9268},{"trials":9251,"activeCount":114},[],{"trials":9253,"activeCount":114},[],{"trials":9255,"activeCount":114},[],{"trials":9257,"activeCount":114},[],{"trials":9259,"activeCount":114},[9260],{"nctId":9261,"briefTitle":9262,"status":105,"phases":9263,"primaryCompletion":420,"completion":5972,"start":9264,"enrollment":123,"conditions":9265,"interventions":9267},"NCT00239551","Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer",[93],"2005-10",[9266],"Stomach Ulcer",[9248],{"trials":9269,"activeCount":114},[],{"intervention":9271,"totalTrials":186,"cells":9272},"Tenofovir disoproxil fumarate\u002Femtricitabine",{"EARLY_PHASE1":9273,"PHASE1":9275,"PHASE2":9277,"PHASE3":9279,"PHASE4":9281,"NA":9291},{"trials":9274,"activeCount":114},[],{"trials":9276,"activeCount":114},[],{"trials":9278,"activeCount":114},[],{"trials":9280,"activeCount":114},[],{"trials":9282,"activeCount":114},[9283],{"nctId":9284,"briefTitle":9285,"status":105,"phases":9286,"primaryCompletion":9287,"completion":9287,"start":9288,"enrollment":3053,"conditions":9289,"interventions":9290},"NCT04298697","Biomarkers for Event-driven PrEP Adherence",[93],"2022-08-09","2020-02-28",[822],[9271],{"trials":9292,"activeCount":114},[],{"intervention":6311,"totalTrials":186,"cells":9294},{"EARLY_PHASE1":9295,"PHASE1":9297,"PHASE2":9299,"PHASE3":9301,"PHASE4":9303,"NA":9309},{"trials":9296,"activeCount":114},[],{"trials":9298,"activeCount":114},[],{"trials":9300,"activeCount":114},[],{"trials":9302,"activeCount":114},[],{"trials":9304,"activeCount":114},[9305],{"nctId":6303,"briefTitle":6304,"status":2022,"phases":9306,"primaryCompletion":6306,"completion":6306,"start":594,"enrollment":114,"conditions":9307,"interventions":9308},[93],[6308,5928],[6310,6311],{"trials":9310,"activeCount":114},[],{"intervention":9312,"totalTrials":186,"cells":9313},"Yellow Fever Vaccine",{"EARLY_PHASE1":9314,"PHASE1":9316,"PHASE2":9318,"PHASE3":9320,"PHASE4":9322,"NA":9333},{"trials":9315,"activeCount":114},[],{"trials":9317,"activeCount":114},[],{"trials":9319,"activeCount":114},[],{"trials":9321,"activeCount":114},[],{"trials":9323,"activeCount":114},[9324],{"nctId":9325,"briefTitle":9326,"status":105,"phases":9327,"primaryCompletion":9328,"completion":9328,"start":3643,"enrollment":9329,"conditions":9330,"interventions":9332},"NCT00694655","Human Immune Responses to Yellow Fever Vaccination",[93],"2024-08-29",239,[9331],"Yellow Fever",[9312],{"trials":9334,"activeCount":114},[],{"intervention":6048,"totalTrials":186,"cells":9336},{"EARLY_PHASE1":9337,"PHASE1":9339,"PHASE2":9341,"PHASE3":9343,"PHASE4":9345,"NA":9351},{"trials":9338,"activeCount":114},[],{"trials":9340,"activeCount":114},[],{"trials":9342,"activeCount":114},[],{"trials":9344,"activeCount":114},[],{"trials":9346,"activeCount":114},[9347],{"nctId":6041,"briefTitle":6042,"status":105,"phases":9348,"primaryCompletion":6044,"completion":6044,"start":6045,"enrollment":4870,"conditions":9349,"interventions":9350},[93],[5928],[6048,5932,6049],{"trials":9352,"activeCount":114},[],{"intervention":6049,"totalTrials":186,"cells":9354},{"EARLY_PHASE1":9355,"PHASE1":9357,"PHASE2":9359,"PHASE3":9361,"PHASE4":9363,"NA":9369},{"trials":9356,"activeCount":114},[],{"trials":9358,"activeCount":114},[],{"trials":9360,"activeCount":114},[],{"trials":9362,"activeCount":114},[],{"trials":9364,"activeCount":114},[9365],{"nctId":6041,"briefTitle":6042,"status":105,"phases":9366,"primaryCompletion":6044,"completion":6044,"start":6045,"enrollment":4870,"conditions":9367,"interventions":9368},[93],[5928],[6048,5932,6049],{"trials":9370,"activeCount":114},[],{"intervention":9372,"totalTrials":186,"cells":9373},"Offering of on-demand oral PrEP",{"EARLY_PHASE1":9374,"PHASE1":9376,"PHASE2":9378,"PHASE3":9380,"PHASE4":9382,"NA":9396},{"trials":9375,"activeCount":114},[],{"trials":9377,"activeCount":114},[],{"trials":9379,"activeCount":114},[],{"trials":9381,"activeCount":114},[],{"trials":9383,"activeCount":114},[9384],{"nctId":9385,"briefTitle":9386,"status":105,"phases":9387,"primaryCompletion":9388,"completion":9388,"start":9389,"enrollment":9390,"conditions":9391,"interventions":9393},"NCT05072093","Parrying the Pitfalls of PrEP: Project PEACH",[93],"2025-03-31","2021-11-20",240,[15,9392],"STI",[9372,9394,9395],"Offering of STI PEP","Injectable PrEP",{"trials":9397,"activeCount":114},[],{"intervention":9394,"totalTrials":186,"cells":9399},{"EARLY_PHASE1":9400,"PHASE1":9402,"PHASE2":9404,"PHASE3":9406,"PHASE4":9408,"NA":9414},{"trials":9401,"activeCount":114},[],{"trials":9403,"activeCount":114},[],{"trials":9405,"activeCount":114},[],{"trials":9407,"activeCount":114},[],{"trials":9409,"activeCount":114},[9410],{"nctId":9385,"briefTitle":9386,"status":105,"phases":9411,"primaryCompletion":9388,"completion":9388,"start":9389,"enrollment":9390,"conditions":9412,"interventions":9413},[93],[15,9392],[9372,9394,9395],{"trials":9415,"activeCount":114},[],{"intervention":9395,"totalTrials":186,"cells":9417},{"EARLY_PHASE1":9418,"PHASE1":9420,"PHASE2":9422,"PHASE3":9424,"PHASE4":9426,"NA":9432},{"trials":9419,"activeCount":114},[],{"trials":9421,"activeCount":114},[],{"trials":9423,"activeCount":114},[],{"trials":9425,"activeCount":114},[],{"trials":9427,"activeCount":114},[9428],{"nctId":9385,"briefTitle":9386,"status":105,"phases":9429,"primaryCompletion":9388,"completion":9388,"start":9389,"enrollment":9390,"conditions":9430,"interventions":9431},[93],[15,9392],[9372,9394,9395],{"trials":9433,"activeCount":114},[],{"intervention":9435,"totalTrials":186,"cells":9436},"Estradiol 2 mg",{"EARLY_PHASE1":9437,"PHASE1":9439,"PHASE2":9441,"PHASE3":9443,"PHASE4":9445,"NA":9456},{"trials":9438,"activeCount":114},[],{"trials":9440,"activeCount":114},[],{"trials":9442,"activeCount":114},[],{"trials":9444,"activeCount":114},[],{"trials":9446,"activeCount":114},[9447],{"nctId":9448,"briefTitle":9449,"status":2022,"phases":9450,"primaryCompletion":9451,"completion":9451,"start":9452,"enrollment":114,"conditions":9453,"interventions":9455},"NCT03724955","Pilot E2 for Hypogonadal Women With CFBD",[93],"2021-06","2019-04",[9454],"Cystic Fibrosis Related Bone Disease",[9435],{"trials":9457,"activeCount":114},[],{"intervention":9459,"totalTrials":186,"cells":9460},"antibiotic",{"EARLY_PHASE1":9461,"PHASE1":9463,"PHASE2":9465,"PHASE3":9467,"PHASE4":9469,"NA":9480},{"trials":9462,"activeCount":114},[],{"trials":9464,"activeCount":114},[],{"trials":9466,"activeCount":114},[],{"trials":9468,"activeCount":114},[],{"trials":9470,"activeCount":114},[9471],{"nctId":9472,"briefTitle":9473,"status":2022,"phases":9474,"primaryCompletion":9475,"completion":9476,"start":497,"enrollment":114,"conditions":9477,"interventions":9479},"NCT01899690","Antibiotics and Tissue Expanders in Breast Reconstruction",[93],"2017-08","2017-12",[9478],"Complications; Breast Prosthesis, Infection or Inflammation",[9459],{"trials":9481,"activeCount":114},[],{"intervention":9483,"totalTrials":186,"cells":9484},"Desipramine",{"EARLY_PHASE1":9485,"PHASE1":9487,"PHASE2":9489,"PHASE3":9491,"PHASE4":9493,"NA":9503},{"trials":9486,"activeCount":114},[],{"trials":9488,"activeCount":114},[],{"trials":9490,"activeCount":114},[],{"trials":9492,"activeCount":114},[],{"trials":9494,"activeCount":114},[9495],{"nctId":9496,"briefTitle":9497,"status":105,"phases":9498,"primaryCompletion":9499,"completion":9499,"start":9500,"enrollment":1796,"conditions":9501,"interventions":9502},"NCT00166114","Depression, Epinephrine, and Platelet Function",[93],"2009-01","2002-02",[2625],[7762,9483],{"trials":9504,"activeCount":114},[],{"intervention":9506,"totalTrials":186,"cells":9507},"0.5 mg DEX",{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9514,"PHASE4":9516,"NA":9526},{"trials":9509,"activeCount":114},[],{"trials":9511,"activeCount":114},[],{"trials":9513,"activeCount":114},[],{"trials":9515,"activeCount":114},[],{"trials":9517,"activeCount":114},[9518],{"nctId":9519,"briefTitle":9520,"status":105,"phases":9521,"primaryCompletion":6425,"completion":9522,"start":594,"enrollment":9523,"conditions":9524,"interventions":9525},"NCT01965366","Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD",[93],"2017-06",27,[4092],[9506],{"trials":9527,"activeCount":114},[],{"intervention":9529,"totalTrials":186,"cells":9530},"Levodopa+carbidopa",{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9535,"PHASE3":9537,"PHASE4":9539,"NA":9550},{"trials":9532,"activeCount":114},[],{"trials":9534,"activeCount":114},[],{"trials":9536,"activeCount":114},[],{"trials":9538,"activeCount":114},[],{"trials":9540,"activeCount":114},[9541],{"nctId":9542,"briefTitle":9543,"status":105,"phases":9544,"primaryCompletion":9545,"completion":9546,"start":9547,"enrollment":557,"conditions":9548,"interventions":9549},"NCT02513485","Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa",[93],"2020-02-21","2020-08-01","2015-10-09",[21],[9529],{"trials":9551,"activeCount":114},[],{"intervention":9553,"totalTrials":186,"cells":9554},"Reamings",{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9561,"PHASE4":9563,"NA":9574},{"trials":9556,"activeCount":114},[],{"trials":9558,"activeCount":114},[],{"trials":9560,"activeCount":114},[],{"trials":9562,"activeCount":114},[],{"trials":9564,"activeCount":114},[9565],{"nctId":9566,"briefTitle":9567,"status":105,"phases":9568,"primaryCompletion":5972,"completion":9569,"start":8717,"enrollment":37,"conditions":9570,"interventions":9573},"NCT00299052","Efficacy of DBM on Fractures of the Shinbone (Tibia)",[93],"2008-09",[9571,9572],"Closed Fracture","Open Fracture",[9553],{"trials":9575,"activeCount":114},[],{"intervention":9577,"totalTrials":186,"cells":9578},"Clopidogrel",{"EARLY_PHASE1":9579,"PHASE1":9581,"PHASE2":9583,"PHASE3":9585,"PHASE4":9587,"NA":9595},{"trials":9580,"activeCount":114},[],{"trials":9582,"activeCount":114},[],{"trials":9584,"activeCount":114},[],{"trials":9586,"activeCount":114},[],{"trials":9588,"activeCount":114},[9589],{"nctId":9590,"briefTitle":9591,"status":105,"phases":9592,"primaryCompletion":3660,"completion":3660,"start":7121,"enrollment":6065,"conditions":9593,"interventions":9594},"NCT01283282","Investigation of the Athero-Protective Effects of Clopidogrel",[93],[27],[9577],{"trials":9596,"activeCount":114},[],{"intervention":9598,"totalTrials":186,"cells":9599},"Gabitril",{"EARLY_PHASE1":9600,"PHASE1":9602,"PHASE2":9604,"PHASE3":9606,"PHASE4":9608,"NA":9619},{"trials":9601,"activeCount":114},[],{"trials":9603,"activeCount":114},[],{"trials":9605,"activeCount":114},[],{"trials":9607,"activeCount":114},[],{"trials":9609,"activeCount":114},[9610],{"nctId":9611,"briefTitle":9612,"status":105,"phases":9613,"completion":9614,"start":9615,"enrollment":391,"conditions":9616,"interventions":9618},"NCT00208741","Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder",[93],"2003-11","2002-06",[9617],"Social Anxiety Disorder",[9598],{"trials":9620,"activeCount":114},[],{"intervention":2163,"totalTrials":362,"cells":9622},{"EARLY_PHASE1":9623,"PHASE1":9625,"PHASE2":9634,"PHASE3":9640,"PHASE4":9651,"NA":9653},{"trials":9624,"activeCount":114},[],{"trials":9626,"activeCount":114},[9627],{"nctId":9628,"briefTitle":9629,"status":230,"phases":9630,"primaryCompletion":9522,"completion":9522,"start":181,"enrollment":327,"conditions":9631,"interventions":9633},"NCT02460354","Metformin and Congenital Nephrogenic Diabetes Insipidus",[90],[9632],"Diabetes Insipidus",[2163],{"trials":9635,"activeCount":114},[9636],{"nctId":2151,"briefTitle":2152,"status":105,"phases":9637,"primaryCompletion":2154,"completion":2155,"start":2156,"enrollment":243,"conditions":9638,"interventions":9639},[91],[1772,2158,2159,1780,1782,1784,2160,2161],[2163,57],{"trials":9641,"activeCount":114},[9642],{"nctId":9643,"briefTitle":9644,"status":105,"phases":9645,"primaryCompletion":3503,"completion":3503,"start":3671,"enrollment":11,"conditions":9646,"interventions":9648},"NCT01792830","Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients",[92],[9647],"Poor Glycemic Control",[2163,9649,9650],"Glargine insulin","Glulisine",{"trials":9652,"activeCount":114},[],{"trials":9654,"activeCount":114},[],{"intervention":9656,"totalTrials":362,"cells":9657},"FACBC",{"EARLY_PHASE1":9658,"PHASE1":9675,"PHASE2":9677,"PHASE3":9679,"PHASE4":9688,"NA":9690},{"trials":9659,"activeCount":114},[9660,9667],{"nctId":9661,"briefTitle":9662,"status":105,"phases":9663,"primaryCompletion":9664,"completion":9664,"start":2769,"enrollment":870,"conditions":9665,"interventions":9666},"NCT01659645","Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast",[89],"2015-01",[30],[9656],{"nctId":9668,"briefTitle":9669,"status":2022,"phases":9670,"primaryCompletion":9671,"completion":9671,"start":3679,"enrollment":114,"conditions":9672,"interventions":9674},"NCT01933269","FACBC for Head and Neck Cancers",[89],"2018-02-01",[9673],"Cancers of the Head and Neck",[9656],{"trials":9676,"activeCount":114},[],{"trials":9678,"activeCount":114},[],{"trials":9680,"activeCount":114},[9681],{"nctId":9682,"briefTitle":9683,"status":105,"phases":9684,"primaryCompletion":636,"completion":636,"start":9685,"enrollment":322,"conditions":9686,"interventions":9687},"NCT01666808","FACBC Outcomes for Post Prostatectomy",[91,92],"2012-09",[3651],[9656],{"trials":9689,"activeCount":114},[],{"trials":9691,"activeCount":114},[],{"intervention":9693,"totalTrials":362,"cells":9694},"D-cycloserine",{"EARLY_PHASE1":9695,"PHASE1":9697,"PHASE2":9699,"PHASE3":9717,"PHASE4":9730,"NA":9732},{"trials":9696,"activeCount":114},[],{"trials":9698,"activeCount":114},[],{"trials":9700,"activeCount":114},[9701,9708],{"nctId":9702,"briefTitle":9703,"status":105,"phases":9704,"primaryCompletion":6965,"completion":6965,"start":2880,"enrollment":1218,"conditions":9705,"interventions":9707},"NCT02082912","NMDA Receptors in Motor Learning in Humans",[91],[9706],"Stroke",[9693],{"nctId":9709,"briefTitle":9710,"status":105,"phases":9711,"primaryCompletion":3466,"completion":3524,"start":7099,"enrollment":37,"conditions":9712,"interventions":9715},"NCT01923896","D-cycloserine and Treatment of Feeding Disorders",[90,91],[9713,9714],"Feeding Disorders","Specific Phobia",[9716],"d-cycloserine",{"trials":9718,"activeCount":114},[9719],{"nctId":9720,"briefTitle":9721,"status":105,"phases":9722,"primaryCompletion":9723,"completion":9723,"start":9724,"enrollment":3242,"conditions":9725,"interventions":9727},"NCT00356278","D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD",[91,92],"2014-06","2006-09",[9726],"Stress Disorder, Post Traumatic",[9728,9729],"D-Cycloserine","Alprazolam",{"trials":9731,"activeCount":114},[],{"trials":9733,"activeCount":114},[],{"intervention":2442,"totalTrials":327,"cells":9735},{"EARLY_PHASE1":9736,"PHASE1":9738,"PHASE2":9740,"PHASE3":9746,"PHASE4":9752,"NA":9754},{"trials":9737,"activeCount":114},[],{"trials":9739,"activeCount":114},[],{"trials":9741,"activeCount":114},[9742],{"nctId":3667,"briefTitle":3668,"status":105,"phases":9743,"primaryCompletion":3670,"completion":3671,"start":3578,"enrollment":3672,"conditions":9744,"interventions":9745},[91],[30],[2039,2442],{"trials":9747,"activeCount":114},[9748],{"nctId":2428,"briefTitle":2429,"status":2022,"phases":9749,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":114,"conditions":9750,"interventions":9751},[92],[2434,2435,2436,2437,2438,2439,2440],[2442,2382,1982],{"trials":9753,"activeCount":114},[],{"trials":9755,"activeCount":114},[],{"intervention":9757,"totalTrials":186,"cells":9758},"Standard of Care Insulin Therapy + CGM",{"EARLY_PHASE1":9759,"PHASE1":9761,"PHASE2":9763,"PHASE3":9765,"PHASE4":9775,"NA":9777},{"trials":9760,"activeCount":114},[],{"trials":9762,"activeCount":114},[],{"trials":9764,"activeCount":114},[],{"trials":9766,"activeCount":114},[9767],{"nctId":9768,"briefTitle":9769,"status":105,"phases":9770,"primaryCompletion":9771,"completion":9771,"start":9772,"enrollment":7123,"conditions":9773,"interventions":9774},"NCT06418880","Automated Insulin Delivery for Inpatients With Dysglycemia",[92],"2025-10-31","2025-01-22",[6308,5928],[9757],{"trials":9776,"activeCount":114},[],{"trials":9778,"activeCount":114},[],{"intervention":9780,"totalTrials":186,"cells":9781},"Glutamine dipeptide with 15% Clinisol",{"EARLY_PHASE1":9782,"PHASE1":9784,"PHASE2":9786,"PHASE3":9788,"PHASE4":9797,"NA":9799},{"trials":9783,"activeCount":114},[],{"trials":9785,"activeCount":114},[],{"trials":9787,"activeCount":114},[],{"trials":9789,"activeCount":114},[9790],{"nctId":9791,"briefTitle":9792,"status":105,"phases":9793,"primaryCompletion":2563,"completion":2563,"start":9724,"enrollment":1281,"conditions":9794,"interventions":9795},"NCT00248638","Efficacy and Mechanisms of GLN Dipeptide in the SICU",[92],[6391],[9780,9796],"15% Clinisol",{"trials":9798,"activeCount":114},[],{"trials":9800,"activeCount":114},[],{"intervention":9796,"totalTrials":186,"cells":9802},{"EARLY_PHASE1":9803,"PHASE1":9805,"PHASE2":9807,"PHASE3":9809,"PHASE4":9815,"NA":9817},{"trials":9804,"activeCount":114},[],{"trials":9806,"activeCount":114},[],{"trials":9808,"activeCount":114},[],{"trials":9810,"activeCount":114},[9811],{"nctId":9791,"briefTitle":9792,"status":105,"phases":9812,"primaryCompletion":2563,"completion":2563,"start":9724,"enrollment":1281,"conditions":9813,"interventions":9814},[92],[6391],[9780,9796],{"trials":9816,"activeCount":114},[],{"trials":9818,"activeCount":114},[],{"intervention":9820,"totalTrials":186,"cells":9821},"Oxygen (15-O) Water",{"EARLY_PHASE1":9822,"PHASE1":9824,"PHASE2":9826,"PHASE3":9828,"PHASE4":9845,"NA":9847},{"trials":9823,"activeCount":114},[],{"trials":9825,"activeCount":114},[],{"trials":9827,"activeCount":114},[],{"trials":9829,"activeCount":114},[9830],{"nctId":9831,"briefTitle":9832,"status":105,"phases":9833,"primaryCompletion":5467,"completion":9834,"start":9835,"enrollment":454,"conditions":9836,"interventions":9844},"NCT04556552","Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders",[92],"2022-09-13","2020-11-13",[9837,9838,9839,9840,9841,9842,9843,560],"Substance-Related Disorders","Substance Use Disorders","Substance Abuse, Intravenous","Substance Withdrawal","Substance Abuse","Opioid-use Disorder","Opioid Use Disorder, Severe",[9820],{"trials":9846,"activeCount":114},[],{"trials":9848,"activeCount":114},[],{"intervention":9850,"totalTrials":186,"cells":9851},"O-15 water",{"EARLY_PHASE1":9852,"PHASE1":9854,"PHASE2":9856,"PHASE3":9858,"PHASE4":9869,"NA":9871},{"trials":9853,"activeCount":114},[],{"trials":9855,"activeCount":114},[],{"trials":9857,"activeCount":114},[],{"trials":9859,"activeCount":114},[9860],{"nctId":9861,"briefTitle":9862,"status":105,"phases":9863,"primaryCompletion":9864,"completion":9864,"start":9865,"enrollment":5378,"conditions":9866,"interventions":9868},"NCT02992899","Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder",[92],"2019-09-21","2017-04-19",[9867],"PostTraumatic Stress Disorder",[9850],{"trials":9870,"activeCount":114},[],{"trials":9872,"activeCount":114},[],{"intervention":9874,"totalTrials":186,"cells":9875},"NmCV-5",{"EARLY_PHASE1":9876,"PHASE1":9878,"PHASE2":9880,"PHASE3":9882,"PHASE4":9896,"NA":9898},{"trials":9877,"activeCount":114},[],{"trials":9879,"activeCount":114},[],{"trials":9881,"activeCount":114},[],{"trials":9883,"activeCount":114},[9884],{"nctId":9885,"briefTitle":9886,"status":105,"phases":9887,"primaryCompletion":9888,"completion":9889,"start":9890,"enrollment":9891,"conditions":9892,"interventions":9894},"NCT05093829","Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine",[92],"2023-03-10","2025-02-20","2022-03-24",1325,[9893],"Meningitis",[9874,9895],"MenACWY-TT",{"trials":9897,"activeCount":114},[],{"trials":9899,"activeCount":114},[],{"intervention":9895,"totalTrials":186,"cells":9901},{"EARLY_PHASE1":9902,"PHASE1":9904,"PHASE2":9906,"PHASE3":9908,"PHASE4":9914,"NA":9916},{"trials":9903,"activeCount":114},[],{"trials":9905,"activeCount":114},[],{"trials":9907,"activeCount":114},[],{"trials":9909,"activeCount":114},[9910],{"nctId":9885,"briefTitle":9886,"status":105,"phases":9911,"primaryCompletion":9888,"completion":9889,"start":9890,"enrollment":9891,"conditions":9912,"interventions":9913},[92],[9893],[9874,9895],{"trials":9915,"activeCount":114},[],{"trials":9917,"activeCount":114},[],{"intervention":9919,"totalTrials":186,"cells":9920},"Intralipid",{"EARLY_PHASE1":9921,"PHASE1":9923,"PHASE2":9925,"PHASE3":9927,"PHASE4":9940,"NA":9942},{"trials":9922,"activeCount":114},[],{"trials":9924,"activeCount":114},[],{"trials":9926,"activeCount":114},[],{"trials":9928,"activeCount":114},[9929],{"nctId":9930,"briefTitle":9931,"status":105,"phases":9932,"primaryCompletion":9933,"completion":9933,"start":6748,"enrollment":870,"conditions":9934,"interventions":9937},"NCT02185729","Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers",[91,92],"2012-03",[9935,9936],"Diseases, Metabolic","Insulin Sensitivity",[9919,9938,9939],"ClinOleic","Dextrose",{"trials":9941,"activeCount":114},[],{"trials":9943,"activeCount":114},[],{"intervention":9938,"totalTrials":186,"cells":9945},{"EARLY_PHASE1":9946,"PHASE1":9948,"PHASE2":9950,"PHASE3":9952,"PHASE4":9958,"NA":9960},{"trials":9947,"activeCount":114},[],{"trials":9949,"activeCount":114},[],{"trials":9951,"activeCount":114},[],{"trials":9953,"activeCount":114},[9954],{"nctId":9930,"briefTitle":9931,"status":105,"phases":9955,"primaryCompletion":9933,"completion":9933,"start":6748,"enrollment":870,"conditions":9956,"interventions":9957},[91,92],[9935,9936],[9919,9938,9939],{"trials":9959,"activeCount":114},[],{"trials":9961,"activeCount":114},[],{"intervention":9939,"totalTrials":186,"cells":9963},{"EARLY_PHASE1":9964,"PHASE1":9966,"PHASE2":9968,"PHASE3":9970,"PHASE4":9976,"NA":9978},{"trials":9965,"activeCount":114},[],{"trials":9967,"activeCount":114},[],{"trials":9969,"activeCount":114},[],{"trials":9971,"activeCount":114},[9972],{"nctId":9930,"briefTitle":9931,"status":105,"phases":9973,"primaryCompletion":9933,"completion":9933,"start":6748,"enrollment":870,"conditions":9974,"interventions":9975},[91,92],[9935,9936],[9919,9938,9939],{"trials":9977,"activeCount":114},[],{"trials":9979,"activeCount":114},[],{"intervention":9981,"totalTrials":186,"cells":9982},"Tamsulosin",{"EARLY_PHASE1":9983,"PHASE1":9985,"PHASE2":9987,"PHASE3":9989,"PHASE4":10000,"NA":10002},{"trials":9984,"activeCount":114},[],{"trials":9986,"activeCount":114},[],{"trials":9988,"activeCount":114},[],{"trials":9990,"activeCount":114},[9991],{"nctId":9992,"briefTitle":9993,"status":105,"phases":9994,"primaryCompletion":9995,"completion":9995,"start":9996,"enrollment":2977,"conditions":9997,"interventions":9999},"NCT06257576","Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter",[92],"2025-11-12","2024-02-26",[9998],"Postoperative Urinary Tract Infection",[9981],{"trials":10001,"activeCount":114},[],{"trials":10003,"activeCount":114},[],{"intervention":9649,"totalTrials":186,"cells":10005},{"EARLY_PHASE1":10006,"PHASE1":10008,"PHASE2":10010,"PHASE3":10012,"PHASE4":10018,"NA":10020},{"trials":10007,"activeCount":114},[],{"trials":10009,"activeCount":114},[],{"trials":10011,"activeCount":114},[],{"trials":10013,"activeCount":114},[10014],{"nctId":9643,"briefTitle":9644,"status":105,"phases":10015,"primaryCompletion":3503,"completion":3503,"start":3671,"enrollment":11,"conditions":10016,"interventions":10017},[92],[9647],[2163,9649,9650],{"trials":10019,"activeCount":114},[],{"trials":10021,"activeCount":114},[],{"intervention":9650,"totalTrials":186,"cells":10023},{"EARLY_PHASE1":10024,"PHASE1":10026,"PHASE2":10028,"PHASE3":10030,"PHASE4":10036,"NA":10038},{"trials":10025,"activeCount":114},[],{"trials":10027,"activeCount":114},[],{"trials":10029,"activeCount":114},[],{"trials":10031,"activeCount":114},[10032],{"nctId":9643,"briefTitle":9644,"status":105,"phases":10033,"primaryCompletion":3503,"completion":3503,"start":3671,"enrollment":11,"conditions":10034,"interventions":10035},[92],[9647],[2163,9649,9650],{"trials":10037,"activeCount":114},[],{"trials":10039,"activeCount":114},[],{"intervention":10041,"totalTrials":186,"cells":10042},"ClinOleic 20% Intravenous Emulsion",{"EARLY_PHASE1":10043,"PHASE1":10045,"PHASE2":10047,"PHASE3":10049,"PHASE4":10059,"NA":10061},{"trials":10044,"activeCount":114},[],{"trials":10046,"activeCount":114},[],{"trials":10048,"activeCount":114},[],{"trials":10050,"activeCount":114},[10051],{"nctId":10052,"briefTitle":10053,"status":105,"phases":10054,"primaryCompletion":3660,"completion":3660,"start":10055,"enrollment":345,"conditions":10056,"interventions":10057},"NCT00672854","Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN",[91,92],"2008-11",[6393],[10041,10058],"Intralipid, 20% Intravenous Emulsion",{"trials":10060,"activeCount":114},[],{"trials":10062,"activeCount":114},[],{"intervention":10058,"totalTrials":186,"cells":10064},{"EARLY_PHASE1":10065,"PHASE1":10067,"PHASE2":10069,"PHASE3":10071,"PHASE4":10077,"NA":10079},{"trials":10066,"activeCount":114},[],{"trials":10068,"activeCount":114},[],{"trials":10070,"activeCount":114},[],{"trials":10072,"activeCount":114},[10073],{"nctId":10052,"briefTitle":10053,"status":105,"phases":10074,"primaryCompletion":3660,"completion":3660,"start":10055,"enrollment":345,"conditions":10075,"interventions":10076},[91,92],[6393],[10041,10058],{"trials":10078,"activeCount":114},[],{"trials":10080,"activeCount":114},[],{"intervention":10082,"totalTrials":186,"cells":10083},"Dupilumab",{"EARLY_PHASE1":10084,"PHASE1":10086,"PHASE2":10088,"PHASE3":10090,"PHASE4":10102,"NA":10104},{"trials":10085,"activeCount":114},[],{"trials":10087,"activeCount":114},[],{"trials":10089,"activeCount":114},[],{"trials":10091,"activeCount":114},[10092],{"nctId":10093,"briefTitle":10094,"status":230,"phases":10095,"primaryCompletion":10096,"completion":10096,"start":10097,"enrollment":292,"conditions":10098,"interventions":10100},"NCT05545072","Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)",[92],"2024-07-10","2023-10-26",[10099],"Allergic Fungal Rhinosinusitis",[10082,10101],"Intranasal Corticosteroid Sprays",{"trials":10103,"activeCount":114},[],{"trials":10105,"activeCount":114},[],{"intervention":10101,"totalTrials":186,"cells":10107},{"EARLY_PHASE1":10108,"PHASE1":10110,"PHASE2":10112,"PHASE3":10114,"PHASE4":10120,"NA":10122},{"trials":10109,"activeCount":114},[],{"trials":10111,"activeCount":114},[],{"trials":10113,"activeCount":114},[],{"trials":10115,"activeCount":114},[10116],{"nctId":10093,"briefTitle":10094,"status":230,"phases":10117,"primaryCompletion":10096,"completion":10096,"start":10097,"enrollment":292,"conditions":10118,"interventions":10119},[92],[10099],[10082,10101],{"trials":10121,"activeCount":114},[],{"trials":10123,"activeCount":114},[],{"intervention":10125,"totalTrials":186,"cells":10126},"Betamethasone",{"EARLY_PHASE1":10127,"PHASE1":10129,"PHASE2":10131,"PHASE3":10133,"PHASE4":10146,"NA":10148},{"trials":10128,"activeCount":114},[],{"trials":10130,"activeCount":114},[],{"trials":10132,"activeCount":114},[],{"trials":10134,"activeCount":114},[10135],{"nctId":10136,"briefTitle":10137,"status":230,"phases":10138,"primaryCompletion":10139,"completion":10140,"start":10141,"enrollment":10142,"conditions":10143,"interventions":10145},"NCT00139256","Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section",[91,92],"2007-04","2007-09","2005-08",67,[10144],"Respiratory Distress Syndrome, Newborn",[10125],{"trials":10147,"activeCount":114},[],{"trials":10149,"activeCount":114},[],{"intervention":710,"totalTrials":186,"cells":10151},{"EARLY_PHASE1":10152,"PHASE1":10154,"PHASE2":10156,"PHASE3":10158,"PHASE4":10164,"NA":10166},{"trials":10153,"activeCount":114},[],{"trials":10155,"activeCount":114},[],{"trials":10157,"activeCount":114},[],{"trials":10159,"activeCount":114},[10160],{"nctId":702,"briefTitle":703,"status":230,"phases":10161,"primaryCompletion":705,"completion":705,"start":706,"enrollment":292,"conditions":10162,"interventions":10163},[92],[708],[710,308,711,712],{"trials":10165,"activeCount":114},[],{"trials":10167,"activeCount":114},[],{"intervention":711,"totalTrials":186,"cells":10169},{"EARLY_PHASE1":10170,"PHASE1":10172,"PHASE2":10174,"PHASE3":10176,"PHASE4":10182,"NA":10184},{"trials":10171,"activeCount":114},[],{"trials":10173,"activeCount":114},[],{"trials":10175,"activeCount":114},[],{"trials":10177,"activeCount":114},[10178],{"nctId":702,"briefTitle":703,"status":230,"phases":10179,"primaryCompletion":705,"completion":705,"start":706,"enrollment":292,"conditions":10180,"interventions":10181},[92],[708],[710,308,711,712],{"trials":10183,"activeCount":114},[],{"trials":10185,"activeCount":114},[],{"intervention":712,"totalTrials":186,"cells":10187},{"EARLY_PHASE1":10188,"PHASE1":10190,"PHASE2":10192,"PHASE3":10194,"PHASE4":10200,"NA":10202},{"trials":10189,"activeCount":114},[],{"trials":10191,"activeCount":114},[],{"trials":10193,"activeCount":114},[],{"trials":10195,"activeCount":114},[10196],{"nctId":702,"briefTitle":703,"status":230,"phases":10197,"primaryCompletion":705,"completion":705,"start":706,"enrollment":292,"conditions":10198,"interventions":10199},[92],[708],[710,308,711,712],{"trials":10201,"activeCount":114},[],{"trials":10203,"activeCount":114},[],{"intervention":9729,"totalTrials":186,"cells":10205},{"EARLY_PHASE1":10206,"PHASE1":10208,"PHASE2":10210,"PHASE3":10212,"PHASE4":10218,"NA":10220},{"trials":10207,"activeCount":114},[],{"trials":10209,"activeCount":114},[],{"trials":10211,"activeCount":114},[],{"trials":10213,"activeCount":114},[10214],{"nctId":9720,"briefTitle":9721,"status":105,"phases":10215,"primaryCompletion":9723,"completion":9723,"start":9724,"enrollment":3242,"conditions":10216,"interventions":10217},[91,92],[9726],[9728,9729],{"trials":10219,"activeCount":114},[],{"trials":10221,"activeCount":114},[],{"intervention":10223,"totalTrials":186,"cells":10224},"Fibrinogen Concentrate",{"EARLY_PHASE1":10225,"PHASE1":10227,"PHASE2":10229,"PHASE3":10231,"PHASE4":10244,"NA":10246},{"trials":10226,"activeCount":114},[],{"trials":10228,"activeCount":114},[],{"trials":10230,"activeCount":114},[],{"trials":10232,"activeCount":114},[10233],{"nctId":10234,"briefTitle":10235,"status":105,"phases":10236,"primaryCompletion":10237,"completion":10238,"start":10239,"enrollment":1153,"conditions":10240,"interventions":10242},"NCT03932240","In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)",[92],"2021-04-09","2021-11-16","2019-08-13",[10241],"Hemostasis",[10223,10243],"Cryoprecipitate",{"trials":10245,"activeCount":114},[],{"trials":10247,"activeCount":114},[],{"intervention":10243,"totalTrials":186,"cells":10249},{"EARLY_PHASE1":10250,"PHASE1":10252,"PHASE2":10254,"PHASE3":10256,"PHASE4":10262,"NA":10264},{"trials":10251,"activeCount":114},[],{"trials":10253,"activeCount":114},[],{"trials":10255,"activeCount":114},[],{"trials":10257,"activeCount":114},[10258],{"nctId":10234,"briefTitle":10235,"status":105,"phases":10259,"primaryCompletion":10237,"completion":10238,"start":10239,"enrollment":1153,"conditions":10260,"interventions":10261},[92],[10241],[10223,10243],{"trials":10263,"activeCount":114},[],{"trials":10265,"activeCount":114},[],{"intervention":10267,"totalTrials":186,"cells":10268},"Trinity multipotent stem cells",{"EARLY_PHASE1":10269,"PHASE1":10271,"PHASE2":10273,"PHASE3":10275,"PHASE4":10286,"NA":10288},{"trials":10270,"activeCount":114},[],{"trials":10272,"activeCount":114},[],{"trials":10274,"activeCount":114},[],{"trials":10276,"activeCount":114},[10277],{"nctId":10278,"briefTitle":10279,"status":2022,"phases":10280,"primaryCompletion":10281,"completion":10281,"start":3644,"enrollment":114,"conditions":10282,"interventions":10284},"NCT00851162","Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions",[91,92],"2010-03",[10283],"Bone Neoplasms",[10267,10285],"Demineralized bone matrix",{"trials":10287,"activeCount":114},[],{"trials":10289,"activeCount":114},[],{"intervention":10285,"totalTrials":186,"cells":10291},{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10296,"PHASE3":10298,"PHASE4":10304,"NA":10306},{"trials":10293,"activeCount":114},[],{"trials":10295,"activeCount":114},[],{"trials":10297,"activeCount":114},[],{"trials":10299,"activeCount":114},[10300],{"nctId":10278,"briefTitle":10279,"status":2022,"phases":10301,"primaryCompletion":10281,"completion":10281,"start":3644,"enrollment":114,"conditions":10302,"interventions":10303},[91,92],[10283],[10267,10285],{"trials":10305,"activeCount":114},[],{"trials":10307,"activeCount":114},[],{"intervention":10309,"totalTrials":186,"cells":10310},"Oxcarbazepine",{"EARLY_PHASE1":10311,"PHASE1":10313,"PHASE2":10315,"PHASE3":10317,"PHASE4":10330,"NA":10332},{"trials":10312,"activeCount":114},[],{"trials":10314,"activeCount":114},[],{"trials":10316,"activeCount":114},[],{"trials":10318,"activeCount":114},[10319],{"nctId":10320,"briefTitle":10321,"status":230,"phases":10322,"primaryCompletion":10323,"completion":10323,"start":233,"enrollment":1403,"conditions":10324,"interventions":10327},"NCT01891890","Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)",[92],"2015-10-23",[10325,10326],"Epilepsy, Partial","Epilepsy, Localization Related",[10309,10328,10329],"Levetiracetam","Lamotrigine",{"trials":10331,"activeCount":114},[],{"trials":10333,"activeCount":114},[],{"intervention":10328,"totalTrials":186,"cells":10335},{"EARLY_PHASE1":10336,"PHASE1":10338,"PHASE2":10340,"PHASE3":10342,"PHASE4":10348,"NA":10350},{"trials":10337,"activeCount":114},[],{"trials":10339,"activeCount":114},[],{"trials":10341,"activeCount":114},[],{"trials":10343,"activeCount":114},[10344],{"nctId":10320,"briefTitle":10321,"status":230,"phases":10345,"primaryCompletion":10323,"completion":10323,"start":233,"enrollment":1403,"conditions":10346,"interventions":10347},[92],[10325,10326],[10309,10328,10329],{"trials":10349,"activeCount":114},[],{"trials":10351,"activeCount":114},[],{"intervention":10353,"totalTrials":186,"cells":10354},"Levosimendan",{"EARLY_PHASE1":10355,"PHASE1":10357,"PHASE2":10359,"PHASE3":10361,"PHASE4":10369,"NA":10371},{"trials":10356,"activeCount":114},[],{"trials":10358,"activeCount":114},[],{"trials":10360,"activeCount":114},[],{"trials":10362,"activeCount":114},[10363],{"nctId":10364,"briefTitle":10365,"status":230,"phases":10366,"completion":6861,"start":2675,"enrollment":186,"conditions":10367,"interventions":10368},"NCT00166127","Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery",[92],[4739],[10353],{"trials":10370,"activeCount":114},[],{"trials":10372,"activeCount":114},[],{"intervention":6333,"totalTrials":186,"cells":10374},{"EARLY_PHASE1":10375,"PHASE1":10377,"PHASE2":10379,"PHASE3":10381,"PHASE4":10387,"NA":10389},{"trials":10376,"activeCount":114},[],{"trials":10378,"activeCount":114},[],{"trials":10380,"activeCount":114},[],{"trials":10382,"activeCount":114},[10383],{"nctId":6326,"briefTitle":6327,"status":105,"phases":10384,"primaryCompletion":2835,"completion":2835,"start":6329,"enrollment":6330,"conditions":10385,"interventions":10386},[92],[1109],[6333,6334,6335,6315],{"trials":10388,"activeCount":114},[],{"trials":10390,"activeCount":114},[],{"intervention":6334,"totalTrials":186,"cells":10392},{"EARLY_PHASE1":10393,"PHASE1":10395,"PHASE2":10397,"PHASE3":10399,"PHASE4":10405,"NA":10407},{"trials":10394,"activeCount":114},[],{"trials":10396,"activeCount":114},[],{"trials":10398,"activeCount":114},[],{"trials":10400,"activeCount":114},[10401],{"nctId":6326,"briefTitle":6327,"status":105,"phases":10402,"primaryCompletion":2835,"completion":2835,"start":6329,"enrollment":6330,"conditions":10403,"interventions":10404},[92],[1109],[6333,6334,6335,6315],{"trials":10406,"activeCount":114},[],{"trials":10408,"activeCount":114},[],{"intervention":6335,"totalTrials":186,"cells":10410},{"EARLY_PHASE1":10411,"PHASE1":10413,"PHASE2":10415,"PHASE3":10417,"PHASE4":10423,"NA":10425},{"trials":10412,"activeCount":114},[],{"trials":10414,"activeCount":114},[],{"trials":10416,"activeCount":114},[],{"trials":10418,"activeCount":114},[10419],{"nctId":6326,"briefTitle":6327,"status":105,"phases":10420,"primaryCompletion":2835,"completion":2835,"start":6329,"enrollment":6330,"conditions":10421,"interventions":10422},[92],[1109],[6333,6334,6335,6315],{"trials":10424,"activeCount":114},[],{"trials":10426,"activeCount":114},[],{"intervention":1272,"totalTrials":186,"cells":10428},{"EARLY_PHASE1":10429,"PHASE1":10431,"PHASE2":10433,"PHASE3":10435,"PHASE4":10441,"NA":10443},{"trials":10430,"activeCount":114},[],{"trials":10432,"activeCount":114},[],{"trials":10434,"activeCount":114},[],{"trials":10436,"activeCount":114},[10437],{"nctId":1262,"briefTitle":1263,"status":105,"phases":10438,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":10439,"interventions":10440},[92],[1269,1270],[1251,1272],{"trials":10442,"activeCount":114},[],{"trials":10444,"activeCount":114},[],{"intervention":5717,"totalTrials":186,"cells":10446},{"EARLY_PHASE1":10447,"PHASE1":10449,"PHASE2":10451,"PHASE3":10453,"PHASE4":10459,"NA":10461},{"trials":10448,"activeCount":114},[],{"trials":10450,"activeCount":114},[],{"trials":10452,"activeCount":114},[],{"trials":10454,"activeCount":114},[10455],{"nctId":5711,"briefTitle":5712,"status":2022,"phases":10456,"primaryCompletion":5714,"completion":5714,"start":5624,"enrollment":114,"conditions":10457,"interventions":10458},[92],[1453],[1469,5717,1469],{"trials":10460,"activeCount":114},[],{"trials":10462,"activeCount":114},[],{"intervention":10464,"totalTrials":186,"cells":10465},"Twenty-four Hour TPN and Saline",{"EARLY_PHASE1":10466,"PHASE1":10468,"PHASE2":10470,"PHASE3":10472,"PHASE4":10481,"NA":10483},{"trials":10467,"activeCount":114},[],{"trials":10469,"activeCount":114},[],{"trials":10471,"activeCount":114},[],{"trials":10473,"activeCount":114},[10474],{"nctId":10475,"briefTitle":10476,"status":2022,"phases":10477,"primaryCompletion":7806,"completion":7806,"start":10478,"enrollment":114,"conditions":10479,"interventions":10480},"NCT00989339","Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers",[91,92],"2009-11",[18,6155,33],[10464],{"trials":10482,"activeCount":114},[],{"trials":10484,"activeCount":114},[],{"intervention":10486,"totalTrials":186,"cells":10487},"Vitamin C",{"EARLY_PHASE1":10488,"PHASE1":10490,"PHASE2":10492,"PHASE3":10494,"PHASE4":10510,"NA":10512},{"trials":10489,"activeCount":114},[],{"trials":10491,"activeCount":114},[],{"trials":10493,"activeCount":114},[],{"trials":10495,"activeCount":114},[10496],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10499,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10503,"interventions":10504},"NCT03509350","Vitamin C, Thiamine, and Steroids in Sepsis",[92],"2020-01-29","2018-08-22",501,[7809],[10486,10505,10506,10507,10508,10509],"Thiamine","Hydrocortisone","Vitamin C Placebo","Thiamine Placebo","Hydrocortisone Placebo",{"trials":10511,"activeCount":114},[],{"trials":10513,"activeCount":114},[],{"intervention":10505,"totalTrials":186,"cells":10515},{"EARLY_PHASE1":10516,"PHASE1":10518,"PHASE2":10520,"PHASE3":10522,"PHASE4":10528,"NA":10530},{"trials":10517,"activeCount":114},[],{"trials":10519,"activeCount":114},[],{"trials":10521,"activeCount":114},[],{"trials":10523,"activeCount":114},[10524],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10525,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10526,"interventions":10527},[92],[7809],[10486,10505,10506,10507,10508,10509],{"trials":10529,"activeCount":114},[],{"trials":10531,"activeCount":114},[],{"intervention":10506,"totalTrials":186,"cells":10533},{"EARLY_PHASE1":10534,"PHASE1":10536,"PHASE2":10538,"PHASE3":10540,"PHASE4":10546,"NA":10548},{"trials":10535,"activeCount":114},[],{"trials":10537,"activeCount":114},[],{"trials":10539,"activeCount":114},[],{"trials":10541,"activeCount":114},[10542],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10543,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10544,"interventions":10545},[92],[7809],[10486,10505,10506,10507,10508,10509],{"trials":10547,"activeCount":114},[],{"trials":10549,"activeCount":114},[],{"intervention":10507,"totalTrials":186,"cells":10551},{"EARLY_PHASE1":10552,"PHASE1":10554,"PHASE2":10556,"PHASE3":10558,"PHASE4":10564,"NA":10566},{"trials":10553,"activeCount":114},[],{"trials":10555,"activeCount":114},[],{"trials":10557,"activeCount":114},[],{"trials":10559,"activeCount":114},[10560],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10561,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10562,"interventions":10563},[92],[7809],[10486,10505,10506,10507,10508,10509],{"trials":10565,"activeCount":114},[],{"trials":10567,"activeCount":114},[],{"intervention":10508,"totalTrials":186,"cells":10569},{"EARLY_PHASE1":10570,"PHASE1":10572,"PHASE2":10574,"PHASE3":10576,"PHASE4":10582,"NA":10584},{"trials":10571,"activeCount":114},[],{"trials":10573,"activeCount":114},[],{"trials":10575,"activeCount":114},[],{"trials":10577,"activeCount":114},[10578],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10579,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10580,"interventions":10581},[92],[7809],[10486,10505,10506,10507,10508,10509],{"trials":10583,"activeCount":114},[],{"trials":10585,"activeCount":114},[],{"intervention":10509,"totalTrials":186,"cells":10587},{"EARLY_PHASE1":10588,"PHASE1":10590,"PHASE2":10592,"PHASE3":10594,"PHASE4":10600,"NA":10602},{"trials":10589,"activeCount":114},[],{"trials":10591,"activeCount":114},[],{"trials":10593,"activeCount":114},[],{"trials":10595,"activeCount":114},[10596],{"nctId":10497,"briefTitle":10498,"status":105,"phases":10597,"primaryCompletion":2986,"completion":10500,"start":10501,"enrollment":10502,"conditions":10598,"interventions":10599},[92],[7809],[10486,10505,10506,10507,10508,10509],{"trials":10601,"activeCount":114},[],{"trials":10603,"activeCount":114},[],{"intervention":6504,"totalTrials":186,"cells":10605},{"EARLY_PHASE1":10606,"PHASE1":10608,"PHASE2":10610,"PHASE3":10612,"PHASE4":10618,"NA":10620},{"trials":10607,"activeCount":114},[],{"trials":10609,"activeCount":114},[],{"trials":10611,"activeCount":114},[],{"trials":10613,"activeCount":114},[10614],{"nctId":6497,"briefTitle":6498,"status":105,"phases":10615,"primaryCompletion":6500,"completion":6500,"start":2156,"enrollment":6501,"conditions":10616,"interventions":10617},[92],[510],[6504,6505,6506],{"trials":10619,"activeCount":114},[],{"trials":10621,"activeCount":114},[],{"intervention":6505,"totalTrials":186,"cells":10623},{"EARLY_PHASE1":10624,"PHASE1":10626,"PHASE2":10628,"PHASE3":10630,"PHASE4":10636,"NA":10638},{"trials":10625,"activeCount":114},[],{"trials":10627,"activeCount":114},[],{"trials":10629,"activeCount":114},[],{"trials":10631,"activeCount":114},[10632],{"nctId":6497,"briefTitle":6498,"status":105,"phases":10633,"primaryCompletion":6500,"completion":6500,"start":2156,"enrollment":6501,"conditions":10634,"interventions":10635},[92],[510],[6504,6505,6506],{"trials":10637,"activeCount":114},[],{"trials":10639,"activeCount":114},[],{"intervention":10641,"totalTrials":186,"cells":10642},"5% human albumin",{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10649,"PHASE4":10660,"NA":10662},{"trials":10644,"activeCount":114},[],{"trials":10646,"activeCount":114},[],{"trials":10648,"activeCount":114},[],{"trials":10650,"activeCount":114},[10651],{"nctId":10652,"briefTitle":10653,"status":230,"phases":10654,"primaryCompletion":1497,"completion":160,"start":9499,"enrollment":595,"conditions":10655,"interventions":10658},"NCT00796419","Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)",[92],[10656,10657],"Lung Injury, Acute (ALI)","Respiratory Distress Syndrome, Acute (ARDS)",[10641,10659],"6% hetastarch",{"trials":10661,"activeCount":114},[],{"trials":10663,"activeCount":114},[],{"intervention":10659,"totalTrials":186,"cells":10665},{"EARLY_PHASE1":10666,"PHASE1":10668,"PHASE2":10670,"PHASE3":10672,"PHASE4":10678,"NA":10680},{"trials":10667,"activeCount":114},[],{"trials":10669,"activeCount":114},[],{"trials":10671,"activeCount":114},[],{"trials":10673,"activeCount":114},[10674],{"nctId":10652,"briefTitle":10653,"status":230,"phases":10675,"primaryCompletion":1497,"completion":160,"start":9499,"enrollment":595,"conditions":10676,"interventions":10677},[92],[10656,10657],[10641,10659],{"trials":10679,"activeCount":114},[],{"trials":10681,"activeCount":114},[],{"intervention":10683,"totalTrials":186,"cells":10684},"ACTH",{"EARLY_PHASE1":10685,"PHASE1":10687,"PHASE2":10689,"PHASE3":10691,"PHASE4":10701,"NA":10703},{"trials":10686,"activeCount":114},[],{"trials":10688,"activeCount":114},[],{"trials":10690,"activeCount":114},[],{"trials":10692,"activeCount":114},[10693],{"nctId":10694,"briefTitle":10695,"status":105,"phases":10696,"primaryCompletion":10697,"completion":6035,"start":3427,"enrollment":595,"conditions":10698,"interventions":10700},"NCT02132195","Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome",[92],"2018-01",[10699],"Nephrotic Syndrome",[10683],{"trials":10702,"activeCount":114},[],{"trials":10704,"activeCount":114},[],{"intervention":2472,"totalTrials":182,"cells":10706},{"EARLY_PHASE1":10707,"PHASE1":10709,"PHASE2":10744,"PHASE3":10784,"PHASE4":10786,"NA":10788},{"trials":10708,"activeCount":114},[],{"trials":10710,"activeCount":114},[10711,10720,10731,10735],{"nctId":10712,"briefTitle":10713,"status":105,"phases":10714,"primaryCompletion":10715,"completion":10715,"start":7806,"enrollment":2481,"conditions":10716,"interventions":10718},"NCT01469572","Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases",[90],"2018-10",[10717],"Neuroendocrine Tumors",[10719,2472],"Pasireotide",{"nctId":10721,"briefTitle":10722,"status":105,"phases":10723,"primaryCompletion":10724,"completion":10724,"start":10725,"enrollment":10726,"conditions":10727,"interventions":10730},"NCT01218555","Study of Everolimus (RAD001) in Combination With Lenalidomide",[90],"2020-11-05","2010-09-09",44,[10728,10729,10717],"Solid Organ Malignancies","Adenoidcystic Carcinoma",[128,2472],{"nctId":2463,"briefTitle":2464,"status":105,"phases":10732,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":182,"conditions":10733,"interventions":10734},[90],[2469,2470],[2472,2473,154,2474],{"nctId":10736,"briefTitle":10737,"status":105,"phases":10738,"primaryCompletion":10739,"completion":10739,"start":173,"enrollment":3053,"conditions":10740,"interventions":10742},"NCT01470209","A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies",[90],"2017-05",[10741,3648],"Solid Tumors",[10743,2472],"BKM120",{"trials":10745,"activeCount":114},[10746,10750,10758,10767],{"nctId":5558,"briefTitle":5559,"status":230,"phases":10747,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":10748,"interventions":10749},[91],[5563,5564,5565,5566,3538,3540,3542,3543],[5568,5569,5570,5571,5572,5573],{"nctId":10751,"briefTitle":10752,"status":105,"phases":10753,"primaryCompletion":2683,"completion":2683,"start":10754,"enrollment":208,"conditions":10755,"interventions":10756},"NCT00912340","Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer",[91],"2009-05",[30],[2472,10757],"Trastuzumab",{"nctId":10759,"briefTitle":10760,"status":105,"phases":10761,"primaryCompletion":3708,"completion":3708,"start":10762,"enrollment":445,"conditions":10763,"interventions":10765},"NCT01270321","Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer",[91],"2010-11",[10764],"Thyroid Cancer",[2472,10719,10766],"Everolimus and Pasireotide",{"nctId":10768,"briefTitle":10769,"status":230,"phases":10770,"primaryCompletion":3877,"completion":3877,"start":3426,"enrollment":327,"conditions":10771,"interventions":10783},"NCT02273752","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",[91],[5563,10772,10773,5564,10774,10775,10776,10777,5565,5566,10778,10779,10780,10781,3538,3540,3542,3543,10782],"Gastrinoma","Glucagonoma","Insulinoma","Mucositis","Oral Complications","Pancreatic Polypeptide Tumor","Recurrent Islet Cell Carcinoma","Recurrent Renal Cell Cancer","Somatostatinoma","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer",[2472],{"trials":10785,"activeCount":114},[],{"trials":10787,"activeCount":114},[],{"trials":10789,"activeCount":114},[],{"intervention":3665,"totalTrials":470,"cells":10791},{"EARLY_PHASE1":10792,"PHASE1":10794,"PHASE2":10806,"PHASE3":10816,"PHASE4":10818,"NA":10820},{"trials":10793,"activeCount":114},[],{"trials":10795,"activeCount":114},[10796,10800],{"nctId":3705,"briefTitle":3706,"status":105,"phases":10797,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":276,"conditions":10798,"interventions":10799},[90],[3711,3712],[3665,3714,1981],{"nctId":10801,"briefTitle":10802,"status":105,"phases":10803,"primaryCompletion":6152,"completion":6152,"start":3662,"enrollment":16,"conditions":10804,"interventions":10805},"NCT00401778","Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)",[90],[3648],[3665],{"trials":10807,"activeCount":114},[10808,10812],{"nctId":3657,"briefTitle":3658,"status":230,"phases":10809,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":22,"conditions":10810,"interventions":10811},[90,91],[3648],[3665,2039],{"nctId":3730,"briefTitle":3731,"status":105,"phases":10813,"primaryCompletion":3524,"completion":3426,"start":3733,"enrollment":454,"conditions":10814,"interventions":10815},[90,91],[3735,3736],[1981,3738,3665],{"trials":10817,"activeCount":114},[],{"trials":10819,"activeCount":114},[],{"trials":10821,"activeCount":114},[],{"intervention":128,"totalTrials":470,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10836,"PHASE3":10846,"PHASE4":10848,"NA":10850},{"trials":10825,"activeCount":114},[],{"trials":10827,"activeCount":114},[10828,10832],{"nctId":118,"briefTitle":119,"status":105,"phases":10829,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":10830,"interventions":10831},[90],[125],[127,128,97,129],{"nctId":10721,"briefTitle":10722,"status":105,"phases":10833,"primaryCompletion":10724,"completion":10724,"start":10725,"enrollment":10726,"conditions":10834,"interventions":10835},[90],[10728,10729,10717],[128,2472],{"trials":10837,"activeCount":114},[10838,10842],{"nctId":203,"briefTitle":204,"status":105,"phases":10839,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":10840,"interventions":10841},[91],[138,210],[97,201,128],{"nctId":271,"briefTitle":272,"status":230,"phases":10843,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":10844,"interventions":10845},[91],[198,278],[127,200,97,128,280],{"trials":10847,"activeCount":114},[],{"trials":10849,"activeCount":114},[],{"trials":10851,"activeCount":114},[],{"intervention":10853,"totalTrials":470,"cells":10854},"Melatonin",{"EARLY_PHASE1":10855,"PHASE1":10857,"PHASE2":10859,"PHASE3":10887,"PHASE4":10889,"NA":10891},{"trials":10856,"activeCount":114},[],{"trials":10858,"activeCount":114},[],{"trials":10860,"activeCount":114},[10861,10868,10874,10880],{"nctId":10862,"briefTitle":10863,"status":230,"phases":10864,"primaryCompletion":7807,"completion":7807,"start":9499,"enrollment":362,"conditions":10865,"interventions":10867},"NCT00790478","Melatonin and Ulcerative Colitis: A Pilot Clinical Trial",[91],[10866],"Ulcerative Colitis",[10853],{"nctId":10869,"briefTitle":10870,"status":105,"phases":10871,"primaryCompletion":3466,"completion":8364,"start":10281,"enrollment":1499,"conditions":10872,"interventions":10873},"NCT01114360","Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study",[91],[6155],[10853],{"nctId":10875,"briefTitle":10876,"status":105,"phases":10877,"primaryCompletion":3466,"completion":8364,"start":2880,"enrollment":1796,"conditions":10878,"interventions":10879},"NCT01114373","Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study",[91],[6155],[10853],{"nctId":10881,"briefTitle":10882,"status":105,"phases":10883,"primaryCompletion":5940,"completion":5971,"start":3670,"enrollment":2582,"conditions":10884,"interventions":10886},"NCT01038921","Melatonin and the Metabolic Syndrome",[91],[10885],"Metabolic Syndrome",[10853],{"trials":10888,"activeCount":114},[],{"trials":10890,"activeCount":114},[],{"trials":10892,"activeCount":114},[],{"intervention":10894,"totalTrials":362,"cells":10895},"efalizumab",{"EARLY_PHASE1":10896,"PHASE1":10898,"PHASE2":10900,"PHASE3":10921,"PHASE4":10923,"NA":10925},{"trials":10897,"activeCount":114},[],{"trials":10899,"activeCount":114},[],{"trials":10901,"activeCount":114},[10902,10909,10913],{"nctId":10903,"briefTitle":10904,"status":2022,"phases":10905,"primaryCompletion":10478,"completion":10478,"start":2366,"enrollment":114,"conditions":10906,"interventions":10908},"NCT00737763","Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab",[91],[10907],"Diabetes Mellitus, Type 1",[10894],{"nctId":2962,"briefTitle":2963,"status":105,"phases":10910,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":292,"conditions":10911,"interventions":10912},[91],[2968],[2970,2931,2971],{"nctId":10914,"briefTitle":10915,"status":230,"phases":10916,"primaryCompletion":252,"completion":252,"start":10917,"enrollment":292,"conditions":10918,"interventions":10920},"NCT00472082","Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients",[90,91],"2007-05",[3402,10919],"Chronic Kidney Failure",[10894],{"trials":10922,"activeCount":114},[],{"trials":10924,"activeCount":114},[],{"trials":10926,"activeCount":114},[],{"intervention":3550,"totalTrials":362,"cells":10928},{"EARLY_PHASE1":10929,"PHASE1":10931,"PHASE2":10948,"PHASE3":10954,"PHASE4":10956,"NA":10958},{"trials":10930,"activeCount":114},[],{"trials":10932,"activeCount":114},[10933,10944],{"nctId":10934,"briefTitle":10935,"status":2022,"phases":10936,"primaryCompletion":10937,"completion":10937,"start":10938,"enrollment":114,"conditions":10939,"interventions":10941},"NCT04585724","Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",[90],"2021-09-13","2020-06-12",[10940,5582,111,1853],"Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8",[10942,3550,10943],"Abemaciclib","Ribociclib",{"nctId":3530,"briefTitle":3531,"status":105,"phases":10945,"primaryCompletion":3533,"completion":3533,"start":3534,"enrollment":3535,"conditions":10946,"interventions":10947},[90],[3537,1777,3538,3539,3540,3541,3542,3543,1869,1783,1785,3544,3545,2566,3546,3547,3548],[1981,2382,3550],{"trials":10949,"activeCount":114},[10950],{"nctId":5575,"briefTitle":5576,"status":105,"phases":10951,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":10952,"interventions":10953},[91],[1839,5580,5581,5582,5583,5584,1853],[5586,3682,5587,5538,3550,5588],{"trials":10955,"activeCount":114},[],{"trials":10957,"activeCount":114},[],{"trials":10959,"activeCount":114},[],{"intervention":10961,"totalTrials":362,"cells":10962},"GM-CSF",{"EARLY_PHASE1":10963,"PHASE1":10965,"PHASE2":10967,"PHASE3":10996,"PHASE4":10998,"NA":11000},{"trials":10964,"activeCount":114},[],{"trials":10966,"activeCount":114},[],{"trials":10968,"activeCount":114},[10969,10977,10986],{"nctId":10970,"briefTitle":10971,"status":105,"phases":10972,"primaryCompletion":1555,"completion":1555,"start":6861,"enrollment":1754,"conditions":10973,"interventions":10975},"NCT00548847","Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",[91],[10974],"Leukemia",[10961,10976],"Interferon-α-2b",{"nctId":10978,"briefTitle":10979,"status":230,"phases":10980,"primaryCompletion":5902,"completion":5939,"start":10981,"enrollment":391,"conditions":10982,"interventions":10984},"NCT00208949","A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF",[91],"2002-09",[10983],"Hematologic Diseases",[10985,10961],"G-CSF",{"nctId":10987,"briefTitle":10988,"status":105,"phases":10989,"primaryCompletion":10990,"completion":10990,"start":10991,"enrollment":10992,"conditions":10993,"interventions":10995},"NCT03304821","Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease",[91],"2025-07-05","2017-12-19",151,[10994],"Peripheral Artery Disease (PAD)",[10961],{"trials":10997,"activeCount":114},[],{"trials":10999,"activeCount":114},[],{"trials":11001,"activeCount":114},[],{"intervention":11003,"totalTrials":327,"cells":11004},"Genistein",{"EARLY_PHASE1":11005,"PHASE1":11007,"PHASE2":11009,"PHASE3":11028,"PHASE4":11030,"NA":11032},{"trials":11006,"activeCount":114},[],{"trials":11008,"activeCount":114},[],{"trials":11010,"activeCount":114},[11011,11018],{"nctId":11012,"briefTitle":11013,"status":230,"phases":11014,"primaryCompletion":3201,"completion":3201,"start":11015,"enrollment":2075,"conditions":11016,"interventions":11017},"NCT02766478","Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer",[91],"2017-10-16",[3651],[11003],{"nctId":11019,"briefTitle":11020,"status":105,"phases":11021,"primaryCompletion":11022,"completion":11023,"start":11024,"enrollment":1153,"conditions":11025,"interventions":11026},"NCT01489813","Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment",[91],"2023-08-31","2024-08-31","2017-05-19",[3547],[11003,11027],"Sugar pill",{"trials":11029,"activeCount":114},[],{"trials":11031,"activeCount":114},[],{"trials":11033,"activeCount":114},[],{"intervention":11035,"totalTrials":327,"cells":11036},"Candesartan",{"EARLY_PHASE1":11037,"PHASE1":11039,"PHASE2":11041,"PHASE3":11062,"PHASE4":11064,"NA":11066},{"trials":11038,"activeCount":114},[],{"trials":11040,"activeCount":114},[],{"trials":11042,"activeCount":114},[11043,11052],{"nctId":11044,"briefTitle":11045,"status":105,"phases":11046,"primaryCompletion":11047,"completion":11047,"start":11048,"enrollment":8365,"conditions":11049,"interventions":11051},"NCT02646982","Candesartan's Effects on Alzheimer's Disease And Related Biomarkers",[91],"2020-08-17","2016-06-30",[11050],"Mild Cognitive Impairment",[11035],{"nctId":11053,"briefTitle":11054,"status":105,"phases":11055,"primaryCompletion":11056,"completion":11056,"start":11057,"enrollment":11058,"conditions":11059,"interventions":11060},"NCT01984164","CAndesartan vs LIsinopril Effects on the BRain",[91],"2018-12-03","2014-08-20",176,[6155,11050],[11035,11061],"Lisinopril",{"trials":11063,"activeCount":114},[],{"trials":11065,"activeCount":114},[],{"trials":11067,"activeCount":114},[],{"intervention":10719,"totalTrials":327,"cells":11069},{"EARLY_PHASE1":11070,"PHASE1":11072,"PHASE2":11078,"PHASE3":11084,"PHASE4":11086,"NA":11088},{"trials":11071,"activeCount":114},[],{"trials":11073,"activeCount":114},[11074],{"nctId":10712,"briefTitle":10713,"status":105,"phases":11075,"primaryCompletion":10715,"completion":10715,"start":7806,"enrollment":2481,"conditions":11076,"interventions":11077},[90],[10717],[10719,2472],{"trials":11079,"activeCount":114},[11080],{"nctId":10759,"briefTitle":10760,"status":105,"phases":11081,"primaryCompletion":3708,"completion":3708,"start":10762,"enrollment":445,"conditions":11082,"interventions":11083},[91],[10764],[2472,10719,10766],{"trials":11085,"activeCount":114},[],{"trials":11087,"activeCount":114},[],{"trials":11089,"activeCount":114},[],{"intervention":5569,"totalTrials":327,"cells":11091},{"EARLY_PHASE1":11092,"PHASE1":11094,"PHASE2":11096,"PHASE3":11106,"PHASE4":11108,"NA":11110},{"trials":11093,"activeCount":114},[],{"trials":11095,"activeCount":114},[],{"trials":11097,"activeCount":114},[11098,11102],{"nctId":5558,"briefTitle":5559,"status":230,"phases":11099,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":11100,"interventions":11101},[91],[5563,5564,5565,5566,3538,3540,3542,3543],[5568,5569,5570,5571,5572,5573],{"nctId":5575,"briefTitle":5576,"status":105,"phases":11103,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":11104,"interventions":11105},[91],[1839,5580,5581,5582,5583,5584,1853],[5586,3682,5587,5538,3550,5588],{"trials":11107,"activeCount":114},[],{"trials":11109,"activeCount":114},[],{"trials":11111,"activeCount":114},[],{"intervention":5572,"totalTrials":327,"cells":11113},{"EARLY_PHASE1":11114,"PHASE1":11116,"PHASE2":11118,"PHASE3":11128,"PHASE4":11130,"NA":11132},{"trials":11115,"activeCount":114},[],{"trials":11117,"activeCount":114},[],{"trials":11119,"activeCount":114},[11120,11124],{"nctId":5558,"briefTitle":5559,"status":230,"phases":11121,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":11122,"interventions":11123},[91],[5563,5564,5565,5566,3538,3540,3542,3543],[5568,5569,5570,5571,5572,5573],{"nctId":5575,"briefTitle":5576,"status":105,"phases":11125,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":11126,"interventions":11127},[91],[1839,5580,5581,5582,5583,5584,1853],[5586,3682,5587,5538,3550,5588],{"trials":11129,"activeCount":114},[],{"trials":11131,"activeCount":114},[],{"trials":11133,"activeCount":114},[],{"intervention":11135,"totalTrials":327,"cells":11136},"Tetrahydrobiopterin",{"EARLY_PHASE1":11137,"PHASE1":11146,"PHASE2":11148,"PHASE3":11158,"PHASE4":11160,"NA":11162},{"trials":11138,"activeCount":114},[11139],{"nctId":11140,"briefTitle":11141,"status":105,"phases":11142,"primaryCompletion":2966,"completion":2966,"start":11143,"enrollment":31,"conditions":11144,"interventions":11145},"NCT00208780","Effects of Tetrahydrobiopterin on Blood Pressure",[89],"2004-12",[6155],[11135,11135],{"trials":11147,"activeCount":114},[],{"trials":11149,"activeCount":114},[11150],{"nctId":11151,"briefTitle":11152,"status":105,"phases":11153,"primaryCompletion":3427,"completion":3427,"start":11154,"enrollment":8910,"conditions":11155,"interventions":11157},"NCT01356966","Exercise Intolerance in Renal Failure",[91],"2011-05",[11156],"Kidney Failure, Chronic",[11135],{"trials":11159,"activeCount":114},[],{"trials":11161,"activeCount":114},[],{"trials":11163,"activeCount":114},[],{"intervention":2916,"totalTrials":327,"cells":11165},{"EARLY_PHASE1":11166,"PHASE1":11168,"PHASE2":11174,"PHASE3":11180,"PHASE4":11182,"NA":11184},{"trials":11167,"activeCount":114},[],{"trials":11169,"activeCount":114},[11170],{"nctId":3874,"briefTitle":3875,"status":2022,"phases":11171,"primaryCompletion":2135,"completion":2135,"start":3877,"enrollment":114,"conditions":11172,"interventions":11173},[90],[2913],[3880,3057,2916,3881,3882],{"trials":11175,"activeCount":114},[11176],{"nctId":2907,"briefTitle":2908,"status":230,"phases":11177,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":11178,"interventions":11179},[91],[2913,2914],[2916,2917,2918,2474,2919,2883],{"trials":11181,"activeCount":114},[],{"trials":11183,"activeCount":114},[],{"trials":11185,"activeCount":114},[],{"intervention":2883,"totalTrials":327,"cells":11187},{"EARLY_PHASE1":11188,"PHASE1":11190,"PHASE2":11192,"PHASE3":11202,"PHASE4":11204,"NA":11206},{"trials":11189,"activeCount":114},[],{"trials":11191,"activeCount":114},[],{"trials":11193,"activeCount":114},[11194,11198],{"nctId":2907,"briefTitle":2908,"status":230,"phases":11195,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":11196,"interventions":11197},[91],[2913,2914],[2916,2917,2918,2474,2919,2883],{"nctId":2877,"briefTitle":2878,"status":230,"phases":11199,"primaryCompletion":2533,"completion":2533,"start":2880,"enrollment":28,"conditions":11200,"interventions":11201},[91],[30],[2883,2382,1980],{"trials":11203,"activeCount":114},[],{"trials":11205,"activeCount":114},[],{"trials":11207,"activeCount":114},[],{"intervention":280,"totalTrials":327,"cells":11209},{"EARLY_PHASE1":11210,"PHASE1":11212,"PHASE2":11214,"PHASE3":11228,"PHASE4":11230,"NA":11232},{"trials":11211,"activeCount":114},[],{"trials":11213,"activeCount":114},[],{"trials":11215,"activeCount":114},[11216,11224],{"nctId":11217,"briefTitle":11218,"status":230,"phases":11219,"completion":7613,"start":8504,"enrollment":327,"conditions":11220,"interventions":11223},"NCT00209014","Phase II Trial of Thalidomide in Refractory\u002FRelapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease",[91],[11221,11222],"B-Cell Lymphoma","Hodgkin's Disease",[280],{"nctId":271,"briefTitle":272,"status":230,"phases":11225,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":11226,"interventions":11227},[91],[198,278],[127,200,97,128,280],{"trials":11229,"activeCount":114},[],{"trials":11231,"activeCount":114},[],{"trials":11233,"activeCount":114},[],{"intervention":11235,"totalTrials":327,"cells":11236},"Hydromorphone",{"EARLY_PHASE1":11237,"PHASE1":11239,"PHASE2":11241,"PHASE3":11257,"PHASE4":11259,"NA":11261},{"trials":11238,"activeCount":114},[],{"trials":11240,"activeCount":114},[],{"trials":11242,"activeCount":114},[11243,11250],{"nctId":11244,"briefTitle":11245,"status":105,"phases":11246,"primaryCompletion":9723,"completion":8364,"start":3661,"enrollment":454,"conditions":11247,"interventions":11249},"NCT01598545","Hydromorphone and C-section",[91],[11248],"Postoperative Pain",[11235],{"nctId":11251,"briefTitle":11252,"status":105,"phases":11253,"primaryCompletion":3503,"completion":3503,"start":3466,"enrollment":162,"conditions":11254,"interventions":11256},"NCT01598506","Intrathecal Hydromorphone for Labor Analgesia",[91],[11255],"Labor Pain",[11235],{"trials":11258,"activeCount":114},[],{"trials":11260,"activeCount":114},[],{"trials":11262,"activeCount":114},[],{"intervention":542,"totalTrials":327,"cells":11264},{"EARLY_PHASE1":11265,"PHASE1":11267,"PHASE2":11269,"PHASE3":11284,"PHASE4":11286,"NA":11288},{"trials":11266,"activeCount":114},[],{"trials":11268,"activeCount":114},[],{"trials":11270,"activeCount":114},[11271,11280],{"nctId":11272,"briefTitle":11273,"status":105,"phases":11274,"primaryCompletion":9569,"completion":9569,"start":11275,"enrollment":4781,"conditions":11276,"interventions":11278},"NCT00590317","Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department",[91],"2005-03",[11277],"Nausea and Vomiting",[11279,542],"Prochlorperazine",{"nctId":533,"briefTitle":534,"status":230,"phases":11281,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":11282,"interventions":11283},[91],[540],[542,349],{"trials":11285,"activeCount":114},[],{"trials":11287,"activeCount":114},[],{"trials":11289,"activeCount":114},[],{"intervention":11291,"totalTrials":327,"cells":11292},"Fluciclovine F18",{"EARLY_PHASE1":11293,"PHASE1":11295,"PHASE2":11309,"PHASE3":11320,"PHASE4":11322,"NA":11324},{"trials":11294,"activeCount":114},[],{"trials":11296,"activeCount":114},[11297],{"nctId":11298,"briefTitle":11299,"status":105,"phases":11300,"primaryCompletion":11301,"completion":11302,"start":11303,"enrollment":454,"conditions":11304,"interventions":11307},"NCT04750473","Fluciclovine and PSMA PET\u002FCT for the Classification and Improved Staging of Invasive Lobular Breast Cancer",[90],"2023-03-21","2024-03-21","2021-07-16",[1839,11305,11306,1853],"Invasive Breast Lobular Carcinoma","Metastatic Breast Lobular Carcinoma",[11291,11308],"Gallium Ga 68 Gozetotide",{"trials":11310,"activeCount":114},[11311],{"nctId":11312,"briefTitle":11313,"status":2833,"phases":11314,"primaryCompletion":11315,"completion":11316,"start":11317,"enrollment":5514,"conditions":11318,"interventions":11319},"NCT03762759","Fluciclovine F18 or Ga68-PSMA PET\u002FCT to Enhance Prostate Cancer Outcomes",[91],"2025-05-31","2025-12-31","2019-05-10",[4444],[11291],{"trials":11321,"activeCount":114},[],{"trials":11323,"activeCount":114},[],{"trials":11325,"activeCount":114},[],{"intervention":1505,"totalTrials":327,"cells":11327},{"EARLY_PHASE1":11328,"PHASE1":11330,"PHASE2":11332,"PHASE3":11342,"PHASE4":11344,"NA":11346},{"trials":11329,"activeCount":114},[],{"trials":11331,"activeCount":114},[],{"trials":11333,"activeCount":114},[11334,11338],{"nctId":1494,"briefTitle":1495,"status":105,"phases":11335,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":11336,"interventions":11337},[90,91],[1501,1502],[127,1504,1505,154,1506,565],{"nctId":2530,"briefTitle":2531,"status":230,"phases":11339,"primaryCompletion":2533,"completion":2533,"start":321,"enrollment":2277,"conditions":11340,"interventions":11341},[91],[254,30,2535,255,2536,2537],[2539,1505,154,2540],{"trials":11343,"activeCount":114},[],{"trials":11345,"activeCount":114},[],{"trials":11347,"activeCount":114},[],{"intervention":4127,"totalTrials":327,"cells":11349},{"EARLY_PHASE1":11350,"PHASE1":11352,"PHASE2":11354,"PHASE3":11369,"PHASE4":11371,"NA":11373},{"trials":11351,"activeCount":114},[],{"trials":11353,"activeCount":114},[],{"trials":11355,"activeCount":114},[11356,11365],{"nctId":11357,"briefTitle":11358,"status":2022,"phases":11359,"primaryCompletion":7344,"completion":7344,"enrollment":114,"conditions":11360,"interventions":11363},"NCT00681148","Botulinum Toxin Injection With Prostate Brachytherapy",[91],[3651,11361,11362],"Lower Urinary Tract Symptoms","Radioactive Seed Implantation",[11364,4127],"Botox",{"nctId":4113,"briefTitle":4114,"status":230,"phases":11366,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":11367,"interventions":11368},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":11370,"activeCount":114},[],{"trials":11372,"activeCount":114},[],{"trials":11374,"activeCount":114},[],{"intervention":3880,"totalTrials":327,"cells":11376},{"EARLY_PHASE1":11377,"PHASE1":11379,"PHASE2":11385,"PHASE3":11398,"PHASE4":11400,"NA":11402},{"trials":11378,"activeCount":114},[],{"trials":11380,"activeCount":114},[11381],{"nctId":3874,"briefTitle":3875,"status":2022,"phases":11382,"primaryCompletion":2135,"completion":2135,"start":3877,"enrollment":114,"conditions":11383,"interventions":11384},[90],[2913],[3880,3057,2916,3881,3882],{"trials":11386,"activeCount":114},[11387],{"nctId":11388,"briefTitle":11389,"status":230,"phases":11390,"primaryCompletion":11391,"completion":11391,"start":4547,"enrollment":2277,"conditions":11392,"interventions":11395},"NCT02709083","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",[91],"2018-07",[11393,11394,10974],"Chronic Myelogenous Leukemia","Chronic Myeloid Leukemia",[3880,11396,11397],"Imatinib Mesylate","Nilotinib",{"trials":11399,"activeCount":114},[],{"trials":11401,"activeCount":114},[],{"trials":11403,"activeCount":114},[],{"intervention":600,"totalTrials":327,"cells":11405},{"EARLY_PHASE1":11406,"PHASE1":11408,"PHASE2":11410,"PHASE3":11420,"PHASE4":11422,"NA":11424},{"trials":11407,"activeCount":114},[],{"trials":11409,"activeCount":114},[],{"trials":11411,"activeCount":114},[11412,11416],{"nctId":591,"briefTitle":592,"status":105,"phases":11413,"primaryCompletion":487,"completion":487,"start":594,"enrollment":595,"conditions":11414,"interventions":11415},[91],[597],[599,310,565,600,601],{"nctId":2680,"briefTitle":2681,"status":230,"phases":11417,"primaryCompletion":2683,"completion":2683,"start":2684,"enrollment":292,"conditions":11418,"interventions":11419},[91],[2686,2687,2688,2689,1502,2690,2691,2692,2693,2694,2695,2696],[2698,127,600],{"trials":11421,"activeCount":114},[],{"trials":11423,"activeCount":114},[],{"trials":11425,"activeCount":114},[],{"intervention":11427,"totalTrials":327,"cells":11428},"Plerixafor",{"EARLY_PHASE1":11429,"PHASE1":11431,"PHASE2":11433,"PHASE3":11450,"PHASE4":11452,"NA":11454},{"trials":11430,"activeCount":114},[],{"trials":11432,"activeCount":114},[],{"trials":11434,"activeCount":114},[11435,11442],{"nctId":11436,"briefTitle":11437,"status":105,"phases":11438,"primaryCompletion":7806,"start":2880,"enrollment":288,"conditions":11439,"interventions":11441},"NCT01149863","Alteration in Timing of Plerixafor Administration",[91],[11440],"Autologous Transplantation",[11427],{"nctId":11443,"briefTitle":11444,"status":105,"phases":11445,"primaryCompletion":5939,"completion":3503,"start":10281,"enrollment":5818,"conditions":11446,"interventions":11449},"NCT01095757","Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection",[91],[11447,11448],"Myeloma","Lymphoma",[11427],{"trials":11451,"activeCount":114},[],{"trials":11453,"activeCount":114},[],{"trials":11455,"activeCount":114},[],{"intervention":3682,"totalTrials":327,"cells":11457},{"EARLY_PHASE1":11458,"PHASE1":11460,"PHASE2":11462,"PHASE3":11472,"PHASE4":11474,"NA":11476},{"trials":11459,"activeCount":114},[],{"trials":11461,"activeCount":114},[],{"trials":11463,"activeCount":114},[11464,11468],{"nctId":3676,"briefTitle":3677,"status":105,"phases":11465,"primaryCompletion":3679,"completion":3679,"start":3670,"enrollment":595,"conditions":11466,"interventions":11467},[91],[30],[3682,2039,3683],{"nctId":5575,"briefTitle":5576,"status":105,"phases":11469,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":11470,"interventions":11471},[91],[1839,5580,5581,5582,5583,5584,1853],[5586,3682,5587,5538,3550,5588],{"trials":11473,"activeCount":114},[],{"trials":11475,"activeCount":114},[],{"trials":11477,"activeCount":114},[],{"intervention":11479,"totalTrials":327,"cells":11480},"Duvelisib",{"EARLY_PHASE1":11481,"PHASE1":11495,"PHASE2":11497,"PHASE3":11506,"PHASE4":11508,"NA":11510},{"trials":11482,"activeCount":114},[11483],{"nctId":11484,"briefTitle":11485,"status":105,"phases":11486,"primaryCompletion":11487,"completion":11488,"start":11489,"enrollment":470,"conditions":11490,"interventions":11493},"NCT04890236","Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study",[89],"2024-03-20","2024-09-04","2022-01-13",[11491,11492],"Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[11479,11494],"Tisagenlecleucel",{"trials":11496,"activeCount":114},[],{"trials":11498,"activeCount":114},[11499],{"nctId":11500,"briefTitle":11501,"status":105,"phases":11502,"primaryCompletion":1768,"completion":1768,"start":11503,"enrollment":1770,"conditions":11504,"interventions":11505},"NCT04487886","Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)",[91],"2020-11-18",[708],[11479],{"trials":11507,"activeCount":114},[],{"trials":11509,"activeCount":114},[],{"trials":11511,"activeCount":114},[],{"intervention":11513,"totalTrials":186,"cells":11514},"Kuvan",{"EARLY_PHASE1":11515,"PHASE1":11517,"PHASE2":11519,"PHASE3":11529,"PHASE4":11531,"NA":11533},{"trials":11516,"activeCount":114},[],{"trials":11518,"activeCount":114},[],{"trials":11520,"activeCount":114},[11521],{"nctId":11522,"briefTitle":11523,"status":230,"phases":11524,"primaryCompletion":11525,"completion":11525,"start":434,"enrollment":870,"conditions":11526,"interventions":11528},"NCT01395394","Phenylketonuria, Oxidative Stress, and BH4",[91],"2013-06",[11527],"Phenylketonuria",[11513],{"trials":11530,"activeCount":114},[],{"trials":11532,"activeCount":114},[],{"trials":11534,"activeCount":114},[],{"intervention":11536,"totalTrials":186,"cells":11537},"Intranasal ketamine",{"EARLY_PHASE1":11538,"PHASE1":11540,"PHASE2":11542,"PHASE3":11552,"PHASE4":11554,"NA":11556},{"trials":11539,"activeCount":114},[],{"trials":11541,"activeCount":114},[],{"trials":11543,"activeCount":114},[11544],{"nctId":11545,"briefTitle":11546,"status":105,"phases":11547,"primaryCompletion":11548,"completion":11548,"start":11549,"enrollment":2075,"conditions":11550,"interventions":11551},"NCT03146806","Intranasal (NAS) Ketamine for Cancer Pain",[90,91],"2020-04-22","2017-07-25",[2332,1358],[11536],{"trials":11553,"activeCount":114},[],{"trials":11555,"activeCount":114},[],{"trials":11557,"activeCount":114},[],{"intervention":11559,"totalTrials":186,"cells":11560},"VSL#3",{"EARLY_PHASE1":11561,"PHASE1":11563,"PHASE2":11565,"PHASE3":11577,"PHASE4":11579,"NA":11581},{"trials":11562,"activeCount":114},[],{"trials":11564,"activeCount":114},[],{"trials":11566,"activeCount":114},[11567],{"nctId":11568,"briefTitle":11569,"status":230,"phases":11570,"primaryCompletion":11571,"completion":11571,"start":11572,"enrollment":11573,"conditions":11574,"interventions":11576},"NCT03165747","Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women",[91],"2019-03-23","2017-10-01",35,[11575],"Menopausal Osteoporosis",[11559],{"trials":11578,"activeCount":114},[],{"trials":11580,"activeCount":114},[],{"trials":11582,"activeCount":114},[],{"intervention":11584,"totalTrials":186,"cells":11585},"Gemcabene",{"EARLY_PHASE1":11586,"PHASE1":11588,"PHASE2":11590,"PHASE3":11601,"PHASE4":11603,"NA":11605},{"trials":11587,"activeCount":114},[],{"trials":11589,"activeCount":114},[],{"trials":11591,"activeCount":114},[11592],{"nctId":11593,"briefTitle":11594,"status":230,"phases":11595,"primaryCompletion":11596,"completion":11596,"start":11597,"enrollment":538,"conditions":11598,"interventions":11600},"NCT03436420","Gemcabene for the Treatment of Pediatric NAFLD",[91],"2019-08-27","2018-03-29",[11599],"Non-Alcoholic Fatty Liver Disease",[11584],{"trials":11602,"activeCount":114},[],{"trials":11604,"activeCount":114},[],{"trials":11606,"activeCount":114},[],{"intervention":2358,"totalTrials":186,"cells":11608},{"EARLY_PHASE1":11609,"PHASE1":11611,"PHASE2":11613,"PHASE3":11619,"PHASE4":11621,"NA":11623},{"trials":11610,"activeCount":114},[],{"trials":11612,"activeCount":114},[],{"trials":11614,"activeCount":114},[11615],{"nctId":2349,"briefTitle":2350,"status":105,"phases":11616,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2075,"conditions":11617,"interventions":11618},[91],[2355,1773,2356],[1982,2358,1979,2359],{"trials":11620,"activeCount":114},[],{"trials":11622,"activeCount":114},[],{"trials":11624,"activeCount":114},[],{"intervention":2359,"totalTrials":186,"cells":11626},{"EARLY_PHASE1":11627,"PHASE1":11629,"PHASE2":11631,"PHASE3":11637,"PHASE4":11639,"NA":11641},{"trials":11628,"activeCount":114},[],{"trials":11630,"activeCount":114},[],{"trials":11632,"activeCount":114},[11633],{"nctId":2349,"briefTitle":2350,"status":105,"phases":11634,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":2075,"conditions":11635,"interventions":11636},[91],[2355,1773,2356],[1982,2358,1979,2359],{"trials":11638,"activeCount":114},[],{"trials":11640,"activeCount":114},[],{"trials":11642,"activeCount":114},[],{"intervention":11644,"totalTrials":186,"cells":11645},"Gemcitabine\u002FBevacizumab",{"EARLY_PHASE1":11646,"PHASE1":11648,"PHASE2":11650,"PHASE3":11660,"PHASE4":11662,"NA":11664},{"trials":11647,"activeCount":114},[],{"trials":11649,"activeCount":114},[],{"trials":11651,"activeCount":114},[11652],{"nctId":11653,"briefTitle":11654,"status":2022,"phases":11655,"primaryCompletion":2674,"completion":2674,"start":3733,"enrollment":114,"conditions":11656,"interventions":11659},"NCT01131039","Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer",[91],[11657,3548,11658],"Fallopian Tube Neoplasms","Primary Peritoneal",[11644],{"trials":11661,"activeCount":114},[],{"trials":11663,"activeCount":114},[],{"trials":11665,"activeCount":114},[],{"intervention":5571,"totalTrials":186,"cells":11667},{"EARLY_PHASE1":11668,"PHASE1":11670,"PHASE2":11672,"PHASE3":11678,"PHASE4":11680,"NA":11682},{"trials":11669,"activeCount":114},[],{"trials":11671,"activeCount":114},[],{"trials":11673,"activeCount":114},[11674],{"nctId":5558,"briefTitle":5559,"status":230,"phases":11675,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":11676,"interventions":11677},[91],[5563,5564,5565,5566,3538,3540,3542,3543],[5568,5569,5570,5571,5572,5573],{"trials":11679,"activeCount":114},[],{"trials":11681,"activeCount":114},[],{"trials":11683,"activeCount":114},[],{"intervention":5573,"totalTrials":186,"cells":11685},{"EARLY_PHASE1":11686,"PHASE1":11688,"PHASE2":11690,"PHASE3":11696,"PHASE4":11698,"NA":11700},{"trials":11687,"activeCount":114},[],{"trials":11689,"activeCount":114},[],{"trials":11691,"activeCount":114},[11692],{"nctId":5558,"briefTitle":5559,"status":230,"phases":11693,"primaryCompletion":5377,"completion":5377,"start":5561,"enrollment":362,"conditions":11694,"interventions":11695},[91],[5563,5564,5565,5566,3538,3540,3542,3543],[5568,5569,5570,5571,5572,5573],{"trials":11697,"activeCount":114},[],{"trials":11699,"activeCount":114},[],{"trials":11701,"activeCount":114},[],{"intervention":11703,"totalTrials":186,"cells":11704},"Preoperative Ketorolac",{"EARLY_PHASE1":11705,"PHASE1":11707,"PHASE2":11709,"PHASE3":11720,"PHASE4":11722,"NA":11724},{"trials":11706,"activeCount":114},[],{"trials":11708,"activeCount":114},[],{"trials":11710,"activeCount":114},[11711],{"nctId":11712,"briefTitle":11713,"status":230,"phases":11714,"primaryCompletion":11715,"completion":11715,"start":11716,"enrollment":265,"conditions":11717,"interventions":11719},"NCT04495894","Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma",[91],"2024-02-01","2020-08-24",[11718,2485],"Non-small Cell Lung Cancer",[11703],{"trials":11721,"activeCount":114},[],{"trials":11723,"activeCount":114},[],{"trials":11725,"activeCount":114},[],{"intervention":11727,"totalTrials":186,"cells":11728},"Pre operativeTrastuzumab",{"EARLY_PHASE1":11729,"PHASE1":11731,"PHASE2":11733,"PHASE3":11743,"PHASE4":11745,"NA":11747},{"trials":11730,"activeCount":114},[],{"trials":11732,"activeCount":114},[],{"trials":11734,"activeCount":114},[11735],{"nctId":11736,"briefTitle":11737,"status":105,"phases":11738,"primaryCompletion":6389,"completion":6389,"start":1320,"enrollment":9523,"conditions":11739,"interventions":11740},"NCT00503750","Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)",[91],[30],[11727,11741,11742],"ABI-007","Vinorelbine",{"trials":11744,"activeCount":114},[],{"trials":11746,"activeCount":114},[],{"trials":11748,"activeCount":114},[],{"intervention":11741,"totalTrials":186,"cells":11750},{"EARLY_PHASE1":11751,"PHASE1":11753,"PHASE2":11755,"PHASE3":11761,"PHASE4":11763,"NA":11765},{"trials":11752,"activeCount":114},[],{"trials":11754,"activeCount":114},[],{"trials":11756,"activeCount":114},[11757],{"nctId":11736,"briefTitle":11737,"status":105,"phases":11758,"primaryCompletion":6389,"completion":6389,"start":1320,"enrollment":9523,"conditions":11759,"interventions":11760},[91],[30],[11727,11741,11742],{"trials":11762,"activeCount":114},[],{"trials":11764,"activeCount":114},[],{"trials":11766,"activeCount":114},[],{"intervention":11742,"totalTrials":186,"cells":11768},{"EARLY_PHASE1":11769,"PHASE1":11771,"PHASE2":11773,"PHASE3":11779,"PHASE4":11781,"NA":11783},{"trials":11770,"activeCount":114},[],{"trials":11772,"activeCount":114},[],{"trials":11774,"activeCount":114},[11775],{"nctId":11736,"briefTitle":11737,"status":105,"phases":11776,"primaryCompletion":6389,"completion":6389,"start":1320,"enrollment":9523,"conditions":11777,"interventions":11778},[91],[30],[11727,11741,11742],{"trials":11780,"activeCount":114},[],{"trials":11782,"activeCount":114},[],{"trials":11784,"activeCount":114},[],{"intervention":11786,"totalTrials":186,"cells":11787},"Granulocyte-Macrophage Stimulating Factor",{"EARLY_PHASE1":11788,"PHASE1":11790,"PHASE2":11792,"PHASE3":11802,"PHASE4":11804,"NA":11806},{"trials":11789,"activeCount":114},[],{"trials":11791,"activeCount":114},[],{"trials":11793,"activeCount":114},[11794],{"nctId":11795,"briefTitle":11796,"status":105,"phases":11797,"primaryCompletion":3501,"start":3577,"enrollment":11798,"conditions":11799,"interventions":11801},"NCT01041417","Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease",[91],159,[11800],"Peripheral Arterial Disease",[11786],{"trials":11803,"activeCount":114},[],{"trials":11805,"activeCount":114},[],{"trials":11807,"activeCount":114},[],{"intervention":11809,"totalTrials":186,"cells":11810},"aminocamptothecin colloidal dispersion",{"EARLY_PHASE1":11811,"PHASE1":11813,"PHASE2":11815,"PHASE3":11825,"PHASE4":11827,"NA":11829},{"trials":11812,"activeCount":114},[],{"trials":11814,"activeCount":114},[],{"trials":11816,"activeCount":114},[11817],{"nctId":11818,"briefTitle":11819,"status":105,"phases":11820,"completion":11821,"start":11822,"conditions":11823,"interventions":11824},"NCT00003551","Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer",[91],"2004-09","1998-08",[1965],[11809],{"trials":11826,"activeCount":114},[],{"trials":11828,"activeCount":114},[],{"trials":11830,"activeCount":114},[],{"intervention":6393,"totalTrials":186,"cells":11832},{"EARLY_PHASE1":11833,"PHASE1":11835,"PHASE2":11837,"PHASE3":11843,"PHASE4":11845,"NA":11847},{"trials":11834,"activeCount":114},[],{"trials":11836,"activeCount":114},[],{"trials":11838,"activeCount":114},[11839],{"nctId":6385,"briefTitle":6386,"status":230,"phases":11840,"primaryCompletion":6388,"completion":6388,"start":6389,"enrollment":870,"conditions":11841,"interventions":11842},[91],[6391],[6393,574,6394,6395,6396],{"trials":11844,"activeCount":114},[],{"trials":11846,"activeCount":114},[],{"trials":11848,"activeCount":114},[],{"intervention":6394,"totalTrials":186,"cells":11850},{"EARLY_PHASE1":11851,"PHASE1":11853,"PHASE2":11855,"PHASE3":11861,"PHASE4":11863,"NA":11865},{"trials":11852,"activeCount":114},[],{"trials":11854,"activeCount":114},[],{"trials":11856,"activeCount":114},[11857],{"nctId":6385,"briefTitle":6386,"status":230,"phases":11858,"primaryCompletion":6388,"completion":6388,"start":6389,"enrollment":870,"conditions":11859,"interventions":11860},[91],[6391],[6393,574,6394,6395,6396],{"trials":11862,"activeCount":114},[],{"trials":11864,"activeCount":114},[],{"trials":11866,"activeCount":114},[],{"intervention":6395,"totalTrials":186,"cells":11868},{"EARLY_PHASE1":11869,"PHASE1":11871,"PHASE2":11873,"PHASE3":11879,"PHASE4":11881,"NA":11883},{"trials":11870,"activeCount":114},[],{"trials":11872,"activeCount":114},[],{"trials":11874,"activeCount":114},[11875],{"nctId":6385,"briefTitle":6386,"status":230,"phases":11876,"primaryCompletion":6388,"completion":6388,"start":6389,"enrollment":870,"conditions":11877,"interventions":11878},[91],[6391],[6393,574,6394,6395,6396],{"trials":11880,"activeCount":114},[],{"trials":11882,"activeCount":114},[],{"trials":11884,"activeCount":114},[],{"intervention":6396,"totalTrials":186,"cells":11886},{"EARLY_PHASE1":11887,"PHASE1":11889,"PHASE2":11891,"PHASE3":11897,"PHASE4":11899,"NA":11901},{"trials":11888,"activeCount":114},[],{"trials":11890,"activeCount":114},[],{"trials":11892,"activeCount":114},[11893],{"nctId":6385,"briefTitle":6386,"status":230,"phases":11894,"primaryCompletion":6388,"completion":6388,"start":6389,"enrollment":870,"conditions":11895,"interventions":11896},[91],[6391],[6393,574,6394,6395,6396],{"trials":11898,"activeCount":114},[],{"trials":11900,"activeCount":114},[],{"trials":11902,"activeCount":114},[],{"intervention":11904,"totalTrials":186,"cells":11905},"Voxelotor",{"EARLY_PHASE1":11906,"PHASE1":11908,"PHASE2":11910,"PHASE3":11921,"PHASE4":11923,"NA":11925},{"trials":11907,"activeCount":114},[],{"trials":11909,"activeCount":114},[],{"trials":11911,"activeCount":114},[11912],{"nctId":11913,"briefTitle":11914,"status":230,"phases":11915,"primaryCompletion":11916,"completion":11916,"start":11917,"enrollment":162,"conditions":11918,"interventions":11920},"NCT05018728","The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia",[91],"2024-10-22","2022-03-28",[11919],"Sickle Cell Anemia in Children",[11904],{"trials":11922,"activeCount":114},[],{"trials":11924,"activeCount":114},[],{"trials":11926,"activeCount":114},[],{"intervention":11928,"totalTrials":186,"cells":11929},"Pravastatin",{"EARLY_PHASE1":11930,"PHASE1":11932,"PHASE2":11934,"PHASE3":11945,"PHASE4":11947,"NA":11949},{"trials":11931,"activeCount":114},[],{"trials":11933,"activeCount":114},[],{"trials":11935,"activeCount":114},[11936],{"nctId":11937,"briefTitle":11938,"status":105,"phases":11939,"primaryCompletion":11940,"completion":252,"start":11821,"enrollment":1153,"conditions":11941,"interventions":11944},"NCT00166036","Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells",[91],"2008-03",[510,11942,11943],"Metabolic Syndrome X","Hypercholesterolemia",[678,11928],{"trials":11946,"activeCount":114},[],{"trials":11948,"activeCount":114},[],{"trials":11950,"activeCount":114},[],{"intervention":2735,"totalTrials":186,"cells":11952},{"EARLY_PHASE1":11953,"PHASE1":11955,"PHASE2":11957,"PHASE3":11963,"PHASE4":11965,"NA":11967},{"trials":11954,"activeCount":114},[],{"trials":11956,"activeCount":114},[],{"trials":11958,"activeCount":114},[11959],{"nctId":2726,"briefTitle":2727,"status":2022,"phases":11960,"primaryCompletion":2242,"completion":2242,"start":2729,"enrollment":114,"conditions":11961,"interventions":11962},[91],[2731,2732,2733,2392,2393],[2382,2735,2736,1979],{"trials":11964,"activeCount":114},[],{"trials":11966,"activeCount":114},[],{"trials":11968,"activeCount":114},[],{"intervention":2736,"totalTrials":186,"cells":11970},{"EARLY_PHASE1":11971,"PHASE1":11973,"PHASE2":11975,"PHASE3":11981,"PHASE4":11983,"NA":11985},{"trials":11972,"activeCount":114},[],{"trials":11974,"activeCount":114},[],{"trials":11976,"activeCount":114},[11977],{"nctId":2726,"briefTitle":2727,"status":2022,"phases":11978,"primaryCompletion":2242,"completion":2242,"start":2729,"enrollment":114,"conditions":11979,"interventions":11980},[91],[2731,2732,2733,2392,2393],[2382,2735,2736,1979],{"trials":11982,"activeCount":114},[],{"trials":11984,"activeCount":114},[],{"trials":11986,"activeCount":114},[],{"intervention":11988,"totalTrials":186,"cells":11989},"GSK561679",{"EARLY_PHASE1":11990,"PHASE1":11992,"PHASE2":11994,"PHASE3":12002,"PHASE4":12004,"NA":12006},{"trials":11991,"activeCount":114},[],{"trials":11993,"activeCount":114},[],{"trials":11995,"activeCount":114},[11996],{"nctId":11997,"briefTitle":11998,"status":105,"phases":11999,"primaryCompletion":161,"completion":161,"start":5970,"enrollment":7166,"conditions":12000,"interventions":12001},"NCT01018992","Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder",[91],[3453],[11988],{"trials":12003,"activeCount":114},[],{"trials":12005,"activeCount":114},[],{"trials":12007,"activeCount":114},[],{"intervention":2917,"totalTrials":186,"cells":12009},{"EARLY_PHASE1":12010,"PHASE1":12012,"PHASE2":12014,"PHASE3":12020,"PHASE4":12022,"NA":12024},{"trials":12011,"activeCount":114},[],{"trials":12013,"activeCount":114},[],{"trials":12015,"activeCount":114},[12016],{"nctId":2907,"briefTitle":2908,"status":230,"phases":12017,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":12018,"interventions":12019},[91],[2913,2914],[2916,2917,2918,2474,2919,2883],{"trials":12021,"activeCount":114},[],{"trials":12023,"activeCount":114},[],{"trials":12025,"activeCount":114},[],{"intervention":2918,"totalTrials":186,"cells":12027},{"EARLY_PHASE1":12028,"PHASE1":12030,"PHASE2":12032,"PHASE3":12038,"PHASE4":12040,"NA":12042},{"trials":12029,"activeCount":114},[],{"trials":12031,"activeCount":114},[],{"trials":12033,"activeCount":114},[12034],{"nctId":2907,"briefTitle":2908,"status":230,"phases":12035,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":12036,"interventions":12037},[91],[2913,2914],[2916,2917,2918,2474,2919,2883],{"trials":12039,"activeCount":114},[],{"trials":12041,"activeCount":114},[],{"trials":12043,"activeCount":114},[],{"intervention":2919,"totalTrials":186,"cells":12045},{"EARLY_PHASE1":12046,"PHASE1":12048,"PHASE2":12050,"PHASE3":12056,"PHASE4":12058,"NA":12060},{"trials":12047,"activeCount":114},[],{"trials":12049,"activeCount":114},[],{"trials":12051,"activeCount":114},[12052],{"nctId":2907,"briefTitle":2908,"status":230,"phases":12053,"primaryCompletion":2910,"completion":2910,"start":2911,"enrollment":182,"conditions":12054,"interventions":12055},[91],[2913,2914],[2916,2917,2918,2474,2919,2883],{"trials":12057,"activeCount":114},[],{"trials":12059,"activeCount":114},[],{"trials":12061,"activeCount":114},[],{"intervention":12063,"totalTrials":186,"cells":12064},"Vaxchora",{"EARLY_PHASE1":12065,"PHASE1":12067,"PHASE2":12069,"PHASE3":12081,"PHASE4":12083,"NA":12085},{"trials":12066,"activeCount":114},[],{"trials":12068,"activeCount":114},[],{"trials":12070,"activeCount":114},[12071],{"nctId":12072,"briefTitle":12073,"status":105,"phases":12074,"primaryCompletion":12075,"completion":12076,"start":12077,"enrollment":288,"conditions":12078,"interventions":12080},"NCT03251495","Immunologic Responses to a Live Attenuated Oral Cholera Vaccine",[91],"2024-12-10","2025-11-06","2017-08-29",[12079],"Cholera",[12063],{"trials":12082,"activeCount":114},[],{"trials":12084,"activeCount":114},[],{"trials":12086,"activeCount":114},[],{"intervention":12088,"totalTrials":186,"cells":12089},"Tyrosine Kinase Inhibitor",{"EARLY_PHASE1":12090,"PHASE1":12092,"PHASE2":12094,"PHASE3":12105,"PHASE4":12107,"NA":12109},{"trials":12091,"activeCount":114},[],{"trials":12093,"activeCount":114},[],{"trials":12095,"activeCount":114},[12096],{"nctId":12097,"briefTitle":12098,"status":230,"phases":12099,"primaryCompletion":11391,"completion":11391,"start":12100,"enrollment":2448,"conditions":12101,"interventions":12103},"NCT02730195","Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia",[91],"2016-05",[2688,12102],"Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",[12104,12088],"Pioglitazone",{"trials":12106,"activeCount":114},[],{"trials":12108,"activeCount":114},[],{"trials":12110,"activeCount":114},[],{"intervention":12112,"totalTrials":186,"cells":12113},"Mogamulizumab",{"EARLY_PHASE1":12114,"PHASE1":12116,"PHASE2":12118,"PHASE3":12130,"PHASE4":12132,"NA":12134},{"trials":12115,"activeCount":114},[],{"trials":12117,"activeCount":114},[],{"trials":12119,"activeCount":114},[12120],{"nctId":12121,"briefTitle":12122,"status":230,"phases":12123,"primaryCompletion":747,"completion":747,"start":12124,"enrollment":292,"conditions":12125,"interventions":12129},"NCT04676087","Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides",[90,91],"2021-04-21",[12126,12127,12128],"Mycosis Fungoides","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Sezary Syndrome",[12112],{"trials":12131,"activeCount":114},[],{"trials":12133,"activeCount":114},[],{"trials":12135,"activeCount":114},[],{"intervention":10976,"totalTrials":186,"cells":12137},{"EARLY_PHASE1":12138,"PHASE1":12140,"PHASE2":12142,"PHASE3":12148,"PHASE4":12150,"NA":12152},{"trials":12139,"activeCount":114},[],{"trials":12141,"activeCount":114},[],{"trials":12143,"activeCount":114},[12144],{"nctId":10970,"briefTitle":10971,"status":105,"phases":12145,"primaryCompletion":1555,"completion":1555,"start":6861,"enrollment":1754,"conditions":12146,"interventions":12147},[91],[10974],[10961,10976],{"trials":12149,"activeCount":114},[],{"trials":12151,"activeCount":114},[],{"trials":12153,"activeCount":114},[],{"intervention":10757,"totalTrials":186,"cells":12155},{"EARLY_PHASE1":12156,"PHASE1":12158,"PHASE2":12160,"PHASE3":12166,"PHASE4":12168,"NA":12170},{"trials":12157,"activeCount":114},[],{"trials":12159,"activeCount":114},[],{"trials":12161,"activeCount":114},[12162],{"nctId":10751,"briefTitle":10752,"status":105,"phases":12163,"primaryCompletion":2683,"completion":2683,"start":10754,"enrollment":208,"conditions":12164,"interventions":12165},[91],[30],[2472,10757],{"trials":12167,"activeCount":114},[],{"trials":12169,"activeCount":114},[],{"trials":12171,"activeCount":114},[],{"intervention":12173,"totalTrials":186,"cells":12174},"Pegylated interferon alpha-2b",{"EARLY_PHASE1":12175,"PHASE1":12177,"PHASE2":12179,"PHASE3":12190,"PHASE4":12192,"NA":12194},{"trials":12176,"activeCount":114},[],{"trials":12178,"activeCount":114},[],{"trials":12180,"activeCount":114},[12181],{"nctId":12182,"briefTitle":12183,"status":105,"phases":12184,"primaryCompletion":12185,"completion":12185,"start":3426,"enrollment":2448,"conditions":12186,"interventions":12189},"NCT02343224","Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas",[91],"2020-11-11",[12187,12188],"Juvenile Pilocytic Astrocytomas","Optic Pathway Gliomas",[12173],{"trials":12191,"activeCount":114},[],{"trials":12193,"activeCount":114},[],{"trials":12195,"activeCount":114},[],{"intervention":12197,"totalTrials":186,"cells":12198},"Triamcinolone Acetonide",{"EARLY_PHASE1":12199,"PHASE1":12201,"PHASE2":12203,"PHASE3":12215,"PHASE4":12217,"NA":12219},{"trials":12200,"activeCount":114},[],{"trials":12202,"activeCount":114},[],{"trials":12204,"activeCount":114},[12205],{"nctId":12206,"briefTitle":12207,"status":105,"phases":12208,"primaryCompletion":12209,"completion":12210,"start":12211,"enrollment":265,"conditions":12212,"interventions":12214},"NCT04002362","Symptom Clusters in Children With Exacerbation-prone Asthma",[91],"2025-01-16","2025-12-24","2019-11-13",[12213],"Asthma in Children",[12197],{"trials":12216,"activeCount":114},[],{"trials":12218,"activeCount":114},[],{"trials":12220,"activeCount":114},[],{"intervention":12222,"totalTrials":186,"cells":12223},"chemotherapy",{"EARLY_PHASE1":12224,"PHASE1":12226,"PHASE2":12228,"PHASE3":12240,"PHASE4":12242,"NA":12244},{"trials":12225,"activeCount":114},[],{"trials":12227,"activeCount":114},[],{"trials":12229,"activeCount":114},[12230],{"nctId":12231,"briefTitle":12232,"status":105,"phases":12233,"completion":12234,"start":12235,"conditions":12236,"interventions":12238},"NCT00002639","Suramin in Treating Patients With Recurrent Primary Brain Tumors",[91],"2004-05","1995-07",[12237],"Brain and Central Nervous System Tumors",[12222,12239],"suramin",{"trials":12241,"activeCount":114},[],{"trials":12243,"activeCount":114},[],{"trials":12245,"activeCount":114},[],{"intervention":12239,"totalTrials":186,"cells":12247},{"EARLY_PHASE1":12248,"PHASE1":12250,"PHASE2":12252,"PHASE3":12258,"PHASE4":12260,"NA":12262},{"trials":12249,"activeCount":114},[],{"trials":12251,"activeCount":114},[],{"trials":12253,"activeCount":114},[12254],{"nctId":12231,"briefTitle":12232,"status":105,"phases":12255,"completion":12234,"start":12235,"conditions":12256,"interventions":12257},[91],[12237],[12222,12239],{"trials":12259,"activeCount":114},[],{"trials":12261,"activeCount":114},[],{"trials":12263,"activeCount":114},[],{"intervention":12265,"totalTrials":186,"cells":12266},"Storage-aged red blood cells (saRBCs) units",{"EARLY_PHASE1":12267,"PHASE1":12269,"PHASE2":12271,"PHASE3":12282,"PHASE4":12284,"NA":12286},{"trials":12268,"activeCount":114},[],{"trials":12270,"activeCount":114},[],{"trials":12272,"activeCount":114},[12273],{"nctId":12274,"briefTitle":12275,"status":105,"phases":12276,"primaryCompletion":12277,"completion":594,"start":252,"enrollment":3053,"conditions":12278,"interventions":12280},"NCT02280655","Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)",[91],"2012-11",[12279],"Cardiovascular Diseases",[12265,12281],"Fresh red blood cells units",{"trials":12283,"activeCount":114},[],{"trials":12285,"activeCount":114},[],{"trials":12287,"activeCount":114},[],{"intervention":12281,"totalTrials":186,"cells":12289},{"EARLY_PHASE1":12290,"PHASE1":12292,"PHASE2":12294,"PHASE3":12300,"PHASE4":12302,"NA":12304},{"trials":12291,"activeCount":114},[],{"trials":12293,"activeCount":114},[],{"trials":12295,"activeCount":114},[12296],{"nctId":12274,"briefTitle":12275,"status":105,"phases":12297,"primaryCompletion":12277,"completion":594,"start":252,"enrollment":3053,"conditions":12298,"interventions":12299},[91],[12279],[12265,12281],{"trials":12301,"activeCount":114},[],{"trials":12303,"activeCount":114},[],{"trials":12305,"activeCount":114},[],{"intervention":12307,"totalTrials":186,"cells":12308},"dipyridamole",{"EARLY_PHASE1":12309,"PHASE1":12311,"PHASE2":12313,"PHASE3":12328,"PHASE4":12330,"NA":12332},{"trials":12310,"activeCount":114},[],{"trials":12312,"activeCount":114},[],{"trials":12314,"activeCount":114},[12315],{"nctId":12316,"briefTitle":12317,"status":105,"phases":12318,"primaryCompletion":12319,"completion":12319,"start":12320,"conditions":12321,"interventions":12326},"NCT00000527","Recurrent Carotid Stenosis",[91],"1998-11","1986-08",[12279,12322,12323,12324,12325],"Carotid Stenosis","Cerebrovascular Disorders","Heart Diseases","Vascular Diseases",[12327,12307],"aspirin",{"trials":12329,"activeCount":114},[],{"trials":12331,"activeCount":114},[],{"trials":12333,"activeCount":114},[],{"intervention":12335,"totalTrials":186,"cells":12336},"Sorafenib and OSI-906",{"EARLY_PHASE1":12337,"PHASE1":12339,"PHASE2":12341,"PHASE3":12351,"PHASE4":12353,"NA":12355},{"trials":12338,"activeCount":114},[],{"trials":12340,"activeCount":114},[],{"trials":12342,"activeCount":114},[12343],{"nctId":12344,"briefTitle":12345,"status":230,"phases":12346,"primaryCompletion":5941,"completion":7806,"start":12347,"enrollment":362,"conditions":12348,"interventions":12350},"NCT01334710","A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer",[91],"2011-03",[12349],"Liver Cancer",[12335],{"trials":12352,"activeCount":114},[],{"trials":12354,"activeCount":114},[],{"trials":12356,"activeCount":114},[],{"intervention":12358,"totalTrials":186,"cells":12359},"EACA",{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12364,"PHASE3":12377,"PHASE4":12379,"NA":12381},{"trials":12361,"activeCount":114},[],{"trials":12363,"activeCount":114},[],{"trials":12365,"activeCount":114},[12366],{"nctId":12367,"briefTitle":12368,"status":230,"phases":12369,"primaryCompletion":12370,"completion":12371,"start":12372,"enrollment":243,"conditions":12373,"interventions":12376},"NCT02074436","PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)",[91],"2020-11-24","2021-05-14","2014-05-23",[12374,12375],"Hematological Malignancies","Thrombocytopenia",[12358],{"trials":12378,"activeCount":114},[],{"trials":12380,"activeCount":114},[],{"trials":12382,"activeCount":114},[],{"intervention":12384,"totalTrials":186,"cells":12385},"Busulfan, Cyclophosphamide and Fludarabine",{"EARLY_PHASE1":12386,"PHASE1":12388,"PHASE2":12390,"PHASE3":12400,"PHASE4":12402,"NA":12404},{"trials":12387,"activeCount":114},[],{"trials":12389,"activeCount":114},[],{"trials":12391,"activeCount":114},[12392],{"nctId":12393,"briefTitle":12394,"status":105,"phases":12395,"primaryCompletion":6473,"completion":6473,"start":12396,"enrollment":2507,"conditions":12397,"interventions":12399},"NCT00208923","Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies",[91],"1998-07",[12398],"Hematologic Malignancies",[12384],{"trials":12401,"activeCount":114},[],{"trials":12403,"activeCount":114},[],{"trials":12405,"activeCount":114},[],{"intervention":12407,"totalTrials":186,"cells":12408},"Erlotinib & Celecoxib",{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12413,"PHASE3":12422,"PHASE4":12424,"NA":12426},{"trials":12410,"activeCount":114},[],{"trials":12412,"activeCount":114},[],{"trials":12414,"activeCount":114},[12415],{"nctId":12416,"briefTitle":12417,"status":105,"phases":12418,"primaryCompletion":12277,"completion":12277,"start":420,"enrollment":276,"conditions":12419,"interventions":12421},"NCT00314262","Phase I\u002FII Study of Chemoprevention With EGFR and COX-2 Inhibitor",[90,91],[12420],"Precancerous Conditions",[12407],{"trials":12423,"activeCount":114},[],{"trials":12425,"activeCount":114},[],{"trials":12427,"activeCount":114},[],{"intervention":12429,"totalTrials":186,"cells":12430},"Mitoxantrone\u002FCyclophosphamide, Fludarabine, Rituximab and GM-CSF",{"EARLY_PHASE1":12431,"PHASE1":12433,"PHASE2":12435,"PHASE3":12443,"PHASE4":12445,"NA":12447},{"trials":12432,"activeCount":114},[],{"trials":12434,"activeCount":114},[],{"trials":12436,"activeCount":114},[12437],{"nctId":12438,"briefTitle":12439,"status":230,"phases":12440,"primaryCompletion":5970,"completion":2674,"start":4117,"enrollment":1754,"conditions":12441,"interventions":12442},"NCT00208975","Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab",[91],[11448],[12429],{"trials":12444,"activeCount":114},[],{"trials":12446,"activeCount":114},[],{"trials":12448,"activeCount":114},[],{"intervention":11279,"totalTrials":186,"cells":12450},{"EARLY_PHASE1":12451,"PHASE1":12453,"PHASE2":12455,"PHASE3":12461,"PHASE4":12463,"NA":12465},{"trials":12452,"activeCount":114},[],{"trials":12454,"activeCount":114},[],{"trials":12456,"activeCount":114},[12457],{"nctId":11272,"briefTitle":11273,"status":105,"phases":12458,"primaryCompletion":9569,"completion":9569,"start":11275,"enrollment":4781,"conditions":12459,"interventions":12460},[91],[11277],[11279,542],{"trials":12462,"activeCount":114},[],{"trials":12464,"activeCount":114},[],{"trials":12466,"activeCount":114},[],{"intervention":12468,"totalTrials":186,"cells":12469},"Fresh blood",{"EARLY_PHASE1":12470,"PHASE1":12472,"PHASE2":12474,"PHASE3":12484,"PHASE4":12486,"NA":12488},{"trials":12471,"activeCount":114},[],{"trials":12473,"activeCount":114},[],{"trials":12475,"activeCount":114},[12476],{"nctId":12477,"briefTitle":12478,"status":105,"phases":12479,"primaryCompletion":7267,"completion":594,"start":252,"enrollment":31,"conditions":12480,"interventions":12482},"NCT00838331","Adverse Effects of RBC Transfusions: A Unifying Hypothesis",[91],[12481],"Healthy Volunteers",[12468,12483],"Aged blood",{"trials":12485,"activeCount":114},[],{"trials":12487,"activeCount":114},[],{"trials":12489,"activeCount":114},[],{"intervention":12483,"totalTrials":186,"cells":12491},{"EARLY_PHASE1":12492,"PHASE1":12494,"PHASE2":12496,"PHASE3":12502,"PHASE4":12504,"NA":12506},{"trials":12493,"activeCount":114},[],{"trials":12495,"activeCount":114},[],{"trials":12497,"activeCount":114},[12498],{"nctId":12477,"briefTitle":12478,"status":105,"phases":12499,"primaryCompletion":7267,"completion":594,"start":252,"enrollment":31,"conditions":12500,"interventions":12501},[91],[12481],[12468,12483],{"trials":12503,"activeCount":114},[],{"trials":12505,"activeCount":114},[],{"trials":12507,"activeCount":114},[],{"intervention":12509,"totalTrials":186,"cells":12510},"Etanercept",{"EARLY_PHASE1":12511,"PHASE1":12513,"PHASE2":12515,"PHASE3":12525,"PHASE4":12527,"NA":12529},{"trials":12512,"activeCount":114},[],{"trials":12514,"activeCount":114},[],{"trials":12516,"activeCount":114},[12517],{"nctId":12518,"briefTitle":12519,"status":105,"phases":12520,"primaryCompletion":3466,"completion":3466,"start":12521,"enrollment":31,"conditions":12522,"interventions":12524},"NCT01989689","Etanercept and Vascular Function in Psoriasis",[91],"2010-08",[12523],"PSORIASIS",[12509],{"trials":12526,"activeCount":114},[],{"trials":12528,"activeCount":114},[],{"trials":12530,"activeCount":114},[],{"intervention":12532,"totalTrials":186,"cells":12533},"Ranolazine",{"EARLY_PHASE1":12534,"PHASE1":12536,"PHASE2":12538,"PHASE3":12548,"PHASE4":12550,"NA":12552},{"trials":12535,"activeCount":114},[],{"trials":12537,"activeCount":114},[],{"trials":12539,"activeCount":114},[12540],{"nctId":12541,"briefTitle":12542,"status":105,"phases":12543,"primaryCompletion":6035,"completion":12544,"start":8364,"enrollment":25,"conditions":12545,"interventions":12547},"NCT02147067","Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)",[91],"2018-06",[12546],"Microvascular Angina",[12532],{"trials":12549,"activeCount":114},[],{"trials":12551,"activeCount":114},[],{"trials":12553,"activeCount":114},[],{"intervention":12555,"totalTrials":186,"cells":12556},"FACBC PET-CT",{"EARLY_PHASE1":12557,"PHASE1":12559,"PHASE2":12561,"PHASE3":12570,"PHASE4":12572,"NA":12574},{"trials":12558,"activeCount":114},[],{"trials":12560,"activeCount":114},[],{"trials":12562,"activeCount":114},[12563],{"nctId":12564,"briefTitle":12565,"status":105,"phases":12566,"primaryCompletion":12567,"completion":6190,"start":7546,"enrollment":2277,"conditions":12568,"interventions":12569},"NCT02830880","FACBC Prostate Therapy Response",[91],"2018-12-01",[3651],[12555],{"trials":12571,"activeCount":114},[],{"trials":12573,"activeCount":114},[],{"trials":12575,"activeCount":114},[],{"intervention":12577,"totalTrials":186,"cells":12578},"Sertraline and Risperidone",{"EARLY_PHASE1":12579,"PHASE1":12581,"PHASE2":12583,"PHASE3":12594,"PHASE4":12596,"NA":12598},{"trials":12580,"activeCount":114},[],{"trials":12582,"activeCount":114},[],{"trials":12584,"activeCount":114},[12585],{"nctId":12586,"briefTitle":12587,"status":105,"phases":12588,"primaryCompletion":9724,"completion":9724,"start":12589,"enrollment":12590,"conditions":12591,"interventions":12593},"NCT00133822","Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial",[90,91],"2004-04",65,[12592],"Post-Traumatic Stress Disorders",[12577],{"trials":12595,"activeCount":114},[],{"trials":12597,"activeCount":114},[],{"trials":12599,"activeCount":114},[],{"intervention":12601,"totalTrials":186,"cells":12602},"Zoledronic acid",{"EARLY_PHASE1":12603,"PHASE1":12605,"PHASE2":12607,"PHASE3":12619,"PHASE4":12621,"NA":12623},{"trials":12604,"activeCount":114},[],{"trials":12606,"activeCount":114},[],{"trials":12608,"activeCount":114},[12609],{"nctId":12610,"briefTitle":12611,"status":105,"phases":12612,"primaryCompletion":12613,"completion":12613,"start":3733,"enrollment":380,"conditions":12614,"interventions":12618},"NCT01228318","Bone Loss and Immune Reconstitution in HIV\u002FAIDS (BLIR-HIV)",[91],"2017-04-13",[4992,12615,12616,12617],"Bone Loss","Osteopenia","Osteoporosis",[12601],{"trials":12620,"activeCount":114},[],{"trials":12622,"activeCount":114},[],{"trials":12624,"activeCount":114},[],{"intervention":12626,"totalTrials":186,"cells":12627},"Topiramate",{"EARLY_PHASE1":12628,"PHASE1":12630,"PHASE2":12632,"PHASE3":12641,"PHASE4":12643,"NA":12645},{"trials":12629,"activeCount":114},[],{"trials":12631,"activeCount":114},[],{"trials":12633,"activeCount":114},[12634],{"nctId":12635,"briefTitle":12636,"status":105,"phases":12637,"primaryCompletion":7122,"completion":7122,"start":11143,"conditions":12638,"interventions":12640},"NCT00208858","A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving",[91],[12639],"Tobacco Use Disorder",[12626],{"trials":12642,"activeCount":114},[],{"trials":12644,"activeCount":114},[],{"trials":12646,"activeCount":114},[],{"intervention":12648,"totalTrials":186,"cells":12649},"Bevacizumab 25 mg in 1 ml subcutaneously daily",{"EARLY_PHASE1":12650,"PHASE1":12652,"PHASE2":12654,"PHASE3":12662,"PHASE4":12664,"NA":12666},{"trials":12651,"activeCount":114},[],{"trials":12653,"activeCount":114},[],{"trials":12655,"activeCount":114},[12656],{"nctId":12657,"briefTitle":12658,"status":105,"phases":12659,"primaryCompletion":160,"completion":10697,"start":2942,"enrollment":362,"conditions":12660,"interventions":12661},"NCT02157103","A Study of Subcutaneous Bevacizumab in Relapsed \u002F Progressive Glioblastoma",[91],[3263],[12648],{"trials":12663,"activeCount":114},[],{"trials":12665,"activeCount":114},[],{"trials":12667,"activeCount":114},[],{"intervention":12669,"totalTrials":186,"cells":12670},"Telmisartan 20mg",{"EARLY_PHASE1":12671,"PHASE1":12673,"PHASE2":12675,"PHASE3":12688,"PHASE4":12690,"NA":12692},{"trials":12672,"activeCount":114},[],{"trials":12674,"activeCount":114},[],{"trials":12676,"activeCount":114},[12677],{"nctId":12678,"briefTitle":12679,"status":105,"phases":12680,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":12683,"conditions":12684,"interventions":12686},"NCT02471833","Health Evaluation in African Americans Using RAS Therapy",[90,91],"2022-04-15","2015-04",61,[12685],"Alzheimer's Disease",[12669,12687],"Telmisartan 40mg",{"trials":12689,"activeCount":114},[],{"trials":12691,"activeCount":114},[],{"trials":12693,"activeCount":114},[],{"intervention":12687,"totalTrials":186,"cells":12695},{"EARLY_PHASE1":12696,"PHASE1":12698,"PHASE2":12700,"PHASE3":12706,"PHASE4":12708,"NA":12710},{"trials":12697,"activeCount":114},[],{"trials":12699,"activeCount":114},[],{"trials":12701,"activeCount":114},[12702],{"nctId":12678,"briefTitle":12679,"status":105,"phases":12703,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":12683,"conditions":12704,"interventions":12705},[90,91],[12685],[12669,12687],{"trials":12707,"activeCount":114},[],{"trials":12709,"activeCount":114},[],{"trials":12711,"activeCount":114},[],{"intervention":10766,"totalTrials":186,"cells":12713},{"EARLY_PHASE1":12714,"PHASE1":12716,"PHASE2":12718,"PHASE3":12724,"PHASE4":12726,"NA":12728},{"trials":12715,"activeCount":114},[],{"trials":12717,"activeCount":114},[],{"trials":12719,"activeCount":114},[12720],{"nctId":10759,"briefTitle":10760,"status":105,"phases":12721,"primaryCompletion":3708,"completion":3708,"start":10762,"enrollment":445,"conditions":12722,"interventions":12723},[91],[10764],[2472,10719,10766],{"trials":12725,"activeCount":114},[],{"trials":12727,"activeCount":114},[],{"trials":12729,"activeCount":114},[],{"intervention":2522,"totalTrials":186,"cells":12731},{"EARLY_PHASE1":12732,"PHASE1":12734,"PHASE2":12736,"PHASE3":12742,"PHASE4":12744,"NA":12746},{"trials":12733,"activeCount":114},[],{"trials":12735,"activeCount":114},[],{"trials":12737,"activeCount":114},[12738],{"nctId":2514,"briefTitle":2515,"status":105,"phases":12739,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2075,"conditions":12740,"interventions":12741},[91],[24],[2522,2523,2524,154],{"trials":12743,"activeCount":114},[],{"trials":12745,"activeCount":114},[],{"trials":12747,"activeCount":114},[],{"intervention":2523,"totalTrials":186,"cells":12749},{"EARLY_PHASE1":12750,"PHASE1":12752,"PHASE2":12754,"PHASE3":12760,"PHASE4":12762,"NA":12764},{"trials":12751,"activeCount":114},[],{"trials":12753,"activeCount":114},[],{"trials":12755,"activeCount":114},[12756],{"nctId":2514,"briefTitle":2515,"status":105,"phases":12757,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2075,"conditions":12758,"interventions":12759},[91],[24],[2522,2523,2524,154],{"trials":12761,"activeCount":114},[],{"trials":12763,"activeCount":114},[],{"trials":12765,"activeCount":114},[],{"intervention":2524,"totalTrials":186,"cells":12767},{"EARLY_PHASE1":12768,"PHASE1":12770,"PHASE2":12772,"PHASE3":12778,"PHASE4":12780,"NA":12782},{"trials":12769,"activeCount":114},[],{"trials":12771,"activeCount":114},[],{"trials":12773,"activeCount":114},[12774],{"nctId":2514,"briefTitle":2515,"status":105,"phases":12775,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":2075,"conditions":12776,"interventions":12777},[91],[24],[2522,2523,2524,154],{"trials":12779,"activeCount":114},[],{"trials":12781,"activeCount":114},[],{"trials":12783,"activeCount":114},[],{"intervention":12785,"totalTrials":186,"cells":12786},"Tdap",{"EARLY_PHASE1":12787,"PHASE1":12789,"PHASE2":12791,"PHASE3":12803,"PHASE4":12805,"NA":12807},{"trials":12788,"activeCount":114},[],{"trials":12790,"activeCount":114},[],{"trials":12792,"activeCount":114},[12793],{"nctId":12794,"briefTitle":12795,"status":105,"phases":12796,"primaryCompletion":10239,"completion":10239,"start":7546,"enrollment":12797,"conditions":12798,"interventions":12801},"NCT02301702","Maternal Tdap Immunization in Guatemala",[91],286,[12799,12800],"Pertussis","Whooping Cough",[12785,12802],"Td",{"trials":12804,"activeCount":114},[],{"trials":12806,"activeCount":114},[],{"trials":12808,"activeCount":114},[],{"intervention":12802,"totalTrials":186,"cells":12810},{"EARLY_PHASE1":12811,"PHASE1":12813,"PHASE2":12815,"PHASE3":12821,"PHASE4":12823,"NA":12825},{"trials":12812,"activeCount":114},[],{"trials":12814,"activeCount":114},[],{"trials":12816,"activeCount":114},[12817],{"nctId":12794,"briefTitle":12795,"status":105,"phases":12818,"primaryCompletion":10239,"completion":10239,"start":7546,"enrollment":12797,"conditions":12819,"interventions":12820},[91],[12799,12800],[12785,12802],{"trials":12822,"activeCount":114},[],{"trials":12824,"activeCount":114},[],{"trials":12826,"activeCount":114},[],{"intervention":1506,"totalTrials":186,"cells":12828},{"EARLY_PHASE1":12829,"PHASE1":12831,"PHASE2":12833,"PHASE3":12839,"PHASE4":12841,"NA":12843},{"trials":12830,"activeCount":114},[],{"trials":12832,"activeCount":114},[],{"trials":12834,"activeCount":114},[12835],{"nctId":1494,"briefTitle":1495,"status":105,"phases":12836,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":12837,"interventions":12838},[90,91],[1501,1502],[127,1504,1505,154,1506,565],{"trials":12840,"activeCount":114},[],{"trials":12842,"activeCount":114},[],{"trials":12844,"activeCount":114},[],{"intervention":12846,"totalTrials":186,"cells":12847},"carmustine",{"EARLY_PHASE1":12848,"PHASE1":12850,"PHASE2":12852,"PHASE3":12868,"PHASE4":12870,"NA":12872},{"trials":12849,"activeCount":114},[],{"trials":12851,"activeCount":114},[],{"trials":12853,"activeCount":114},[12854],{"nctId":12855,"briefTitle":12856,"status":105,"phases":12857,"completion":12396,"start":12858,"enrollment":11573,"conditions":12859,"interventions":12865},"NCT00004688","Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms",[91],"1996-08",[12860,12861,12862,12863,12864],"Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Mixed Gliomas","Glioblastoma Multiforme","Recurrent Brain Tumor",[12846,12866,12867],"mercaptopurine","streptozocin",{"trials":12869,"activeCount":114},[],{"trials":12871,"activeCount":114},[],{"trials":12873,"activeCount":114},[],{"intervention":12866,"totalTrials":186,"cells":12875},{"EARLY_PHASE1":12876,"PHASE1":12878,"PHASE2":12880,"PHASE3":12886,"PHASE4":12888,"NA":12890},{"trials":12877,"activeCount":114},[],{"trials":12879,"activeCount":114},[],{"trials":12881,"activeCount":114},[12882],{"nctId":12855,"briefTitle":12856,"status":105,"phases":12883,"completion":12396,"start":12858,"enrollment":11573,"conditions":12884,"interventions":12885},[91],[12860,12861,12862,12863,12864],[12846,12866,12867],{"trials":12887,"activeCount":114},[],{"trials":12889,"activeCount":114},[],{"trials":12891,"activeCount":114},[],{"intervention":12867,"totalTrials":186,"cells":12893},{"EARLY_PHASE1":12894,"PHASE1":12896,"PHASE2":12898,"PHASE3":12904,"PHASE4":12906,"NA":12908},{"trials":12895,"activeCount":114},[],{"trials":12897,"activeCount":114},[],{"trials":12899,"activeCount":114},[12900],{"nctId":12855,"briefTitle":12856,"status":105,"phases":12901,"completion":12396,"start":12858,"enrollment":11573,"conditions":12902,"interventions":12903},[91],[12860,12861,12862,12863,12864],[12846,12866,12867],{"trials":12905,"activeCount":114},[],{"trials":12907,"activeCount":114},[],{"trials":12909,"activeCount":114},[],{"intervention":12911,"totalTrials":186,"cells":12912},"IVIG",{"EARLY_PHASE1":12913,"PHASE1":12915,"PHASE2":12917,"PHASE3":12929,"PHASE4":12931,"NA":12933},{"trials":12914,"activeCount":114},[],{"trials":12916,"activeCount":114},[],{"trials":12918,"activeCount":114},[12919],{"nctId":12920,"briefTitle":12921,"status":230,"phases":12922,"primaryCompletion":11525,"completion":233,"start":321,"enrollment":454,"conditions":12923,"interventions":12928},"NCT01545518","IVIG Treatment for Refractory Immune-Related Adult Epilepsy",[91],[12924,10325,12925,12926,12927],"Epilepsy, Cryptogenic","Seizure Disorder","Autoimmune Diseases, Nervous System","Limbic Encephalitis",[12911],{"trials":12930,"activeCount":114},[],{"trials":12932,"activeCount":114},[],{"trials":12934,"activeCount":114},[],{"intervention":12936,"totalTrials":186,"cells":12937},"8 International Units (IU) of Oxytocin",{"EARLY_PHASE1":12938,"PHASE1":12940,"PHASE2":12942,"PHASE3":12955,"PHASE4":12957,"NA":12959},{"trials":12939,"activeCount":114},[],{"trials":12941,"activeCount":114},[],{"trials":12943,"activeCount":114},[12944],{"nctId":12945,"briefTitle":12946,"status":105,"phases":12947,"primaryCompletion":12948,"completion":12948,"start":12949,"enrollment":3672,"conditions":12950,"interventions":12952},"NCT03033784","Autism Oxytocin Brain Project",[91],"2018-10-03","2017-05-10",[12951,1270],"Autism",[12936,12953,12954],"24IU of Oxytocin","48IU of Oxytocin",{"trials":12956,"activeCount":114},[],{"trials":12958,"activeCount":114},[],{"trials":12960,"activeCount":114},[],{"intervention":12953,"totalTrials":186,"cells":12962},{"EARLY_PHASE1":12963,"PHASE1":12965,"PHASE2":12967,"PHASE3":12973,"PHASE4":12975,"NA":12977},{"trials":12964,"activeCount":114},[],{"trials":12966,"activeCount":114},[],{"trials":12968,"activeCount":114},[12969],{"nctId":12945,"briefTitle":12946,"status":105,"phases":12970,"primaryCompletion":12948,"completion":12948,"start":12949,"enrollment":3672,"conditions":12971,"interventions":12972},[91],[12951,1270],[12936,12953,12954],{"trials":12974,"activeCount":114},[],{"trials":12976,"activeCount":114},[],{"trials":12978,"activeCount":114},[],{"intervention":12954,"totalTrials":186,"cells":12980},{"EARLY_PHASE1":12981,"PHASE1":12983,"PHASE2":12985,"PHASE3":12991,"PHASE4":12993,"NA":12995},{"trials":12982,"activeCount":114},[],{"trials":12984,"activeCount":114},[],{"trials":12986,"activeCount":114},[12987],{"nctId":12945,"briefTitle":12946,"status":105,"phases":12988,"primaryCompletion":12948,"completion":12948,"start":12949,"enrollment":3672,"conditions":12989,"interventions":12990},[91],[12951,1270],[12936,12953,12954],{"trials":12992,"activeCount":114},[],{"trials":12994,"activeCount":114},[],{"trials":12996,"activeCount":114},[],{"intervention":11364,"totalTrials":186,"cells":12998},{"EARLY_PHASE1":12999,"PHASE1":13001,"PHASE2":13003,"PHASE3":13009,"PHASE4":13011,"NA":13013},{"trials":13000,"activeCount":114},[],{"trials":13002,"activeCount":114},[],{"trials":13004,"activeCount":114},[13005],{"nctId":11357,"briefTitle":11358,"status":2022,"phases":13006,"primaryCompletion":7344,"completion":7344,"enrollment":114,"conditions":13007,"interventions":13008},[91],[3651,11361,11362],[11364,4127],{"trials":13010,"activeCount":114},[],{"trials":13012,"activeCount":114},[],{"trials":13014,"activeCount":114},[],{"intervention":13016,"totalTrials":186,"cells":13017},"Human fibrinogen concentrate",{"EARLY_PHASE1":13018,"PHASE1":13020,"PHASE2":13022,"PHASE3":13031,"PHASE4":13033,"NA":13035},{"trials":13019,"activeCount":114},[],{"trials":13021,"activeCount":114},[],{"trials":13023,"activeCount":114},[13024],{"nctId":13025,"briefTitle":13026,"status":230,"phases":13027,"primaryCompletion":7267,"completion":7267,"start":3733,"enrollment":25,"conditions":13028,"interventions":13030},"NCT01283321","RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery",[91],[13029,27],"Heart Valve Disease",[13016],{"trials":13032,"activeCount":114},[],{"trials":13034,"activeCount":114},[],{"trials":13036,"activeCount":114},[],{"intervention":10985,"totalTrials":186,"cells":13038},{"EARLY_PHASE1":13039,"PHASE1":13041,"PHASE2":13043,"PHASE3":13049,"PHASE4":13051,"NA":13053},{"trials":13040,"activeCount":114},[],{"trials":13042,"activeCount":114},[],{"trials":13044,"activeCount":114},[13045],{"nctId":10978,"briefTitle":10979,"status":230,"phases":13046,"primaryCompletion":5902,"completion":5939,"start":10981,"enrollment":391,"conditions":13047,"interventions":13048},[91],[10983],[10985,10961],{"trials":13050,"activeCount":114},[],{"trials":13052,"activeCount":114},[],{"trials":13054,"activeCount":114},[],{"intervention":13056,"totalTrials":186,"cells":13057},"Tivozanib",{"EARLY_PHASE1":13058,"PHASE1":13060,"PHASE2":13062,"PHASE3":13071,"PHASE4":13073,"NA":13075},{"trials":13059,"activeCount":114},[],{"trials":13061,"activeCount":114},[],{"trials":13063,"activeCount":114},[13064],{"nctId":13065,"briefTitle":13066,"status":230,"phases":13067,"primaryCompletion":2480,"completion":2480,"start":7099,"enrollment":2277,"conditions":13068,"interventions":13070},"NCT01807156","Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer",[91],[13069],"Hepatocellular Cancer",[13056],{"trials":13072,"activeCount":114},[],{"trials":13074,"activeCount":114},[],{"trials":13076,"activeCount":114},[],{"intervention":13078,"totalTrials":186,"cells":13079},"Temozolomide",{"EARLY_PHASE1":13080,"PHASE1":13082,"PHASE2":13084,"PHASE3":13095,"PHASE4":13097,"NA":13099},{"trials":13081,"activeCount":114},[],{"trials":13083,"activeCount":114},[],{"trials":13085,"activeCount":114},[13086],{"nctId":13087,"briefTitle":13088,"status":105,"phases":13089,"primaryCompletion":13090,"completion":13090,"start":13091,"enrollment":123,"conditions":13092,"interventions":13094},"NCT03137888","Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma",[91],"2024-09-09","2017-09-20",[3263,13093],"Gliosarcoma",[13078],{"trials":13096,"activeCount":114},[],{"trials":13098,"activeCount":114},[],{"trials":13100,"activeCount":114},[],{"intervention":13102,"totalTrials":186,"cells":13103},"Enteral Vitamin D3 50,000 IU",{"EARLY_PHASE1":13104,"PHASE1":13106,"PHASE2":13108,"PHASE3":13118,"PHASE4":13120,"NA":13122},{"trials":13105,"activeCount":114},[],{"trials":13107,"activeCount":114},[],{"trials":13109,"activeCount":114},[13110],{"nctId":13111,"briefTitle":13112,"status":105,"phases":13113,"primaryCompletion":8757,"completion":8757,"start":6389,"enrollment":595,"conditions":13114,"interventions":13116},"NCT01372995","Vitamin D in Ventilated ICU Patients",[91],[13115],"Respiratory Failure",[13102,13117],"Enteral Vitamin D3 100,000IU",{"trials":13119,"activeCount":114},[],{"trials":13121,"activeCount":114},[],{"trials":13123,"activeCount":114},[],{"intervention":13117,"totalTrials":186,"cells":13125},{"EARLY_PHASE1":13126,"PHASE1":13128,"PHASE2":13130,"PHASE3":13136,"PHASE4":13138,"NA":13140},{"trials":13127,"activeCount":114},[],{"trials":13129,"activeCount":114},[],{"trials":13131,"activeCount":114},[13132],{"nctId":13111,"briefTitle":13112,"status":105,"phases":13133,"primaryCompletion":8757,"completion":8757,"start":6389,"enrollment":595,"conditions":13134,"interventions":13135},[91],[13115],[13102,13117],{"trials":13137,"activeCount":114},[],{"trials":13139,"activeCount":114},[],{"trials":13141,"activeCount":114},[],{"intervention":13143,"totalTrials":186,"cells":13144},"Standard Temozolomide",{"EARLY_PHASE1":13145,"PHASE1":13147,"PHASE2":13149,"PHASE3":13161,"PHASE4":13163,"NA":13165},{"trials":13146,"activeCount":114},[],{"trials":13148,"activeCount":114},[],{"trials":13150,"activeCount":114},[13151],{"nctId":13152,"briefTitle":13153,"status":2833,"phases":13154,"primaryCompletion":3812,"completion":13155,"start":13156,"enrollment":243,"conditions":13157,"interventions":13159},"NCT02137759","MRSI to Predict Response to RT\u002FTMZ ± Belinostat in GBM",[91],"2024-08-15","2014-05-07",[13158],"Glioblastoma Multiforme of Brain",[13143,13160],"Belinostat",{"trials":13162,"activeCount":114},[],{"trials":13164,"activeCount":114},[],{"trials":13166,"activeCount":114},[],{"intervention":13160,"totalTrials":186,"cells":13168},{"EARLY_PHASE1":13169,"PHASE1":13171,"PHASE2":13173,"PHASE3":13179,"PHASE4":13181,"NA":13183},{"trials":13170,"activeCount":114},[],{"trials":13172,"activeCount":114},[],{"trials":13174,"activeCount":114},[13175],{"nctId":13152,"briefTitle":13153,"status":2833,"phases":13176,"primaryCompletion":3812,"completion":13155,"start":13156,"enrollment":243,"conditions":13177,"interventions":13178},[91],[13158],[13143,13160],{"trials":13180,"activeCount":114},[],{"trials":13182,"activeCount":114},[],{"trials":13184,"activeCount":114},[],{"intervention":13186,"totalTrials":186,"cells":13187},"Decitabine, LBH589, Tamoxifen",{"EARLY_PHASE1":13188,"PHASE1":13190,"PHASE2":13192,"PHASE3":13200,"PHASE4":13202,"NA":13204},{"trials":13189,"activeCount":114},[],{"trials":13191,"activeCount":114},[],{"trials":13193,"activeCount":114},[13194],{"nctId":13195,"briefTitle":13196,"status":230,"phases":13197,"primaryCompletion":2942,"completion":2942,"start":2416,"enrollment":292,"conditions":13198,"interventions":13199},"NCT01194908","Re-expression of ER in Triple Negative Breast Cancers",[90,91],[30,2535,254],[13186],{"trials":13201,"activeCount":114},[],{"trials":13203,"activeCount":114},[],{"trials":13205,"activeCount":114},[],{"intervention":13207,"totalTrials":186,"cells":13208},"recombinant human growth hormone",{"EARLY_PHASE1":13209,"PHASE1":13211,"PHASE2":13213,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13210,"activeCount":114},[],{"trials":13212,"activeCount":114},[],{"trials":13214,"activeCount":114},[13215],{"nctId":13216,"briefTitle":13217,"status":105,"phases":13218,"primaryCompletion":7122,"completion":7122,"start":13219,"enrollment":9523,"conditions":13220,"interventions":13222},"NCT00067860","Diet\u002FGrowth Factor Mechanisms of Gut Adaptation",[91],"1996-10",[13221],"Short Bowel Syndrome",[13207],{"trials":13224,"activeCount":114},[],{"trials":13226,"activeCount":114},[],{"trials":13228,"activeCount":114},[],{"intervention":13230,"totalTrials":186,"cells":13231},"Shingrix®",{"EARLY_PHASE1":13232,"PHASE1":13234,"PHASE2":13236,"PHASE3":13251,"PHASE4":13253,"NA":13255},{"trials":13233,"activeCount":114},[],{"trials":13235,"activeCount":114},[],{"trials":13237,"activeCount":114},[13238],{"nctId":13239,"briefTitle":13240,"status":105,"phases":13241,"primaryCompletion":13242,"completion":13243,"start":13244,"enrollment":3646,"conditions":13245,"interventions":13250},"NCT04047979","Systems Biology of Zoster Vaccine",[91],"2023-04-03","2023-10-30","2019-11-14",[13246,13247,13248,13249],"Zoster","Zoster Varicella","Shingles","Chicken Pox",[13230],{"trials":13252,"activeCount":114},[],{"trials":13254,"activeCount":114},[],{"trials":13256,"activeCount":114},[],{"intervention":13258,"totalTrials":186,"cells":13259},"Gleevec, Taxotere",{"EARLY_PHASE1":13260,"PHASE1":13262,"PHASE2":13264,"PHASE3":13272,"PHASE4":13274,"NA":13276},{"trials":13261,"activeCount":114},[],{"trials":13263,"activeCount":114},[],{"trials":13265,"activeCount":114},[13266],{"nctId":13267,"briefTitle":13268,"status":230,"phases":13269,"primaryCompletion":10139,"completion":10139,"start":11821,"enrollment":292,"conditions":13270,"interventions":13271},"NCT00209079","Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma",[91],[4783],[13258],{"trials":13273,"activeCount":114},[],{"trials":13275,"activeCount":114},[],{"trials":13277,"activeCount":114},[],{"intervention":13279,"totalTrials":186,"cells":13280},"Oxytocin",{"EARLY_PHASE1":13281,"PHASE1":13283,"PHASE2":13285,"PHASE3":13294,"PHASE4":13296,"NA":13298},{"trials":13282,"activeCount":114},[],{"trials":13284,"activeCount":114},[],{"trials":13286,"activeCount":114},[13287],{"nctId":13288,"briefTitle":13289,"status":105,"phases":13290,"primaryCompletion":13291,"completion":13291,"start":7099,"enrollment":2582,"conditions":13292,"interventions":13293},"NCT01568528","Oxytocin as Adjunctive Treatment of Schizophrenia",[91],"2017-03-15",[456],[13279],{"trials":13295,"activeCount":114},[],{"trials":13297,"activeCount":114},[],{"trials":13299,"activeCount":114},[],{"intervention":13301,"totalTrials":186,"cells":13302},"Taxol, Cisplatin, 5-Fluorouracil, G-CSF",{"EARLY_PHASE1":13303,"PHASE1":13305,"PHASE2":13307,"PHASE3":13317,"PHASE4":13319,"NA":13321},{"trials":13304,"activeCount":114},[],{"trials":13306,"activeCount":114},[],{"trials":13308,"activeCount":114},[13309],{"nctId":13310,"briefTitle":13311,"status":230,"phases":13312,"primaryCompletion":8717,"start":13313,"enrollment":454,"conditions":13314,"interventions":13316},"NCT00208936","Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus",[91],"1996-01",[13315],"Esophageal Diseases",[13301],{"trials":13318,"activeCount":114},[],{"trials":13320,"activeCount":114},[],{"trials":13322,"activeCount":114},[],{"intervention":11396,"totalTrials":186,"cells":13324},{"EARLY_PHASE1":13325,"PHASE1":13327,"PHASE2":13329,"PHASE3":13335,"PHASE4":13337,"NA":13339},{"trials":13326,"activeCount":114},[],{"trials":13328,"activeCount":114},[],{"trials":13330,"activeCount":114},[13331],{"nctId":11388,"briefTitle":11389,"status":230,"phases":13332,"primaryCompletion":11391,"completion":11391,"start":4547,"enrollment":2277,"conditions":13333,"interventions":13334},[91],[11393,11394,10974],[3880,11396,11397],{"trials":13336,"activeCount":114},[],{"trials":13338,"activeCount":114},[],{"trials":13340,"activeCount":114},[],{"intervention":11397,"totalTrials":186,"cells":13342},{"EARLY_PHASE1":13343,"PHASE1":13345,"PHASE2":13347,"PHASE3":13353,"PHASE4":13355,"NA":13357},{"trials":13344,"activeCount":114},[],{"trials":13346,"activeCount":114},[],{"trials":13348,"activeCount":114},[13349],{"nctId":11388,"briefTitle":11389,"status":230,"phases":13350,"primaryCompletion":11391,"completion":11391,"start":4547,"enrollment":2277,"conditions":13351,"interventions":13352},[91],[11393,11394,10974],[3880,11396,11397],{"trials":13354,"activeCount":114},[],{"trials":13356,"activeCount":114},[],{"trials":13358,"activeCount":114},[],{"intervention":11061,"totalTrials":186,"cells":13360},{"EARLY_PHASE1":13361,"PHASE1":13363,"PHASE2":13365,"PHASE3":13371,"PHASE4":13373,"NA":13375},{"trials":13362,"activeCount":114},[],{"trials":13364,"activeCount":114},[],{"trials":13366,"activeCount":114},[13367],{"nctId":11053,"briefTitle":11054,"status":105,"phases":13368,"primaryCompletion":11056,"completion":11056,"start":11057,"enrollment":11058,"conditions":13369,"interventions":13370},[91],[6155,11050],[11035,11061],{"trials":13372,"activeCount":114},[],{"trials":13374,"activeCount":114},[],{"trials":13376,"activeCount":114},[],{"intervention":13378,"totalTrials":186,"cells":13379},"Gallium Ga 68-DOTATATE",{"EARLY_PHASE1":13380,"PHASE1":13382,"PHASE2":13384,"PHASE3":13397,"PHASE4":13399,"NA":13401},{"trials":13381,"activeCount":114},[],{"trials":13383,"activeCount":114},[],{"trials":13385,"activeCount":114},[13386],{"nctId":13387,"briefTitle":13388,"status":105,"phases":13389,"primaryCompletion":13390,"completion":13390,"start":13391,"enrollment":276,"conditions":13392,"interventions":13396},"NCT03448458","Gallium Ga 68-DOTATATE PET\u002FCT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer",[91],"2023-02-06","2018-02-22",[13393,13394,13395],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7",[13378],{"trials":13398,"activeCount":114},[],{"trials":13400,"activeCount":114},[],{"trials":13402,"activeCount":114},[],{"intervention":3738,"totalTrials":186,"cells":13404},{"EARLY_PHASE1":13405,"PHASE1":13407,"PHASE2":13409,"PHASE3":13415,"PHASE4":13417,"NA":13419},{"trials":13406,"activeCount":114},[],{"trials":13408,"activeCount":114},[],{"trials":13410,"activeCount":114},[13411],{"nctId":3730,"briefTitle":3731,"status":105,"phases":13412,"primaryCompletion":3524,"completion":3426,"start":3733,"enrollment":454,"conditions":13413,"interventions":13414},[90,91],[3735,3736],[1981,3738,3665],{"trials":13416,"activeCount":114},[],{"trials":13418,"activeCount":114},[],{"trials":13420,"activeCount":114},[],{"intervention":13422,"totalTrials":186,"cells":13423},"FACBC PET-CT Imaging",{"EARLY_PHASE1":13424,"PHASE1":13426,"PHASE2":13428,"PHASE3":13438,"PHASE4":13440,"NA":13442},{"trials":13425,"activeCount":114},[],{"trials":13427,"activeCount":114},[],{"trials":13429,"activeCount":114},[13430],{"nctId":13431,"briefTitle":13432,"status":105,"phases":13433,"primaryCompletion":13434,"completion":13434,"start":13435,"enrollment":12683,"conditions":13436,"interventions":13437},"NCT03081884","Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease",[91],"2019-12-31","2017-03-01",[2332],[13422],{"trials":13439,"activeCount":114},[],{"trials":13441,"activeCount":114},[],{"trials":13443,"activeCount":114},[],{"intervention":599,"totalTrials":186,"cells":13445},{"EARLY_PHASE1":13446,"PHASE1":13448,"PHASE2":13450,"PHASE3":13456,"PHASE4":13458,"NA":13460},{"trials":13447,"activeCount":114},[],{"trials":13449,"activeCount":114},[],{"trials":13451,"activeCount":114},[13452],{"nctId":591,"briefTitle":592,"status":105,"phases":13453,"primaryCompletion":487,"completion":487,"start":594,"enrollment":595,"conditions":13454,"interventions":13455},[91],[597],[599,310,565,600,601],{"trials":13457,"activeCount":114},[],{"trials":13459,"activeCount":114},[],{"trials":13461,"activeCount":114},[],{"intervention":2411,"totalTrials":186,"cells":13463},{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13474,"PHASE4":13476,"NA":13478},{"trials":13465,"activeCount":114},[],{"trials":13467,"activeCount":114},[],{"trials":13469,"activeCount":114},[13470],{"nctId":2402,"briefTitle":2403,"status":105,"phases":13471,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":136,"conditions":13472,"interventions":13473},[91],[2408,1773,2409,2380,2356],[1982,1979,2411],{"trials":13475,"activeCount":114},[],{"trials":13477,"activeCount":114},[],{"trials":13479,"activeCount":114},[],{"intervention":13481,"totalTrials":186,"cells":13482},"Omacetaxine",{"EARLY_PHASE1":13483,"PHASE1":13485,"PHASE2":13487,"PHASE3":13496,"PHASE4":13498,"NA":13500},{"trials":13484,"activeCount":114},[],{"trials":13486,"activeCount":114},[],{"trials":13488,"activeCount":114},[13489],{"nctId":13490,"briefTitle":13491,"status":230,"phases":13492,"primaryCompletion":11391,"completion":11391,"start":7267,"enrollment":2277,"conditions":13493,"interventions":13495},"NCT01873495","Omacetaxine for Consolidation and Maintenance",[91],[13494],"Acute Myelogenous Leukemia (AML)",[13481],{"trials":13497,"activeCount":114},[],{"trials":13499,"activeCount":114},[],{"trials":13501,"activeCount":114},[],{"intervention":13503,"totalTrials":186,"cells":13504},"Valsartan",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13509,"PHASE3":13519,"PHASE4":13521,"NA":13523},{"trials":13506,"activeCount":114},[],{"trials":13508,"activeCount":114},[],{"trials":13510,"activeCount":114},[13511],{"nctId":13512,"briefTitle":13513,"status":105,"phases":13514,"primaryCompletion":10478,"completion":10478,"start":13515,"enrollment":1346,"conditions":13516,"interventions":13518},"NCT00208767","Effect of Valsartan on Carotid Artery Disease",[91],"2005-02",[13517,3469],"Carotid Artery Diseases",[13503],{"trials":13520,"activeCount":114},[],{"trials":13522,"activeCount":114},[],{"trials":13524,"activeCount":114},[],{"intervention":13526,"totalTrials":186,"cells":13527},"Modafinil",{"EARLY_PHASE1":13528,"PHASE1":13530,"PHASE2":13532,"PHASE3":13545,"PHASE4":13547,"NA":13549},{"trials":13529,"activeCount":114},[],{"trials":13531,"activeCount":114},[],{"trials":13533,"activeCount":114},[13534],{"nctId":13535,"briefTitle":13536,"status":105,"phases":13537,"primaryCompletion":13538,"completion":13538,"start":13539,"enrollment":10726,"conditions":13540,"interventions":13543},"NCT03772314","Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia",[91],"2023-05-04","2019-04-15",[13541,13542],"Idiopathic Hypersomnia","Narcolepsy Without Cataplexy",[13526,13544],"Amphetamine-Dextroamphetamine",{"trials":13546,"activeCount":114},[],{"trials":13548,"activeCount":114},[],{"trials":13550,"activeCount":114},[],{"intervention":13544,"totalTrials":186,"cells":13552},{"EARLY_PHASE1":13553,"PHASE1":13555,"PHASE2":13557,"PHASE3":13563,"PHASE4":13565,"NA":13567},{"trials":13554,"activeCount":114},[],{"trials":13556,"activeCount":114},[],{"trials":13558,"activeCount":114},[13559],{"nctId":13535,"briefTitle":13536,"status":105,"phases":13560,"primaryCompletion":13538,"completion":13538,"start":13539,"enrollment":10726,"conditions":13561,"interventions":13562},[91],[13541,13542],[13526,13544],{"trials":13564,"activeCount":114},[],{"trials":13566,"activeCount":114},[],{"trials":13568,"activeCount":114},[],{"intervention":13570,"totalTrials":186,"cells":13571},"Aflibercept injected Pre- and Post-operatively",{"EARLY_PHASE1":13572,"PHASE1":13574,"PHASE2":13576,"PHASE3":13589,"PHASE4":13591,"NA":13593},{"trials":13573,"activeCount":114},[],{"trials":13575,"activeCount":114},[],{"trials":13577,"activeCount":114},[13578],{"nctId":13579,"briefTitle":13580,"status":2022,"phases":13581,"primaryCompletion":13582,"completion":13582,"start":13583,"enrollment":114,"conditions":13584,"interventions":13587},"NCT03920878","Cataract DME - Peri vs. Intraop",[91],"2020-06","2020-05",[13585,13586],"Diabetic Macular Edema","Cataract",[13570,13588],"Aflibercept injected intraoperatively",{"trials":13590,"activeCount":114},[],{"trials":13592,"activeCount":114},[],{"trials":13594,"activeCount":114},[],{"intervention":13588,"totalTrials":186,"cells":13596},{"EARLY_PHASE1":13597,"PHASE1":13599,"PHASE2":13601,"PHASE3":13607,"PHASE4":13609,"NA":13611},{"trials":13598,"activeCount":114},[],{"trials":13600,"activeCount":114},[],{"trials":13602,"activeCount":114},[13603],{"nctId":13579,"briefTitle":13580,"status":2022,"phases":13604,"primaryCompletion":13582,"completion":13582,"start":13583,"enrollment":114,"conditions":13605,"interventions":13606},[91],[13585,13586],[13570,13588],{"trials":13608,"activeCount":114},[],{"trials":13610,"activeCount":114},[],{"trials":13612,"activeCount":114},[],{"intervention":13614,"totalTrials":186,"cells":13615},"Tdap - IPV Vaccine",{"EARLY_PHASE1":13616,"PHASE1":13618,"PHASE2":13620,"PHASE3":13632,"PHASE4":13634,"NA":13636},{"trials":13617,"activeCount":114},[],{"trials":13619,"activeCount":114},[],{"trials":13621,"activeCount":114},[13622],{"nctId":13623,"briefTitle":13624,"status":105,"phases":13625,"primaryCompletion":13626,"completion":13626,"start":13627,"enrollment":1107,"conditions":13628,"interventions":13630},"NCT02589678","Zambia SiVET MMR Tdap-IPV",[90,91],"2017-05-16","2015-08",[13629],"High Risk for HIV",[13614,13631],"MMR Vaccine",{"trials":13633,"activeCount":114},[],{"trials":13635,"activeCount":114},[],{"trials":13637,"activeCount":114},[],{"intervention":13631,"totalTrials":186,"cells":13639},{"EARLY_PHASE1":13640,"PHASE1":13642,"PHASE2":13644,"PHASE3":13650,"PHASE4":13652,"NA":13654},{"trials":13641,"activeCount":114},[],{"trials":13643,"activeCount":114},[],{"trials":13645,"activeCount":114},[13646],{"nctId":13623,"briefTitle":13624,"status":105,"phases":13647,"primaryCompletion":13626,"completion":13626,"start":13627,"enrollment":1107,"conditions":13648,"interventions":13649},[90,91],[13629],[13614,13631],{"trials":13651,"activeCount":114},[],{"trials":13653,"activeCount":114},[],{"trials":13655,"activeCount":114},[],{"intervention":2875,"totalTrials":186,"cells":13657},{"EARLY_PHASE1":13658,"PHASE1":13660,"PHASE2":13662,"PHASE3":13668,"PHASE4":13670,"NA":13672},{"trials":13659,"activeCount":114},[],{"trials":13661,"activeCount":114},[],{"trials":13663,"activeCount":114},[13664],{"nctId":2867,"briefTitle":2868,"status":2022,"phases":13665,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":114,"conditions":13666,"interventions":13667},[91],[1756,2873,1757,1758,1759],[1981,2589,1980,2875],{"trials":13669,"activeCount":114},[],{"trials":13671,"activeCount":114},[],{"trials":13673,"activeCount":114},[],{"intervention":3683,"totalTrials":186,"cells":13675},{"EARLY_PHASE1":13676,"PHASE1":13678,"PHASE2":13680,"PHASE3":13686,"PHASE4":13688,"NA":13690},{"trials":13677,"activeCount":114},[],{"trials":13679,"activeCount":114},[],{"trials":13681,"activeCount":114},[13682],{"nctId":3676,"briefTitle":3677,"status":105,"phases":13683,"primaryCompletion":3679,"completion":3679,"start":3670,"enrollment":595,"conditions":13684,"interventions":13685},[91],[30],[3682,2039,3683],{"trials":13687,"activeCount":114},[],{"trials":13689,"activeCount":114},[],{"trials":13691,"activeCount":114},[],{"intervention":13693,"totalTrials":186,"cells":13694},"Lapatinib and Everolimus",{"EARLY_PHASE1":13695,"PHASE1":13697,"PHASE2":13699,"PHASE3":13707,"PHASE4":13709,"NA":13711},{"trials":13696,"activeCount":114},[],{"trials":13698,"activeCount":114},[],{"trials":13700,"activeCount":114},[13701],{"nctId":13702,"briefTitle":13703,"status":230,"phases":13704,"primaryCompletion":4116,"completion":2942,"start":3660,"enrollment":292,"conditions":13705,"interventions":13706},"NCT01272141","A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer",[91],[254,30,255],[13693],{"trials":13708,"activeCount":114},[],{"trials":13710,"activeCount":114},[],{"trials":13712,"activeCount":114},[],{"intervention":13714,"totalTrials":186,"cells":13715},"Low Dose - AbobotulinumtoxinA",{"EARLY_PHASE1":13716,"PHASE1":13718,"PHASE2":13720,"PHASE3":13731,"PHASE4":13733,"NA":13735},{"trials":13717,"activeCount":114},[],{"trials":13719,"activeCount":114},[],{"trials":13721,"activeCount":114},[13722],{"nctId":13723,"briefTitle":13724,"status":105,"phases":13725,"primaryCompletion":13726,"completion":13726,"start":233,"enrollment":98,"conditions":13727,"interventions":13730},"NCT01921270","Dysport for the Treatment of OMD",[90,91],"2017-02-08",[13728,13729],"Oral Dystonia","Tardive Dystonia",[13714],{"trials":13732,"activeCount":114},[],{"trials":13734,"activeCount":114},[],{"trials":13736,"activeCount":114},[],{"intervention":13738,"totalTrials":186,"cells":13739},"Transplantation of Human Islets",{"EARLY_PHASE1":13740,"PHASE1":13742,"PHASE2":13744,"PHASE3":13752,"PHASE4":13754,"NA":13756},{"trials":13741,"activeCount":114},[],{"trials":13743,"activeCount":114},[],{"trials":13745,"activeCount":114},[13746],{"nctId":13747,"briefTitle":13748,"status":105,"phases":13749,"primaryCompletion":2965,"completion":2965,"start":4117,"enrollment":182,"conditions":13750,"interventions":13751},"NCT00133809","Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression",[91],[10907],[13738],{"trials":13753,"activeCount":114},[],{"trials":13755,"activeCount":114},[],{"trials":13757,"activeCount":114},[],{"intervention":5588,"totalTrials":186,"cells":13759},{"EARLY_PHASE1":13760,"PHASE1":13762,"PHASE2":13764,"PHASE3":13770,"PHASE4":13772,"NA":13774},{"trials":13761,"activeCount":114},[],{"trials":13763,"activeCount":114},[],{"trials":13765,"activeCount":114},[13766],{"nctId":5575,"briefTitle":5576,"status":105,"phases":13767,"primaryCompletion":1878,"completion":1878,"start":5578,"enrollment":1153,"conditions":13768,"interventions":13769},[91],[1839,5580,5581,5582,5583,5584,1853],[5586,3682,5587,5538,3550,5588],{"trials":13771,"activeCount":114},[],{"trials":13773,"activeCount":114},[],{"trials":13775,"activeCount":114},[],{"intervention":13777,"totalTrials":186,"cells":13778},"N-acetylcysteine",{"EARLY_PHASE1":13779,"PHASE1":13781,"PHASE2":13783,"PHASE3":13792,"PHASE4":13794,"NA":13796},{"trials":13780,"activeCount":114},[],{"trials":13782,"activeCount":114},[],{"trials":13784,"activeCount":114},[13785],{"nctId":13786,"briefTitle":13787,"status":105,"phases":13788,"primaryCompletion":13789,"completion":13789,"start":7569,"enrollment":182,"conditions":13790,"interventions":13791},"NCT03008889","A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder",[91],"2019-09-12",[1270],[13777],{"trials":13793,"activeCount":114},[],{"trials":13795,"activeCount":114},[],{"trials":13797,"activeCount":114},[],{"intervention":13799,"totalTrials":186,"cells":13800},"Bevacizumab, cetuximab",{"EARLY_PHASE1":13801,"PHASE1":13803,"PHASE2":13805,"PHASE3":13814,"PHASE4":13816,"NA":13818},{"trials":13802,"activeCount":114},[],{"trials":13804,"activeCount":114},[],{"trials":13806,"activeCount":114},[13807],{"nctId":13808,"briefTitle":13809,"status":2022,"phases":13810,"primaryCompletion":10281,"completion":9933,"start":2366,"enrollment":114,"conditions":13811,"interventions":13813},"NCT00636298","Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy",[91],[13812],"Esophageal Carcinoma",[13799],{"trials":13815,"activeCount":114},[],{"trials":13817,"activeCount":114},[],{"trials":13819,"activeCount":114},[],{"intervention":257,"totalTrials":186,"cells":13821},{"EARLY_PHASE1":13822,"PHASE1":13824,"PHASE2":13826,"PHASE3":13832,"PHASE4":13834,"NA":13836},{"trials":13823,"activeCount":114},[],{"trials":13825,"activeCount":114},[],{"trials":13827,"activeCount":114},[13828],{"nctId":248,"briefTitle":249,"status":230,"phases":13829,"primaryCompletion":251,"completion":251,"start":252,"enrollment":136,"conditions":13830,"interventions":13831},[91],[254,30,255],[257,97],{"trials":13833,"activeCount":114},[],{"trials":13835,"activeCount":114},[],{"trials":13837,"activeCount":114},[],{"intervention":13839,"totalTrials":186,"cells":13840},"Busulfan, Fludarabine and ATG",{"EARLY_PHASE1":13841,"PHASE1":13843,"PHASE2":13845,"PHASE3":13855,"PHASE4":13857,"NA":13859},{"trials":13842,"activeCount":114},[],{"trials":13844,"activeCount":114},[],{"trials":13846,"activeCount":114},[13847],{"nctId":13848,"briefTitle":13849,"status":105,"phases":13850,"completion":3662,"conditions":13851,"interventions":13854},"NCT00228852","IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency",[90,91],[13852,13853],"T-Cell Immune Deficiency Diseases","Severe Combined Immunodeficiency",[13839],{"trials":13856,"activeCount":114},[],{"trials":13858,"activeCount":114},[],{"trials":13860,"activeCount":114},[],{"intervention":2698,"totalTrials":186,"cells":13862},{"EARLY_PHASE1":13863,"PHASE1":13865,"PHASE2":13867,"PHASE3":13873,"PHASE4":13875,"NA":13877},{"trials":13864,"activeCount":114},[],{"trials":13866,"activeCount":114},[],{"trials":13868,"activeCount":114},[13869],{"nctId":2680,"briefTitle":2681,"status":230,"phases":13870,"primaryCompletion":2683,"completion":2683,"start":2684,"enrollment":292,"conditions":13871,"interventions":13872},[91],[2686,2687,2688,2689,1502,2690,2691,2692,2693,2694,2695,2696],[2698,127,600],{"trials":13874,"activeCount":114},[],{"trials":13876,"activeCount":114},[],{"trials":13878,"activeCount":114},[],{"intervention":2539,"totalTrials":186,"cells":13880},{"EARLY_PHASE1":13881,"PHASE1":13883,"PHASE2":13885,"PHASE3":13891,"PHASE4":13893,"NA":13895},{"trials":13882,"activeCount":114},[],{"trials":13884,"activeCount":114},[],{"trials":13886,"activeCount":114},[13887],{"nctId":2530,"briefTitle":2531,"status":230,"phases":13888,"primaryCompletion":2533,"completion":2533,"start":321,"enrollment":2277,"conditions":13889,"interventions":13890},[91],[254,30,2535,255,2536,2537],[2539,1505,154,2540],{"trials":13892,"activeCount":114},[],{"trials":13894,"activeCount":114},[],{"trials":13896,"activeCount":114},[],{"intervention":2540,"totalTrials":186,"cells":13898},{"EARLY_PHASE1":13899,"PHASE1":13901,"PHASE2":13903,"PHASE3":13909,"PHASE4":13911,"NA":13913},{"trials":13900,"activeCount":114},[],{"trials":13902,"activeCount":114},[],{"trials":13904,"activeCount":114},[13905],{"nctId":2530,"briefTitle":2531,"status":230,"phases":13906,"primaryCompletion":2533,"completion":2533,"start":321,"enrollment":2277,"conditions":13907,"interventions":13908},[91],[254,30,2535,255,2536,2537],[2539,1505,154,2540],{"trials":13910,"activeCount":114},[],{"trials":13912,"activeCount":114},[],{"trials":13914,"activeCount":114},[],{"intervention":3583,"totalTrials":186,"cells":13916},{"EARLY_PHASE1":13917,"PHASE1":13919,"PHASE2":13921,"PHASE3":13927,"PHASE4":13929,"NA":13931},{"trials":13918,"activeCount":114},[],{"trials":13920,"activeCount":114},[],{"trials":13922,"activeCount":114},[13923],{"nctId":3574,"briefTitle":3575,"status":230,"phases":13924,"primaryCompletion":3577,"completion":3577,"start":3578,"enrollment":1218,"conditions":13925,"interventions":13926},[91],[3580,3581],[2039,2382,3583],{"trials":13928,"activeCount":114},[],{"trials":13930,"activeCount":114},[],{"trials":13932,"activeCount":114},[],{"intervention":13934,"totalTrials":186,"cells":13935},"Siltuximab",{"EARLY_PHASE1":13936,"PHASE1":13938,"PHASE2":13940,"PHASE3":13951,"PHASE4":13953,"NA":13955},{"trials":13937,"activeCount":114},[],{"trials":13939,"activeCount":114},[],{"trials":13941,"activeCount":114},[13942],{"nctId":13943,"briefTitle":13944,"status":105,"phases":13945,"primaryCompletion":13946,"completion":13946,"start":13947,"enrollment":11573,"conditions":13948,"interventions":13949},"NCT04191421","Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer",[90,91],"2023-04-05","2020-01-17",[1773,2356],[13934,13950],"Spartalizumab",{"trials":13952,"activeCount":114},[],{"trials":13954,"activeCount":114},[],{"trials":13956,"activeCount":114},[],{"intervention":13950,"totalTrials":186,"cells":13958},{"EARLY_PHASE1":13959,"PHASE1":13961,"PHASE2":13963,"PHASE3":13969,"PHASE4":13971,"NA":13973},{"trials":13960,"activeCount":114},[],{"trials":13962,"activeCount":114},[],{"trials":13964,"activeCount":114},[13965],{"nctId":13943,"briefTitle":13944,"status":105,"phases":13966,"primaryCompletion":13946,"completion":13946,"start":13947,"enrollment":11573,"conditions":13967,"interventions":13968},[90,91],[1773,2356],[13934,13950],{"trials":13970,"activeCount":114},[],{"trials":13972,"activeCount":114},[],{"trials":13974,"activeCount":114},[],{"intervention":13976,"totalTrials":186,"cells":13977},"Atomoxetine",{"EARLY_PHASE1":13978,"PHASE1":13980,"PHASE2":13982,"PHASE3":13992,"PHASE4":13994,"NA":13996},{"trials":13979,"activeCount":114},[],{"trials":13981,"activeCount":114},[],{"trials":13983,"activeCount":114},[13984],{"nctId":13985,"briefTitle":13986,"status":105,"phases":13987,"primaryCompletion":13988,"completion":13989,"start":9933,"enrollment":2582,"conditions":13990,"interventions":13991},"NCT01522404","Effects of Atomoxetine in Mild Cognitive Impairment",[91],"2017-10-31","2018-06-30",[11050],[13976],{"trials":13993,"activeCount":114},[],{"trials":13995,"activeCount":114},[],{"trials":13997,"activeCount":114},[],{"intervention":13999,"totalTrials":186,"cells":14000},"G-CSF, GM-CSF administered at extremities",{"EARLY_PHASE1":14001,"PHASE1":14003,"PHASE2":14005,"PHASE3":14016,"PHASE4":14018,"NA":14020},{"trials":14002,"activeCount":114},[],{"trials":14004,"activeCount":114},[],{"trials":14006,"activeCount":114},[14007],{"nctId":14008,"briefTitle":14009,"status":230,"phases":14010,"primaryCompletion":3577,"completion":14011,"start":1320,"enrollment":11573,"conditions":14012,"interventions":14014},"NCT00646763","A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation",[91],"2011-02",[14013],"Cytokines",[13999,14015],"G-CSF and GMCSF administered at abdomen",{"trials":14017,"activeCount":114},[],{"trials":14019,"activeCount":114},[],{"trials":14021,"activeCount":114},[],{"intervention":14015,"totalTrials":186,"cells":14023},{"EARLY_PHASE1":14024,"PHASE1":14026,"PHASE2":14028,"PHASE3":14034,"PHASE4":14036,"NA":14038},{"trials":14025,"activeCount":114},[],{"trials":14027,"activeCount":114},[],{"trials":14029,"activeCount":114},[14030],{"nctId":14008,"briefTitle":14009,"status":230,"phases":14031,"primaryCompletion":3577,"completion":14011,"start":1320,"enrollment":11573,"conditions":14032,"interventions":14033},[91],[14013],[13999,14015],{"trials":14035,"activeCount":114},[],{"trials":14037,"activeCount":114},[],{"trials":14039,"activeCount":114},[],{"intervention":14041,"totalTrials":186,"cells":14042},"Clarithromycin",{"EARLY_PHASE1":14043,"PHASE1":14045,"PHASE2":14047,"PHASE3":14058,"PHASE4":14060,"NA":14062},{"trials":14044,"activeCount":114},[],{"trials":14046,"activeCount":114},[],{"trials":14048,"activeCount":114},[14049],{"nctId":14050,"briefTitle":14051,"status":105,"phases":14052,"primaryCompletion":14053,"completion":14053,"start":6213,"enrollment":14054,"conditions":14055,"interventions":14057},"NCT04026958","Clarithromycin Mechanisms in Hypersomnia Syndromes",[91],"2025-06-18",83,[13542,13541,14056],"Narcolepsy With Cataplexy",[14041],{"trials":14059,"activeCount":114},[],{"trials":14061,"activeCount":114},[],{"trials":14063,"activeCount":114},[],{"intervention":2249,"totalTrials":186,"cells":14065},{"EARLY_PHASE1":14066,"PHASE1":14068,"PHASE2":14070,"PHASE3":14076,"PHASE4":14078,"NA":14080},{"trials":14067,"activeCount":114},[],{"trials":14069,"activeCount":114},[],{"trials":14071,"activeCount":114},[14072],{"nctId":2238,"briefTitle":2239,"status":2240,"phases":14073,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":2075,"conditions":14074,"interventions":14075},[91],[2246,2247],[2249,57],{"trials":14077,"activeCount":114},[],{"trials":14079,"activeCount":114},[],{"trials":14081,"activeCount":114},[],{"intervention":14083,"totalTrials":186,"cells":14084},"Arsenic Trioxide",{"EARLY_PHASE1":14085,"PHASE1":14087,"PHASE2":14089,"PHASE3":14101,"PHASE4":14103,"NA":14105},{"trials":14086,"activeCount":114},[],{"trials":14088,"activeCount":114},[],{"trials":14090,"activeCount":114},[14091],{"nctId":14092,"briefTitle":14093,"status":105,"phases":14094,"primaryCompletion":487,"completion":487,"start":5941,"enrollment":454,"conditions":14095,"interventions":14100},"NCT01470248","Study of Arsenic Trioxide in Small Cell Lung Cancer",[91],[3648,14096,14097,14098,14099],"Cancer of Lung","Pulmonary Cancer","Pulmonary Neoplasms","Carcinoma, Small Cell",[14083],{"trials":14102,"activeCount":114},[],{"trials":14104,"activeCount":114},[],{"trials":14106,"activeCount":114},[],{"intervention":14108,"totalTrials":186,"cells":14109},"Conditioning Regimen with Bone Marrow Transplant",{"EARLY_PHASE1":14110,"PHASE1":14112,"PHASE2":14114,"PHASE3":14122,"PHASE4":14124,"NA":14126},{"trials":14111,"activeCount":114},[],{"trials":14113,"activeCount":114},[],{"trials":14115,"activeCount":114},[14116],{"nctId":14117,"briefTitle":14118,"status":105,"phases":14119,"primaryCompletion":11048,"completion":11048,"start":9933,"enrollment":162,"conditions":14120,"interventions":14121},"NCT01565616","Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease",[91],[24],[14108],{"trials":14123,"activeCount":114},[],{"trials":14125,"activeCount":114},[],{"trials":14127,"activeCount":114},[],{"intervention":14129,"totalTrials":186,"cells":14130},"L-arginine",{"EARLY_PHASE1":14131,"PHASE1":14133,"PHASE2":14135,"PHASE3":14147,"PHASE4":14149,"NA":14151},{"trials":14132,"activeCount":114},[],{"trials":14134,"activeCount":114},[],{"trials":14136,"activeCount":114},[14137],{"nctId":14138,"briefTitle":14139,"status":105,"phases":14140,"primaryCompletion":14141,"completion":14141,"start":171,"enrollment":14142,"conditions":14143,"interventions":14145},"NCT02536170","Arginine Therapy for Sickle Cell Disease Pain",[91],"2021-02-21",108,[24,14144],"Vaso-occlusive Pain Episode",[14129,14146],"L-arginine Loading Dose",{"trials":14148,"activeCount":114},[],{"trials":14150,"activeCount":114},[],{"trials":14152,"activeCount":114},[],{"intervention":14146,"totalTrials":186,"cells":14154},{"EARLY_PHASE1":14155,"PHASE1":14157,"PHASE2":14159,"PHASE3":14165,"PHASE4":14167,"NA":14169},{"trials":14156,"activeCount":114},[],{"trials":14158,"activeCount":114},[],{"trials":14160,"activeCount":114},[14161],{"nctId":14138,"briefTitle":14139,"status":105,"phases":14162,"primaryCompletion":14141,"completion":14141,"start":171,"enrollment":14142,"conditions":14163,"interventions":14164},[91],[24,14144],[14129,14146],{"trials":14166,"activeCount":114},[],{"trials":14168,"activeCount":114},[],{"trials":14170,"activeCount":114},[],{"intervention":14172,"totalTrials":186,"cells":14173},"FACBC PET-CT Scan",{"EARLY_PHASE1":14174,"PHASE1":14176,"PHASE2":14178,"PHASE3":14188,"PHASE4":14190,"NA":14192},{"trials":14175,"activeCount":114},[],{"trials":14177,"activeCount":114},[],{"trials":14179,"activeCount":114},[14180],{"nctId":14181,"briefTitle":14182,"status":105,"phases":14183,"primaryCompletion":14184,"completion":14184,"start":1497,"enrollment":1930,"conditions":14185,"interventions":14187},"NCT02744534","Targeted Fusion Biopsy of the Prostate",[91],"2018-03-31",[14186],"Prostatic Neoplasms",[14172],{"trials":14189,"activeCount":114},[],{"trials":14191,"activeCount":114},[],{"trials":14193,"activeCount":114},[],{"intervention":4122,"totalTrials":186,"cells":14195},{"EARLY_PHASE1":14196,"PHASE1":14198,"PHASE2":14200,"PHASE3":14206,"PHASE4":14208,"NA":14210},{"trials":14197,"activeCount":114},[],{"trials":14199,"activeCount":114},[],{"trials":14201,"activeCount":114},[14202],{"nctId":4113,"briefTitle":4114,"status":230,"phases":14203,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":14204,"interventions":14205},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":14207,"activeCount":114},[],{"trials":14209,"activeCount":114},[],{"trials":14211,"activeCount":114},[],{"intervention":4123,"totalTrials":186,"cells":14213},{"EARLY_PHASE1":14214,"PHASE1":14216,"PHASE2":14218,"PHASE3":14224,"PHASE4":14226,"NA":14228},{"trials":14215,"activeCount":114},[],{"trials":14217,"activeCount":114},[],{"trials":14219,"activeCount":114},[14220],{"nctId":4113,"briefTitle":4114,"status":230,"phases":14221,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":14222,"interventions":14223},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":14225,"activeCount":114},[],{"trials":14227,"activeCount":114},[],{"trials":14229,"activeCount":114},[],{"intervention":4124,"totalTrials":186,"cells":14231},{"EARLY_PHASE1":14232,"PHASE1":14234,"PHASE2":14236,"PHASE3":14242,"PHASE4":14244,"NA":14246},{"trials":14233,"activeCount":114},[],{"trials":14235,"activeCount":114},[],{"trials":14237,"activeCount":114},[14238],{"nctId":4113,"briefTitle":4114,"status":230,"phases":14239,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":14240,"interventions":14241},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":14243,"activeCount":114},[],{"trials":14245,"activeCount":114},[],{"trials":14247,"activeCount":114},[],{"intervention":4126,"totalTrials":186,"cells":14249},{"EARLY_PHASE1":14250,"PHASE1":14252,"PHASE2":14254,"PHASE3":14260,"PHASE4":14262,"NA":14264},{"trials":14251,"activeCount":114},[],{"trials":14253,"activeCount":114},[],{"trials":14255,"activeCount":114},[14256],{"nctId":4113,"briefTitle":4114,"status":230,"phases":14257,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":14258,"interventions":14259},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":14261,"activeCount":114},[],{"trials":14263,"activeCount":114},[],{"trials":14265,"activeCount":114},[],{"intervention":4128,"totalTrials":186,"cells":14267},{"EARLY_PHASE1":14268,"PHASE1":14270,"PHASE2":14272,"PHASE3":14278,"PHASE4":14280,"NA":14282},{"trials":14269,"activeCount":114},[],{"trials":14271,"activeCount":114},[],{"trials":14273,"activeCount":114},[14274],{"nctId":4113,"briefTitle":4114,"status":230,"phases":14275,"primaryCompletion":4116,"completion":4116,"start":4117,"enrollment":4118,"conditions":14276,"interventions":14277},[91],[4120],[4122,4123,4124,4125,4126,4127,4128],{"trials":14279,"activeCount":114},[],{"trials":14281,"activeCount":114},[],{"trials":14283,"activeCount":114},[],{"intervention":14285,"totalTrials":362,"cells":14286},"Rifaximin",{"EARLY_PHASE1":14287,"PHASE1":14298,"PHASE2":14324,"PHASE3":14326,"PHASE4":14328,"NA":14330},{"trials":14288,"activeCount":114},[14289],{"nctId":14290,"briefTitle":14291,"status":105,"phases":14292,"primaryCompletion":14293,"completion":14294,"start":7783,"enrollment":25,"conditions":14295,"interventions":14297},"NCT03529825","Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",[89],"2020-10-19","2021-09-10",[14296],"Microbial Colonization",[14285],{"trials":14299,"activeCount":114},[14300,14317],{"nctId":14301,"briefTitle":14302,"status":105,"phases":14303,"primaryCompletion":14304,"completion":14304,"start":14305,"enrollment":391,"conditions":14306,"interventions":14316},"NCT03820817","Rifaximin in Patients With Monoclonal Gammopathy",[90],"2025-11-30","2019-05-15",[14307,14308,14309,14310,14311,14312,14313,14314,14315],"IgA Monoclonal Gammopathy","IgG Monoclonal Gammopathy","IgM Monoclonal Gammopathy","Light Chain Deposition Disease","Monoclonal Gammopathy","Smoldering Waldenstrom Macroglobulinemia","Waldenstrom Macroglobulinemia","Gammopathy, Monoclonal","Gammopathy Igg",[14285],{"nctId":14318,"briefTitle":14319,"status":105,"phases":14320,"primaryCompletion":252,"completion":252,"start":10139,"enrollment":454,"conditions":14321,"interventions":14323},"NCT00967096","Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)",[90],[14322,3870],"Malignancy",[14285],{"trials":14325,"activeCount":114},[],{"trials":14327,"activeCount":114},[],{"trials":14329,"activeCount":114},[],{"trials":14331,"activeCount":114},[],{"intervention":2568,"totalTrials":327,"cells":14333},{"EARLY_PHASE1":14334,"PHASE1":14336,"PHASE2":14350,"PHASE3":14352,"PHASE4":14354,"NA":14356},{"trials":14335,"activeCount":114},[],{"trials":14337,"activeCount":114},[14338,14342],{"nctId":2560,"briefTitle":2561,"status":105,"phases":14339,"primaryCompletion":2563,"completion":160,"start":2564,"enrollment":2075,"conditions":14340,"interventions":14341},[90],[2566],[2568,2512],{"nctId":14343,"briefTitle":14344,"status":105,"phases":14345,"primaryCompletion":14346,"completion":14346,"start":10281,"enrollment":28,"conditions":14347,"interventions":14349},"NCT01116336","Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck",[90],"2018-05",[3526,14348],"Neoplasms, Head and Neck",[2568],{"trials":14351,"activeCount":114},[],{"trials":14353,"activeCount":114},[],{"trials":14355,"activeCount":114},[],{"trials":14357,"activeCount":114},[],{"intervention":10942,"totalTrials":327,"cells":14359},{"EARLY_PHASE1":14360,"PHASE1":14362,"PHASE2":14382,"PHASE3":14384,"PHASE4":14386,"NA":14388},{"trials":14361,"activeCount":114},[],{"trials":14363,"activeCount":114},[14364,14378],{"nctId":14365,"briefTitle":14366,"status":105,"phases":14367,"primaryCompletion":14368,"completion":14368,"start":171,"enrollment":7879,"conditions":14369,"interventions":14377},"NCT02644460","Abemaciclib in Children With DIPG or Recurrent\u002FRefractory Solid Tumors",[90],"2023-10-10",[3170,14370,14371,14372,14373,14374,14375,14376],"Brain Tumor, Recurrent","Solid Tumor, Recurrent","Neuroblastoma, Recurrent, Refractory","Ewing Sarcoma, Recurrent, Refractory","Rhabdomyosarcoma, Recurrent, Refractory","Osteosarcoma, Recurrent, Refractory","Rhabdoid Tumor, Recurrent, Refractory",[10942],{"nctId":10934,"briefTitle":10935,"status":2022,"phases":14379,"primaryCompletion":10937,"completion":10937,"start":10938,"enrollment":114,"conditions":14380,"interventions":14381},[90],[10940,5582,111,1853],[10942,3550,10943],{"trials":14383,"activeCount":114},[],{"trials":14385,"activeCount":114},[],{"trials":14387,"activeCount":114},[],{"trials":14389,"activeCount":114},[],{"intervention":6069,"totalTrials":327,"cells":14391},{"EARLY_PHASE1":14392,"PHASE1":14394,"PHASE2":14409,"PHASE3":14411,"PHASE4":14413,"NA":14415},{"trials":14393,"activeCount":114},[],{"trials":14395,"activeCount":114},[14396,14400],{"nctId":6060,"briefTitle":6061,"status":105,"phases":14397,"primaryCompletion":6063,"completion":6063,"start":6064,"enrollment":6065,"conditions":14398,"interventions":14399},[90],[6067],[6053,6069],{"nctId":14401,"briefTitle":14402,"status":105,"phases":14403,"primaryCompletion":14404,"completion":14404,"start":14405,"enrollment":2109,"conditions":14406,"interventions":14408},"NCT03976752","Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens",[90],"2019-09-20","2019-03-13",[14407],"HIV\u002FAIDS",[6069],{"trials":14410,"activeCount":114},[],{"trials":14412,"activeCount":114},[],{"trials":14414,"activeCount":114},[],{"trials":14416,"activeCount":114},[],{"intervention":185,"totalTrials":327,"cells":14418},{"EARLY_PHASE1":14419,"PHASE1":14421,"PHASE2":14449,"PHASE3":14451,"PHASE4":14453,"NA":14455},{"trials":14420,"activeCount":114},[],{"trials":14422,"activeCount":114},[14423,14445],{"nctId":14424,"briefTitle":14425,"status":230,"phases":14426,"primaryCompletion":171,"completion":171,"start":2965,"enrollment":362,"conditions":14427,"interventions":14444},"NCT02334319","Ganetespib Window of Opportunity Study in Head and Neck Cancers",[90],[14428,14429,14430,14431,14432,14433,14434,14435,14436,14437,14438,14439,14440,14441,14442,14443],"Stage I Hypopharyngeal Squamous Cell Carcinoma","Stage I Laryngeal Squamous Cell Carcinoma","Stage I Oral Cavity Squamous Cell Carcinoma","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Hypopharyngeal Squamous Cell Carcinoma","Stage II Laryngeal Squamous Cell Carcinoma","Stage II Oral Cavity Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Hypopharyngeal Squamous Cell Carcinoma","Stage III Laryngeal Squamous Cell Carcinoma","Stage III Oral Cavity Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IVA Hypopharyngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Squamous Cell Carcinoma","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma",[185],{"nctId":178,"briefTitle":179,"status":105,"phases":14446,"primaryCompletion":181,"completion":181,"start":173,"enrollment":182,"conditions":14447,"interventions":14448},[90],[125],[185,127,97],{"trials":14450,"activeCount":114},[],{"trials":14452,"activeCount":114},[],{"trials":14454,"activeCount":114},[],{"trials":14456,"activeCount":114},[],{"intervention":14458,"totalTrials":327,"cells":14459},"Temsirolimus",{"EARLY_PHASE1":14460,"PHASE1":14462,"PHASE2":14479,"PHASE3":14481,"PHASE4":14483,"NA":14485},{"trials":14461,"activeCount":114},[],{"trials":14463,"activeCount":114},[14464,14472],{"nctId":14465,"briefTitle":14466,"status":105,"phases":14467,"primaryCompletion":3501,"completion":3501,"start":14468,"enrollment":2481,"conditions":14469,"interventions":14470},"NCT01529138","Study of Axitinib and Temsirolimus in Solid Tumors",[90],"2011-10",[2332],[14471,14458],"Axitinib",{"nctId":14473,"briefTitle":14474,"status":2022,"phases":14475,"primaryCompletion":5902,"completion":5902,"start":3670,"enrollment":114,"conditions":14476,"interventions":14478},"NCT00949026","Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis",[90],[14477],"Brain Neoplasms",[14458],{"trials":14480,"activeCount":114},[],{"trials":14482,"activeCount":114},[],{"trials":14484,"activeCount":114},[],{"trials":14486,"activeCount":114},[],{"intervention":1489,"totalTrials":186,"cells":14488},{"EARLY_PHASE1":14489,"PHASE1":14491,"PHASE2":14497,"PHASE3":14499,"PHASE4":14501,"NA":14503},{"trials":14490,"activeCount":114},[],{"trials":14492,"activeCount":114},[14493],{"nctId":1481,"briefTitle":1482,"status":230,"phases":14494,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":186,"conditions":14495,"interventions":14496},[90],[1487],[1489,1490,565],{"trials":14498,"activeCount":114},[],{"trials":14500,"activeCount":114},[],{"trials":14502,"activeCount":114},[],{"trials":14504,"activeCount":114},[],{"intervention":1490,"totalTrials":186,"cells":14506},{"EARLY_PHASE1":14507,"PHASE1":14509,"PHASE2":14515,"PHASE3":14517,"PHASE4":14519,"NA":14521},{"trials":14508,"activeCount":114},[],{"trials":14510,"activeCount":114},[14511],{"nctId":1481,"briefTitle":1482,"status":230,"phases":14512,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":186,"conditions":14513,"interventions":14514},[90],[1487],[1489,1490,565],{"trials":14516,"activeCount":114},[],{"trials":14518,"activeCount":114},[],{"trials":14520,"activeCount":114},[],{"trials":14522,"activeCount":114},[],{"intervention":14524,"totalTrials":186,"cells":14525},"Indocyanine green",{"EARLY_PHASE1":14526,"PHASE1":14528,"PHASE2":14536,"PHASE3":14538,"PHASE4":14540,"NA":14542},{"trials":14527,"activeCount":114},[],{"trials":14529,"activeCount":114},[14530],{"nctId":14531,"briefTitle":14532,"status":105,"phases":14533,"primaryCompletion":9664,"completion":9664,"start":5940,"enrollment":31,"conditions":14534,"interventions":14535},"NCT01884584","Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer",[90],[5101],[14524],{"trials":14537,"activeCount":114},[],{"trials":14539,"activeCount":114},[],{"trials":14541,"activeCount":114},[],{"trials":14543,"activeCount":114},[],{"intervention":14545,"totalTrials":186,"cells":14546},"AMD3100",{"EARLY_PHASE1":14547,"PHASE1":14549,"PHASE2":14559,"PHASE3":14561,"PHASE4":14563,"NA":14565},{"trials":14548,"activeCount":114},[],{"trials":14550,"activeCount":114},[14551],{"nctId":14552,"briefTitle":14553,"status":230,"phases":14554,"primaryCompletion":8757,"completion":8757,"start":5940,"enrollment":186,"conditions":14555,"interventions":14558},"NCT01655875","AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia",[90],[14556,14557],"Pediatric Acute Myeloblastic Leukemia, Relapsed","Pediatric Acute Lymphoblastic Leukemia, Relapsed",[14545],{"trials":14560,"activeCount":114},[],{"trials":14562,"activeCount":114},[],{"trials":14564,"activeCount":114},[],{"trials":14566,"activeCount":114},[],{"intervention":14568,"totalTrials":186,"cells":14569},"capecitabine + ganetespib",{"EARLY_PHASE1":14570,"PHASE1":14572,"PHASE2":14581,"PHASE3":14583,"PHASE4":14585,"NA":14587},{"trials":14571,"activeCount":114},[],{"trials":14573,"activeCount":114},[14574],{"nctId":14575,"briefTitle":14576,"status":105,"phases":14577,"primaryCompletion":1555,"completion":2533,"start":5939,"enrollment":37,"conditions":14578,"interventions":14580},"NCT01554969","Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer",[90],[14579],"Rectal Cancer",[14568],{"trials":14582,"activeCount":114},[],{"trials":14584,"activeCount":114},[],{"trials":14586,"activeCount":114},[],{"trials":14588,"activeCount":114},[],{"intervention":14590,"totalTrials":186,"cells":14591},"Acute Intermittent Hypoxia",{"EARLY_PHASE1":14592,"PHASE1":14594,"PHASE2":14603,"PHASE3":14605,"PHASE4":14607,"NA":14609},{"trials":14593,"activeCount":114},[],{"trials":14595,"activeCount":114},[14596],{"nctId":14597,"briefTitle":14598,"status":105,"phases":14599,"primaryCompletion":233,"completion":251,"start":3660,"enrollment":7879,"conditions":14600,"interventions":14602},"NCT01272336","Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI",[90],[14601],"Spinal Cord Injury",[14590],{"trials":14604,"activeCount":114},[],{"trials":14606,"activeCount":114},[],{"trials":14608,"activeCount":114},[],{"trials":14610,"activeCount":114},[],{"intervention":14612,"totalTrials":186,"cells":14613},"Fludeoxyglucose F-18",{"EARLY_PHASE1":14614,"PHASE1":14616,"PHASE2":14634,"PHASE3":14636,"PHASE4":14638,"NA":14640},{"trials":14615,"activeCount":114},[],{"trials":14617,"activeCount":114},[14618],{"nctId":14619,"briefTitle":14620,"status":105,"phases":14621,"primaryCompletion":14622,"completion":14622,"start":14623,"enrollment":34,"conditions":14624,"interventions":14633},"NCT03493789","Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy",[90],"2019-03-19","2018-04-13",[14625,14626,14627,14628,14629,14630,14631,14632],"Stage I Lung Cancer","Stage I Non-Small Cell Lung Cancer AJCC v7","Stage IA Non-Small Cell Lung Carcinoma AJCC v7","Stage IB Non-Small Cell Lung Carcinoma AJCC v7","Stage II Lung Cancer","Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7",[14612],{"trials":14635,"activeCount":114},[],{"trials":14637,"activeCount":114},[],{"trials":14639,"activeCount":114},[],{"trials":14641,"activeCount":114},[],{"intervention":1788,"totalTrials":186,"cells":14643},{"EARLY_PHASE1":14644,"PHASE1":14646,"PHASE2":14652,"PHASE3":14654,"PHASE4":14656,"NA":14658},{"trials":14645,"activeCount":114},[],{"trials":14647,"activeCount":114},[14648],{"nctId":1765,"briefTitle":1766,"status":105,"phases":14649,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":1770,"conditions":14650,"interventions":14651},[90],[1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784,1785,1786],[1788,1743],{"trials":14653,"activeCount":114},[],{"trials":14655,"activeCount":114},[],{"trials":14657,"activeCount":114},[],{"trials":14659,"activeCount":114},[],{"intervention":14661,"totalTrials":186,"cells":14662},"Bortezomib and Tipifarnib",{"EARLY_PHASE1":14663,"PHASE1":14665,"PHASE2":14673,"PHASE3":14675,"PHASE4":14677,"NA":14679},{"trials":14664,"activeCount":114},[],{"trials":14666,"activeCount":114},[14667],{"nctId":14668,"briefTitle":14669,"status":105,"phases":14670,"primaryCompletion":5970,"completion":1555,"start":7122,"enrollment":870,"conditions":14671,"interventions":14672},"NCT00972712","Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma",[90],[125],[14661],{"trials":14674,"activeCount":114},[],{"trials":14676,"activeCount":114},[],{"trials":14678,"activeCount":114},[],{"trials":14680,"activeCount":114},[],{"intervention":3714,"totalTrials":186,"cells":14682},{"EARLY_PHASE1":14683,"PHASE1":14685,"PHASE2":14691,"PHASE3":14693,"PHASE4":14695,"NA":14697},{"trials":14684,"activeCount":114},[],{"trials":14686,"activeCount":114},[14687],{"nctId":3705,"briefTitle":3706,"status":105,"phases":14688,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":276,"conditions":14689,"interventions":14690},[90],[3711,3712],[3665,3714,1981],{"trials":14692,"activeCount":114},[],{"trials":14694,"activeCount":114},[],{"trials":14696,"activeCount":114},[],{"trials":14698,"activeCount":114},[],{"intervention":14700,"totalTrials":186,"cells":14701},"Single dose of Genvoya® and a single 800 mg dose of Darunavir®",{"EARLY_PHASE1":14702,"PHASE1":14704,"PHASE2":14714,"PHASE3":14716,"PHASE4":14718,"NA":14720},{"trials":14703,"activeCount":114},[],{"trials":14705,"activeCount":114},[14706],{"nctId":14707,"briefTitle":14708,"status":105,"phases":14709,"primaryCompletion":14710,"completion":14710,"start":14711,"enrollment":11573,"conditions":14712,"interventions":14713},"NCT03472963","Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.",[90],"2019-03-29","2018-04-27",[6067],[14700],{"trials":14715,"activeCount":114},[],{"trials":14717,"activeCount":114},[],{"trials":14719,"activeCount":114},[],{"trials":14721,"activeCount":114},[],{"intervention":129,"totalTrials":186,"cells":14723},{"EARLY_PHASE1":14724,"PHASE1":14726,"PHASE2":14732,"PHASE3":14734,"PHASE4":14736,"NA":14738},{"trials":14725,"activeCount":114},[],{"trials":14727,"activeCount":114},[14728],{"nctId":118,"briefTitle":119,"status":105,"phases":14729,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":14730,"interventions":14731},[90],[125],[127,128,97,129],{"trials":14733,"activeCount":114},[],{"trials":14735,"activeCount":114},[],{"trials":14737,"activeCount":114},[],{"trials":14739,"activeCount":114},[],{"intervention":141,"totalTrials":186,"cells":14741},{"EARLY_PHASE1":14742,"PHASE1":14744,"PHASE2":14750,"PHASE3":14752,"PHASE4":14754,"NA":14756},{"trials":14743,"activeCount":114},[],{"trials":14745,"activeCount":114},[14746],{"nctId":131,"briefTitle":132,"status":105,"phases":14747,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":14748,"interventions":14749},[90],[138],[140,97,57,141],{"trials":14751,"activeCount":114},[],{"trials":14753,"activeCount":114},[],{"trials":14755,"activeCount":114},[],{"trials":14757,"activeCount":114},[],{"intervention":14759,"totalTrials":186,"cells":14760},"Sunitinib and Bortezomib",{"EARLY_PHASE1":14761,"PHASE1":14763,"PHASE2":14771,"PHASE3":14773,"PHASE4":14775,"NA":14777},{"trials":14762,"activeCount":114},[],{"trials":14764,"activeCount":114},[14765],{"nctId":14766,"briefTitle":14767,"status":105,"phases":14768,"primaryCompletion":2416,"completion":2416,"start":1498,"enrollment":123,"conditions":14769,"interventions":14770},"NCT00720148","A Phase I Trial of Bortezomib and Sunitinib",[90],[10741],[14759],{"trials":14772,"activeCount":114},[],{"trials":14774,"activeCount":114},[],{"trials":14776,"activeCount":114},[],{"trials":14778,"activeCount":114},[],{"intervention":14780,"totalTrials":186,"cells":14781},"Biotin-Labeled Red Blood Cells",{"EARLY_PHASE1":14782,"PHASE1":14784,"PHASE2":14795,"PHASE3":14797,"PHASE4":14799,"NA":14801},{"trials":14783,"activeCount":114},[],{"trials":14785,"activeCount":114},[14786],{"nctId":14787,"briefTitle":14788,"status":105,"phases":14789,"primaryCompletion":14790,"completion":14790,"start":14791,"enrollment":292,"conditions":14792,"interventions":14794},"NCT02757898","Transfusion of Biotinylated Red Blood Cells",[90],"2018-11-13","2017-01-11",[14793],"Anemia",[14780],{"trials":14796,"activeCount":114},[],{"trials":14798,"activeCount":114},[],{"trials":14800,"activeCount":114},[],{"trials":14802,"activeCount":114},[],{"intervention":10943,"totalTrials":186,"cells":14804},{"EARLY_PHASE1":14805,"PHASE1":14807,"PHASE2":14813,"PHASE3":14815,"PHASE4":14817,"NA":14819},{"trials":14806,"activeCount":114},[],{"trials":14808,"activeCount":114},[14809],{"nctId":10934,"briefTitle":10935,"status":2022,"phases":14810,"primaryCompletion":10937,"completion":10937,"start":10938,"enrollment":114,"conditions":14811,"interventions":14812},[90],[10940,5582,111,1853],[10942,3550,10943],{"trials":14814,"activeCount":114},[],{"trials":14816,"activeCount":114},[],{"trials":14818,"activeCount":114},[],{"trials":14820,"activeCount":114},[],{"intervention":14822,"totalTrials":186,"cells":14823},"Desmopressin",{"EARLY_PHASE1":14824,"PHASE1":14826,"PHASE2":14835,"PHASE3":14837,"PHASE4":14839,"NA":14841},{"trials":14825,"activeCount":114},[],{"trials":14827,"activeCount":114},[14828],{"nctId":14829,"briefTitle":14830,"status":105,"phases":14831,"primaryCompletion":14832,"completion":14832,"start":320,"enrollment":327,"conditions":14833,"interventions":14834},"NCT02506023","Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers",[90],"2018-06-15",[1453],[14822],{"trials":14836,"activeCount":114},[],{"trials":14838,"activeCount":114},[],{"trials":14840,"activeCount":114},[],{"trials":14842,"activeCount":114},[],{"intervention":14844,"totalTrials":186,"cells":14845},"18F-FACBC Radiotracer",{"EARLY_PHASE1":14846,"PHASE1":14848,"PHASE2":14856,"PHASE3":14858,"PHASE4":14860,"NA":14862},{"trials":14847,"activeCount":114},[],{"trials":14849,"activeCount":114},[14850],{"nctId":14851,"briefTitle":14852,"status":105,"phases":14853,"primaryCompletion":5940,"completion":4116,"start":10754,"enrollment":2075,"conditions":14854,"interventions":14855},"NCT01502670","Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule",[90],[3648],[14844],{"trials":14857,"activeCount":114},[],{"trials":14859,"activeCount":114},[],{"trials":14861,"activeCount":114},[],{"trials":14863,"activeCount":114},[],{"intervention":14865,"totalTrials":186,"cells":14866},"Modified FOLFIRINOX",{"EARLY_PHASE1":14867,"PHASE1":14869,"PHASE2":14882,"PHASE3":14884,"PHASE4":14886,"NA":14888},{"trials":14868,"activeCount":114},[],{"trials":14870,"activeCount":114},[14871],{"nctId":14872,"briefTitle":14873,"status":105,"phases":14874,"primaryCompletion":1555,"completion":1555,"start":321,"enrollment":2481,"conditions":14875,"interventions":14881},"NCT01446458","Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer",[90],[14876,14877,14878,14879,14880],"Cancer of Pancreas","Cancer of the Pancreas","Neoplasms, Pancreatic","Pancreas Cancer","Pancreas Neoplasms",[14865],{"trials":14883,"activeCount":114},[],{"trials":14885,"activeCount":114},[],{"trials":14887,"activeCount":114},[],{"trials":14889,"activeCount":114},[],{"intervention":3528,"totalTrials":186,"cells":14891},{"EARLY_PHASE1":14892,"PHASE1":14894,"PHASE2":14900,"PHASE3":14902,"PHASE4":14904,"NA":14906},{"trials":14893,"activeCount":114},[],{"trials":14895,"activeCount":114},[14896],{"nctId":3520,"briefTitle":3521,"status":105,"phases":14897,"primaryCompletion":3523,"completion":3523,"start":3524,"enrollment":31,"conditions":14898,"interventions":14899},[90],[3526],[3528,2382],{"trials":14901,"activeCount":114},[],{"trials":14903,"activeCount":114},[],{"trials":14905,"activeCount":114},[],{"trials":14907,"activeCount":114},[],{"intervention":14909,"totalTrials":186,"cells":14910},"Tolvaptan 30 mg + IV Diuretics",{"EARLY_PHASE1":14911,"PHASE1":14913,"PHASE2":14926,"PHASE3":14928,"PHASE4":14930,"NA":14932},{"trials":14912,"activeCount":114},[],{"trials":14914,"activeCount":114},[14915],{"nctId":14916,"briefTitle":14917,"status":105,"phases":14918,"primaryCompletion":14919,"completion":14919,"start":487,"enrollment":1218,"conditions":14920,"interventions":14923},"NCT02646540","AiDing Diuresis wIth Tolvaptan (ADD-IT)",[90],"2018-12-30",[14921,14922],"Cardiomyopathy","Congestive Heart Failure",[14909,14924,14925],"Metolazone 5 mg + IV Diuretics","2.5 times the Diuretics Dose",{"trials":14927,"activeCount":114},[],{"trials":14929,"activeCount":114},[],{"trials":14931,"activeCount":114},[],{"trials":14933,"activeCount":114},[],{"intervention":14924,"totalTrials":186,"cells":14935},{"EARLY_PHASE1":14936,"PHASE1":14938,"PHASE2":14944,"PHASE3":14946,"PHASE4":14948,"NA":14950},{"trials":14937,"activeCount":114},[],{"trials":14939,"activeCount":114},[14940],{"nctId":14916,"briefTitle":14917,"status":105,"phases":14941,"primaryCompletion":14919,"completion":14919,"start":487,"enrollment":1218,"conditions":14942,"interventions":14943},[90],[14921,14922],[14909,14924,14925],{"trials":14945,"activeCount":114},[],{"trials":14947,"activeCount":114},[],{"trials":14949,"activeCount":114},[],{"trials":14951,"activeCount":114},[],{"intervention":14925,"totalTrials":186,"cells":14953},{"EARLY_PHASE1":14954,"PHASE1":14956,"PHASE2":14962,"PHASE3":14964,"PHASE4":14966,"NA":14968},{"trials":14955,"activeCount":114},[],{"trials":14957,"activeCount":114},[14958],{"nctId":14916,"briefTitle":14917,"status":105,"phases":14959,"primaryCompletion":14919,"completion":14919,"start":487,"enrollment":1218,"conditions":14960,"interventions":14961},[90],[14921,14922],[14909,14924,14925],{"trials":14963,"activeCount":114},[],{"trials":14965,"activeCount":114},[],{"trials":14967,"activeCount":114},[],{"trials":14969,"activeCount":114},[],{"intervention":14971,"totalTrials":186,"cells":14972},"autologous mesenchymal stromal cell",{"EARLY_PHASE1":14973,"PHASE1":14975,"PHASE2":14984,"PHASE3":14986,"PHASE4":14988,"NA":14990},{"trials":14974,"activeCount":114},[],{"trials":14976,"activeCount":114},[14977],{"nctId":14978,"briefTitle":14979,"status":105,"phases":14980,"primaryCompletion":320,"start":7344,"enrollment":37,"conditions":14981,"interventions":14983},"NCT01659762","A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.",[90],[14982],"Crohn's Disease",[14971],{"trials":14985,"activeCount":114},[],{"trials":14987,"activeCount":114},[],{"trials":14989,"activeCount":114},[],{"trials":14991,"activeCount":114},[],{"intervention":2104,"totalTrials":186,"cells":14993},{"EARLY_PHASE1":14994,"PHASE1":14996,"PHASE2":15002,"PHASE3":15004,"PHASE4":15006,"NA":15008},{"trials":14995,"activeCount":114},[],{"trials":14997,"activeCount":114},[14998],{"nctId":2093,"briefTitle":2094,"status":2022,"phases":14999,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":114,"conditions":15000,"interventions":15001},[90],[2099,2100,2101,1911,2102],[154,2104,57],{"trials":15003,"activeCount":114},[],{"trials":15005,"activeCount":114},[],{"trials":15007,"activeCount":114},[],{"trials":15009,"activeCount":114},[],{"intervention":2774,"totalTrials":186,"cells":15011},{"EARLY_PHASE1":15012,"PHASE1":15014,"PHASE2":15020,"PHASE3":15022,"PHASE4":15024,"NA":15026},{"trials":15013,"activeCount":114},[],{"trials":15015,"activeCount":114},[15016],{"nctId":2766,"briefTitle":2767,"status":2022,"phases":15017,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":114,"conditions":15018,"interventions":15019},[90],[2772],[2511,2774],{"trials":15021,"activeCount":114},[],{"trials":15023,"activeCount":114},[],{"trials":15025,"activeCount":114},[],{"trials":15027,"activeCount":114},[],{"intervention":15029,"totalTrials":186,"cells":15030},"Gemcitabine with TheraSphere",{"EARLY_PHASE1":15031,"PHASE1":15033,"PHASE2":15042,"PHASE3":15044,"PHASE4":15046,"NA":15048},{"trials":15032,"activeCount":114},[],{"trials":15034,"activeCount":114},[15035],{"nctId":15036,"briefTitle":15037,"status":230,"phases":15038,"primaryCompletion":2942,"completion":8364,"start":2674,"enrollment":2448,"conditions":15039,"interventions":15041},"NCT01434459","Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin",[90],[2418,15040],"Cholangiocarcinoma",[15029],{"trials":15043,"activeCount":114},[],{"trials":15045,"activeCount":114},[],{"trials":15047,"activeCount":114},[],{"trials":15049,"activeCount":114},[],{"intervention":15051,"totalTrials":186,"cells":15052},"YF-VAX® plus saline",{"EARLY_PHASE1":15053,"PHASE1":15055,"PHASE2":15065,"PHASE3":15067,"PHASE4":15069,"NA":15071},{"trials":15054,"activeCount":114},[],{"trials":15056,"activeCount":114},[15057],{"nctId":15058,"briefTitle":15059,"status":105,"phases":15060,"primaryCompletion":10055,"completion":10055,"start":7613,"enrollment":498,"conditions":15061,"interventions":15063},"NCT00254826","Yellow Fever Virus Vaccine and Immune Globulin Study",[90],[15062],"Viremia",[15051,15064],"17D YF Vaccine plus Ig,",{"trials":15066,"activeCount":114},[],{"trials":15068,"activeCount":114},[],{"trials":15070,"activeCount":114},[],{"trials":15072,"activeCount":114},[],{"intervention":15064,"totalTrials":186,"cells":15074},{"EARLY_PHASE1":15075,"PHASE1":15077,"PHASE2":15083,"PHASE3":15085,"PHASE4":15087,"NA":15089},{"trials":15076,"activeCount":114},[],{"trials":15078,"activeCount":114},[15079],{"nctId":15058,"briefTitle":15059,"status":105,"phases":15080,"primaryCompletion":10055,"completion":10055,"start":7613,"enrollment":498,"conditions":15081,"interventions":15082},[90],[15062],[15051,15064],{"trials":15084,"activeCount":114},[],{"trials":15086,"activeCount":114},[],{"trials":15088,"activeCount":114},[],{"trials":15090,"activeCount":114},[],{"intervention":15092,"totalTrials":186,"cells":15093},"Curcumin",{"EARLY_PHASE1":15094,"PHASE1":15096,"PHASE2":15106,"PHASE3":15108,"PHASE4":15110,"NA":15112},{"trials":15095,"activeCount":114},[],{"trials":15097,"activeCount":114},[15098],{"nctId":15099,"briefTitle":15100,"status":105,"phases":15101,"primaryCompletion":2797,"completion":173,"start":6966,"enrollment":2481,"conditions":15102,"interventions":15104},"NCT01035580","Trial on Safety and Pharmacokinetics of Intravaginal Curcumin",[90],[15103],"Uterine Cervical Dysplasia",[15092,15105],"curcumin",{"trials":15107,"activeCount":114},[],{"trials":15109,"activeCount":114},[],{"trials":15111,"activeCount":114},[],{"trials":15113,"activeCount":114},[],{"intervention":15115,"totalTrials":186,"cells":15116},"Low Dose Sinemet CR",{"EARLY_PHASE1":15117,"PHASE1":15119,"PHASE2":15129,"PHASE3":15131,"PHASE4":15133,"NA":15135},{"trials":15118,"activeCount":114},[],{"trials":15120,"activeCount":114},[15121],{"nctId":15122,"briefTitle":15123,"status":105,"phases":15124,"primaryCompletion":15125,"completion":15125,"start":487,"enrollment":436,"conditions":15126,"interventions":15127},"NCT02706977","The Effect of Dopamine on Diabetic Retinopathy",[90],"2019-08-15",[18],[15115,15128],"High Dose Sinemet CR",{"trials":15130,"activeCount":114},[],{"trials":15132,"activeCount":114},[],{"trials":15134,"activeCount":114},[],{"trials":15136,"activeCount":114},[],{"intervention":15128,"totalTrials":186,"cells":15138},{"EARLY_PHASE1":15139,"PHASE1":15141,"PHASE2":15147,"PHASE3":15149,"PHASE4":15151,"NA":15153},{"trials":15140,"activeCount":114},[],{"trials":15142,"activeCount":114},[15143],{"nctId":15122,"briefTitle":15123,"status":105,"phases":15144,"primaryCompletion":15125,"completion":15125,"start":487,"enrollment":436,"conditions":15145,"interventions":15146},[90],[18],[15115,15128],{"trials":15148,"activeCount":114},[],{"trials":15150,"activeCount":114},[],{"trials":15152,"activeCount":114},[],{"trials":15154,"activeCount":114},[],{"intervention":15156,"totalTrials":186,"cells":15157},"WP1066",{"EARLY_PHASE1":15158,"PHASE1":15160,"PHASE2":15172,"PHASE3":15174,"PHASE4":15176,"NA":15178},{"trials":15159,"activeCount":114},[],{"trials":15161,"activeCount":114},[15162],{"nctId":15163,"briefTitle":15164,"status":105,"phases":15165,"primaryCompletion":15166,"completion":15166,"start":15167,"enrollment":2075,"conditions":15168,"interventions":15171},"NCT04334863","WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors",[90],"2023-02-03","2020-05-04",[15169,2805,15170],"Brain Tumor","Brain Metastases",[15156],{"trials":15173,"activeCount":114},[],{"trials":15175,"activeCount":114},[],{"trials":15177,"activeCount":114},[],{"trials":15179,"activeCount":114},[],{"intervention":15181,"totalTrials":186,"cells":15182},"Isotretinoin",{"EARLY_PHASE1":15183,"PHASE1":15185,"PHASE2":15193,"PHASE3":15195,"PHASE4":15197,"NA":15199},{"trials":15184,"activeCount":114},[],{"trials":15186,"activeCount":114},[15187],{"nctId":15188,"briefTitle":15189,"status":2022,"phases":15190,"primaryCompletion":6152,"completion":6152,"start":12347,"enrollment":114,"conditions":15191,"interventions":15192},"NCT01319838","Aflac ST1001 Prolonged Isotretinoin",[90],[2489],[15181],{"trials":15194,"activeCount":114},[],{"trials":15196,"activeCount":114},[],{"trials":15198,"activeCount":114},[],{"trials":15200,"activeCount":114},[],{"intervention":15202,"totalTrials":186,"cells":15203},"Sodium chloride \u002Fsodium acetate",{"EARLY_PHASE1":15204,"PHASE1":15206,"PHASE2":15221,"PHASE3":15223,"PHASE4":15225,"NA":15227},{"trials":15205,"activeCount":114},[],{"trials":15207,"activeCount":114},[15208],{"nctId":15209,"briefTitle":15210,"status":105,"phases":15211,"primaryCompletion":15212,"completion":15212,"start":15213,"enrollment":15214,"conditions":15215,"interventions":15218},"NCT03204955","A Low ChloridE hyperTonic Solution for Brain Edema",[90],"2018-09-30","2017-06-28",59,[15216,15217],"Subarachnoid Hemorrhage","Acute Kidney Injury",[15202,15219,15220],"Sodium chloride","PlasmaLyte",{"trials":15222,"activeCount":114},[],{"trials":15224,"activeCount":114},[],{"trials":15226,"activeCount":114},[],{"trials":15228,"activeCount":114},[],{"intervention":15219,"totalTrials":186,"cells":15230},{"EARLY_PHASE1":15231,"PHASE1":15233,"PHASE2":15239,"PHASE3":15241,"PHASE4":15243,"NA":15245},{"trials":15232,"activeCount":114},[],{"trials":15234,"activeCount":114},[15235],{"nctId":15209,"briefTitle":15210,"status":105,"phases":15236,"primaryCompletion":15212,"completion":15212,"start":15213,"enrollment":15214,"conditions":15237,"interventions":15238},[90],[15216,15217],[15202,15219,15220],{"trials":15240,"activeCount":114},[],{"trials":15242,"activeCount":114},[],{"trials":15244,"activeCount":114},[],{"trials":15246,"activeCount":114},[],{"intervention":15220,"totalTrials":186,"cells":15248},{"EARLY_PHASE1":15249,"PHASE1":15251,"PHASE2":15257,"PHASE3":15259,"PHASE4":15261,"NA":15263},{"trials":15250,"activeCount":114},[],{"trials":15252,"activeCount":114},[15253],{"nctId":15209,"briefTitle":15210,"status":105,"phases":15254,"primaryCompletion":15212,"completion":15212,"start":15213,"enrollment":15214,"conditions":15255,"interventions":15256},[90],[15216,15217],[15202,15219,15220],{"trials":15258,"activeCount":114},[],{"trials":15260,"activeCount":114},[],{"trials":15262,"activeCount":114},[],{"trials":15264,"activeCount":114},[],{"intervention":15266,"totalTrials":186,"cells":15267},"Intra-coronary",{"EARLY_PHASE1":15268,"PHASE1":15270,"PHASE2":15279,"PHASE3":15281,"PHASE4":15283,"NA":15285},{"trials":15269,"activeCount":114},[],{"trials":15271,"activeCount":114},[15272],{"nctId":15273,"briefTitle":15274,"status":105,"phases":15275,"primaryCompletion":3644,"completion":7099,"start":8717,"enrollment":595,"conditions":15276,"interventions":15278},"NCT00313339","Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction",[90],[15277,27],"Myocardial Infarction",[15266],{"trials":15280,"activeCount":114},[],{"trials":15282,"activeCount":114},[],{"trials":15284,"activeCount":114},[],{"trials":15286,"activeCount":114},[],{"intervention":176,"totalTrials":186,"cells":15288},{"EARLY_PHASE1":15289,"PHASE1":15291,"PHASE2":15297,"PHASE3":15299,"PHASE4":15301,"NA":15303},{"trials":15290,"activeCount":114},[],{"trials":15292,"activeCount":114},[15293],{"nctId":168,"briefTitle":169,"status":105,"phases":15294,"primaryCompletion":171,"completion":172,"start":173,"enrollment":19,"conditions":15295,"interventions":15296},[90],[125],[176,140,97],{"trials":15298,"activeCount":114},[],{"trials":15300,"activeCount":114},[],{"trials":15302,"activeCount":114},[],{"trials":15304,"activeCount":114},[],{"intervention":15306,"totalTrials":186,"cells":15307},"Decitabine",{"EARLY_PHASE1":15308,"PHASE1":15310,"PHASE2":15318,"PHASE3":15320,"PHASE4":15322,"NA":15324},{"trials":15309,"activeCount":114},[],{"trials":15311,"activeCount":114},[15312],{"nctId":15313,"briefTitle":15314,"status":230,"phases":15315,"primaryCompletion":171,"completion":12100,"start":3524,"enrollment":362,"conditions":15316,"interventions":15317},"NCT02234037","Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60",[90],[10974],[15306],{"trials":15319,"activeCount":114},[],{"trials":15321,"activeCount":114},[],{"trials":15323,"activeCount":114},[],{"trials":15325,"activeCount":114},[],{"intervention":3636,"totalTrials":186,"cells":15327},{"EARLY_PHASE1":15328,"PHASE1":15330,"PHASE2":15336,"PHASE3":15338,"PHASE4":15340,"NA":15342},{"trials":15329,"activeCount":114},[],{"trials":15331,"activeCount":114},[15332],{"nctId":3628,"briefTitle":3629,"status":230,"phases":15333,"primaryCompletion":3631,"completion":3631,"start":536,"enrollment":470,"conditions":15334,"interventions":15335},[90],[3633,2246,3634],[3636,2039,3637,3638],{"trials":15337,"activeCount":114},[],{"trials":15339,"activeCount":114},[],{"trials":15341,"activeCount":114},[],{"trials":15343,"activeCount":114},[],{"intervention":3637,"totalTrials":186,"cells":15345},{"EARLY_PHASE1":15346,"PHASE1":15348,"PHASE2":15354,"PHASE3":15356,"PHASE4":15358,"NA":15360},{"trials":15347,"activeCount":114},[],{"trials":15349,"activeCount":114},[15350],{"nctId":3628,"briefTitle":3629,"status":230,"phases":15351,"primaryCompletion":3631,"completion":3631,"start":536,"enrollment":470,"conditions":15352,"interventions":15353},[90],[3633,2246,3634],[3636,2039,3637,3638],{"trials":15355,"activeCount":114},[],{"trials":15357,"activeCount":114},[],{"trials":15359,"activeCount":114},[],{"trials":15361,"activeCount":114},[],{"intervention":3638,"totalTrials":186,"cells":15363},{"EARLY_PHASE1":15364,"PHASE1":15366,"PHASE2":15372,"PHASE3":15374,"PHASE4":15376,"NA":15378},{"trials":15365,"activeCount":114},[],{"trials":15367,"activeCount":114},[15368],{"nctId":3628,"briefTitle":3629,"status":230,"phases":15369,"primaryCompletion":3631,"completion":3631,"start":536,"enrollment":470,"conditions":15370,"interventions":15371},[90],[3633,2246,3634],[3636,2039,3637,3638],{"trials":15373,"activeCount":114},[],{"trials":15375,"activeCount":114},[],{"trials":15377,"activeCount":114},[],{"trials":15379,"activeCount":114},[],{"intervention":15381,"totalTrials":186,"cells":15382},"1000 IU of Vitamin D3",{"EARLY_PHASE1":15383,"PHASE1":15385,"PHASE2":15395,"PHASE3":15397,"PHASE4":15399,"NA":15401},{"trials":15384,"activeCount":114},[],{"trials":15386,"activeCount":114},[15387],{"nctId":15388,"briefTitle":15389,"status":105,"phases":15390,"primaryCompletion":15391,"completion":15391,"start":3466,"enrollment":8548,"conditions":15392,"interventions":15393},"NCT01909115","Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease",[90],"2014-09-26",[3232],[15381,15394],"4000 IU of Vitamin D3",{"trials":15396,"activeCount":114},[],{"trials":15398,"activeCount":114},[],{"trials":15400,"activeCount":114},[],{"trials":15402,"activeCount":114},[],{"intervention":15394,"totalTrials":186,"cells":15404},{"EARLY_PHASE1":15405,"PHASE1":15407,"PHASE2":15413,"PHASE3":15415,"PHASE4":15417,"NA":15419},{"trials":15406,"activeCount":114},[],{"trials":15408,"activeCount":114},[15409],{"nctId":15388,"briefTitle":15389,"status":105,"phases":15410,"primaryCompletion":15391,"completion":15391,"start":3466,"enrollment":8548,"conditions":15411,"interventions":15412},[90],[3232],[15381,15394],{"trials":15414,"activeCount":114},[],{"trials":15416,"activeCount":114},[],{"trials":15418,"activeCount":114},[],{"trials":15420,"activeCount":114},[],{"intervention":15422,"totalTrials":186,"cells":15423},"Temozolomide, bevacizumab and bortezomib",{"EARLY_PHASE1":15424,"PHASE1":15426,"PHASE2":15434,"PHASE3":15436,"PHASE4":15438,"NA":15440},{"trials":15425,"activeCount":114},[],{"trials":15427,"activeCount":114},[15428],{"nctId":15429,"briefTitle":15430,"status":105,"phases":15431,"primaryCompletion":5925,"completion":5925,"start":7806,"enrollment":870,"conditions":15432,"interventions":15433},"NCT01435395","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",[90],[12863],[15422],{"trials":15435,"activeCount":114},[],{"trials":15437,"activeCount":114},[],{"trials":15439,"activeCount":114},[],{"trials":15441,"activeCount":114},[],{"intervention":15443,"totalTrials":186,"cells":15444},"Autologous mesenchymal stromal cells",{"EARLY_PHASE1":15445,"PHASE1":15447,"PHASE2":15459,"PHASE3":15461,"PHASE4":15463,"NA":15465},{"trials":15446,"activeCount":114},[],{"trials":15448,"activeCount":114},[15449],{"nctId":15450,"briefTitle":15451,"status":105,"phases":15452,"primaryCompletion":15453,"completion":15454,"start":9664,"enrollment":150,"conditions":15455,"interventions":15458},"NCT02359929","BMT Autologous MSCs for GvHD",[90],"2020-06-15","2021-01-11",[2690,15456,15457],"Acute Graft Versus Host Disease","Chronic Graft Versus Host Disease",[15443],{"trials":15460,"activeCount":114},[],{"trials":15462,"activeCount":114},[],{"trials":15464,"activeCount":114},[],{"trials":15466,"activeCount":114},[],{"intervention":2473,"totalTrials":186,"cells":15468},{"EARLY_PHASE1":15469,"PHASE1":15471,"PHASE2":15477,"PHASE3":15479,"PHASE4":15481,"NA":15483},{"trials":15470,"activeCount":114},[],{"trials":15472,"activeCount":114},[15473],{"nctId":2463,"briefTitle":2464,"status":105,"phases":15474,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":182,"conditions":15475,"interventions":15476},[90],[2469,2470],[2472,2473,154,2474],{"trials":15478,"activeCount":114},[],{"trials":15480,"activeCount":114},[],{"trials":15482,"activeCount":114},[],{"trials":15484,"activeCount":114},[],{"intervention":3653,"totalTrials":186,"cells":15486},{"EARLY_PHASE1":15487,"PHASE1":15489,"PHASE2":15495,"PHASE3":15497,"PHASE4":15499,"NA":15501},{"trials":15488,"activeCount":114},[],{"trials":15490,"activeCount":114},[15491],{"nctId":3640,"briefTitle":3641,"status":230,"phases":15492,"primaryCompletion":3643,"completion":3644,"start":3645,"enrollment":3646,"conditions":15493,"interventions":15494},[90],[3648,3649,3650,30,3651],[3653,2039],{"trials":15496,"activeCount":114},[],{"trials":15498,"activeCount":114},[],{"trials":15500,"activeCount":114},[],{"trials":15502,"activeCount":114},[],{"intervention":14471,"totalTrials":186,"cells":15504},{"EARLY_PHASE1":15505,"PHASE1":15507,"PHASE2":15513,"PHASE3":15515,"PHASE4":15517,"NA":15519},{"trials":15506,"activeCount":114},[],{"trials":15508,"activeCount":114},[15509],{"nctId":14465,"briefTitle":14466,"status":105,"phases":15510,"primaryCompletion":3501,"completion":3501,"start":14468,"enrollment":2481,"conditions":15511,"interventions":15512},[90],[2332],[14471,14458],{"trials":15514,"activeCount":114},[],{"trials":15516,"activeCount":114},[],{"trials":15518,"activeCount":114},[],{"trials":15520,"activeCount":114},[],{"intervention":15522,"totalTrials":186,"cells":15523},"Buparlisib",{"EARLY_PHASE1":15524,"PHASE1":15526,"PHASE2":15541,"PHASE3":15543,"PHASE4":15545,"NA":15547},{"trials":15525,"activeCount":114},[],{"trials":15527,"activeCount":114},[15528],{"nctId":15529,"briefTitle":15530,"status":230,"phases":15531,"primaryCompletion":15532,"completion":15532,"start":487,"enrollment":186,"conditions":15533,"interventions":15538},"NCT02614508","Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[90],"2019-08",[15534,15535,15536,15537],"Recurrent Chronic Lymphocytic Leukemia","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Small Lymphocytic Lymphoma",[15522,15539,15540],"Ibrutinib","Ofatumumab",{"trials":15542,"activeCount":114},[],{"trials":15544,"activeCount":114},[],{"trials":15546,"activeCount":114},[],{"trials":15548,"activeCount":114},[],{"intervention":15539,"totalTrials":186,"cells":15550},{"EARLY_PHASE1":15551,"PHASE1":15553,"PHASE2":15559,"PHASE3":15561,"PHASE4":15563,"NA":15565},{"trials":15552,"activeCount":114},[],{"trials":15554,"activeCount":114},[15555],{"nctId":15529,"briefTitle":15530,"status":230,"phases":15556,"primaryCompletion":15532,"completion":15532,"start":487,"enrollment":186,"conditions":15557,"interventions":15558},[90],[15534,15535,15536,15537],[15522,15539,15540],{"trials":15560,"activeCount":114},[],{"trials":15562,"activeCount":114},[],{"trials":15564,"activeCount":114},[],{"trials":15566,"activeCount":114},[],{"intervention":15540,"totalTrials":186,"cells":15568},{"EARLY_PHASE1":15569,"PHASE1":15571,"PHASE2":15577,"PHASE3":15579,"PHASE4":15581,"NA":15583},{"trials":15570,"activeCount":114},[],{"trials":15572,"activeCount":114},[15573],{"nctId":15529,"briefTitle":15530,"status":230,"phases":15574,"primaryCompletion":15532,"completion":15532,"start":487,"enrollment":186,"conditions":15575,"interventions":15576},[90],[15534,15535,15536,15537],[15522,15539,15540],{"trials":15578,"activeCount":114},[],{"trials":15580,"activeCount":114},[],{"trials":15582,"activeCount":114},[],{"trials":15584,"activeCount":114},[],{"intervention":15586,"totalTrials":186,"cells":15587},"Vitamin D3 450,000 IU orally",{"EARLY_PHASE1":15588,"PHASE1":15590,"PHASE2":15602,"PHASE3":15604,"PHASE4":15606,"NA":15608},{"trials":15589,"activeCount":114},[],{"trials":15591,"activeCount":114},[15592],{"nctId":15593,"briefTitle":15594,"status":230,"phases":15595,"primaryCompletion":15596,"completion":15596,"start":15597,"enrollment":2277,"conditions":15598,"interventions":15601},"NCT03270709","Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV",[90],"2018-10-15","2018-04-11",[14407,15599,15600],"Vitamin D Deficiency","Smoker Lung",[15586],{"trials":15603,"activeCount":114},[],{"trials":15605,"activeCount":114},[],{"trials":15607,"activeCount":114},[],{"trials":15609,"activeCount":114},[],{"intervention":3881,"totalTrials":186,"cells":15611},{"EARLY_PHASE1":15612,"PHASE1":15614,"PHASE2":15620,"PHASE3":15622,"PHASE4":15624,"NA":15626},{"trials":15613,"activeCount":114},[],{"trials":15615,"activeCount":114},[15616],{"nctId":3874,"briefTitle":3875,"status":2022,"phases":15617,"primaryCompletion":2135,"completion":2135,"start":3877,"enrollment":114,"conditions":15618,"interventions":15619},[90],[2913],[3880,3057,2916,3881,3882],{"trials":15621,"activeCount":114},[],{"trials":15623,"activeCount":114},[],{"trials":15625,"activeCount":114},[],{"trials":15627,"activeCount":114},[],{"intervention":3882,"totalTrials":186,"cells":15629},{"EARLY_PHASE1":15630,"PHASE1":15632,"PHASE2":15638,"PHASE3":15640,"PHASE4":15642,"NA":15644},{"trials":15631,"activeCount":114},[],{"trials":15633,"activeCount":114},[15634],{"nctId":3874,"briefTitle":3875,"status":2022,"phases":15635,"primaryCompletion":2135,"completion":2135,"start":3877,"enrollment":114,"conditions":15636,"interventions":15637},[90],[2913],[3880,3057,2916,3881,3882],{"trials":15639,"activeCount":114},[],{"trials":15641,"activeCount":114},[],{"trials":15643,"activeCount":114},[],{"trials":15645,"activeCount":114},[],{"intervention":15647,"totalTrials":186,"cells":15648},"Intensive insulin therapy",{"EARLY_PHASE1":15649,"PHASE1":15651,"PHASE2":15660,"PHASE3":15662,"PHASE4":15664,"NA":15666},{"trials":15650,"activeCount":114},[],{"trials":15652,"activeCount":114},[15653],{"nctId":15654,"briefTitle":15655,"status":105,"phases":15656,"primaryCompletion":2966,"completion":7122,"start":7520,"enrollment":9,"conditions":15657,"interventions":15659},"NCT00209144","Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.",[90],[15658],"Acute Myocardial Infarction",[15647],{"trials":15661,"activeCount":114},[],{"trials":15663,"activeCount":114},[],{"trials":15665,"activeCount":114},[],{"trials":15667,"activeCount":114},[],{"intervention":15669,"totalTrials":186,"cells":15670},"OSI-906 and Pemetrexed",{"EARLY_PHASE1":15671,"PHASE1":15673,"PHASE2":15682,"PHASE3":15684,"PHASE4":15686,"NA":15688},{"trials":15672,"activeCount":114},[],{"trials":15674,"activeCount":114},[15675],{"nctId":15676,"briefTitle":15677,"status":2022,"phases":15678,"primaryCompletion":594,"completion":594,"start":5939,"enrollment":114,"conditions":15679,"interventions":15681},"NCT01567384","A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies",[90],[2332,164,15680],"Tumors",[15669],{"trials":15683,"activeCount":114},[],{"trials":15685,"activeCount":114},[],{"trials":15687,"activeCount":114},[],{"trials":15689,"activeCount":114},[],{"intervention":15691,"totalTrials":186,"cells":15692},"[C-11]MENET",{"EARLY_PHASE1":15693,"PHASE1":15695,"PHASE2":15705,"PHASE3":15707,"PHASE4":15709,"NA":15711},{"trials":15694,"activeCount":114},[],{"trials":15696,"activeCount":114},[15697],{"nctId":15698,"briefTitle":15699,"status":105,"phases":15700,"primaryCompletion":15701,"completion":5971,"start":5940,"enrollment":2448,"conditions":15702,"interventions":15704},"NCT01799837","Norepinephrine Transporter Availability in PTSD",[90],"2013-04",[15703],"Posttraumatic Stress Disorder",[15691],{"trials":15706,"activeCount":114},[],{"trials":15708,"activeCount":114},[],{"trials":15710,"activeCount":114},[],{"trials":15712,"activeCount":114},[],{"intervention":15714,"totalTrials":186,"cells":15715},"Autologous MSCs",{"EARLY_PHASE1":15716,"PHASE1":15718,"PHASE2":15728,"PHASE3":15730,"PHASE4":15732,"NA":15734},{"trials":15717,"activeCount":114},[],{"trials":15719,"activeCount":114},[15720],{"nctId":15721,"briefTitle":15722,"status":2022,"phases":15723,"primaryCompletion":15724,"completion":15724,"start":15725,"enrollment":114,"conditions":15726,"interventions":15727},"NCT03298399","Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease",[90],"2018-10-25","2017-12-21",[24],[15714,15714,15714],{"trials":15729,"activeCount":114},[],{"trials":15731,"activeCount":114},[],{"trials":15733,"activeCount":114},[],{"trials":15735,"activeCount":114},[],{"intervention":15737,"totalTrials":186,"cells":15738},"Lenalidomide, Rituximab, and Cyclophosphamide",{"EARLY_PHASE1":15739,"PHASE1":15741,"PHASE2":15751,"PHASE3":15753,"PHASE4":15755,"NA":15757},{"trials":15740,"activeCount":114},[],{"trials":15742,"activeCount":114},[15743],{"nctId":15744,"briefTitle":15745,"status":230,"phases":15746,"primaryCompletion":3671,"start":2416,"enrollment":538,"conditions":15747,"interventions":15750},"NCT01005979","A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed\u002FRefractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)",[90],[15748,2687,15749],"Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, Small Lymphocytic",[15737],{"trials":15752,"activeCount":114},[],{"trials":15754,"activeCount":114},[],{"trials":15756,"activeCount":114},[],{"trials":15758,"activeCount":114},[],{"intervention":2147,"totalTrials":186,"cells":15760},{"EARLY_PHASE1":15761,"PHASE1":15763,"PHASE2":15769,"PHASE3":15771,"PHASE4":15773,"NA":15775},{"trials":15762,"activeCount":114},[],{"trials":15764,"activeCount":114},[15765],{"nctId":2131,"briefTitle":2132,"status":105,"phases":15766,"primaryCompletion":2134,"completion":2134,"start":2135,"enrollment":2075,"conditions":15767,"interventions":15768},[90],[2137,1772,2138,2139,2140,2141,2142,2143,2144,2145,1777,1780,1782,1784],[2147,67,57],{"trials":15770,"activeCount":114},[],{"trials":15772,"activeCount":114},[],{"trials":15774,"activeCount":114},[],{"trials":15776,"activeCount":114},[],{"intervention":2497,"totalTrials":186,"cells":15778},{"EARLY_PHASE1":15779,"PHASE1":15781,"PHASE2":15787,"PHASE3":15789,"PHASE4":15791,"NA":15793},{"trials":15780,"activeCount":114},[],{"trials":15782,"activeCount":114},[15783],{"nctId":2476,"briefTitle":2477,"status":105,"phases":15784,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":15785,"interventions":15786},[90],[2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494],[2496,154,2497,2498],{"trials":15788,"activeCount":114},[],{"trials":15790,"activeCount":114},[],{"trials":15792,"activeCount":114},[],{"trials":15794,"activeCount":114},[],{"intervention":2498,"totalTrials":186,"cells":15796},{"EARLY_PHASE1":15797,"PHASE1":15799,"PHASE2":15805,"PHASE3":15807,"PHASE4":15809,"NA":15811},{"trials":15798,"activeCount":114},[],{"trials":15800,"activeCount":114},[15801],{"nctId":2476,"briefTitle":2477,"status":105,"phases":15802,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":15803,"interventions":15804},[90],[2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494],[2496,154,2497,2498],{"trials":15806,"activeCount":114},[],{"trials":15808,"activeCount":114},[],{"trials":15810,"activeCount":114},[],{"trials":15812,"activeCount":114},[],{"intervention":11308,"totalTrials":186,"cells":15814},{"EARLY_PHASE1":15815,"PHASE1":15817,"PHASE2":15823,"PHASE3":15825,"PHASE4":15827,"NA":15829},{"trials":15816,"activeCount":114},[],{"trials":15818,"activeCount":114},[15819],{"nctId":11298,"briefTitle":11299,"status":105,"phases":15820,"primaryCompletion":11301,"completion":11302,"start":11303,"enrollment":454,"conditions":15821,"interventions":15822},[90],[1839,11305,11306,1853],[11291,11308],{"trials":15824,"activeCount":114},[],{"trials":15826,"activeCount":114},[],{"trials":15828,"activeCount":114},[],{"trials":15830,"activeCount":114},[],{"intervention":10743,"totalTrials":186,"cells":15832},{"EARLY_PHASE1":15833,"PHASE1":15835,"PHASE2":15841,"PHASE3":15843,"PHASE4":15845,"NA":15847},{"trials":15834,"activeCount":114},[],{"trials":15836,"activeCount":114},[15837],{"nctId":10736,"briefTitle":10737,"status":105,"phases":15838,"primaryCompletion":10739,"completion":10739,"start":173,"enrollment":3053,"conditions":15839,"interventions":15840},[90],[10741,3648],[10743,2472],{"trials":15842,"activeCount":114},[],{"trials":15844,"activeCount":114},[],{"trials":15846,"activeCount":114},[],{"trials":15848,"activeCount":114},[],{"intervention":15850,"totalTrials":186,"cells":15851},"Fecal Microbiota Transplant",{"EARLY_PHASE1":15852,"PHASE1":15854,"PHASE2":15864,"PHASE3":15866,"PHASE4":15868,"NA":15870},{"trials":15853,"activeCount":114},[],{"trials":15855,"activeCount":114},[15856],{"nctId":15857,"briefTitle":15858,"status":230,"phases":15859,"primaryCompletion":15860,"completion":15860,"start":7545,"enrollment":150,"conditions":15861,"interventions":15863},"NCT02922816","FMT for MDRO Colonization After Infection in Renal Transplant Recipients",[90],"2021-12-03",[15862],"Infection Due to Resistant Organism",[15850],{"trials":15865,"activeCount":114},[],{"trials":15867,"activeCount":114},[],{"trials":15869,"activeCount":114},[],{"trials":15871,"activeCount":114},[],{"intervention":15873,"totalTrials":186,"cells":15874},"maraviroc",{"EARLY_PHASE1":15875,"PHASE1":15877,"PHASE2":15885,"PHASE3":15887,"PHASE4":15889,"NA":15891},{"trials":15876,"activeCount":114},[],{"trials":15878,"activeCount":114},[15879],{"nctId":15880,"briefTitle":15881,"status":105,"phases":15882,"primaryCompletion":3679,"completion":3679,"start":2563,"enrollment":595,"conditions":15883,"interventions":15884},"NCT01749566","Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women",[90],[15],[15873],{"trials":15886,"activeCount":114},[],{"trials":15888,"activeCount":114},[],{"trials":15890,"activeCount":114},[],{"trials":15892,"activeCount":114},[],{"intervention":15894,"totalTrials":186,"cells":15895},"Recombinant FVIII Fc fusion product Eloctate",{"EARLY_PHASE1":15896,"PHASE1":15908,"PHASE2":15910,"PHASE3":15912,"PHASE4":15914,"NA":15916},{"trials":15897,"activeCount":114},[15898],{"nctId":15899,"briefTitle":15900,"status":105,"phases":15901,"primaryCompletion":13434,"completion":13434,"start":15902,"enrollment":362,"conditions":15903,"interventions":15906},"NCT03272568","Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers",[89],"2018-02-14",[15904,15905],"Hemophilia","Menstrual Flow Excessive",[15894,15907],"Recombinant FIX Fc fusion product Alprolix",{"trials":15909,"activeCount":114},[],{"trials":15911,"activeCount":114},[],{"trials":15913,"activeCount":114},[],{"trials":15915,"activeCount":114},[],{"trials":15917,"activeCount":114},[],{"intervention":15907,"totalTrials":186,"cells":15919},{"EARLY_PHASE1":15920,"PHASE1":15926,"PHASE2":15928,"PHASE3":15930,"PHASE4":15932,"NA":15934},{"trials":15921,"activeCount":114},[15922],{"nctId":15899,"briefTitle":15900,"status":105,"phases":15923,"primaryCompletion":13434,"completion":13434,"start":15902,"enrollment":362,"conditions":15924,"interventions":15925},[89],[15904,15905],[15894,15907],{"trials":15927,"activeCount":114},[],{"trials":15929,"activeCount":114},[],{"trials":15931,"activeCount":114},[],{"trials":15933,"activeCount":114},[],{"trials":15935,"activeCount":114},[],{"intervention":15937,"totalTrials":186,"cells":15938},"Convalescent Plasma",{"EARLY_PHASE1":15939,"PHASE1":15951,"PHASE2":15953,"PHASE3":15955,"PHASE4":15957,"NA":15959},{"trials":15940,"activeCount":114},[15941],{"nctId":15942,"briefTitle":15943,"status":105,"phases":15944,"primaryCompletion":15945,"completion":15945,"start":15946,"enrollment":362,"conditions":15947,"interventions":15949},"NCT04458363","Convalescent Plasma in Pediatric COVID-19",[89],"2020-09-01","2020-07-04",[15948],"COVID",[15937,15950],"Standard COVID-19 therapies",{"trials":15952,"activeCount":114},[],{"trials":15954,"activeCount":114},[],{"trials":15956,"activeCount":114},[],{"trials":15958,"activeCount":114},[],{"trials":15960,"activeCount":114},[],{"intervention":15950,"totalTrials":186,"cells":15962},{"EARLY_PHASE1":15963,"PHASE1":15969,"PHASE2":15971,"PHASE3":15973,"PHASE4":15975,"NA":15977},{"trials":15964,"activeCount":114},[15965],{"nctId":15942,"briefTitle":15943,"status":105,"phases":15966,"primaryCompletion":15945,"completion":15945,"start":15946,"enrollment":362,"conditions":15967,"interventions":15968},[89],[15948],[15937,15950],{"trials":15970,"activeCount":114},[],{"trials":15972,"activeCount":114},[],{"trials":15974,"activeCount":114},[],{"trials":15976,"activeCount":114},[],{"trials":15978,"activeCount":114},[],{"intervention":15980,"totalTrials":186,"cells":15981},"Neostigmine Methylsulfate",{"EARLY_PHASE1":15982,"PHASE1":15992,"PHASE2":15994,"PHASE3":15996,"PHASE4":15998,"NA":16000},{"trials":15983,"activeCount":114},[15984],{"nctId":15985,"briefTitle":15986,"status":230,"phases":15987,"primaryCompletion":14622,"completion":14622,"start":15988,"enrollment":186,"conditions":15989,"interventions":15991},"NCT03316963","Neostigmine For Snoring During DISE",[89],"2017-11-14",[15990],"Snoring",[15980],{"trials":15993,"activeCount":114},[],{"trials":15995,"activeCount":114},[],{"trials":15997,"activeCount":114},[],{"trials":15999,"activeCount":114},[],{"trials":16001,"activeCount":114},[],{"intervention":16003,"totalTrials":186,"cells":16004},"Botox and rehab",{"EARLY_PHASE1":16005,"PHASE1":16013,"PHASE2":16015,"PHASE3":16017,"PHASE4":16019,"NA":16021},{"trials":16006,"activeCount":114},[16007],{"nctId":16008,"briefTitle":16009,"status":105,"phases":16010,"primaryCompletion":5970,"completion":7806,"start":6473,"enrollment":28,"conditions":16011,"interventions":16012},"NCT00565201","Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients",[89],[9706],[16003],{"trials":16014,"activeCount":114},[],{"trials":16016,"activeCount":114},[],{"trials":16018,"activeCount":114},[],{"trials":16020,"activeCount":114},[],{"trials":16022,"activeCount":114},[],{"intervention":16024,"totalTrials":186,"cells":16025},"Estradiol patch",{"EARLY_PHASE1":16026,"PHASE1":16037,"PHASE2":16039,"PHASE3":16041,"PHASE4":16043,"NA":16045},{"trials":16027,"activeCount":114},[16028],{"nctId":16029,"briefTitle":16030,"status":105,"phases":16031,"primaryCompletion":2229,"completion":2229,"start":16032,"enrollment":16033,"conditions":16034,"interventions":16036},"NCT03973229","Neuroendocrine Risk for PTSD in Women",[89],"2019-11-11",250,[4092,16035],"Trauma",[16024],{"trials":16038,"activeCount":114},[],{"trials":16040,"activeCount":114},[],{"trials":16042,"activeCount":114},[],{"trials":16044,"activeCount":114},[],{"trials":16046,"activeCount":114},[],{"intervention":16048,"totalTrials":186,"cells":16049},"Liothyronine",{"EARLY_PHASE1":16050,"PHASE1":16063,"PHASE2":16065,"PHASE3":16067,"PHASE4":16069,"NA":16071},{"trials":16051,"activeCount":114},[16052],{"nctId":16053,"briefTitle":16054,"status":2022,"phases":16055,"primaryCompletion":16056,"completion":16056,"start":16057,"enrollment":114,"conditions":16058,"interventions":16060},"NCT05017610","Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma",[89],"2022-10-14","2021-10-20",[3264,16059],"Recurrent Gliosarcoma",[16048,16061,16062],"Lomustine","Methimazole",{"trials":16064,"activeCount":114},[],{"trials":16066,"activeCount":114},[],{"trials":16068,"activeCount":114},[],{"trials":16070,"activeCount":114},[],{"trials":16072,"activeCount":114},[],{"intervention":16061,"totalTrials":186,"cells":16074},{"EARLY_PHASE1":16075,"PHASE1":16081,"PHASE2":16083,"PHASE3":16085,"PHASE4":16087,"NA":16089},{"trials":16076,"activeCount":114},[16077],{"nctId":16053,"briefTitle":16054,"status":2022,"phases":16078,"primaryCompletion":16056,"completion":16056,"start":16057,"enrollment":114,"conditions":16079,"interventions":16080},[89],[3264,16059],[16048,16061,16062],{"trials":16082,"activeCount":114},[],{"trials":16084,"activeCount":114},[],{"trials":16086,"activeCount":114},[],{"trials":16088,"activeCount":114},[],{"trials":16090,"activeCount":114},[],{"intervention":16062,"totalTrials":186,"cells":16092},{"EARLY_PHASE1":16093,"PHASE1":16099,"PHASE2":16101,"PHASE3":16103,"PHASE4":16105,"NA":16107},{"trials":16094,"activeCount":114},[16095],{"nctId":16053,"briefTitle":16054,"status":2022,"phases":16096,"primaryCompletion":16056,"completion":16056,"start":16057,"enrollment":114,"conditions":16097,"interventions":16098},[89],[3264,16059],[16048,16061,16062],{"trials":16100,"activeCount":114},[],{"trials":16102,"activeCount":114},[],{"trials":16104,"activeCount":114},[],{"trials":16106,"activeCount":114},[],{"trials":16108,"activeCount":114},[],{"intervention":11494,"totalTrials":186,"cells":16110},{"EARLY_PHASE1":16111,"PHASE1":16117,"PHASE2":16119,"PHASE3":16121,"PHASE4":16123,"NA":16125},{"trials":16112,"activeCount":114},[16113],{"nctId":11484,"briefTitle":11485,"status":105,"phases":16114,"primaryCompletion":11487,"completion":11488,"start":11489,"enrollment":470,"conditions":16115,"interventions":16116},[89],[11491,11492],[11479,11494],{"trials":16118,"activeCount":114},[],{"trials":16120,"activeCount":114},[],{"trials":16122,"activeCount":114},[],{"trials":16124,"activeCount":114},[],{"trials":16126,"activeCount":114},[],{"intervention":16128,"totalTrials":186,"cells":16129},"Therapeutic Progesterone",{"EARLY_PHASE1":16130,"PHASE1":16140,"PHASE2":16142,"PHASE3":16144,"PHASE4":16146,"NA":16148},{"trials":16131,"activeCount":114},[16132],{"nctId":16133,"briefTitle":16134,"status":230,"phases":16135,"primaryCompletion":16136,"completion":16137,"start":2025,"enrollment":470,"conditions":16138,"interventions":16139},"NCT05091866","Natural Progesterone for the Treatment of Recurrent Glioblastoma",[89],"2024-12-20","2026-03-09",[13093,3264],[16128],{"trials":16141,"activeCount":114},[],{"trials":16143,"activeCount":114},[],{"trials":16145,"activeCount":114},[],{"trials":16147,"activeCount":114},[],{"trials":16149,"activeCount":114},[],{"intervention":7762,"totalTrials":2277,"cells":16151},{"EARLY_PHASE1":16152,"PHASE1":16154,"PHASE2":16156,"PHASE3":16158,"PHASE4":16160,"NA":16187},{"trials":16153,"activeCount":114},[],{"trials":16155,"activeCount":114},[],{"trials":16157,"activeCount":114},[],{"trials":16159,"activeCount":114},[],{"trials":16161,"activeCount":114},[16162,16169,16175,16179,16183],{"nctId":16163,"briefTitle":16164,"status":105,"phases":16165,"completion":7965,"start":8717,"enrollment":123,"conditions":16166,"interventions":16167},"NCT00231335","Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia",[93],[456,6885],[16168],"escitalopram",{"nctId":16170,"briefTitle":16171,"status":105,"phases":16172,"primaryCompletion":3643,"completion":3643,"start":12234,"enrollment":454,"conditions":16173,"interventions":16174},"NCT00209170","Depression-Diabetes Mechanisms: Urban African Americans",[93],[18,21],[7762],{"nctId":7756,"briefTitle":7757,"status":105,"phases":16176,"primaryCompletion":2190,"completion":2190,"start":7759,"enrollment":98,"conditions":16177,"interventions":16178},[93],[4404],[7743,7762],{"nctId":8842,"briefTitle":8843,"status":105,"phases":16180,"primaryCompletion":8845,"completion":8845,"start":8846,"enrollment":454,"conditions":16181,"interventions":16182},[93],[21],[7762,8829],{"nctId":9496,"briefTitle":9497,"status":105,"phases":16184,"primaryCompletion":9499,"completion":9499,"start":9500,"enrollment":1796,"conditions":16185,"interventions":16186},[93],[2625],[7762,9483],{"trials":16188,"activeCount":114},[16189,16196],{"nctId":16190,"briefTitle":16191,"status":105,"phases":16192,"primaryCompletion":5941,"completion":5971,"start":3578,"enrollment":16193,"conditions":16194,"interventions":16195},"NCT00367341","Imaging Predictors of Treatment Response in Depression",[94],82,[2625],[16168],{"nctId":16197,"briefTitle":16198,"status":105,"phases":16199,"primaryCompletion":12682,"completion":12682,"start":3578,"enrollment":16200,"conditions":16201,"interventions":16202},"NCT00360399","Identifying Factors That Predict Antidepressant Treatment Response",[94],344,[21],[7762,16203],"Duloxetine",{"intervention":12104,"totalTrials":470,"cells":16205},{"EARLY_PHASE1":16206,"PHASE1":16208,"PHASE2":16210,"PHASE3":16225,"PHASE4":16227,"NA":16229},{"trials":16207,"activeCount":114},[],{"trials":16209,"activeCount":114},[],{"trials":16211,"activeCount":114},[16212,16216],{"nctId":12097,"briefTitle":12098,"status":230,"phases":16213,"primaryCompletion":11391,"completion":11391,"start":12100,"enrollment":2448,"conditions":16214,"interventions":16215},[91],[2688,12102],[12104,12088],{"nctId":16217,"briefTitle":16218,"status":230,"phases":16219,"primaryCompletion":16220,"completion":16220,"start":16221,"enrollment":391,"conditions":16222,"interventions":16224},"NCT03060772","A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)",[91],"2020-01-28","2018-01-03",[16223],"Alcoholism",[12104],{"trials":16226,"activeCount":114},[],{"trials":16228,"activeCount":114},[],{"trials":16230,"activeCount":114},[16231,16244],{"nctId":16232,"briefTitle":16233,"status":105,"phases":16234,"primaryCompletion":16235,"completion":6389,"start":252,"enrollment":2075,"conditions":16236,"interventions":16243},"NCT00927355","Effect of Thiazolidinediones on Human Bone",[94],"2010-10",[16237,16238,16239,16240,16241,16242],"Osteoblast","Adipocytes","Bone Density","Osteocalcin","Adiponectin","Mesenchymal Stem Cells",[12104],{"nctId":16245,"briefTitle":16246,"status":105,"phases":16247,"primaryCompletion":12521,"completion":12521,"start":10917,"enrollment":10726,"conditions":16248,"interventions":16250},"NCT00426413","Ketosis Prone Diabetes in African-Americans",[],[872,8912,16249],"Severe Hyperglycemia",[16251],"pioglitazone",{"intervention":678,"totalTrials":470,"cells":16253},{"EARLY_PHASE1":16254,"PHASE1":16256,"PHASE2":16258,"PHASE3":16264,"PHASE4":16273,"NA":16279},{"trials":16255,"activeCount":114},[],{"trials":16257,"activeCount":114},[],{"trials":16259,"activeCount":114},[16260],{"nctId":11937,"briefTitle":11938,"status":105,"phases":16261,"primaryCompletion":11940,"completion":252,"start":11821,"enrollment":1153,"conditions":16262,"interventions":16263},[91],[510,11942,11943],[678,11928],{"trials":16265,"activeCount":114},[16266],{"nctId":16267,"briefTitle":16268,"status":230,"phases":16269,"primaryCompletion":10055,"completion":2365,"start":9264,"enrollment":4781,"conditions":16270,"interventions":16272},"NCT00252967","Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)",[92],[16271,7455],"Atrial Fibrillation",[678],{"trials":16274,"activeCount":114},[16275],{"nctId":670,"briefTitle":671,"status":105,"phases":16276,"primaryCompletion":673,"completion":673,"start":674,"enrollment":380,"conditions":16277,"interventions":16278},[93],[676],[678,657],{"trials":16280,"activeCount":114},[16281],{"nctId":16282,"briefTitle":16283,"status":105,"phases":16284,"primaryCompletion":10281,"completion":10281,"start":7965,"enrollment":9523,"conditions":16285,"interventions":16286},"NCT00576576","Evaluation of Atorvastatin on Atherosclerosis Composition",[94],[3469],[678],{"intervention":16288,"totalTrials":362,"cells":16289},"paroxetine",{"EARLY_PHASE1":16290,"PHASE1":16292,"PHASE2":16294,"PHASE3":16296,"PHASE4":16298,"NA":16315},{"trials":16291,"activeCount":114},[],{"trials":16293,"activeCount":114},[],{"trials":16295,"activeCount":114},[],{"trials":16297,"activeCount":114},[],{"trials":16299,"activeCount":114},[16300,16308],{"nctId":16301,"briefTitle":16302,"status":105,"phases":16303,"primaryCompletion":10140,"completion":10140,"start":16304,"enrollment":1796,"conditions":16305,"interventions":16307},"NCT00672776","Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)",[93],"2003-05",[16306],"Posttraumatic Stress Disorder (PTSD)",[16288],{"nctId":16309,"briefTitle":16310,"status":105,"phases":16311,"primaryCompletion":320,"completion":320,"start":3670,"enrollment":6162,"conditions":16312,"interventions":16313},"NCT01681849","Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder",[93],[4092],[16314],"Paroxetine",{"trials":16316,"activeCount":114},[16317],{"nctId":16318,"briefTitle":16319,"status":105,"phases":16320,"completion":6862,"enrollment":436,"conditions":16321,"interventions":16324},"NCT00209118","Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C",[94],[16322,21,16323],"Hepatitis C","Interferon-alpha Associated Side Effects",[16288],{"intervention":7721,"totalTrials":362,"cells":16326},{"EARLY_PHASE1":16327,"PHASE1":16329,"PHASE2":16331,"PHASE3":16333,"PHASE4":16335,"NA":16341},{"trials":16328,"activeCount":114},[],{"trials":16330,"activeCount":114},[],{"trials":16332,"activeCount":114},[],{"trials":16334,"activeCount":114},[],{"trials":16336,"activeCount":114},[16337],{"nctId":7714,"briefTitle":7715,"status":105,"phases":16338,"primaryCompletion":5970,"completion":5970,"start":7717,"enrollment":1153,"conditions":16339,"interventions":16340},[93],[5928,6155],[7701,7720,7721],{"trials":16342,"activeCount":114},[16343,16351],{"nctId":16344,"briefTitle":16345,"status":105,"phases":16346,"primaryCompletion":12347,"completion":12347,"start":3670,"enrollment":1153,"conditions":16347,"interventions":16348},"NCT02406586","Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)",[94],[6155,18],[16349,16350,7721],"Salsalate","Carvedilol",{"nctId":16352,"briefTitle":16353,"status":105,"phases":16354,"primaryCompletion":5970,"completion":5970,"start":7717,"enrollment":22,"conditions":16355,"interventions":16356},"NCT00753142","Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises",[94],[1700],[7721,16357],"Glucose",{"intervention":1504,"totalTrials":362,"cells":16359},{"EARLY_PHASE1":16360,"PHASE1":16362,"PHASE2":16364,"PHASE3":16374,"PHASE4":16376,"NA":16378},{"trials":16361,"activeCount":114},[],{"trials":16363,"activeCount":114},[],{"trials":16365,"activeCount":114},[16366,16370],{"nctId":3809,"briefTitle":3810,"status":2833,"phases":16367,"primaryCompletion":3812,"completion":3813,"start":3814,"enrollment":870,"conditions":16368,"interventions":16369},[90,91],[2691],[201,1504],{"nctId":1494,"briefTitle":1495,"status":105,"phases":16371,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":16372,"interventions":16373},[90,91],[1501,1502],[127,1504,1505,154,1506,565],{"trials":16375,"activeCount":114},[],{"trials":16377,"activeCount":114},[],{"trials":16379,"activeCount":114},[16380],{"nctId":16381,"briefTitle":16382,"status":230,"phases":16383,"primaryCompletion":3671,"completion":3671,"start":7830,"enrollment":186,"conditions":16384,"interventions":16386},"NCT01230788","Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia",[94],[10974,2772,16385],"ALL",[16387],"rituximab",{"intervention":16389,"totalTrials":327,"cells":16390},"Nesiritide",{"EARLY_PHASE1":16391,"PHASE1":16393,"PHASE2":16395,"PHASE3":16397,"PHASE4":16399,"NA":16407},{"trials":16392,"activeCount":114},[],{"trials":16394,"activeCount":114},[],{"trials":16396,"activeCount":114},[],{"trials":16398,"activeCount":114},[],{"trials":16400,"activeCount":114},[16401],{"nctId":16402,"briefTitle":16403,"status":230,"phases":16404,"primaryCompletion":10140,"completion":10140,"start":7855,"enrollment":276,"conditions":16405,"interventions":16406},"NCT00453453","BNP Therapy Observation Unit Outcomes STudy (BOOST)",[93],[14922],[16389],{"trials":16408,"activeCount":114},[16409],{"nctId":16410,"briefTitle":16411,"status":2022,"phases":16412,"primaryCompletion":2880,"completion":2880,"start":7520,"enrollment":114,"conditions":16413,"interventions":16416},"NCT00166010","Effects of Nesiritide in Pediatric Patients With Heart Failure",[94],[4739,16414,16415],"Ventricular Dysfunction","Heart Decompensation",[16389],{"intervention":7229,"totalTrials":327,"cells":16418},{"EARLY_PHASE1":16419,"PHASE1":16421,"PHASE2":16423,"PHASE3":16425,"PHASE4":16427,"NA":16433},{"trials":16420,"activeCount":114},[],{"trials":16422,"activeCount":114},[],{"trials":16424,"activeCount":114},[],{"trials":16426,"activeCount":114},[],{"trials":16428,"activeCount":114},[16429],{"nctId":7222,"briefTitle":7223,"status":105,"phases":16430,"primaryCompletion":7225,"completion":7225,"start":320,"enrollment":4781,"conditions":16431,"interventions":16432},[93],[1358],[7209,7228,7229],{"trials":16434,"activeCount":114},[16435],{"nctId":16436,"briefTitle":16437,"status":105,"phases":16438,"primaryCompletion":1320,"completion":8909,"start":3578,"enrollment":2481,"conditions":16439,"interventions":16441},"NCT00589888","FFA-Induced Hypertension and Endothelial Dysfunction",[94],[16440,6155],"Endothelial Dysfunction",[16442,16443,16444],"Intralipid 20% @ 20cc\u002Fhour","Intralipid 20%@ 40cc\u002Fhour","Normal Saline",{"intervention":16446,"totalTrials":327,"cells":16447},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":16448,"PHASE1":16450,"PHASE2":16452,"PHASE3":16454,"PHASE4":16456,"NA":16458},{"trials":16449,"activeCount":114},[],{"trials":16451,"activeCount":114},[],{"trials":16453,"activeCount":114},[],{"trials":16455,"activeCount":114},[],{"trials":16457,"activeCount":114},[],{"trials":16459,"activeCount":114},[16460,16466],{"nctId":16461,"briefTitle":16462,"status":230,"phases":16463,"primaryCompletion":9664,"completion":9664,"start":12589,"enrollment":182,"conditions":16464,"interventions":16465},"NCT00228813","G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome",[94],[12398],[16446],{"nctId":16467,"briefTitle":16468,"status":105,"phases":16469,"primaryCompletion":321,"completion":321,"start":8504,"enrollment":2075,"conditions":16470,"interventions":16471},"NCT00231309","Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)",[94],[10983,12398],[16446],{"intervention":10329,"totalTrials":327,"cells":16473},{"EARLY_PHASE1":16474,"PHASE1":16476,"PHASE2":16478,"PHASE3":16480,"PHASE4":16486,"NA":16488},{"trials":16475,"activeCount":114},[],{"trials":16477,"activeCount":114},[],{"trials":16479,"activeCount":114},[],{"trials":16481,"activeCount":114},[16482],{"nctId":10320,"briefTitle":10321,"status":230,"phases":16483,"primaryCompletion":10323,"completion":10323,"start":233,"enrollment":1403,"conditions":16484,"interventions":16485},[92],[10325,10326],[10309,10328,10329],{"trials":16487,"activeCount":114},[],{"trials":16489,"activeCount":114},[16490],{"nctId":16491,"briefTitle":16492,"status":105,"phases":16493,"primaryCompletion":5925,"completion":5925,"start":11154,"enrollment":1499,"conditions":16494,"interventions":16495},"NCT01463111","Decision-Making in Bipolar Disorder",[94],[6968],[16496,16497,10329],"Lithium","Valproate",{"intervention":7573,"totalTrials":327,"cells":16499},{"EARLY_PHASE1":16500,"PHASE1":16502,"PHASE2":16504,"PHASE3":16506,"PHASE4":16508,"NA":16514},{"trials":16501,"activeCount":114},[],{"trials":16503,"activeCount":114},[],{"trials":16505,"activeCount":114},[],{"trials":16507,"activeCount":114},[],{"trials":16509,"activeCount":114},[16510],{"nctId":7565,"briefTitle":7566,"status":105,"phases":16511,"primaryCompletion":7568,"completion":7568,"start":7569,"enrollment":1499,"conditions":16512,"interventions":16513},[93],[7571],[7552,7573,7574,7575],{"trials":16515,"activeCount":114},[16516],{"nctId":16517,"briefTitle":16518,"status":105,"phases":16519,"primaryCompletion":16520,"completion":16520,"start":12682,"enrollment":16,"conditions":16521,"interventions":16522},"NCT02154061","Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics",[94],"2017-05-26",[847],[16523,7573,16524,7574],"IIV Flu Vaccine","Neomycin",{"intervention":7574,"totalTrials":327,"cells":16526},{"EARLY_PHASE1":16527,"PHASE1":16529,"PHASE2":16531,"PHASE3":16533,"PHASE4":16535,"NA":16541},{"trials":16528,"activeCount":114},[],{"trials":16530,"activeCount":114},[],{"trials":16532,"activeCount":114},[],{"trials":16534,"activeCount":114},[],{"trials":16536,"activeCount":114},[16537],{"nctId":7565,"briefTitle":7566,"status":105,"phases":16538,"primaryCompletion":7568,"completion":7568,"start":7569,"enrollment":1499,"conditions":16539,"interventions":16540},[93],[7571],[7552,7573,7574,7575],{"trials":16542,"activeCount":114},[16543],{"nctId":16517,"briefTitle":16518,"status":105,"phases":16544,"primaryCompletion":16520,"completion":16520,"start":12682,"enrollment":16,"conditions":16545,"interventions":16546},[94],[847],[16523,7573,16524,7574],{"intervention":12327,"totalTrials":327,"cells":16548},{"EARLY_PHASE1":16549,"PHASE1":16551,"PHASE2":16553,"PHASE3":16559,"PHASE4":16561,"NA":16563},{"trials":16550,"activeCount":114},[],{"trials":16552,"activeCount":114},[],{"trials":16554,"activeCount":114},[16555],{"nctId":12316,"briefTitle":12317,"status":105,"phases":16556,"primaryCompletion":12319,"completion":12319,"start":12320,"conditions":16557,"interventions":16558},[91],[12279,12322,12323,12324,12325],[12327,12307],{"trials":16560,"activeCount":114},[],{"trials":16562,"activeCount":114},[],{"trials":16564,"activeCount":114},[16565],{"nctId":16566,"briefTitle":16567,"status":105,"phases":16568,"primaryCompletion":11154,"completion":11154,"start":2675,"enrollment":16569,"conditions":16570,"interventions":16573},"NCT00122447","Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance",[94],84,[16571,16572],"Impaired Glucose Tolerance","Prediabetic State",[16574,16575,16576],"Aspirin","Alpha lipoic acid","Olmesartan",{"intervention":16578,"totalTrials":327,"cells":16579},"Regadenoson",{"EARLY_PHASE1":16580,"PHASE1":16582,"PHASE2":16584,"PHASE3":16592,"PHASE4":16594,"NA":16596},{"trials":16581,"activeCount":114},[],{"trials":16583,"activeCount":114},[],{"trials":16585,"activeCount":114},[16586],{"nctId":16587,"briefTitle":16588,"status":2022,"phases":16589,"primaryCompletion":3427,"completion":3427,"start":594,"enrollment":114,"conditions":16590,"interventions":16591},"NCT01840696","Phase Analysis and Obstructive CAD on Rubidium PET",[91],[27],[16578],{"trials":16593,"activeCount":114},[],{"trials":16595,"activeCount":114},[],{"trials":16597,"activeCount":114},[16598],{"nctId":16599,"briefTitle":16600,"status":105,"phases":16601,"primaryCompletion":16602,"completion":16602,"start":16603,"enrollment":454,"conditions":16604,"interventions":16605},"NCT04316676","The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI",[94],"2024-09-24","2021-06-16",[27],[16578],{"intervention":16607,"totalTrials":327,"cells":16608},"Spironolactone",{"EARLY_PHASE1":16609,"PHASE1":16611,"PHASE2":16613,"PHASE3":16615,"PHASE4":16617,"NA":16627},{"trials":16610,"activeCount":114},[],{"trials":16612,"activeCount":114},[],{"trials":16614,"activeCount":114},[],{"trials":16616,"activeCount":114},[],{"trials":16618,"activeCount":114},[16619],{"nctId":16620,"briefTitle":16621,"status":105,"phases":16622,"primaryCompletion":16623,"completion":16623,"start":16624,"enrollment":28,"conditions":16625,"interventions":16626},"NCT04522739","Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia",[93],"2025-09-23","2022-09-06",[11050,406],[16607],{"trials":16628,"activeCount":114},[16629],{"nctId":16630,"briefTitle":16631,"status":105,"phases":16632,"primaryCompletion":6748,"completion":6748,"start":16633,"enrollment":870,"conditions":16634,"interventions":16636},"NCT00211081","Spironolactone in Patients With Single Ventricle Heart",[94],"2004-11",[16635],"Congenital Disorders",[16607],{"intervention":16638,"totalTrials":327,"cells":16639},"Mycophenolate Mofetil",{"EARLY_PHASE1":16640,"PHASE1":16642,"PHASE2":16644,"PHASE3":16650,"PHASE4":16652,"NA":16654},{"trials":16641,"activeCount":114},[],{"trials":16643,"activeCount":114},[],{"trials":16645,"activeCount":114},[16646],{"nctId":591,"briefTitle":592,"status":105,"phases":16647,"primaryCompletion":487,"completion":487,"start":594,"enrollment":595,"conditions":16648,"interventions":16649},[91],[597],[599,310,565,600,601],{"trials":16651,"activeCount":114},[],{"trials":16653,"activeCount":114},[],{"trials":16655,"activeCount":114},[16656],{"nctId":16657,"briefTitle":16658,"status":230,"phases":16659,"completion":2675,"start":16660,"enrollment":123,"conditions":16661,"interventions":16663},"NCT00166153","Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept",[94],"2003-01",[16662],"Cardiac Transplantation",[16638],{"intervention":11027,"totalTrials":327,"cells":16665},{"EARLY_PHASE1":16666,"PHASE1":16668,"PHASE2":16670,"PHASE3":16676,"PHASE4":16678,"NA":16680},{"trials":16667,"activeCount":114},[],{"trials":16669,"activeCount":114},[],{"trials":16671,"activeCount":114},[16672],{"nctId":11019,"briefTitle":11020,"status":105,"phases":16673,"primaryCompletion":11022,"completion":11023,"start":11024,"enrollment":1153,"conditions":16674,"interventions":16675},[91],[3547],[11003,11027],{"trials":16677,"activeCount":114},[],{"trials":16679,"activeCount":114},[],{"trials":16681,"activeCount":114},[16682],{"nctId":16683,"briefTitle":16684,"status":230,"phases":16685,"primaryCompletion":3868,"completion":3868,"start":16686,"enrollment":31,"conditions":16687,"interventions":16689},"NCT00209131","Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy",[94],"2005-04",[16688],"Urolithiasis",[16690,11027],"Flomax",{"intervention":8393,"totalTrials":327,"cells":16692},{"EARLY_PHASE1":16693,"PHASE1":16695,"PHASE2":16697,"PHASE3":16699,"PHASE4":16701,"NA":16707},{"trials":16694,"activeCount":114},[],{"trials":16696,"activeCount":114},[],{"trials":16698,"activeCount":114},[],{"trials":16700,"activeCount":114},[],{"trials":16702,"activeCount":114},[16703],{"nctId":8384,"briefTitle":8385,"status":105,"phases":16704,"primaryCompletion":8387,"completion":8388,"start":8389,"enrollment":322,"conditions":16705,"interventions":16706},[93],[8391],[8371,8393],{"trials":16708,"activeCount":114},[16709],{"nctId":16710,"briefTitle":16711,"status":105,"phases":16712,"primaryCompletion":14468,"completion":14468,"start":16235,"enrollment":685,"conditions":16713,"interventions":16714},"NCT01232868","Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly",[94],[847],[16715],"trivalent Influenza vaccine",{"intervention":8784,"totalTrials":327,"cells":16717},{"EARLY_PHASE1":16718,"PHASE1":16720,"PHASE2":16722,"PHASE3":16724,"PHASE4":16726,"NA":16732},{"trials":16719,"activeCount":114},[],{"trials":16721,"activeCount":114},[],{"trials":16723,"activeCount":114},[],{"trials":16725,"activeCount":114},[],{"trials":16727,"activeCount":114},[16728],{"nctId":8776,"briefTitle":8777,"status":105,"phases":16729,"primaryCompletion":8779,"completion":8779,"start":8780,"enrollment":1796,"conditions":16730,"interventions":16731},[93],[5904,8782],[8784,8763],{"trials":16733,"activeCount":114},[16734],{"nctId":16735,"briefTitle":16736,"status":105,"phases":16737,"primaryCompletion":434,"completion":434,"start":9499,"enrollment":16738,"conditions":16739,"interventions":16741},"NCT00912782","Vitamin D and Arteriovenous Fistulae",[94],52,[16740],"End-stage Renal Disease",[8784],{"intervention":16743,"totalTrials":327,"cells":16744},"Fluoxetine",{"EARLY_PHASE1":16745,"PHASE1":16747,"PHASE2":16749,"PHASE3":16751,"PHASE4":16753,"NA":16755},{"trials":16746,"activeCount":114},[],{"trials":16748,"activeCount":114},[],{"trials":16750,"activeCount":114},[],{"trials":16752,"activeCount":114},[],{"trials":16754,"activeCount":114},[],{"trials":16756,"activeCount":114},[16757,16763],{"nctId":16758,"briefTitle":16759,"status":230,"phases":16760,"primaryCompletion":3501,"completion":3501,"start":4116,"enrollment":362,"conditions":16761,"interventions":16762},"NCT01740726","Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression",[94],[2625],[16743],{"nctId":16764,"briefTitle":16765,"status":105,"phases":16766,"primaryCompletion":16767,"completion":16767,"start":16768,"enrollment":498,"conditions":16769,"interventions":16770},"NCT00208897","Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?",[94],"2007-11","1997-12",[2625],[16743],{"intervention":16772,"totalTrials":186,"cells":16773},"Misoprostol",{"EARLY_PHASE1":16774,"PHASE1":16776,"PHASE2":16778,"PHASE3":16780,"PHASE4":16782,"NA":16784},{"trials":16775,"activeCount":114},[],{"trials":16777,"activeCount":114},[],{"trials":16779,"activeCount":114},[],{"trials":16781,"activeCount":114},[],{"trials":16783,"activeCount":114},[],{"trials":16785,"activeCount":114},[16786],{"nctId":16787,"briefTitle":16788,"status":105,"phases":16789,"primaryCompletion":2674,"completion":2674,"start":2880,"enrollment":16790,"conditions":16791,"interventions":16793},"NCT01147497","Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women",[94],78,[16792],"Contraception",[16772],{"intervention":16795,"totalTrials":186,"cells":16796},"Alefacept",{"EARLY_PHASE1":16797,"PHASE1":16799,"PHASE2":16801,"PHASE3":16803,"PHASE4":16805,"NA":16807},{"trials":16798,"activeCount":114},[],{"trials":16800,"activeCount":114},[],{"trials":16802,"activeCount":114},[],{"trials":16804,"activeCount":114},[],{"trials":16806,"activeCount":114},[],{"trials":16808,"activeCount":114},[16809],{"nctId":16810,"briefTitle":16811,"status":230,"phases":16812,"primaryCompletion":3466,"completion":3466,"start":7830,"enrollment":362,"conditions":16813,"interventions":16817},"NCT01319851","Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation",[94],[16814,24,2946,2947,16815,2949,2950,16816,2952,2945,2953,2954,2955],"Thalassemia","Chronic-granulomatous Disease","Schwachman-Diamond Syndrome",[16795],{"intervention":16819,"totalTrials":186,"cells":16820},"Truvada qd",{"EARLY_PHASE1":16821,"PHASE1":16823,"PHASE2":16825,"PHASE3":16827,"PHASE4":16829,"NA":16831},{"trials":16822,"activeCount":114},[],{"trials":16824,"activeCount":114},[],{"trials":16826,"activeCount":114},[],{"trials":16828,"activeCount":114},[],{"trials":16830,"activeCount":114},[],{"trials":16832,"activeCount":114},[16833],{"nctId":16834,"briefTitle":16835,"status":230,"phases":16836,"primaryCompletion":16837,"completion":16837,"start":9664,"enrollment":470,"conditions":16838,"interventions":16839},"NCT02333045","Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women",[94],"2016-10-28",[15],[16819,16840],"Maraviroc 300 qd",{"intervention":16840,"totalTrials":186,"cells":16842},{"EARLY_PHASE1":16843,"PHASE1":16845,"PHASE2":16847,"PHASE3":16849,"PHASE4":16851,"NA":16853},{"trials":16844,"activeCount":114},[],{"trials":16846,"activeCount":114},[],{"trials":16848,"activeCount":114},[],{"trials":16850,"activeCount":114},[],{"trials":16852,"activeCount":114},[],{"trials":16854,"activeCount":114},[16855],{"nctId":16834,"briefTitle":16835,"status":230,"phases":16856,"primaryCompletion":16837,"completion":16837,"start":9664,"enrollment":470,"conditions":16857,"interventions":16858},[94],[15],[16819,16840],{"intervention":16860,"totalTrials":186,"cells":16861},"[F-18]MHF",{"EARLY_PHASE1":16862,"PHASE1":16864,"PHASE2":16866,"PHASE3":16868,"PHASE4":16870,"NA":16872},{"trials":16863,"activeCount":114},[],{"trials":16865,"activeCount":114},[],{"trials":16867,"activeCount":114},[],{"trials":16869,"activeCount":114},[],{"trials":16871,"activeCount":114},[],{"trials":16873,"activeCount":114},[16874],{"nctId":16875,"briefTitle":16876,"status":105,"phases":16877,"primaryCompletion":16878,"completion":16878,"start":16879,"enrollment":98,"conditions":16880,"interventions":16883},"NCT05889286","F18-MHF: Implants-Associated Infection Detection",[],"2026-03-31","2024-11-04",[16881,16882],"Knee Disease","Knee Infection",[16860],{"intervention":16349,"totalTrials":186,"cells":16885},{"EARLY_PHASE1":16886,"PHASE1":16888,"PHASE2":16890,"PHASE3":16892,"PHASE4":16894,"NA":16896},{"trials":16887,"activeCount":114},[],{"trials":16889,"activeCount":114},[],{"trials":16891,"activeCount":114},[],{"trials":16893,"activeCount":114},[],{"trials":16895,"activeCount":114},[],{"trials":16897,"activeCount":114},[16898],{"nctId":16344,"briefTitle":16345,"status":105,"phases":16899,"primaryCompletion":12347,"completion":12347,"start":3670,"enrollment":1153,"conditions":16900,"interventions":16901},[94],[6155,18],[16349,16350,7721],{"intervention":16350,"totalTrials":186,"cells":16903},{"EARLY_PHASE1":16904,"PHASE1":16906,"PHASE2":16908,"PHASE3":16910,"PHASE4":16912,"NA":16914},{"trials":16905,"activeCount":114},[],{"trials":16907,"activeCount":114},[],{"trials":16909,"activeCount":114},[],{"trials":16911,"activeCount":114},[],{"trials":16913,"activeCount":114},[],{"trials":16915,"activeCount":114},[16916],{"nctId":16344,"briefTitle":16345,"status":105,"phases":16917,"primaryCompletion":12347,"completion":12347,"start":3670,"enrollment":1153,"conditions":16918,"interventions":16919},[94],[6155,18],[16349,16350,7721],{"intervention":16921,"totalTrials":186,"cells":16922},"DEX-CRF stimulation test",{"EARLY_PHASE1":16923,"PHASE1":16925,"PHASE2":16927,"PHASE3":16929,"PHASE4":16931,"NA":16933},{"trials":16924,"activeCount":114},[],{"trials":16926,"activeCount":114},[],{"trials":16928,"activeCount":114},[],{"trials":16930,"activeCount":114},[],{"trials":16932,"activeCount":114},[],{"trials":16934,"activeCount":114},[16935],{"nctId":16936,"briefTitle":16937,"status":105,"phases":16938,"primaryCompletion":5970,"completion":12347,"start":16939,"enrollment":16940,"conditions":16941,"interventions":16942},"NCT00209105","Characterizing Psychological Consequences of Childhood Trauma",[],"2005-01",113,[2625],[16921],{"intervention":16944,"totalTrials":186,"cells":16945},"Pegylated Interfon Alpha 2B",{"EARLY_PHASE1":16946,"PHASE1":16948,"PHASE2":16950,"PHASE3":16952,"PHASE4":16954,"NA":16956},{"trials":16947,"activeCount":114},[],{"trials":16949,"activeCount":114},[],{"trials":16951,"activeCount":114},[],{"trials":16953,"activeCount":114},[],{"trials":16955,"activeCount":114},[],{"trials":16957,"activeCount":114},[16958],{"nctId":16959,"briefTitle":16960,"status":2022,"phases":16961,"primaryCompletion":6748,"start":7855,"enrollment":114,"conditions":16962,"interventions":16963},"NCT00621439","Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye",[94],[1868],[16944],{"intervention":1325,"totalTrials":186,"cells":16965},{"EARLY_PHASE1":16966,"PHASE1":16968,"PHASE2":16970,"PHASE3":16972,"PHASE4":16974,"NA":16976},{"trials":16967,"activeCount":114},[],{"trials":16969,"activeCount":114},[],{"trials":16971,"activeCount":114},[],{"trials":16973,"activeCount":114},[],{"trials":16975,"activeCount":114},[],{"trials":16977,"activeCount":114},[16978],{"nctId":1317,"briefTitle":1318,"status":105,"phases":16979,"primaryCompletion":160,"completion":160,"start":1320,"enrollment":1321,"conditions":16980,"interventions":16981},[94],[1323],[1325,1326,1327,1328,350],{"intervention":1326,"totalTrials":186,"cells":16983},{"EARLY_PHASE1":16984,"PHASE1":16986,"PHASE2":16988,"PHASE3":16990,"PHASE4":16992,"NA":16994},{"trials":16985,"activeCount":114},[],{"trials":16987,"activeCount":114},[],{"trials":16989,"activeCount":114},[],{"trials":16991,"activeCount":114},[],{"trials":16993,"activeCount":114},[],{"trials":16995,"activeCount":114},[16996],{"nctId":1317,"briefTitle":1318,"status":105,"phases":16997,"primaryCompletion":160,"completion":160,"start":1320,"enrollment":1321,"conditions":16998,"interventions":16999},[94],[1323],[1325,1326,1327,1328,350],{"intervention":1327,"totalTrials":186,"cells":17001},{"EARLY_PHASE1":17002,"PHASE1":17004,"PHASE2":17006,"PHASE3":17008,"PHASE4":17010,"NA":17012},{"trials":17003,"activeCount":114},[],{"trials":17005,"activeCount":114},[],{"trials":17007,"activeCount":114},[],{"trials":17009,"activeCount":114},[],{"trials":17011,"activeCount":114},[],{"trials":17013,"activeCount":114},[17014],{"nctId":1317,"briefTitle":1318,"status":105,"phases":17015,"primaryCompletion":160,"completion":160,"start":1320,"enrollment":1321,"conditions":17016,"interventions":17017},[94],[1323],[1325,1326,1327,1328,350],{"intervention":1328,"totalTrials":186,"cells":17019},{"EARLY_PHASE1":17020,"PHASE1":17022,"PHASE2":17024,"PHASE3":17026,"PHASE4":17028,"NA":17030},{"trials":17021,"activeCount":114},[],{"trials":17023,"activeCount":114},[],{"trials":17025,"activeCount":114},[],{"trials":17027,"activeCount":114},[],{"trials":17029,"activeCount":114},[],{"trials":17031,"activeCount":114},[17032],{"nctId":1317,"briefTitle":1318,"status":105,"phases":17033,"primaryCompletion":160,"completion":160,"start":1320,"enrollment":1321,"conditions":17034,"interventions":17035},[94],[1323],[1325,1326,1327,1328,350],{"intervention":17037,"totalTrials":186,"cells":17038},"Recombinant activated factor VII",{"EARLY_PHASE1":17039,"PHASE1":17041,"PHASE2":17043,"PHASE3":17045,"PHASE4":17047,"NA":17049},{"trials":17040,"activeCount":114},[],{"trials":17042,"activeCount":114},[],{"trials":17044,"activeCount":114},[],{"trials":17046,"activeCount":114},[],{"trials":17048,"activeCount":114},[],{"trials":17050,"activeCount":114},[17051],{"nctId":17052,"briefTitle":17053,"status":105,"phases":17054,"primaryCompletion":5940,"completion":5940,"start":12347,"enrollment":31,"conditions":17055,"interventions":17057},"NCT01352143","Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass",[],[17056],"Cardiopulmonary Bypass",[17037,17058],"Prothrombin Complex Concentrate",{"intervention":17058,"totalTrials":186,"cells":17060},{"EARLY_PHASE1":17061,"PHASE1":17063,"PHASE2":17065,"PHASE3":17067,"PHASE4":17069,"NA":17071},{"trials":17062,"activeCount":114},[],{"trials":17064,"activeCount":114},[],{"trials":17066,"activeCount":114},[],{"trials":17068,"activeCount":114},[],{"trials":17070,"activeCount":114},[],{"trials":17072,"activeCount":114},[17073],{"nctId":17052,"briefTitle":17053,"status":105,"phases":17074,"primaryCompletion":5940,"completion":5940,"start":12347,"enrollment":31,"conditions":17075,"interventions":17076},[],[17056],[17037,17058],{"intervention":17078,"totalTrials":186,"cells":17079},"Pre-exposure prophylaxis with FTC\u002FTDF",{"EARLY_PHASE1":17080,"PHASE1":17082,"PHASE2":17084,"PHASE3":17086,"PHASE4":17088,"NA":17090},{"trials":17081,"activeCount":114},[],{"trials":17083,"activeCount":114},[],{"trials":17085,"activeCount":114},[],{"trials":17087,"activeCount":114},[],{"trials":17089,"activeCount":114},[],{"trials":17091,"activeCount":114},[17092],{"nctId":17093,"briefTitle":17094,"status":105,"phases":17095,"primaryCompletion":4547,"completion":6425,"start":2480,"enrollment":345,"conditions":17096,"interventions":17097},"NCT02043015","Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)",[94],[15],[17078],{"intervention":17099,"totalTrials":186,"cells":17100},"iNO",{"EARLY_PHASE1":17101,"PHASE1":17103,"PHASE2":17105,"PHASE3":17107,"PHASE4":17109,"NA":17111},{"trials":17102,"activeCount":114},[],{"trials":17104,"activeCount":114},[],{"trials":17106,"activeCount":114},[],{"trials":17108,"activeCount":114},[],{"trials":17110,"activeCount":114},[],{"trials":17112,"activeCount":114},[17113],{"nctId":17114,"briefTitle":17115,"status":105,"phases":17116,"primaryCompletion":10140,"completion":10140,"start":10141,"enrollment":17117,"conditions":17118,"interventions":17119},"NCT00139217","NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn",[94],400,[4173],[17099],{"intervention":17121,"totalTrials":186,"cells":17122},"Gadopentetate dimeglumine",{"EARLY_PHASE1":17123,"PHASE1":17125,"PHASE2":17127,"PHASE3":17129,"PHASE4":17131,"NA":17133},{"trials":17124,"activeCount":114},[],{"trials":17126,"activeCount":114},[],{"trials":17128,"activeCount":114},[],{"trials":17130,"activeCount":114},[],{"trials":17132,"activeCount":114},[],{"trials":17134,"activeCount":114},[17135],{"nctId":17136,"briefTitle":17137,"status":2022,"phases":17138,"primaryCompletion":160,"completion":160,"start":2480,"enrollment":114,"conditions":17139,"interventions":17141},"NCT02371798","Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?",[94],[17140],"Meniere Disease",[17121],{"intervention":16496,"totalTrials":186,"cells":17143},{"EARLY_PHASE1":17144,"PHASE1":17146,"PHASE2":17148,"PHASE3":17150,"PHASE4":17152,"NA":17154},{"trials":17145,"activeCount":114},[],{"trials":17147,"activeCount":114},[],{"trials":17149,"activeCount":114},[],{"trials":17151,"activeCount":114},[],{"trials":17153,"activeCount":114},[],{"trials":17155,"activeCount":114},[17156],{"nctId":16491,"briefTitle":16492,"status":105,"phases":17157,"primaryCompletion":5925,"completion":5925,"start":11154,"enrollment":1499,"conditions":17158,"interventions":17159},[94],[6968],[16496,16497,10329],{"intervention":16497,"totalTrials":186,"cells":17161},{"EARLY_PHASE1":17162,"PHASE1":17164,"PHASE2":17166,"PHASE3":17168,"PHASE4":17170,"NA":17172},{"trials":17163,"activeCount":114},[],{"trials":17165,"activeCount":114},[],{"trials":17167,"activeCount":114},[],{"trials":17169,"activeCount":114},[],{"trials":17171,"activeCount":114},[],{"trials":17173,"activeCount":114},[17174],{"nctId":16491,"briefTitle":16492,"status":105,"phases":17175,"primaryCompletion":5925,"completion":5925,"start":11154,"enrollment":1499,"conditions":17176,"interventions":17177},[94],[6968],[16496,16497,10329],{"intervention":16523,"totalTrials":186,"cells":17179},{"EARLY_PHASE1":17180,"PHASE1":17182,"PHASE2":17184,"PHASE3":17186,"PHASE4":17188,"NA":17190},{"trials":17181,"activeCount":114},[],{"trials":17183,"activeCount":114},[],{"trials":17185,"activeCount":114},[],{"trials":17187,"activeCount":114},[],{"trials":17189,"activeCount":114},[],{"trials":17191,"activeCount":114},[17192],{"nctId":16517,"briefTitle":16518,"status":105,"phases":17193,"primaryCompletion":16520,"completion":16520,"start":12682,"enrollment":16,"conditions":17194,"interventions":17195},[94],[847],[16523,7573,16524,7574],{"intervention":16524,"totalTrials":186,"cells":17197},{"EARLY_PHASE1":17198,"PHASE1":17200,"PHASE2":17202,"PHASE3":17204,"PHASE4":17206,"NA":17208},{"trials":17199,"activeCount":114},[],{"trials":17201,"activeCount":114},[],{"trials":17203,"activeCount":114},[],{"trials":17205,"activeCount":114},[],{"trials":17207,"activeCount":114},[],{"trials":17209,"activeCount":114},[17210],{"nctId":16517,"briefTitle":16518,"status":105,"phases":17211,"primaryCompletion":16520,"completion":16520,"start":12682,"enrollment":16,"conditions":17212,"interventions":17213},[94],[847],[16523,7573,16524,7574],{"intervention":17215,"totalTrials":186,"cells":17216},"Flu Vaccine",{"EARLY_PHASE1":17217,"PHASE1":17219,"PHASE2":17221,"PHASE3":17223,"PHASE4":17225,"NA":17227},{"trials":17218,"activeCount":114},[],{"trials":17220,"activeCount":114},[],{"trials":17222,"activeCount":114},[],{"trials":17224,"activeCount":114},[],{"trials":17226,"activeCount":114},[],{"trials":17228,"activeCount":114},[17229],{"nctId":17230,"briefTitle":17231,"status":105,"phases":17232,"primaryCompletion":4116,"completion":4116,"start":3733,"enrollment":3053,"conditions":17233,"interventions":17235},"NCT01733056","Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression",[94],[17234],"Immunosuppression",[17215],{"intervention":17237,"totalTrials":186,"cells":17238},"Estrogen",{"EARLY_PHASE1":17239,"PHASE1":17241,"PHASE2":17243,"PHASE3":17245,"PHASE4":17247,"NA":17249},{"trials":17240,"activeCount":114},[],{"trials":17242,"activeCount":114},[],{"trials":17244,"activeCount":114},[],{"trials":17246,"activeCount":114},[],{"trials":17248,"activeCount":114},[],{"trials":17250,"activeCount":114},[17251],{"nctId":17252,"briefTitle":17253,"status":105,"phases":17254,"primaryCompletion":17255,"completion":17255,"start":17256,"enrollment":17257,"conditions":17258,"interventions":17260},"NCT04531943","Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women",[],"2024-04-04","2020-10-01",285,[17259],"HIV Prevention",[17237,17261],"Estrogen plus Progesterone",{"intervention":17261,"totalTrials":186,"cells":17263},{"EARLY_PHASE1":17264,"PHASE1":17266,"PHASE2":17268,"PHASE3":17270,"PHASE4":17272,"NA":17274},{"trials":17265,"activeCount":114},[],{"trials":17267,"activeCount":114},[],{"trials":17269,"activeCount":114},[],{"trials":17271,"activeCount":114},[],{"trials":17273,"activeCount":114},[],{"trials":17275,"activeCount":114},[17276],{"nctId":17252,"briefTitle":17253,"status":105,"phases":17277,"primaryCompletion":17255,"completion":17255,"start":17256,"enrollment":17257,"conditions":17278,"interventions":17279},[],[17259],[17237,17261],{"intervention":17281,"totalTrials":186,"cells":17282},"Licensed or EUA SARS-CoV-2 vaccine",{"EARLY_PHASE1":17283,"PHASE1":17285,"PHASE2":17287,"PHASE3":17289,"PHASE4":17291,"NA":17293},{"trials":17284,"activeCount":114},[],{"trials":17286,"activeCount":114},[],{"trials":17288,"activeCount":114},[],{"trials":17290,"activeCount":114},[],{"trials":17292,"activeCount":114},[],{"trials":17294,"activeCount":114},[17295],{"nctId":17296,"briefTitle":17297,"status":105,"phases":17298,"primaryCompletion":17299,"completion":17299,"start":17300,"enrollment":17301,"conditions":17302,"interventions":17303},"NCT05031468","Multisite Observational Maternal and Infant Study for COVID-19",[],"2023-08-16","2021-07-06",562,[708],[17281],{"intervention":17305,"totalTrials":186,"cells":17306},"Epinephrine",{"EARLY_PHASE1":17307,"PHASE1":17309,"PHASE2":17311,"PHASE3":17313,"PHASE4":17315,"NA":17317},{"trials":17308,"activeCount":114},[],{"trials":17310,"activeCount":114},[],{"trials":17312,"activeCount":114},[],{"trials":17314,"activeCount":114},[],{"trials":17316,"activeCount":114},[],{"trials":17318,"activeCount":114},[17319],{"nctId":17320,"briefTitle":17321,"status":230,"phases":17322,"primaryCompletion":173,"completion":5940,"start":1498,"enrollment":2277,"conditions":17323,"interventions":17324},"NCT00548886","Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients",[94],[16635],[17305],{"intervention":17326,"totalTrials":186,"cells":17327},"epidural steroid",{"EARLY_PHASE1":17328,"PHASE1":17330,"PHASE2":17332,"PHASE3":17334,"PHASE4":17336,"NA":17338},{"trials":17329,"activeCount":114},[],{"trials":17331,"activeCount":114},[],{"trials":17333,"activeCount":114},[],{"trials":17335,"activeCount":114},[],{"trials":17337,"activeCount":114},[],{"trials":17339,"activeCount":114},[17340],{"nctId":17341,"briefTitle":17342,"status":2022,"phases":17343,"primaryCompletion":17344,"completion":9476,"start":2942,"enrollment":114,"conditions":17345,"interventions":17347},"NCT02103543","Comparison of the Order of Treatment in Lumbar Spinal Stenosis",[94],"2017-01",[17346],"Lumbar Spinal Stenosis",[17326],{"intervention":17349,"totalTrials":186,"cells":17350},"SHINGRIX",{"EARLY_PHASE1":17351,"PHASE1":17353,"PHASE2":17355,"PHASE3":17357,"PHASE4":17359,"NA":17361},{"trials":17352,"activeCount":114},[],{"trials":17354,"activeCount":114},[],{"trials":17356,"activeCount":114},[],{"trials":17358,"activeCount":114},[],{"trials":17360,"activeCount":114},[],{"trials":17362,"activeCount":114},[17363],{"nctId":17364,"briefTitle":17365,"status":230,"phases":17366,"primaryCompletion":17367,"completion":17367,"start":17368,"enrollment":327,"conditions":17369,"interventions":17371},"NCT03993717","Solid Organ Transplant SHINGRIX",[],"2020-08-08","2020-01-30",[17370],"Kidney Transplant; Complications",[17349],{"intervention":17373,"totalTrials":186,"cells":17374},"Cola beverage",{"EARLY_PHASE1":17375,"PHASE1":17377,"PHASE2":17379,"PHASE3":17381,"PHASE4":17383,"NA":17385},{"trials":17376,"activeCount":114},[],{"trials":17378,"activeCount":114},[],{"trials":17380,"activeCount":114},[],{"trials":17382,"activeCount":114},[],{"trials":17384,"activeCount":114},[],{"trials":17386,"activeCount":114},[17387],{"nctId":17388,"briefTitle":17389,"status":105,"phases":17390,"primaryCompletion":14468,"completion":14468,"start":9614,"enrollment":2481,"conditions":17391,"interventions":17393},"NCT00289120","Effect of Cola on Urinary Stone Risk Factors",[94],[17392],"Kidney Stone",[17373,17394],"Deionized water",{"intervention":17394,"totalTrials":186,"cells":17396},{"EARLY_PHASE1":17397,"PHASE1":17399,"PHASE2":17401,"PHASE3":17403,"PHASE4":17405,"NA":17407},{"trials":17398,"activeCount":114},[],{"trials":17400,"activeCount":114},[],{"trials":17402,"activeCount":114},[],{"trials":17404,"activeCount":114},[],{"trials":17406,"activeCount":114},[],{"trials":17408,"activeCount":114},[17409],{"nctId":17388,"briefTitle":17389,"status":105,"phases":17410,"primaryCompletion":14468,"completion":14468,"start":9614,"enrollment":2481,"conditions":17411,"interventions":17412},[94],[17392],[17373,17394],{"intervention":17414,"totalTrials":186,"cells":17415},"Carbidopa-Levodopa",{"EARLY_PHASE1":17416,"PHASE1":17418,"PHASE2":17420,"PHASE3":17422,"PHASE4":17424,"NA":17426},{"trials":17417,"activeCount":114},[],{"trials":17419,"activeCount":114},[],{"trials":17421,"activeCount":114},[],{"trials":17423,"activeCount":114},[],{"trials":17425,"activeCount":114},[],{"trials":17427,"activeCount":114},[17428],{"nctId":17429,"briefTitle":17430,"status":105,"phases":17431,"primaryCompletion":2684,"completion":2684,"start":10139,"enrollment":16,"conditions":17432,"interventions":17433},"NCT00715520","Neurobiological Principles Applied to the Rehabilitation of Stroke Patients",[94],[9706],[17414,17434,17435],"Methylphenidate","Amphetamine Sulfate",{"intervention":17434,"totalTrials":186,"cells":17437},{"EARLY_PHASE1":17438,"PHASE1":17440,"PHASE2":17442,"PHASE3":17444,"PHASE4":17446,"NA":17448},{"trials":17439,"activeCount":114},[],{"trials":17441,"activeCount":114},[],{"trials":17443,"activeCount":114},[],{"trials":17445,"activeCount":114},[],{"trials":17447,"activeCount":114},[],{"trials":17449,"activeCount":114},[17450],{"nctId":17429,"briefTitle":17430,"status":105,"phases":17451,"primaryCompletion":2684,"completion":2684,"start":10139,"enrollment":16,"conditions":17452,"interventions":17453},[94],[9706],[17414,17434,17435],{"intervention":17435,"totalTrials":186,"cells":17455},{"EARLY_PHASE1":17456,"PHASE1":17458,"PHASE2":17460,"PHASE3":17462,"PHASE4":17464,"NA":17466},{"trials":17457,"activeCount":114},[],{"trials":17459,"activeCount":114},[],{"trials":17461,"activeCount":114},[],{"trials":17463,"activeCount":114},[],{"trials":17465,"activeCount":114},[],{"trials":17467,"activeCount":114},[17468],{"nctId":17429,"briefTitle":17430,"status":105,"phases":17469,"primaryCompletion":2684,"completion":2684,"start":10139,"enrollment":16,"conditions":17470,"interventions":17471},[94],[9706],[17414,17434,17435],{"intervention":17473,"totalTrials":186,"cells":17474},"G-CSF mobilized CD34+ selected cells for transplantation",{"EARLY_PHASE1":17475,"PHASE1":17477,"PHASE2":17479,"PHASE3":17481,"PHASE4":17483,"NA":17485},{"trials":17476,"activeCount":114},[],{"trials":17478,"activeCount":114},[],{"trials":17480,"activeCount":114},[],{"trials":17482,"activeCount":114},[],{"trials":17484,"activeCount":114},[],{"trials":17486,"activeCount":114},[17487],{"nctId":17488,"briefTitle":17489,"status":17490,"phases":17491,"conditions":17492,"interventions":17493},"NCT02258490","Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation","NO_LONGER_AVAILABLE",[],[11394,2693,2913],[17473],{"intervention":17495,"totalTrials":186,"cells":17496},"KuvanTM Therapy",{"EARLY_PHASE1":17497,"PHASE1":17499,"PHASE2":17501,"PHASE3":17503,"PHASE4":17505,"NA":17507},{"trials":17498,"activeCount":114},[],{"trials":17500,"activeCount":114},[],{"trials":17502,"activeCount":114},[],{"trials":17504,"activeCount":114},[],{"trials":17506,"activeCount":114},[],{"trials":17508,"activeCount":114},[17509],{"nctId":17510,"briefTitle":17511,"status":105,"phases":17512,"primaryCompletion":16235,"completion":16235,"start":2366,"enrollment":9,"conditions":17513,"interventions":17514},"NCT00688844","Nutritional and Neurotransmitter Changes in PKU Subjects on BH4",[],[11527],[17495],{"intervention":17516,"totalTrials":186,"cells":17517},"Iron",{"EARLY_PHASE1":17518,"PHASE1":17520,"PHASE2":17522,"PHASE3":17524,"PHASE4":17526,"NA":17528},{"trials":17519,"activeCount":114},[],{"trials":17521,"activeCount":114},[],{"trials":17523,"activeCount":114},[],{"trials":17525,"activeCount":114},[],{"trials":17527,"activeCount":114},[],{"trials":17529,"activeCount":114},[17530],{"nctId":17531,"briefTitle":17532,"status":2022,"phases":17533,"primaryCompletion":11525,"completion":11525,"start":10139,"enrollment":114,"conditions":17534,"interventions":17535},"NCT00459225","Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease",[94],[14793],[17516],{"intervention":17537,"totalTrials":186,"cells":17538},"Blood Collection",{"EARLY_PHASE1":17539,"PHASE1":17541,"PHASE2":17543,"PHASE3":17545,"PHASE4":17547,"NA":17549},{"trials":17540,"activeCount":114},[],{"trials":17542,"activeCount":114},[],{"trials":17544,"activeCount":114},[],{"trials":17546,"activeCount":114},[],{"trials":17548,"activeCount":114},[],{"trials":17550,"activeCount":114},[17551],{"nctId":17552,"briefTitle":17553,"status":2022,"phases":17554,"start":6389,"enrollment":114,"conditions":17555,"interventions":17560},"NCT00453219","FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity",[],[17556,17557,17558,17559],"Anovulation","FHA","Eumenorrhea","Polycystic Ovary Syndrome",[17537],{"intervention":17562,"totalTrials":186,"cells":17563},"Copper IUD",{"EARLY_PHASE1":17564,"PHASE1":17566,"PHASE2":17568,"PHASE3":17570,"PHASE4":17572,"NA":17574},{"trials":17565,"activeCount":114},[],{"trials":17567,"activeCount":114},[],{"trials":17569,"activeCount":114},[],{"trials":17571,"activeCount":114},[],{"trials":17573,"activeCount":114},[],{"trials":17575,"activeCount":114},[17576],{"nctId":17577,"briefTitle":17578,"status":105,"phases":17579,"primaryCompletion":7806,"completion":7806,"start":2416,"enrollment":220,"conditions":17580,"interventions":17581},"NCT01191203","Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi",[94],[15],[17562,17582],"Depo Medroxyprogesterone acetate",{"intervention":17582,"totalTrials":186,"cells":17584},{"EARLY_PHASE1":17585,"PHASE1":17587,"PHASE2":17589,"PHASE3":17591,"PHASE4":17593,"NA":17595},{"trials":17586,"activeCount":114},[],{"trials":17588,"activeCount":114},[],{"trials":17590,"activeCount":114},[],{"trials":17592,"activeCount":114},[],{"trials":17594,"activeCount":114},[],{"trials":17596,"activeCount":114},[17597],{"nctId":17577,"briefTitle":17578,"status":105,"phases":17598,"primaryCompletion":7806,"completion":7806,"start":2416,"enrollment":220,"conditions":17599,"interventions":17600},[94],[15],[17562,17582],{"intervention":16575,"totalTrials":186,"cells":17602},{"EARLY_PHASE1":17603,"PHASE1":17605,"PHASE2":17607,"PHASE3":17609,"PHASE4":17611,"NA":17613},{"trials":17604,"activeCount":114},[],{"trials":17606,"activeCount":114},[],{"trials":17608,"activeCount":114},[],{"trials":17610,"activeCount":114},[],{"trials":17612,"activeCount":114},[],{"trials":17614,"activeCount":114},[17615],{"nctId":16566,"briefTitle":16567,"status":105,"phases":17616,"primaryCompletion":11154,"completion":11154,"start":2675,"enrollment":16569,"conditions":17617,"interventions":17618},[94],[16571,16572],[16574,16575,16576],{"intervention":16576,"totalTrials":186,"cells":17620},{"EARLY_PHASE1":17621,"PHASE1":17623,"PHASE2":17625,"PHASE3":17627,"PHASE4":17629,"NA":17631},{"trials":17622,"activeCount":114},[],{"trials":17624,"activeCount":114},[],{"trials":17626,"activeCount":114},[],{"trials":17628,"activeCount":114},[],{"trials":17630,"activeCount":114},[],{"trials":17632,"activeCount":114},[17633],{"nctId":16566,"briefTitle":16567,"status":105,"phases":17634,"primaryCompletion":11154,"completion":11154,"start":2675,"enrollment":16569,"conditions":17635,"interventions":17636},[94],[16571,16572],[16574,16575,16576],{"intervention":17638,"totalTrials":186,"cells":17639},"Defibrotide",{"EARLY_PHASE1":17640,"PHASE1":17642,"PHASE2":17644,"PHASE3":17646,"PHASE4":17648,"NA":17650},{"trials":17641,"activeCount":114},[],{"trials":17643,"activeCount":114},[],{"trials":17645,"activeCount":114},[],{"trials":17647,"activeCount":114},[],{"trials":17649,"activeCount":114},[],{"trials":17651,"activeCount":114},[17652],{"nctId":17653,"briefTitle":17654,"status":17490,"phases":17655,"primaryCompletion":2770,"completion":2770,"start":17656,"conditions":17657,"interventions":17659},"NCT00263978","Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver",[],"2005-11",[17658],"Liver Diseases",[17638],{"intervention":17661,"totalTrials":186,"cells":17662},"Insulin Drip Therapy",{"EARLY_PHASE1":17663,"PHASE1":17665,"PHASE2":17667,"PHASE3":17669,"PHASE4":17671,"NA":17673},{"trials":17664,"activeCount":114},[],{"trials":17666,"activeCount":114},[],{"trials":17668,"activeCount":114},[],{"trials":17670,"activeCount":114},[],{"trials":17672,"activeCount":114},[],{"trials":17674,"activeCount":114},[17675],{"nctId":17676,"briefTitle":17677,"status":105,"phases":17678,"completion":7122,"start":3578,"enrollment":220,"conditions":17679,"interventions":17680},"NCT00412347","Insulin Infusion in the Hospital Wards",[],[500],[17661],{"intervention":17682,"totalTrials":186,"cells":17683},"Activated Charcoal",{"EARLY_PHASE1":17684,"PHASE1":17686,"PHASE2":17688,"PHASE3":17690,"PHASE4":17692,"NA":17694},{"trials":17685,"activeCount":114},[],{"trials":17687,"activeCount":114},[],{"trials":17689,"activeCount":114},[],{"trials":17691,"activeCount":114},[],{"trials":17693,"activeCount":114},[],{"trials":17695,"activeCount":114},[17696],{"nctId":17697,"briefTitle":17698,"status":105,"phases":17699,"primaryCompletion":2416,"completion":173,"start":8909,"enrollment":276,"conditions":17700,"interventions":17702},"NCT00823264","Phenytoin and Multidose Activated Charcoal",[94],[17701],"Phenytoin Toxicity",[17682],{"intervention":17704,"totalTrials":186,"cells":17705},"quadrivalent HPV vaccine",{"EARLY_PHASE1":17706,"PHASE1":17708,"PHASE2":17710,"PHASE3":17712,"PHASE4":17714,"NA":17716},{"trials":17707,"activeCount":114},[],{"trials":17709,"activeCount":114},[],{"trials":17711,"activeCount":114},[],{"trials":17713,"activeCount":114},[],{"trials":17715,"activeCount":114},[],{"trials":17717,"activeCount":114},[17718],{"nctId":17719,"briefTitle":17720,"status":105,"phases":17721,"primaryCompletion":9664,"completion":9664,"start":173,"enrollment":17722,"conditions":17723,"interventions":17724},"NCT01505049","Immune Memory After Papillomavirus Vaccination",[],203,[12481],[17704],{"intervention":16690,"totalTrials":186,"cells":17726},{"EARLY_PHASE1":17727,"PHASE1":17729,"PHASE2":17731,"PHASE3":17733,"PHASE4":17735,"NA":17737},{"trials":17728,"activeCount":114},[],{"trials":17730,"activeCount":114},[],{"trials":17732,"activeCount":114},[],{"trials":17734,"activeCount":114},[],{"trials":17736,"activeCount":114},[],{"trials":17738,"activeCount":114},[17739],{"nctId":16683,"briefTitle":16684,"status":230,"phases":17740,"primaryCompletion":3868,"completion":3868,"start":16686,"enrollment":31,"conditions":17741,"interventions":17742},[94],[16688],[16690,11027],{"intervention":16357,"totalTrials":186,"cells":17744},{"EARLY_PHASE1":17745,"PHASE1":17747,"PHASE2":17749,"PHASE3":17751,"PHASE4":17753,"NA":17755},{"trials":17746,"activeCount":114},[],{"trials":17748,"activeCount":114},[],{"trials":17750,"activeCount":114},[],{"trials":17752,"activeCount":114},[],{"trials":17754,"activeCount":114},[],{"trials":17756,"activeCount":114},[17757],{"nctId":16352,"briefTitle":16353,"status":105,"phases":17758,"primaryCompletion":5970,"completion":5970,"start":7717,"enrollment":22,"conditions":17759,"interventions":17760},[94],[1700],[7721,16357],{"intervention":17762,"totalTrials":186,"cells":17763},"botulinum toxin A",{"EARLY_PHASE1":17764,"PHASE1":17766,"PHASE2":17768,"PHASE3":17770,"PHASE4":17772,"NA":17774},{"trials":17765,"activeCount":114},[],{"trials":17767,"activeCount":114},[],{"trials":17769,"activeCount":114},[],{"trials":17771,"activeCount":114},[],{"trials":17773,"activeCount":114},[],{"trials":17775,"activeCount":114},[17776],{"nctId":17777,"briefTitle":17778,"status":105,"phases":17779,"primaryCompletion":14468,"completion":9933,"start":16235,"enrollment":2075,"conditions":17780,"interventions":17782},"NCT01233999","Botulinum Toxin in the Treatment of Raynaud's",[94],[17781],"Raynaud's Syndrome",[17762],{"intervention":17784,"totalTrials":186,"cells":17785},"Immune globulin",{"EARLY_PHASE1":17786,"PHASE1":17788,"PHASE2":17790,"PHASE3":17792,"PHASE4":17794,"NA":17796},{"trials":17787,"activeCount":114},[],{"trials":17789,"activeCount":114},[],{"trials":17791,"activeCount":114},[],{"trials":17793,"activeCount":114},[],{"trials":17795,"activeCount":114},[],{"trials":17797,"activeCount":114},[17798],{"nctId":17799,"briefTitle":17800,"status":230,"phases":17801,"completion":17802,"start":12235,"enrollment":17803,"conditions":17804,"interventions":17806},"NCT00004833","Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome",[94],"2002-11",170,[17805],"Guillain-Barre Syndrome",[17784],{"intervention":17808,"totalTrials":186,"cells":17809},"Bedtime insulin Aspart",{"EARLY_PHASE1":17810,"PHASE1":17812,"PHASE2":17814,"PHASE3":17816,"PHASE4":17818,"NA":17820},{"trials":17811,"activeCount":114},[],{"trials":17813,"activeCount":114},[],{"trials":17815,"activeCount":114},[],{"trials":17817,"activeCount":114},[],{"trials":17819,"activeCount":114},[],{"trials":17821,"activeCount":114},[17822],{"nctId":17823,"briefTitle":17824,"status":105,"phases":17825,"primaryCompletion":6152,"completion":6152,"start":5939,"enrollment":17826,"conditions":17827,"interventions":17828},"NCT01702311","Point-of-Care Glucose Testing and Insulin Supplementation",[94],235,[18],[17808],{"intervention":17830,"totalTrials":186,"cells":17831},"Depot medroxyprogesterone acetate",{"EARLY_PHASE1":17832,"PHASE1":17834,"PHASE2":17836,"PHASE3":17838,"PHASE4":17840,"NA":17842},{"trials":17833,"activeCount":114},[],{"trials":17835,"activeCount":114},[],{"trials":17837,"activeCount":114},[],{"trials":17839,"activeCount":114},[],{"trials":17841,"activeCount":114},[],{"trials":17843,"activeCount":114},[17844],{"nctId":17845,"briefTitle":17846,"status":105,"phases":17847,"primaryCompletion":2191,"completion":2191,"start":17848,"enrollment":17849,"conditions":17850,"interventions":17852},"NCT03660046","Contraceptive Hormones, Immunity, and Microbiome Evaluation",[],"2018-12-07",155,[17851],"Hormonal Contraception",[17830,17853,17854],"Etonogestrel implant","Levonorgestrel IUD",{"intervention":17853,"totalTrials":186,"cells":17856},{"EARLY_PHASE1":17857,"PHASE1":17859,"PHASE2":17861,"PHASE3":17863,"PHASE4":17865,"NA":17867},{"trials":17858,"activeCount":114},[],{"trials":17860,"activeCount":114},[],{"trials":17862,"activeCount":114},[],{"trials":17864,"activeCount":114},[],{"trials":17866,"activeCount":114},[],{"trials":17868,"activeCount":114},[17869],{"nctId":17845,"briefTitle":17846,"status":105,"phases":17870,"primaryCompletion":2191,"completion":2191,"start":17848,"enrollment":17849,"conditions":17871,"interventions":17872},[],[17851],[17830,17853,17854],{"intervention":17854,"totalTrials":186,"cells":17874},{"EARLY_PHASE1":17875,"PHASE1":17877,"PHASE2":17879,"PHASE3":17881,"PHASE4":17883,"NA":17885},{"trials":17876,"activeCount":114},[],{"trials":17878,"activeCount":114},[],{"trials":17880,"activeCount":114},[],{"trials":17882,"activeCount":114},[],{"trials":17884,"activeCount":114},[],{"trials":17886,"activeCount":114},[17887],{"nctId":17845,"briefTitle":17846,"status":105,"phases":17888,"primaryCompletion":2191,"completion":2191,"start":17848,"enrollment":17849,"conditions":17889,"interventions":17890},[],[17851],[17830,17853,17854],{"intervention":17892,"totalTrials":186,"cells":17893},"Sitagliptin + Pioglitazone PLACEBO",{"EARLY_PHASE1":17894,"PHASE1":17896,"PHASE2":17898,"PHASE3":17900,"PHASE4":17902,"NA":17904},{"trials":17895,"activeCount":114},[],{"trials":17897,"activeCount":114},[],{"trials":17899,"activeCount":114},[],{"trials":17901,"activeCount":114},[],{"trials":17903,"activeCount":114},[],{"trials":17905,"activeCount":114},[17906],{"nctId":17907,"briefTitle":17908,"status":230,"phases":17909,"primaryCompletion":7806,"completion":7806,"start":6389,"enrollment":362,"conditions":17910,"interventions":17911},"NCT01006018","DPP-4 Inhibition and TZD for DM Prevention",[94],[16572],[17892,17912],"Sitagliptin + Pioglitazone",{"intervention":17912,"totalTrials":186,"cells":17914},{"EARLY_PHASE1":17915,"PHASE1":17917,"PHASE2":17919,"PHASE3":17921,"PHASE4":17923,"NA":17925},{"trials":17916,"activeCount":114},[],{"trials":17918,"activeCount":114},[],{"trials":17920,"activeCount":114},[],{"trials":17922,"activeCount":114},[],{"trials":17924,"activeCount":114},[],{"trials":17926,"activeCount":114},[17927],{"nctId":17907,"briefTitle":17908,"status":230,"phases":17928,"primaryCompletion":7806,"completion":7806,"start":6389,"enrollment":362,"conditions":17929,"interventions":17930},[94],[16572],[17892,17912],{"intervention":17932,"totalTrials":186,"cells":17933},"Emtricitabine\u002FTenofovir Disoproxil Fumarate",{"EARLY_PHASE1":17934,"PHASE1":17936,"PHASE2":17938,"PHASE3":17940,"PHASE4":17942,"NA":17944},{"trials":17935,"activeCount":114},[],{"trials":17937,"activeCount":114},[],{"trials":17939,"activeCount":114},[],{"trials":17941,"activeCount":114},[],{"trials":17943,"activeCount":114},[],{"trials":17945,"activeCount":114},[17946],{"nctId":17947,"briefTitle":17948,"status":105,"phases":17949,"primaryCompletion":4547,"completion":6425,"start":3679,"enrollment":612,"conditions":17950,"interventions":17951},"NCT02449733","Comprehensive HIV Prevention Package for MSM in Port Elizabeth",[94],[15],[17932],{"intervention":17953,"totalTrials":186,"cells":17954},"Seasonal trivalent inactivated influenza vaccine",{"EARLY_PHASE1":17955,"PHASE1":17957,"PHASE2":17959,"PHASE3":17961,"PHASE4":17963,"NA":17965},{"trials":17956,"activeCount":114},[],{"trials":17958,"activeCount":114},[],{"trials":17960,"activeCount":114},[],{"trials":17962,"activeCount":114},[],{"trials":17964,"activeCount":114},[],{"trials":17966,"activeCount":114},[17967],{"nctId":17968,"briefTitle":17969,"status":105,"phases":17970,"primaryCompletion":6152,"completion":3501,"start":11525,"enrollment":380,"conditions":17971,"interventions":17973},"NCT01916759","Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda",[94],[15,17972,847],"Acquired Immunodeficiency Syndrome",[17953],{"intervention":17975,"totalTrials":186,"cells":17976},"multivitamin",{"EARLY_PHASE1":17977,"PHASE1":17979,"PHASE2":17981,"PHASE3":17983,"PHASE4":17985,"NA":17987},{"trials":17978,"activeCount":114},[],{"trials":17980,"activeCount":114},[],{"trials":17982,"activeCount":114},[],{"trials":17984,"activeCount":114},[],{"trials":17986,"activeCount":114},[],{"trials":17988,"activeCount":114},[17989],{"nctId":17990,"briefTitle":17991,"status":105,"phases":17992,"primaryCompletion":7613,"completion":7854,"start":3645,"enrollment":17993,"conditions":17994,"interventions":17996},"NCT00394862","Efficacy of Weekly Versus Daily Folic Acid Supplementation",[94],460,[17995],"Neural Tube Defects",[17975],{"intervention":1296,"totalTrials":186,"cells":17998},{"EARLY_PHASE1":17999,"PHASE1":18001,"PHASE2":18003,"PHASE3":18005,"PHASE4":18007,"NA":18009},{"trials":18000,"activeCount":114},[],{"trials":18002,"activeCount":114},[],{"trials":18004,"activeCount":114},[],{"trials":18006,"activeCount":114},[],{"trials":18008,"activeCount":114},[],{"trials":18010,"activeCount":114},[18011],{"nctId":1288,"briefTitle":1289,"status":105,"phases":18012,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":162,"conditions":18013,"interventions":18014},[94],[1269,1294],[1251,1296,1297],{"intervention":1297,"totalTrials":186,"cells":18016},{"EARLY_PHASE1":18017,"PHASE1":18019,"PHASE2":18021,"PHASE3":18023,"PHASE4":18025,"NA":18027},{"trials":18018,"activeCount":114},[],{"trials":18020,"activeCount":114},[],{"trials":18022,"activeCount":114},[],{"trials":18024,"activeCount":114},[],{"trials":18026,"activeCount":114},[],{"trials":18028,"activeCount":114},[18029],{"nctId":1288,"briefTitle":1289,"status":105,"phases":18030,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":162,"conditions":18031,"interventions":18032},[94],[1269,1294],[1251,1296,1297],{"intervention":16203,"totalTrials":186,"cells":18034},{"EARLY_PHASE1":18035,"PHASE1":18037,"PHASE2":18039,"PHASE3":18041,"PHASE4":18043,"NA":18045},{"trials":18036,"activeCount":114},[],{"trials":18038,"activeCount":114},[],{"trials":18040,"activeCount":114},[],{"trials":18042,"activeCount":114},[],{"trials":18044,"activeCount":114},[],{"trials":18046,"activeCount":114},[18047],{"nctId":16197,"briefTitle":16198,"status":105,"phases":18048,"primaryCompletion":12682,"completion":12682,"start":3578,"enrollment":16200,"conditions":18049,"interventions":18050},[94],[21],[7762,16203],{"intervention":18052,"totalTrials":186,"cells":18053},"Aripiprazole",{"EARLY_PHASE1":18054,"PHASE1":18056,"PHASE2":18058,"PHASE3":18060,"PHASE4":18062,"NA":18064},{"trials":18055,"activeCount":114},[],{"trials":18057,"activeCount":114},[],{"trials":18059,"activeCount":114},[],{"trials":18061,"activeCount":114},[],{"trials":18063,"activeCount":114},[],{"trials":18065,"activeCount":114},[18066],{"nctId":18067,"briefTitle":18068,"status":230,"phases":18069,"primaryCompletion":3660,"completion":2797,"start":16686,"enrollment":454,"conditions":18070,"interventions":18071},"NCT00209027","The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia",[94],[456],[18052],{"intervention":18073,"totalTrials":186,"cells":18074},"Abciximab",{"EARLY_PHASE1":18075,"PHASE1":18077,"PHASE2":18079,"PHASE3":18081,"PHASE4":18083,"NA":18085},{"trials":18076,"activeCount":114},[],{"trials":18078,"activeCount":114},[],{"trials":18080,"activeCount":114},[],{"trials":18082,"activeCount":114},[],{"trials":18084,"activeCount":114},[],{"trials":18086,"activeCount":114},[18087],{"nctId":18088,"briefTitle":18089,"status":105,"phases":18090,"primaryCompletion":5970,"completion":5970,"start":16660,"enrollment":18091,"conditions":18092,"interventions":18093},"NCT00379418","Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients",[],220,[27],[18073],{"intervention":16442,"totalTrials":186,"cells":18095},{"EARLY_PHASE1":18096,"PHASE1":18098,"PHASE2":18100,"PHASE3":18102,"PHASE4":18104,"NA":18106},{"trials":18097,"activeCount":114},[],{"trials":18099,"activeCount":114},[],{"trials":18101,"activeCount":114},[],{"trials":18103,"activeCount":114},[],{"trials":18105,"activeCount":114},[],{"trials":18107,"activeCount":114},[18108],{"nctId":16436,"briefTitle":16437,"status":105,"phases":18109,"primaryCompletion":1320,"completion":8909,"start":3578,"enrollment":2481,"conditions":18110,"interventions":18111},[94],[16440,6155],[16442,16443,16444],{"intervention":16443,"totalTrials":186,"cells":18113},{"EARLY_PHASE1":18114,"PHASE1":18116,"PHASE2":18118,"PHASE3":18120,"PHASE4":18122,"NA":18124},{"trials":18115,"activeCount":114},[],{"trials":18117,"activeCount":114},[],{"trials":18119,"activeCount":114},[],{"trials":18121,"activeCount":114},[],{"trials":18123,"activeCount":114},[],{"trials":18125,"activeCount":114},[18126],{"nctId":16436,"briefTitle":16437,"status":105,"phases":18127,"primaryCompletion":1320,"completion":8909,"start":3578,"enrollment":2481,"conditions":18128,"interventions":18129},[94],[16440,6155],[16442,16443,16444],{"intervention":18131,"totalTrials":186,"cells":18132},"Safety tested norovirus inoculum",{"EARLY_PHASE1":18133,"PHASE1":18135,"PHASE2":18137,"PHASE3":18139,"PHASE4":18141,"NA":18143},{"trials":18134,"activeCount":114},[],{"trials":18136,"activeCount":114},[],{"trials":18138,"activeCount":114},[],{"trials":18140,"activeCount":114},[],{"trials":18142,"activeCount":114},[],{"trials":18144,"activeCount":114},[18145],{"nctId":18146,"briefTitle":18147,"status":105,"phases":18148,"primaryCompletion":6861,"completion":2797,"start":18149,"enrollment":2481,"conditions":18150,"interventions":18151},"NCT00313404","Infectivity of Norovirus in Groundwater-Human Challenge Study",[94],"2006-02",[1323],[18131],{"intervention":18153,"totalTrials":186,"cells":18154},"PNEUMOVAX",{"EARLY_PHASE1":18155,"PHASE1":18157,"PHASE2":18159,"PHASE3":18161,"PHASE4":18163,"NA":18165},{"trials":18156,"activeCount":114},[],{"trials":18158,"activeCount":114},[],{"trials":18160,"activeCount":114},[],{"trials":18162,"activeCount":114},[],{"trials":18164,"activeCount":114},[],{"trials":18166,"activeCount":114},[18167],{"nctId":18168,"briefTitle":18169,"status":105,"phases":18170,"primaryCompletion":2683,"completion":2683,"start":8757,"enrollment":18171,"conditions":18172,"interventions":18174},"NCT01307449","Systems Biology of PNEUMOVAX®23 and PREVNAR 13®",[94],88,[18173],"Pneumococcal Infection",[18153,18175],"Prevnar",{"intervention":18175,"totalTrials":186,"cells":18177},{"EARLY_PHASE1":18178,"PHASE1":18180,"PHASE2":18182,"PHASE3":18184,"PHASE4":18186,"NA":18188},{"trials":18179,"activeCount":114},[],{"trials":18181,"activeCount":114},[],{"trials":18183,"activeCount":114},[],{"trials":18185,"activeCount":114},[],{"trials":18187,"activeCount":114},[],{"trials":18189,"activeCount":114},[18190],{"nctId":18168,"briefTitle":18169,"status":105,"phases":18191,"primaryCompletion":2683,"completion":2683,"start":8757,"enrollment":18171,"conditions":18192,"interventions":18193},[94],[18173],[18153,18175],{"intervention":18195,"totalTrials":186,"cells":18196},"ZOSTAVAX",{"EARLY_PHASE1":18197,"PHASE1":18199,"PHASE2":18201,"PHASE3":18203,"PHASE4":18205,"NA":18207},{"trials":18198,"activeCount":114},[],{"trials":18200,"activeCount":114},[],{"trials":18202,"activeCount":114},[],{"trials":18204,"activeCount":114},[],{"trials":18206,"activeCount":114},[],{"trials":18208,"activeCount":114},[18209],{"nctId":18210,"briefTitle":18211,"status":105,"phases":18212,"primaryCompletion":6965,"completion":3671,"start":6389,"enrollment":8365,"conditions":18213,"interventions":18214},"NCT01331161","Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly",[94],[13248],[18195]]